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 Abstract 
 
 
The research described in this thesis aimed to increase our knowledge of the molecular 
mechanisms by which lung cancer cells acquire the capacity to invade. The research can 
be divided into two main sections a) Development of genetic tools for stable, targetable 
transgene overexpression, b) Investigation of the role of differential expression of a group 
of genes, including microRNAs, in cancer invasion. DLKP mildly invasive cell line 
derived from a non-small cell lung carcinoma and its Adriamycin resistant variant 
DLKPA highly invasive were used in this study to evaluate the roles of differentially 
expressed mRNAs and microRNAs. 
 
We developed two targetable DLKP cell lines based on Cre-LoxP technology. These 
were generated by random and homologous recombination (site specific) targeting. These 
cell lines were developed to overcome challenges one faces with non-targetable systems 
including large discrepancies in target gene expression, genomic instability, and 
unpredictable phenotypes. A panel of thirty one DLKP single cell clones were assessed 
for stable and transgene overexpression, over four and a half months with regular 
passages and freeze thaw cycles. Many clones were found to display unstable transgene 
expression over time but several were identified with stable expression and at different 
levels. Two clones were selected based on stable expression level and on invasive 
phenotype, i) high expressing non invasive  clone DLKP 17 and ii) low expressing 
invasive clone DLKP 11.  
 
Microarray profiling studies done in this lab on a panel of lung cancer cell lines with 
various invasive phenotypes identified a list of differentially expressed genes. GLP1R, 
KCNJ8 and TFPI2 genes were stably overexpressed and all induced invasion in non-
invasive DLKP 17. Furthermore GLP1-R induced invasion could be reversed through 
siRNA induced silencing of the transgene. GLP1-R overexpression in non-invasive 
MCF-7 also induced cellular invasion. These findings are the first time that GLP1-R has 
been linked to this phenotype. 
 
 
 
 
 MiRNA expression profiling was performed comparing low invasive DLKP (parent) and 
invasive DLKPA (Adriamycin selected) cell lines. Three differentially regulated miRNAs 
were selected for functional validation. Mir-21 and mir-27a were pro-invasive and mir-
29a anti-invasive in DLKP and DLKPA cell lines. We later confirmed the impact on 
invasion and proliferation through stable overexpression studies with mir-29a. Pre-mir-
29a overexpression in the invasive PANC-1 (pancreatic cancer line) resulted in reduced 
invasion suggesting that the effect of mir-29a was not cell line specific.  
 
2D-DIGE proteomic profiling of cells transfected with mir-29a generated a list of 
differentially regulated protein spots, some of which were identified by MALDI-TOF and 
LC-MS analysis. Bioinformatic analysis revealed that the majority of these proteins were 
involved in cellular processes like apoptosis, proliferation, motility and differentiation. 
We chose GRB2, RAN, MIF and ANXA2 gene targets which were differentially 
downregulated due to mir-29a overexpression and performed siRNA induced knockdown 
in DLKPA cell line. Results revealed RAN to be anti-invasive and anti-proliferative in 
our cell line model. Knockdown of the other three targets did not affect the invasive or 
proliferative phenotype of DLKPA. GFP-RAN 3’-UTR reporter assay indicated a small 
(5-6%) but statistically significant reduction in GFP RAN-UTR expressing cell 
population when transfected with mir-29a. In conclusion we provide evidence that mir-
29a may be an anti-invasive microRNA and that this effect is mediated via modulation of 
the expression of RAN and several other cellular proteins.
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MALDI-TOF  -          Matrix-assisted laser desorption/ionization -Time of Flight 
MAPK  - Mitogen Activated Protein Kinase 
MDR  - Multiple Drug Resistance 
MIF                 -           Macrophage Migration Inhibitory Factor 
Min  - Minutes 
mM                  -          Milli Molar 
M                   -          Micro Molar 
miRNA - microRNA 
MMLV-RT - Moloney Murine Leukaemia Virus- Reverse Transcriptase 
MMPs  - Matrix Metalloproteases 
mRNA  - Messenger RNA 
nM                  -           Nano Molar 
NSCLC - Non-Small Cell Lung Cancer 
 ORF  - Opening reading frame 
PBS   - Phosphate Buffered Saline  
PCR                -           Polymerase Chain Reaction 
PKA  - Protein Kinase A 
PM                  -           Pre-miRNA 
QC  - Quality Control 
qRT-PCR        -           Quantitative real time PCR 
rAAV  - Recombinant adeno viral vector 
RAN               -           RAS related nuclear protein 
RE                   -          Restriction Enzyme 
RISC  - RNA-Induced Silencing Complex 
RNA  - Ribonucleic Acid 
RNase  - Ribonuclease 
RNasin - Ribonuclease Inhibitor 
RQ  - Relative Quantity 
RT-PCR - Reverse Transcriptase PCR 
S100A13         -          S100 calcium binding protein A13 
SCLC  - Small Cell Lung Carcinoma 
Scrm siRNA - Scrambled siRNA 
SD  - Standard Deviation 
SDS  - Sodium Doedecyl Sulphate 
SE  - Standard Error 
SFM  - Serum-Free Medium 
shRNA - short hairpin RNA 
siRNA  - Small interfering RNA 
TAE  - Tris-acetic acid-EDTA buffer 
TE  - Tris-EDTA 
TEMED - N, N, N’, N’-Tetramethyl-Ethylenediamine 
TF  - Transcription factor 
TFPI2  - Tissue factor pathway inhibitor 2 
TGFβ1  - Transforming Growth Factor 1 
TNFAIP8 - Tumour necrosis Factor, Alpha-Induced Protein 8 
Tris  - Tris (hydroxymethyl) Aminomethane 
 TXT  - Taxotere 
TV  - 0.25% Trypsin/ 0.01% EDTA Solution in PBS 
UHP  - Ultra High Pure Water 
uPA  - Urokinase type plasminogen activator 
uPAR  - Urokinase type plasminogen activator receptor 
UTR  - Untranslated Region 
UV  - Ultraviolet 
VCR  - Vincristine 
VEGF  - Vascular Endothelial Growth Factor 
VEGFR - Vascular Endothelial Growth Factor Receptor 
v/v  - Volume/Volume 
w/v  - Weight per Volume 
X-Gal              -          5-Bromo-4-Chloro-3-indolyl--D-galactopyranoside 
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1.0    Introduction 
1.1 Lung cancer  
 
According to the Irish Cancer Society Lung cancer is one of the most prevalent in Ireland, 
with over 1,500 new cases each year. Currently lung cancer tops the list of most common 
cancers worldwide, not only in men but in women as well. The 5 year survival rate for 
lung cancer is < 15% from the time of diagnosis. This is largely due to the late stage of 
diagnosis and the lack of effective treatments, reflecting the need for a better 
understanding of the mechanisms that underlie lung carcinogenesis. Ultimately, this could 
improve the diagnosis, prognosis, and clinical management of patients with lung cancer. 
Other causes of lung cancer include exposure to chemicals such as asbestos, as well as the 
naturally occurring radioactive gas, radon (a colourless, odourless, tasteless, naturally 
occurring radioactive gas produced from the decay of the element radium, which occurs 
naturally in rocks and soil worldwide). Passive inhalation of environmental tobacco 
smoke (ETS) has also been linked with the development of lung cancer in non-smokers.  
Cells defective in the regulatory circuits that control proliferation and homeostasis pose a 
threat to become cancerous (Hanahan and Weinberg, 2000). Cancer is a multistep process 
and a distinguishing feature of malignant cells is their ability to invade surrounding 
normal tissue, metastasize through the blood and lymphatic systems, and re-establish at 
distant secondary locations. The choice of treatment for patients with lung cancer depends 
strongly on the clinical stage. Other details taken into account include pulmonary function 
and cell type. Surgery is the major therapeutic option for lung cancer patients, however 
approximately 75% of lung cancers are inoperable at time of diagnosis therefore surgery 
is only curative in patients with early stage lung cancer. Radiation therapy can also be 
curative for a small percentage of patients. To date, chemotherapy can offer improvement 
in short-term survival, but overall survival from lung cancer is poor. Unlike the study of a 
single gene, protein, or pathway, genomic and proteomic technologies enable a systematic 
overview that provides the potential to improve our understanding of this disease. 
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Figure 1.0 Schematic diagram to illustrate gene targets important for tumor-host 
interaction. Gene targeting technology can be used to target molecules that are 
important for tumor angiogenesis, invasion, metastasis and immune evasion.  
 
 
Symptoms associated with lung cancer are cough, dyspnoea, haemoptysis and post 
obstructive pneumonia, (Hoffman et al, 2000), although lung cancer can present with no 
initial symptoms. Diagnosis is achieved by invasive and non-invasive methods. Non-
invasive methods for diagnosing lung cancer include sputum cytology and chest 
www.nature.com/.../v13/n6/fig_tab/3302694f2.html
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radiography. After this point, invasive techniques such as bronchoscopy and lung biopsy 
are performed. While the location and size of the lung tumour can be estimated from a 
chest x-ray or CT scan, accurate diagnosis and staging requires a biopsy to histologically 
type the cells and determine if local nodes are involved. Staging of lung cancer is very 
important, since it will determine the type of treatment received. The international staging 
system classifies the cancer based on the Tumour, Node, and Metastasis (TNM) 
designation. The designation T1-4 refers to the size and location of the primary tumour. 
N0-N3 describes the extent of lymph node involvement. In cases where distant metastases 
are present (M1), the tumour is diagnosed as stage IV lung cancer. Early stage lung 
cancers are the most treatable, with later stage cancers such as stage IIIB and IV being 
virtually untreatable.  
 
Lung cancer is divided into 2 main groups, small cell lung cancer (SCLC) and non-small 
cell lung cancer (NSCLC). The World Health Organisation (WHO) compiled this 
histologic classification. SCLC and the subtypes of NSCLC – adenocarcinoma, squamous 
cell carcinoma and large cell carcinoma, account for 95% of lung cancers. SCLC presents 
less frequently than NSCLC and generally originates from a central location in the lung. 
These tumours are very aggressive, have a rapid growth rate and generally present with 
distant metastases at diagnosis. These tumours have the poorest prognosis of all lung 
cancer subtypes. NSCLC is divided into three categories, squamous cell carcinoma (30% 
of all lung cancers), adenocarcinoma (40%) and large cell carcinoma (10%). Squamous 
cell carcinoma develops from within a central bronchus in the lung and frequently 
displays central cavitation from necrosis. They are characterised by keratin formation. 
Squamous cell carcinomas have slow growth rates and develop metastases at a late stage. 
Adenocarcinomas generally develop centrally from surface epithelial cells in larger 
bronchi. They are characterised by gland formation and mucus production. These tumours 
tend to metastasise early and have a rapid growth rate. Large cell carcinoma is 
characterised by large cells with large nuclei and prominent nucleoli. These tumours are 
usually poorly differentiated and tend towards large peripheral masses.  
 
Lung cancer, particularly SCLC, is characterised by rapid growth and metastatic spread 
(Yano et al, 2005). By the time of diagnosis clinically undetectable micro metastasis may 
already have developed within the lung. Yano et al, (2005) injected immunodeficient 
mice with SCLC cell lines, SBC-3 and SBC-5 resulting in metastasis formation in liver, 
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bone and kidney. Lung cancer itself often arises as a metastasis from another site, for 
example, cancer of the breast (Horak and Steeg, 2005).  
  
1.2 Invasion 
 
Invasion is the active translocation of neoplastic cells across tissue boundaries and 
through host cellular and extracellular matrix barriers. Invasion is not only due to growth 
pressure but is attributed to additional genetic deregulation over and above those 
molecular events that cause uncontrolled proliferation. At the biochemical level, the 
mechanism of invasion used by tumour cells may be similar to that used by non-
malignant cells which traverse tissue boundaries under normal physiological conditions. 
Mechanisms of invasion are known to involve a complex array of genetic and epigenetic 
changes many of which are specific for different types of tumours and different sites of 
metastasis. The roles of adhesion molecules such as integrins and cadherins in invasion 
have undergone a major transition over the past decade. It is now apparent that these 
molecules have a critical role in signalling from the outside to inside a cell thus 
controlling how a cell can interact with and sense its local environment. It has also 
become clear that proteolytic enzymes and their inhibitors not only degrade the ECM, but 
are involved in the release of factors that can positively or negatively affect the growth of 
tumour cells. In more recent years, the importance of the post-extravasional stages of 
invasion was highlighted, where adhesion and proteolysis are now known to play a role 
along with other processes including apoptosis, dormancy, growth factor-receptor 
interactions and signal transduction. It has also been found that it is not only the 
immediate cellular microenvironment, but also the extended cellular microenvironment 
that can modify cellular gene expression and enhance metastasis. Our improved 
understanding of the expanded roles of the individual molecules involved has resulted in 
a mechanistic blurring of the previously described discrete stages of the metastatic 
process (Cairns et al, 2003). In contrast to malignant invasion, physiological invasion is 
tightly regulated and ceases when the stimulus is removed. Invading tumour cells appear 
to have lost the control mechanism which prevents normal cells from invading 
neighbouring tissue at inappropriate times and places. Thus, the fundamental difference 
between normal and malignant cells is regulation. The difference must lie in the proteins 
that start, stop or maintain the invasion programme at times and places that are 
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inappropriate for non-malignant cells. A major goal is to understand what signals and 
signal transduction pathways are perpetually activated or deregulated in malignant 
invasion (Kohn et al, 1997). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     (Adopted from Physiology 20: 194-200, 2005) 
 
FIGURE 1.1 Schematic of molecular machinery involved during tumour cell 
transformation into a migratory cell, which involves signals for cellular processes 
like proliferation and survival responses. 
 
Liotta et al, (1977) proposed a three step simplified theory of invasion: (1) Tumour cell 
attachment via cell surface receptors which specifically bind to the components of the 
extracellular matrix (ECM); (2) the anchored tumour cell secretes 
hydrolytic enzymes, such as matrix metalloproteinases, to degrade the extracellular 
matrix; (3) tumour cell locomotion into the region of the matrix modified by the 
Receptor tyrosine Adhesion G-protein coupled
Kinases (e.g., integrins) receptors 
Lipid kinase
(PI3K) MAPK/ERK
Migration/Invasion
Survival
Proliferation
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proteolysis. Thus, regulation of the molecular events necessary for invasion requires 
spatial and temporal coordination at an individual cell level.  
 
For cells migrating within a three dimensional extracellular matrix, such as penetrating a 
basement membrane, protrusion of a cylindrical pseudopod occurs prior to translocation 
of the whole cell body (Condeelis, 1993). A number of observations support the central 
role of the cytoskeleton-driven pseudopodia as organs of motility and invasion. 
Pseudopodia aggregate or concentrate cell surface degradative enzymes and adhesion 
receptors (Guirguis et al, 1987). A balance must switch from proteolysis to adhesion in 
order for the advancing pseudopod to grip the matrix and pull the cell forward. General 
unregulated proteolysis alone cannot be responsible for the entire invasion cascade. When 
the cell moves into the zone of lysis, adhesion is required and proteolysis must be shut 
down. At the rear of the cell, dissociation from adjacent cells, and detachment from 
previous attachment sites are necessary to release the cell. This type of motility is 
described as mesenchymal motility (Sahi et al, 2006). 
 
                            (Adopted from Physiology 20: 194-200, 2005) 
FIGURE 1.2A Schematic of active contribution of Stromal cells and ECM 
components to metastatic process. Through cell-cell contacts, cell-matrix contacts, 
and soluble mediators, complex communications initiate and sustain the invasion 
and migration of tumor cells. 
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The basement membrane and interstitial stroma also have important regulatory roles in 
invasion. They serve as a storage depot for latent proteinases, cytokines and growth 
factors, which can be activated or released by the invading cells. The critical pathological 
turning point is in the initiation of local invasion leading to the dissemination of tumour 
cells. Tumour-induced neovascularisation occurs in parallel with invasion and provides 
vascular entry necessary for dissemination. The molecular characterisation of invasion 
has led to the identification of two categories of checkpoints that constitute possible 
intervention targets. The first category includes cell surface and secreted proteins e.g. 
adhesion receptors, degradative enzymes and their inhibitors and motility stimulating 
cytokines. The second checkpoint category includes regulatory proteins and pathways 
such as calcium-mediated signalling, G-protein activation and tyrosine phosphorylation 
events. It is the molecular examination of these checkpoint molecules that may provide 
the basis for the development of therapeutics that can potentially block tumour invasion 
or growth (Kohn et al, 1997). 
 
1.2.1 Survival during invasion 
 
None of the functions of metastasizing cells are unique to cancer cells. An example of 
physiological invasion is smooth muscle cell migration from the tunica media (which 
contains smooth muscle fibres, elastic and collagenous tissue) to the intima (endothelial 
cell layer) of blood vessels. Angiogenesis, nerve growth cone extension and homing, 
embryogenesis and trophoblast implantation are also examples. During embryonic 
development, motile cells are tightly regulated in order to ensure proper homing and 
reversion to a non-motile phenotype after migration into a destined location (Hay, 1995). 
In contrast, cancer cells have lost the ability to recognise specific targets. Their 
inappropriate growth signals are accompanied by mechanisms to avoid apoptosis and the 
potential to elicit angiogenesis for independent nutrient supply.  
 
Hood and Cheresh, (2002) and other studies suggest that  invasion is not simply due to 
growth pressure but involves additional genetic deregulation over and above those 
molecular events that cause uncontrolled proliferation. The difference between the normal 
process and the pathogenic nature of cancer invasion is therefore one of regulation. 
Invading cells must be able to activate survival mechanisms and escape apoptosis. Indeed, 
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integrin-binding to ECM ligands initiates pro-survival mechanisms. Many anti-apoptotic 
pathways are the same as those that are involved in regulating migration. Many targets of 
FAK signalling such as RAS, RAC, PI3K and ERK have also been implicated in cell 
survival. 
 
1.3 Metastasis 
 
Cancer metastasis has been described as a complex series of sequential processes that 
involve: (1) the initial transforming event; (2) proliferation of transformed cells; (3) the 
ability of cancer cells to avoid destruction by immune mechanisms; (4) nutritional supply 
to the tumour mass requiring the release of tumour angiogenesis factors; (5) local 
invasion and destruction of extracellular matrix components and parenchymal cells; (6) 
migration of tumour cells away from the primary tumour mass; (7) penetration of cancer 
cells through the blood vessel wall; (8) embolisation of cancer cells in “clumps” to distant 
organs; (9) arrest of cancer cells in the lumen of small blood vessels or lymphatics; (10) 
reverse penetration of blood vessels; (11) repetition of the process beginning at step 2, 
resulting in the formation of a secondary tumour (metastases) (Fidler, 2002a). In many 
patients, metastases develop some years after the resection of the primary neoplasm 
 
                     
                                                                                      Physiology 20: 194-200, 2005 
 
Figure 1.3A Schematic of a Metastatic sequence 
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 9
By the time of diagnosis, a high proportion of patients have clinically detectable 
metastasis. It is assumed that dissemination is impossible until invasion has occurred. For 
breast cancer, the period of transition from hyper proliferative but non-invasive disease to 
invasive cancer is estimated to average 6 years (Sprat et al, 1986). The time period after 
the invasive carcinoma grows to reach the minimum threshold size of detection (0.25cm 
in diameter), to establishment of the first metastasis, can be less than one year (Sprat et al, 
1986).  
 
Thus transition of preinvasive carcinoma to invasion provides a much larger window for 
intervention compared to the conventional goal, which focuses on established invasive 
carcinoma. Most deaths from cancer are due to metastasis that are resistant to 
conventional therapies. Current therapies fail to eradicate metastasis for three major 
reasons. Firstly, when initially diagnosed, most tumours are well advanced and metastasis 
has already occurred. Secondly, specific organ environment can modify the response of a 
metastatic tumour cell to systemic therapy and alter the efficiency of anticancer agents. 
The third reason and the greatest obstacle to the success of therapy, is the heterogeneous 
composition of tumours, where highly metastatic cells can escape from the effect of 
therapeutic agents. Metastasis is considered to be an inefficient process, as a result large 
numbers of cells can be shed into the circulation from a primary tumour but only a small 
fraction of the cells will succeed in forming metastases. Results from a series of 
experiments using intravital video microscopy (IVVM), a technique which permits direct 
observation of the microcirculation in vivo, suggest that early steps in metastasis, 
including destruction of cells in circulation and extravasion, contribute less to metastatic 
inefficiency than previously assumed. Rather, regulation of growth of individual 
extravasated cells in target tissue appears to be the rate-limiting step (Chambers et al, 
1995). Some metastases will arise on the basis of circulatory anatomy. The lungs are a 
common site of metastasis. The formation of metastases required the interaction of the 
right cells with the compatible organ environment.  
 
Metastasis favours the survival and growth of a few subpopulations of cells that pre-exist 
within the parent neoplasm (Fidler and Kripke, 1977). Thus, metastases can have a clonal 
origin, and different metastases can originate from the proliferation of different single 
cells (Talmadge and Fidler, 1982). In the past inability to accurately diagnose patients at 
high risk for the development of metastasis has precluded the possibility of tailored 
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treatment, increased monitoring, or preventive action. However, advances in gene 
expression profiling have allowed many researchers including Euer, N. et al, (2002) to 
distinguish metastatic primary tumours from non-metastatic primary tumours. These 
results have led to much debate as to the mechanisms of metastatic development.  
 
The ability to identify metastatic tumours using transcriptional signatures from bulk 
tumour tissues suggests that primary oncogenic mutations determine the metastatic 
potential of a tumour. This idea may be viewed as incompatible with the conventional 
theory of tumour progression which predicts that only a small number of cells from the 
primary tumour achieve metastatic potential. Both seemingly contradictory models have a 
variety of supporting data suggesting that both are correct to some extent (Hunter, 2006). 
 
Organ microenvironment can influence the biology of cancer growth and metastasis in 
several different ways. During the interaction of metastatic cells with host tissues, signals 
from autocrine, paracrine or endocrine pathway can influence tumour cell growth and 
proliferation, due to the different concentrations of hormones in particular organs, local 
factors that are differentially expressed or paracrine growth factors concentrated in 
different tissues. In this way metastatic tumour cells can respond to physiological signals 
produced when homeostasis is disturbed. Tumour cells can also originate from or have an 
affinity for growth in a particular organ by responding to these physiological signals 
(Fidler, 2002b). For example, human colon carcinoma (HCC) cells implanted 
subcutaneously (ectopic site) into nude mice produce low levels of secreted type IV 
collagenase, whereas the same cells growing in the wall of the colon (orthotopic site) 
produce high levels of type IV collagenase (Nakajima et al, 1990).  In another study by 
Fidler et al,. (2002) involving highly metastatic clones of human prostate cancer were 
implanted into the prostate (orthotopic site) and subcutis (ectopic site). Tumours growing 
in the prostate exhibited higher levels of epidermal growth factor receptor (EGF-R), basic 
fibroblast growth factor (bFGF), interleukin 8 (IL-8), type IV collagenase and the 
multidrug resistance (mdr-1) gene than those growing in the subcutis. This data indicates 
that the expression level of metastasis-regulating genes by metastatic cells can be induced 
by factors in the organ microenvironment Metastasis is the final stage in tumour 
progression from a normal cell to a fully malignant cell in some cases. The best-
developed example is the characterisation of the molecular progression in colon cancer, in 
which specific changes (e.g. loss of tumour-suppressor genes and mutation of oncogenes) 
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are preferentially associated with specific changes of progression (Fearon and Vogelstein, 
1990); (Kinzler and Vogelstein, 1996). However, the final stage in tumour progression to 
a metastatic phenotype remains to be elucidated at a molecular genetic level in colon and 
other cancers. Transfection with a variety of oncogenes (e.g. ras and src) has been shown 
to produce metastatic cells (Chambers and Tuck, 1993). For example, metastatic H-ras 
transfected NIH-3T3 cells had increased levels of a variety of gene products including 
proteinase and adhesive proteins (Tuck et al, 1991). Loss of tumour-suppressor gene 
function has also been implicated in the conversion to metastatic ability in specific 
tumour types, e.g. nm23 (Chambers et al, 1995), KAI1 (Dong et al, 1995), KiSS-1 (Lee et 
al, 1996), although none is likely to be universally implicated in all tumour types. It 
appears more likely that regulation of expression of genes that contribute functionally to 
metastasis can occur in a tissue-specific manner. The development of gene expression 
profiling may help to elucidate the genes that contribute to metastatic development in 
many cancer types. 
 
 
1.3.1 The extracellular matrix and basement membrane 
 
The extracellular matrix is a complex structure of carbohydrate- and protein-containing 
components that comprise the basement membrane underlying epithelial tissues and that 
surround structural tissues such as bone and muscle (Yurchenko et al, 2002). Almost all 
multicellular organisms have basement membranes. They are the first extracellular 
matrices that are produced during embryogenesis. Epithelial, endothelial and many 
mesenchymal cells are supported by this thin sheet-like ECM structure. The membrane 
acts as a solid regulator of cell attachment, differentiation and growth, as well as a passive 
barrier that segregates tissue compartments. Metastatic cancer cells have to penetrate the 
tumours own basement membrane, that of the vasculature and target tissue in order to 
establish secondary disease sites (Hood and Cheresh, 2002).  
 
The basement membrane has a complex molecular architecture that consists of laminins, 
type IV collagen, entactin and heparan sulphate proteoglycans. Laminins are flexible 
four-armed, 850kDa glycoproteins. Laminin monomers polymerise into 3D structures in a 
time- and concentration- dependent manner. As an initial step in metastasis, many 
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epithelial tumours exhibit altered localisation or expression of laminin-binding integrins 
(e.g. 64). This promotes invasion through the basement membrane and increases 
motility in the stroma, where tumour cells can remodel the matrix by depositing laminin 
(Hood and Cheresh, 2002). The most prevalent protein in the basement membrane is type 
IV collagen. Type IV collagen is a thread-like flexible molecule that can itself form a 
heterotrimer involving hydrophobic and disulphide bonds. The covalent binding of 
collagen provides mechanical stability to the basement membrane. Proteins such as 
entactin, which forms connections between networks of collagen and laminin, further 
stabilise the membrane. Many of the proteases with increased expression in metastatic 
tumours exhibit high enzymatic activity against type IV collagen. The basement 
membrane also contains heparan sulphate proteoglycans – a class of molecules that 
contain a protein core covalently linked to heparan sulphate chains. These molecules are 
linked to the membrane through interactions with laminin and may influence tumour 
biology by acting as a repository for growth factors including fibroblast growth factor. 
 
 
1.4   Proteins involved in Invasion/Metastasis  
1.4.1 Matrix Metalloproteinase (MMPs)   
MMPs are synthesised and secreted in inactive zymogen form and depends on the 
presence of zinc and calcium ions. The production of active enzymes requires the 
proteolytic removal of the pro-domain. Over twenty MMP family members are known to 
exist (Polette et al, 2004). Most MMPs can cleave at least one component of the ECM.  
MMPs can also regulate cell growth, either directly through the release of growth factors 
or indirectly by changes in cell adhesion as described above. MMPs can degrade insulin-
like growth factor (IGF) binding protein 3, which regulates the bioavailability and activity 
of IFG-II (Fowlkes et al, 1995). Powell et al, (1999) demonstrated that MMP-7 
proteolytically generates active soluble Fas ligand and potentiates epithelial cell 
apoptosis. These different effects of MMPs and their inhibitors depend on the balance 
between them in the local microenvironment. MMPs are subdivided into collagenases, 
stromelysins, gelatinases and MT-MMPs based on their substrate preference. MMPs are 
physiologically expressed during various stages of development in processes requiring 
 13
cell migration, tissue remodelling, and wound healing, placentation or tumour 
progression. Many external stimuli can induce the expression of many MMPs. 
 
 
Figure 1.4.1A MMPs regulate invasion by degrading structural ECM components. 
Specifically, the MMPs promote invasion and migration by cleaving laminin 5 (Lam-5). 
MMPs also promote invasion by cleavage of the adhesion molecules CD44 and E-
cadherin (E-cad). The released part of E-cad might then bind and inhibit the function of 
other uncleaved E-cad molecules. In addition, docking of MMP-9 to CD44 is required for 
cancer-cell invasion. MMPs might inhibit metastasis by cleavage of CXCL12, a 
chemokine of the CXC family that promotes breast cancer metastasis. 
Plasmin has been described to proteolytically activate some latent MMPs (Mignatti and 
Rifkin, 1996) and the cooperation between MMPs and the plasminogen activator/ plasmin 
cascade have an important role in the regulation of tumour invasion in vivo. MMPs can 
auto activate in some cases and can also effect mutual activation. For example, MMP1 
can activate latent MMP2 (Nagase et al, 1996). The proteolytic activity of MMPS is 
controlled by tissue inhibitors of MMPs (TIMPs), which specifically block activity of 
active MMPs by binding to the conserved zinc-binding site (Polette et al, 2004). Four 
TIMPs are currently known. According to Knauper et al, (1996) and Wang et al, (1997) 
studies it is revealed that TIMP-1 and –2 inhibit most MMP activity, while TIMP-2 and –
3 inhibit MT1-MMP. TIMP-3 inhibits MMP-1, -2, -3, -7, -9 and –13. TIMP-4 inhibits 
MMP-2 and-7 It was originally thought that tumour cells were involved in the invasion 
process via secreted proteolytic enzymes. However, in vivo in situ hybridisation studies 
demonstrated that stromal cells were the source of MMPs. In 1990, Basset et al, 
(Adopted from Nature Reviews Cancer 2, 161-174 (March 2002) 
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demonstrated that MMP11 was expressed specifically by fibroblasts in breast carcinomas 
and not by their benign counterparts. Thus, host cells have an important role in the 
production of MMPs and tumour invasion due to the cooperation of stromal and tumour 
cells. Extracellular matrix metalloproteinase inducer (EMMPRIN) is produced by tumour 
cells and can stimulate MMP-1 –2 and –3 by fibroblasts (Biswas et al, 1995). EMMPRIN 
mRNA is overexpressed in many carcinomas compared to benign and normal tissues, 
which suggests a role in invasion (Polette et al, 2004). 
A complex interplay exists between cell adhesion molecule organisation and MMP 
expression that can also be involved in the development of an invasive phenotype by 
tumour cells. -catenin is an intracellular attachment protein that can attach cytoplasmic 
actin bundles to cadherin transmembrane adhesion molecules at the site of cell-cell 
junctions. Since tumour cells detach from neighbouring cells in invasion abnormalities in 
the -catenin/E- cadherin complex are likely to be involved (Curran and Murray, 2000). 
-catenin and the DNA binding protein T Cell Factor 4/Transcription factor 4 (TCF4) 
also acts a transcriptional regulator of specific genes. Normally, the protein product of 
tumour suppressor gene adenomatous polyposis coli (APC) binds to cytoplasmic -
catenin and causes its degradation. In most colorectal cancers APC is mutated, so -
catenin accumulates and complexes with TCF which activates the transcription of target 
genes including cyclin D1 and c-myc. (Curran and Murray, 2000).  Brabletz et al, (1999) 
report that MMP-7 is also a target of -catenin/ TCF. Brooks et al, (1996) demonstrated 
that melanoma cells expressing integrin v3 had the ability to bind active MMP-2 
facilitating collagen degradation. Thus, a cell surface receptor known to be involved in 
directed cellular motility can also bind an enzyme that can degrade a major component of 
the basement membrane. Furthermore, the cell surface receptor determinant CD44 which 
is known to promote growth and metastasis of tumour cells, has been shown to associate 
with active MMP-9 at the cell surface of human melanoma cells (Yu and Stamenkovic, 
2000). Disruption of MMP-9/CD44 aggregates decreases the invasiveness of tumour cells 
in vivo. 
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1.4.2 Cytokines  
Cytokines also been shown to regulate MMPs. For example, interleukin –1 (IL-1) induces 
the transcription of MMP-1 and –3 (Borghaei et al, 1998). In a study by Bar-Eli, (1999) 
transfection of human melanoma cells with IL-8 increased the activity of MMP-2 and the 
invasiveness of the cells. 
 
Figure1.4.2B  Schematics Cytokines/MMPs connection (adoptedwww.sigmaaldrich.com) 
 
 
MMPs can also regulate cell growth, either directly through the release of growth factors 
or indirectly by changes in cell adhesion as described above. MMPs can degrade insulin-
like growth factor (IGF) binding protein 3, which regulates the bioavailability and activity 
of IFG-II (Fowlkes, 1994). Powell et al, (1999b) demonstrated that MMP-7 
proteolytically generates active soluble Fas ligand and potentiates epithelial cell 
apoptosis. These different effects of MMPs and their inhibitors depend on the balance 
between them in the local microenvironment. 
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1.4.3 Cathepsin B 
Increased cathepsin B expression, activity and changes in localisation have been observed 
in many different tumours including breast (Poole et al, 1978), colorectal (Campo et al, 
1994) and lung (Sukoh et al, 1994). Koblinski et al, (2000) studies demonstrates that the 
increased expression of cathepsin B at the mRNA level is associated with gene 
amplification, increased transcription, the possible use of multiple promoters and 
alternatively spliced transcripts. Changes in the localisation of cathepsin B seem to 
precede the increase in protein levels, which suggests that alterations in trafficking of 
cathepsin B are independent of increased expression. 
Proteases can interact leading to the activation of proteolytic cascades that can degrade 
ECM components. For example, Procathepsin B can be activated by cathepsin D, tPA, 
uPA, cathepsin G and elastases. Active cathepsin B in  turn activates pro-uPA, which 
converts plasminogen to plasmin, which can degrade several ECM components and 
activate MMP-1, -3, -9, -12 and –13. The MMPs can then degrade other ECM 
components e.g. collagen -I and -IV, gelatins and activate further MMPs (Koblinski et al, 
2000). Cathepsin B can activate MMPs indirectly via the plasminogen activator cascade 
and directly activate MMP-1 and –3. Thus, cathepsin B may be an important regulator of 
the activation of pro-uPA/ plasminogen and pro-MMPs.  
Both direct and indirect interactions between tumour and stromal cells can increase the 
expression of proteases. For example the expression of gelatinases A and B are increased 
in fibroblasts upon contact with tumour cells. These fibroblasts then partake in further 
degradation of the ECM. Expression of cathepsin B and D can also be regulated by 
diffusible factors such as basic fibroblast growth factor (bFGF), insulin growth factor-1 
(IGF-1) and epidermal growth factor (EGF). Paracrine factors secreted from tumour and 
stromal cells can thus regulate the expression of proteases (Koblinski et al, 2000). 
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1.4.4 Urokinase-type plasminogen activator 
 
Urokinase-type plasminogen activator (uPA) is a serine protease that is involved in the 
progression of cancer particularly in invasion and metastasis. Many studies of breast 
cancer patients whose primary cancers have high uPA levels have significantly poorer 
outcome than those with low uPA levels. Paradoxically, high levels of plasminogen 
activator inhibitor-1 (PAI-1) a uPA inhibitor, is also predictive of poorer patient outcome 
(Duffy, 2002). The human uPA gene encodes a 53kDa protein that is initially synthesised 
as a catalytically inactive single chain peptide. Conversion to active form is brought about 
by a number of proteases including plasmin, cathepsin-B and –L. uPA is a 
multifunctional protein involved in both proteolysis and signal transduction. As a protease 
uPA catalyses the conversion of plasminogen to active plasmin. Plasmin can then 
promote the degradation of ECM substrates that include fibrin, fibronectin and laminin. It 
can also activate MMPs and activate or release specific growth factors such as FGF-2 and 
TGF-. uPA-catalysed proteolysis occurs in vivo while the protease is attached to a 
membrane anchored protein receptor, uPAR (Andreasen et al, 1997). 
 
Binding of uPA to its receptor enhances proteolysis and also results in signal 
transduction, including activation of mitogen-activated protein kinase (MAPK), 
extracellular signal-regulated kinases 1 and 2 and other signalling pathways that activate 
Fos and Jun (Ossowski and Aguirre-Ghiso, 2000). uPA activity can be neutralised in vivo 
by two inhibitors called as plasminogen activator inhibitors 1 and 2 (PAI-1 and PAI-2), 
which belong to the serpin family of protease inhibitors and inhibit apoptosis. PAI-1 can 
also modulate adhesion and migration independently of its role as a protease inhibitor 
(Duffy, 2002). 
 
Andreasen et al, (1997) studies demonstrates a positive correlation between uPA levels 
and metastasis which have been found in both cell lines and animal tumours. Transfecting 
cell lines with uPA cDNA enhance the metastasis of the transfected cells. Inhibition of 
uPA activity or expression reduced metastasis in model systems. Blocking uPA:uPAR 
binding also decreases metastasis in systems studied. Tumours in uPA null mice exhibit 
less progression than those in mice expressing uPA. Since metastasis is the main cause of 
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death in cancer patients, and since uPA is an important mediator of this process, uPA is 
an ideal candidate for use as a marker to predict the likely formation of metastasis. 
Indeed, as a predictor of outcome for breast cancer patients, uPA acts as a potent 
biological marker. High levels of uPA are also correlated with poorer patient outcome in 
patients with stomach, colorectal, bladder, ovary, endometrium and brain cancers (Duffy, 
2002b) (Wohn, 1997).  
 
High levels of PAI-1 are also associated with aggressive disease and poorer patient 
outcome. Although the reason for this is not clear, there are many possible explanations. 
For example, a critical PAI-1 concentration may be needed to prevent excessive ECM 
degradation by uPA during cancer invasion, where excessive ECM degradation could 
leave insufficient substrate on which cancer cells could migrate. PAI-1 is also needed for 
angiogenesis to occur and can modulate both cell adhesion and migration and thus 
metastasis and can inhibit apoptosis; hence increased PAI-1 expression is a poor 
prognostic factor (Duffy, 2002; Duffy, 2002b). Both uPA and PAI-1 are possible targets 
for cancer therapeutics, specifically with applications in the prevention of metastases. 
 
1.4.5 Integrins and cancer 
 
Invasive cells undergo changes in integrin expression levels and integrin affinity for ECM 
substrates. Many studies have reported significant differences in the surface expression 
and distribution of integrins in malignant tumours when compared with pre-neoplastic 
tumours of the same type. For example, 53 integrin is strongly expressed at the 
invasive front of melanoma cells and angiogenic blood vessels, but weakly expressed on 
pre-neoplastic melanomas and blood vessels (Brooks et al, 1994). While the expression of 
some integrins is increased during tumuorigenesis, the expression of others decreases. 
Cells can also assume a more migratory and invasive phenotype by altering their adhesive 
and signalling profile by increasing the affinity of integrins for their ligand (Hood and 
Cheresh, 2002).  
 
The integrins, composed of  and  chain heterocomplexes, act as integral cell membrane 
receptors that form focal adhesion contacts with ECM ligands e.g. fibronectin, laminin, 
entactin, intercellular adhesion molecule (ICAM) and the collagens to name but a few. 
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Integrins also interact with cytoplasmic cytoskeletal filament-associated proteins e.g. 
actin, paxillin and talin. The family can form at least 25 distinct pairings of its 18  and 8 
 subunits, with each integrin consisting of a noncovalently linked - and -subunit. Each 
subunit has a large extracellular domain, a single membrane-spanning domain and a short, 
non-catalytic cytoplasmic tail (Mizejewski, 1999). In addition to regulating cell adhesion 
to the ECM, integrins relay molecular cues regarding the cellular environment that 
influence cell shape, proliferation, survival, migration and gene transcription.  
 
Derangement of integrin expression may be responsible for many aberrant cellular 
activities during tumour onset, progression and metastasis. As integrins form connections 
with the extracellular environment, they provide structural support. They also mediate 
intracellular signalling through the activation of focal adhesion kinase (Guo and 
Giancotti, 2004). It is not surprising that the native ECM of a normal cell is a requisite for 
survival. Indeed, removal of a cell from its supportive matrix can cause that cell to die, 
also called "anoikis" (Frisch and Ruoslahti, 1997) Recent work has demonstrated that 
expression of TrkB protein, a neurotrophic receptor, enables a cell to survive, avoiding 
anoikis, when it has been removed from its native matrix (Douma et al, 2004). This 
protein enables the tumor cell to retool its signaling machinery, stimulating the 
phosphatidylionolistol-3-OH and AKT/PKB kinases, leading to inhibition of caspases, 
key mediators of anoikis.  
In highly motile cells, initiation of migration is characterised by the reorganisation of 
actin to the cell edge, the protrusion of a leading lamellipodium and membrane ruffling at 
the advancing front of the lamellipodium. The RHO family of small GTPases can regulate 
these changes. Family members include RHO, CDC42 and RAC. RHO activation is 
dependent on integrins; syndecan-6 and other cell surface receptors, whereas RAC and 
CDC42 are activated by ligation of integrins (Ren et al, 1999). Activation of RHO leads 
to the formation of actin stress fibres and the assembly of focal adhesions. Activation of 
CDC42 is involved in the formation of filopodia and activation of RAC leads to 
membrane ruffling and cell migration (Hood and Cheresh, 2002). The expression of 
active RAC and CDC42 can depolarise differentiated mammary epithelial cells and 
induce integrin-mediated invasion through a 3D collagen matrix (Cotter et al, 1997). 
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During cell migration, the formation of new integrin contacts provides the cell with 
molecular signals that activate ERK signalling. Integrins regulate ERK activity through 
several FAK-dependent and independent pathways and also by modulating growth factor-
stimulated ERK activity. ERK activation influences gene transcription cell survival and 
cell motility (Hood and Cheresh, 2002). During cell migration, the ERK signal decreases 
integrin-mediated adhesion and phosphorylates myosin-light-chain kinase (MLCK), 
which regulates the contractile force within the cell. Klemke et al, (1997) studies show 
that MLCK phosphorylates and activates myosin II, an ATPase found in leading lamellae 
and posterior regions of motile cells that generate force by promoting translational 
movement along actin cables. Activated myosin then generates contractile forces that pull 
the cell forward towards the new integrin contacts and breaks the contacts at the trailing 
edge of the cell. Phosphatidylinositol 3-kinase (PI3K) regulates integrin dependent cell 
movement by modulating integrin responses in normal and neoplastic tissue. PI3K 
activity is needed for CDC42 and RAC-induced cell motility and invasiveness in 
mammary epithelial cells (Cotter et al, 1997). 
The Protein Kinase C (PKC) family of serine/threonine kinases are important in 
regulating integrin function and signalling. For instance, ligation of fibronectin by 
integrins and syndecan-4 recruits PKC to membrane adhesions where it is required for 
focal adhesion formation, phosphorylation of FAK, cell spreading, migration and SHC-
dependent ERK activation (Hood and Cheresh, 2002). 
 
1.5 Proteins with relevance to in vitro cancer cell invasion 
 
Previously in the lab to study the molecular nature of invasion, the gene-expression 
profiles of five lung cancer cell lines (DLKP) with differing levels of invasiveness (as 
determined by an in vitro invasion assay) were analysed using expression microarray 
methodology. A panel of lung cancer cell lines with various levels of invasiveness, two 
invasive, non-drug exposed, variants of the DLKP cell line were used in the study along 
with a non-invasive Vincristine-selected (VCR) cell line, an invasive Taxotere (TXT) 
resistant variant and a non-invasive TXT- selected cell line that had lost its resistance to 
TXT. Differential regulated gene lists were generated from the array data containing 
genes that may potentially serve as transcriptional signatures for invasiveness and/or drug 
resistance in these cell lines. These were IGF-1R, KCNJ8, S100A13, SFN, TFPI2 and 
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GLP1R. Among them we selected four gene targets which were differentially upregulated 
across drug variant invasive cell lines.  
 
1.5.1 Glucagon like Peptide 1 Receptor (GLP1R) 
 
The glucagon-like peptide 1 receptor (GLP1R) is found on chromosome 6 (Thorens, 
1992) (Dillon et al, 1993). The protein encoded by this gene is a member of the glucagon 
receptor family of G protein-coupled receptors (Brubaker and Drucker, 2002). GLP1R 
binds specifically the glucagon-like peptide-1 (GLP1) and has much lower affinity for 
related peptides such as the gastric inhibitory polypeptide and glucagon (Fehmann et al, 
1994). GLP1R is known to be expressed in pancreatic beta cells. Activated GLP1R 
stimulates the adenylyl cyclase pathway which results in increased insulin synthesis and 
release of insulin (Drucker et al, 1987), Consequently GLP1R has been suggested as a 
potential target for the treatment of diabetes (Newcomb et al, 2004). GLP1R is also 
expressed in the brain where it is involved in the control of appetite (Kinzig et al, 2002). 
Studies suggest that mice which over express GLP1R display improved memory and 
learning (During et al, 2003).  
 
 
1.5.2   Inwardly rectifying potassium channel J8 (KCNJ8) 
 
(Inagaki et al, 1995) identified a KATP channel, uKATP-1 (KCNJ8/Kir6.1), which 
represented a new subfamily of the inwardly rectifying K+ channel family. KCNJ8 is of 
particular interest as its role in cancer and invasion has not been previously reported in 
the literature. K+ channels are a diverse class of ion channels in the cytoplasmic 
membrane. Ion channels are pores in the cell membrane that allow the passage of specific 
ions. They are opened and closed by changes in membrane potential, ligand binding, 
intracellular calcium concentration and membrane tension (Laniado et al, 2001). There is 
accumulating evidence that various K+ channels in tumour cells play important roles in 
regulating tumour cell proliferation and apoptosis. There is also increasing interest in the 
potential implications of K+ channels as pharmacological targets for cancer therapy and 
for use as biomarkers to aid diagnosis (Wang, 2004). The potassium channels termed 
“inward rectifiers” of which KCNJ8 is included pass currents over a hyperpolarized 
voltage range. They have an important role in the maintenance of resting membrane 
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potential in many cell types. The gating of some inward rectifiers (including KCNJ8) is 
tightly regulated by intracellular ATP levels, thereby providing a link between cellular 
metabolism and membrane potential. 
 
1.5.3 Tissue Factor Pathway Inhibitor 2 (TFPI2) 
 
Human TFPI2 is a 32kDa serine protease inhibitor that is associated with the ECM. It has 
high homology to TFPI1, a regulator of the extrinsic blood coagulation pathway (Miyagi 
et al, 1994). TFPI2 inhibits the tissue factor VIIa complex and many serine proteases 
including trypsin and plasmin. However, it does not inhibit uPA and tPA (Petersen et al, 
1996). Many studies have demonstrated the down regulation of TFPI2 in the development 
of an invasive phenotype in cancer. For example, (Wojtukiewicz et al, 2003) used 
immunohistochemical procedures to examine TFPI2 expression in neoplastic cells of 
laryngeal, breast, gastric, colon, pancreatic, renal, endometrial cancer and in glial 
neoplasms. A higher staining intensity was observed in more differentiated tumours. This 
group also observed that TFPI2 expression decreased with increased malignancy. In a 
gene expression profile study of invasive cervical carcinomas versus normal cervical 
keratinocytes, TFPI2 expression was lower in the invasive carcinomas (Santin et al, 2005) 
 
1.5.4 S100 calcium binding protein A13 (S100A13) 
 
S100 proteins are small EF hand Ca2+ binding proteins of variable length and sequence. 
There are a number of functions associated with S100 proteins, many associated with 
tumour development. Wicki et al, (1996) identified a new S100 member termed S100A13 
by screening expresses sequence tags (EST) databases. The C-terminus of S100A13 
protein ends with the motif RKK, which is also seen in the metastasis-associated protein 
S100A4 and S100A10 (Kim and Helfman, 2003). The results described in Section 3.6 
describe a novel function for S100A13 in the modulation of an invasive phenotype. 
S100A13 has been demonstrated to be overexpressed in brain tumours in concert with 
FGF-1 (Landriscina et al, 2001) and has been proven to be essential in the regulation and 
release of pro-angiogenic molecules FGF-1 and IL-1 in a copper dependent manner 
(Mandinova et al, 2003). Smirnov et al, (2005) identified S100A13 as a novel predictor of 
metastasis following its detection in circulating tumour cells in blood. 
 23
1.6 DNA Recombination 
 
Recombination is an important phenomenon in genetic exchange. In living systems, 
recombination also plays an important role in the repair of mutations. Crossing over 
allows for a greater number of gene combinations than independent assortment. Gene 
conversion as a result of mismatch repair and recombination further increases the amount 
of change possible in the genome. 
1.6.1 Homologous recombination 
 
Homologous recombination is the exchange (“crossing over”) or replacement (“gene 
conversion”) of a DNA region by its homologous DNA sequence from the homologous 
chromosome or the sister chromatid (Fig. 1.12). Homologous recombination also 
occasionally occurs between similar DNA sequences on nonhomologous chromosomes or 
within a chromosome. A single gene conversion event changes one of the pair of 
homologous sequences without changing any other parts of the genome. 
1.6.2 How it works 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6.2A Schematics representing homologous recombination, involving gene 
conversion and/or crossover. 
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1.6.3 Holiday Model 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6.3A  The Holliday model of DNA crossover. I) Two homologous DNA 
molecules line up (e.g., two nonsister chromatids line up during meiosis). Cuts in one 
strand of both DNAs. The cut strands cross and join homologous strands, forming the 
Holliday structure (or Holliday junction). II) Heteroduplex region is formed by branch 
migration, Resolution of the Holliday structure. The vertical cut will result in crossover 
between f-f' and F-F' regions.  The Heteroduplex region will eventually be corrected by 
mismatch repair. III) A different view of the Holliday junction, DNA strands may be cut 
along either the vertical line or horizontal line.  
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Heteroduplex formation by the RecA/Rad51 family proteins involves homologous pairing 
and strand exchange. Homologous pairing is the formation of core heteroduplex joints by 
searching for homology between double-stranded DNA and single-stranded DNA, and 
strand exchange is the extension of the region of the heteroduplex. Although the ATP-
binding motifs of proteins of this family are conserved, some human Rad51 paralogues 
have been shown to promote in vitro homologous pairing in an ATP-independent manner 
(Kurumizaka et al, 2001). Furthermore the human Rad52 protein which has no homology 
to Rad51 and is required for various homologous recombinations, promotes an ATP-
independent homologous pairing (Kagawa et al, 2001).  
 
In bacteria, the ATP-independent homologous pairing proteins were identified as RecT 
(Noirot and Kolodner, 1998) and RecO (Luisi-DeLuca, 1995) and it was shown that the 
RecT-dependent homologous recombination of plasmid DNA in bacteria does not require 
RecA. E. coli phage lambda also has its own recombination machinery that functions 
independently of the RecA/Rad51 family proteins. Thus it can be postulated that 
homologous recombination in small genomes does not require ATP-dependent 
homologous pairing proteins such as RecA. Although the ATP-hydrolysis-dependent 
reaction of RecA stabilizes heteroduplexes through strand exchange when the 
homologous region is sufficiently large, the same reaction results in the dissociation of 
previously formed heteroduplexes if the homologous region is small (Shibata et al, 1982). 
This suggests that the ATP-dependent reaction prevents heteroduplex formation between 
nonallelic sequences. This corrective system may not be required for the recombination of 
small genomes such as those of viruses and plasmids, or may be harmful to such 
recombination that uses a small homologous region in eukaryotes. This knowledge about 
the natural processes by which genetic information evolves will enable us to develop new 
technology for breeding useful agricultural or industrial organisms and gene therapy. 
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1.6.4 Homologous Recombination as a Genetic Tool 
 
Homologous recombination is a reciprocal exchange of DNA sequences, as in between 
two chromosomes that carry the same genetic loci (Lewin et al, 2004). This process is 
conserved throughout evolution and was demonstrated in bacteria more than 50 years ago 
by the 1958 Nobel Laureate Joshua Lederberg.  The modification of an endogenous 
gene into a designed sequence by homologous recombination, termed gene targeting, has 
broad implications for basic and applied research (Terada et al, 2007). Mario R. 
Capecchi (Capecchi, 1989) Sir Martin J. Evans (Evans et al, 1997) and Oliver 
Smithies (Smithies et al, 1984) had the vision that homologous recombination could be 
used to specifically modify genes in mammalian cells and they worked consistently 
towards this goal. In 2007 they were awarded the prestigious Nobel Prize for their 
contribution in field of Medicine in particular "for their discoveries of principles for 
introducing specific gene modifications in mice by the use of embryonic stem cells". 
Homologous recombination has significantly contributed to genome engineering, because 
it is the basis of homologous gene targeting. For example, a deficient gene can be 
replaced with a functional copy in situ, without any modification elsewhere in the 
genome.  
 
1.7 Gene Targeting  
 
Many genes that participate in interesting canonical pathways are essential for key 
cellular phenotypes. Because gene targeting can be controlled both spatially and 
temporally, the function of a given gene can be studied in the desired cell types and at a 
specific time point. Non targeted random insertion of foreign gene into the genome 
invariably leads to large discrepancies in target expression, genomic instability, 
unpredictable phenotypes, which in turn complicates and prolongs the screening process 
for sub clones suitable for experimentation. Conditional gene modification using Cre-lox 
and Flp-Frt technology allows the gene of interest to be knocked-out in only a subset of 
tissues or only at a particular time circumventing lethality.  These genetic dissections 
facilitate researchers to evaluate gene function in development, physiology or behaviour.  
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1.7.1 FLP-FRT recombinase system 
 
The FLP-FRT recombinase system of yeast can be used to mobilize FRT-flanked donor 
DNA and generate re-integration at a different chromosomal location (Golic et al, 1997). 
The donor DNA is introduced into the recipient chromosome flanked by repeats of the 
FRT recombinase recognition site. The FLP recombinase is introduced under control of a  
promoter, the action of FLP recombinase results in excision of the donor DNA followed 
by a second round of recombination at a target site where another FRT site is present. The 
phenomenon can be observed by having the target FRT site at the locus of a known gene 
where an altered phenotype is detectable. This method is limited by the requirement of a 
target FRT site near a known gene. 
 
1.7.2 Cre-LoxP technology 
 
Cre-Lox recombination is a special type of site-specific recombination which was 
patented in the 1980s by DuPont. Although Prof. Brian Sauer is credited with the 
discovery of this system, many workers from diverse fields have found useful 
applications of this recombination system including gene knockout technology and the 
development of Bacteriophage P1 based vectors - PACs (P1 derived Artificial 
Chromosomes). Cre-LoxP recombination involves the targeting of a specific sequence of 
DNA and splicing it with the help of an enzyme called Cre recombinase. Using this 
technology, specific tissue types or cells of organisms can be genetically modified; whilst 
other tissue remains unchanged. The Cre gene encodes a site specific DNA recombinase 
which can recombine DNA when it locates specific sites in the DNA sequence. These 
sites are known as LoxP (locus of X-over P1)  sequences, which are 34 base pairs long, 
exists an asymmetric 8 bp sequence in between with two sets of palindromic, 13 bp 
sequences flanking it.  
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Figure 1.7.2A Cre-LoxP systems. The loxP site can be inserted on either side of a 
piece of DNA. If Cre recombinase is then expressed in the cell containing the LoxP sites 
insertion in the genome A) the loxP sites will be cut and joined together, removing the 
piece of DNA between the two sites if they are direct repeats. (B) Two loxP sites which 
are inserted on either side of a piece of DNA in opposite directions are cut and the piece 
of DNA inverted and reattached. 
 
 
 
 
 
 
 
 
 
Direct Repeats 
(Gene deletion) 
 
 
 
 
 
Inverted Repeats 
(Gene inversion) 
13bp 8bp 13bp
ATAACTTCGTATA - GCATACAT –TATACGAAGTTAT      LoxP sequence
www.scq.ubc.ca/wp-content/creLoxP.gif
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1.7.3 Vectors 
 
In molecular biology, a vector is any vehicle used to transfer foreign genetic material into 
another cell. The vector itself is generally a DNA sequence that consists of an insert 
(transgene) and a larger sequence that serves of the "backbone" of the vector. Expression 
vectors specifically are for the expression of the transgene in the target cell, and generally 
have a promoter sequence that drives expression of the transgene. Replication vectors can 
be replicated in a target cell but not expressed, unlike expression vectors. Transcription 
vectors are used to amplify their insert. Insertion of a vector into the target cell is 
generally called transfection, although insertion of a viral vector is often called 
transduction. Two common vectors are plasmids and viral vectors. 
 
The term plasmid was first introduced by the American molecular biologist Lederberg, 
(1998). A plasmid is an extra chromosomal DNA molecule separate from the 
chromosomal DNA and capable of sexual replication. In many cases, it is typically 
circular and double-stranded. It usually occurs naturally in bacteria, and is sometimes 
found in eukaryotic organisms (e.g., the 2-micrometre-ring in Saccharomyces cerevisiae). 
Plasmid size varies from 1 to over 200 kilo base pairs (Russell and Klaenhammer, 2001). 
The number of identical plasmids within a single cell can be zero, one, or even thousands 
under some circumstances. Plasmids can be considered to be part of the mobilome, since 
they are often associated with conjugation, a mechanism of horizontal gene transfer. 
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_____________________________________________________________________ 
Figure 1.7.3A Plasmid vector (www.microscopyu.com) 
Plasmids can be considered to be independent life-forms similar to viruses, since both are 
capable of autonomous replication in suitable (host) environments. However the plasmid-
host relationship tends to be more symbiotic than parasitic (although this can also occur 
for viruses, for example with Endoviruses), since plasmids can endow their hosts with 
useful packages of DNA to assist mutual survival in times of severe stress. For example, 
plasmids can convey antibiotic resistance to host bacteria, who may then survive along 
with their life-saving guests who are carried along into future host generations. 
Plasmid vectors minimalistically consist of an origin of replication that allows for semi-
independent replication of the plasmid in the host and also the transgene insert. Modern 
plasmids generally have many more features, notably including a "multiple cloning site" 
which includes nucleotide overhangs for insertion of an insert, and multiple restriction 
enzyme consensus sites to either side of the insert. In the case of plasmids utilized as 
transcription vectors, incubating bacteria with plasmids generates hundreds or thousands 
of copies of the vector within the bacteria in hours, and the vectors can be extracted from 
the bacteria, and the multiple cloning site can be restricted by restriction enzymes to 
excise the hundredfold or thousand fold amplified insert. These plasmid transcription 
vectors characteristically lack crucial sequences that code for polyadenylation sequences 
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and translation termination sequences in translated mRNAs, making expression of 
transcription vectors impossible. 
 
1.7.4 Insulators 
 
In recent years the concept of domain boundaries or insulator elements has developed, 
based on the genetic properties of several eukaryotic genes. These elements serve to 
isolate chromosomal regions, confining regulatory effects of enhancers to the genes they 
are meant to serve. The need for them arises where two adjacent genes on a chromosome 
have very different transcription patterns, and it is critical that the inducing or repressing 
mechanisms of one do not interfere with the neighbouring gene (Burgess-Beusse et al, 
2002). The chicken ß-globin insulator can inhibit activation of the gamma-globin gene 
promoter by the ß-globin locus control region. The Drosophila gypsy insulator functions 
similarly, conferring position-independent transcription to genes and preventing 
activation of promoters by enhancers separated from proximal promoters by insulator 
elements (Gdula et al, 1996). 
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1.7.4.1 Transcriptional regulator model 
 
 
 
 
 
 
 
 
 
 
 
   Buffering transgene from Chromosomal position effect  
 
 
 
 
                                                                          Annu. Rev. Genet. 2001.35:193-208. 
 
Figure 1.7.4.1A   Polar effect of an insulator on enhancer-promoter interactions.  
The DNA and a hypothetical gene with two exons and one intron are shown in yellow. 
En1 and En2 represent two different enhancers and their associated transcription factors 
bound to nucleosomal DNA. Prm is the promoter of the gene where the different 
components of the transcription complex are present. Ins is an insulator element with its 
associated proteins. Solid arrows indicate a positive activation of transcription by the 
enhancer element; an X on the arrows indicates the inability of the enhancer to activate 
transcription. (A) An insulator (Ins), with two associated proteins, located in the 50 
regions of the gene inhibits its transcriptional activation by an upstream enhancer (En1) 
without affecting the function of a second enhancer (En2) located in the intron of the 
gene. (B) When the insulator is located in the intron, expression from the downstream 
enhancer (En2) is blocked, whereas the upstream enhancer (En1) is active. (C) When the 
insulator is located in the intron but distal to the En2 enhancer, both enhancers are active 
and transcription of the gene is normal. This property distinguishes an insulator from a 
typical silencer. (D) If a second gene is located upstream of the En1 enhancer, although 
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this enhancer cannot act on the Prm1 promoter, it is still functional and able to activate 
transcription from the upstream Prm2 promoter. 
 
1.7.4.2   Insulators as buffering agent during repressive action from 
neighbouring gene 
 
 
 
 
 
 
 
 
                                                                              Annu. Rev. Genet. 2001.35:193-208. 
 
Figure 1.7.4.2A Insulator elements buffer gene expression from repressive effects of 
adjacent chromatin. Symbols are as in Figure 1. (A) A transgene (represented by the 
blue DNA) integrated in the chromosome in a region of condensed chromatin is not 
properly expressed; the repressive chromatin structure of the surrounding region 
presumably spreads into transgene sequences, inhibiting enhancer-promoter interactions. 
(B) If the transgene is flanked by insulator elements (in brown), these sequences inhibit 
the spreading of the repressive chromatin, allowing an open chromatin conformation and 
normal transcription of the gene. 
 
A study devised by Cai and Shen (2001) reveals a specialized chromatin structures (scs 
and scs') outside the coding sequence of the Drosophila hsp70 gene. These sequences are 
associated with chromatin structures and serve as boundaries that can prevent activation 
by enhancer elements. Insulators or chromatin boundaries are frequently found in 
multiple copies, flanking enhancers or the genetic locus they regulate, such as the scs and 
scs' elements, the Mcp-1 and Fab boundaries, and the chicken ß-globin 5' and 3' 
boundaries. Selective interactions between neighbouring insulators may regulate the 
access of tissue-specific enhancers to target promoters by forming alternative chromatin 
loop domains. It is conceivable that these domains not only block inappropriate enhancers 
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but also facilitate interaction between distant enhancers and the target promoter. The best 
characterised system is the gypsy chromatin insulator of Drosophila. Gypsy is an 
infectious retrovirus consisting of two long terminal repeat regions that function in viral 
replication and integration and three retroviral genes: gag, pol and env, coding for 
nucleocapsid, reverse transcriptase and envelope proteins respectively (Song et al, 1994). 
The gypsy insulator is located in the 5' transcribed untranslated region of the gypsy 
element. The unlinked gene, suppressor of Hairy-wing plays an essential role in 
functioning of the gypsy insulator. SU (HW) binds to the insulator element, interacting 
directly with an octamer motif present in the gypsy insulator. SU (HW) binds to 
approximately 200 other sites on Drosophila polytene chromosomes, possibly 
corresponding to endogenous insulators that play a role in the organization of the genome 
into higher order chromatin domains that allow for the normal regulation of gene 
expression.  
 
1.8  Micro RNA’s 
 
MicroRNAs (miRNAs) are small, non coding RNA molecules encoded in the eukaryotic 
genome which regulate gene expression at the translational level. They were first 
described in 1993 by Lee and colleagues in the Victor Ambros lab, yet the term 
microRNA was only introduced in 2001 in a set of three articles in Science (Ruvkun, 
2001). These highly conserved, ~21-mer RNAs regulate the expression of genes by 
binding to the 3'-untranslated regions (3'-UTR) of specific mRNAs. MiRNAs are encoded 
by genes that are transcribed from DNA but not translated into protein (non-coding 
RNA); instead they are processed from primary transcripts known as pri-miRNA to short 
stem-loop structures called pre-miRNA and finally to functional miRNA. Mature miRNA 
molecules are partially complementary to one or more messenger RNA (mRNA) 
molecules, and their main function is to down regulate gene expression. This effect was 
first described for the worm C. elegans in 1993 by Victor Ambros and co-workers (Lee et 
al, 1993). MiRNAs have been confirmed in various plants and animals, including C. 
elegans, human and the plant Arabidopsis thaliana. Genes have been found in bacteria 
that are similar in the sense that they control mRNA abundance or translation by binding 
an mRNA by base pairing, however they are not generally considered to be miRNAs 
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because the Dicer enzyme is not involved. In plants, similar RNA species termed short-
interfering RNAs siRNAs are used to prevent the transcription of viral RNA. While this 
siRNA is double-stranded, the mechanism seems to be closely related to that of miRNA, 
especially taking the hairpin structures into account. The siRNAs are also used to regulate 
cellular genes, as miRNAs do.  
 
Approximately 3% of genome encodes for miRNAs and roughly around 30% of human 
protein coding genes are regulated by miRNAs (Barbarotto et al, 2008). The miRNAs can 
have pleiotropic effects on cell proliferation, apoptosis, and cell differentiation. They are 
generally believed to act by binding to imperfectly complementary sequences in the 3' 
untranslated region of target genes, resulting in decreased translation or in the degradation 
of the target transcript in cells as a result leading to tumourous tissue formation, referred 
to as Oncomir (Bagga, 2005). Pairs of oncogenes and the corresponding miRNAs that 
attenuate their expression have been recently identified. These miRNAs, or "anti-
oncomirs," can act as natural inhibitors of oncogene function, indicating the possibility 
that they might be developed as novel therapeutics (Goga, 2007). Examples of oncogene–
anti-oncomir pairs include: RAS–let-7a; Regulation of RAS expression by let-7a is 
noteworthy because this oncogene–miRNA pairing has been conserved from C. elegans to 
humans, implying that oncogene–anti-oncomir pairs have co-evolved to regulate 
developmental programs (Johnson, 2005). BCL2–mir-15 and BCL2–mir-16 (Cimmino, 
2005). ERBB2/ERBB3–mir-125a/b; mir-125a and mir-125b can co-ordinately regulate 
ERBB2 and ERBB3, representing the first example of a single miRNA targeting two 
molecules in the same signalling cascade (Scott, 2007).   
 
The mir-17-92b cluster functions as both an oncomir and anti-oncomir. In addition to its 
ability to cooperate with MYC, mir-17-92b can negatively regulate the expression of E2F, 
a transcription factor required for cell-cycle progression (O'Donnell, 2005). Finally, 
although no specific miRNA has yet been identified that directly targets MYC oncogene 
expression, MYC is likely a target of regulation by anti-oncomirs because loss of Dicer 
enzyme results in increased MYC expression (Kumar, 2007).  Recent studies showed that 
the levels of the mir 17-92 cluster increased in lymphoma samples (He et al, 2005b). 
Also, the acceleration of tumor development was found to be increased in mice when c-
Myc expression was acting simultaneously with mir-17-92 cluster expression.  
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1.8.1 MicroRNAs processing and gene regulation 
 
Figure 1.8.1A Represents miRNA processing and gene regulation in animals (Slack 
et.al. 2006) 
 
1. Transcription 
 
MicroRNAs are initially expressed as part of transcripts termed primary miRNAs (pri-
miRNAs) (Lee et al, 2002). They are apparently transcribed by RNA Polymerase II, and 
include 5' caps and 3' poly (A) tails (Smalheiser, 2003); Cai et al, 2004). The miRNA 
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portion of the pri-miRNA transcript likely forms a hairpin with signals for dsRNA-
specific nuclease cleavage. 
 
2. Hairpin release in the nucleus 
 
The dsRNA-specific ribonuclease Drosha digests the pri-miRNA in the nucleus to release 
hairpin, precursor miRNA (pre-miRNA) (Lee et al, 2003). Pre-miRNAs appear to be 
approximately 70 nt RNAs with 1–4 nt 3' overhangs, 25–30 bp stems, and relatively small 
loops. Drosha also generates either the 5' or 3' end of the mature miRNA, depending on 
which strand of the pre-miRNA is selected by RISC (Lee et al, 2003; Yi et al, 2003).  
3. Export to the cytoplasm 
Exportin-5 (Exp5) seems to be responsible for export of pre-miRNAs from the nucleus to 
the cytoplasm. Exp5 has been shown to bind directly and specifically to correctly 
processed pre-miRNAs. It is required for miRNA biogenesis, with a probable role in 
coordination of nuclear and cytoplasmic processing steps. (Lund et al, 2004; Yi et al, 
2003). 
4. Dicer processing 
Dicer is a member of the RNase III superfamily of bidentate nucleases that has been 
implicated in RNA interference in nematodes, insect, and plants. Once in the cytoplasm, 
Dicer cleaves the pre-miRNA approximately 19 bp from the Drosha cut site (Lee 2003, 
Yi 2003). The resulting double-stranded RNA has 1–4 nt 3' overhangs at either end (Lund 
2003). Only one of the two strands is the mature miRNA; some mature miRNAs derive 
from the leading strand of the pri-miRNA transcript, and with other miRNAs the lagging 
strand is the mature miRNA. 
 
5. Strand selection by RISC 
To control the translation of target mRNAs, the double-stranded RNA produced by Dicer 
must strand separate, and the single-stranded mature miRNA must associate with the 
RISC (Hutvagner and Zamore, 2002). Selection of the active strand from the dsRNA 
appears to be based primarily on the stability of the termini of the two ends of the dsRNA 
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(Schwarz et al, 2003), (Khvorova et al, 2003). The strand with lower stability base pairing 
of the 2–4 nt at the 5' end of the duplex preferentially associates with RISC and thus 
becomes the active miRNA (Schwarz et al, 2003).  
 
In plants, gene regulation/silencing occurs via the RNA-mediated interference (RNAi) 
pathway, in which miRNAs bind with perfect complementarity to protein coding mRNA 
sequences. mRNA transcripts are then cleaved by ribonucleases in the miRNA-
associated, multiprotein RNA-induced-silencing complex (miRISC), which results in the 
degradation of target mRNAs (Chan and Slack, 2006). In animals, miRNAs exert their 
regulatory/silencing effects by binding to imperfect complementary sites within the 3’ 
untranslated regions (UTRs) of their mRNA targets. Here, they repress target-gene 
expression post-transcriptionally as well as degrading mRNA via RNA-induced silencing 
complex (RISC) (Esquela-Kerscher and Slack, 2006). 
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1.8.2 MicroRNA Bio-Arrays 
 
 
__________________________________________________________________ 
Figure 1.8.2A Overview of the mirVana™ miRNA Array System (source 
www.ambion.com) 
 
Ambion® mirVana™ miRNA Bioarrays Version 9.2 are high-quality microarrays with 
probes representing a comprehensive panel of human, mouse, and rat microRNAs. 
Version 9.2 of mirVana miRNA Bioarrays coincides with Version 9.2 of miRBase 
Sequence Database, which is curated by the Sanger Institute 
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(microrna.sanger.ac.uk/sequences). Version 9.2 also features probes to detect an exclusive 
set of 153 human miRNAs. Called Ambi-miRs, these novel miRNAs have been identified 
through a combination of bioinformatics prediction, cloning, and detection in human total 
RNA samples. 
 
Table 1.1 Version 9.2 Content for Ambion® mirVana™ miRNA Bioarrays 
 
 
Probe Sets Number 
Human 471 
Mouse* 380(221) 
Rat** 238(41) 
Ambi-miRs™ 153 
Controls*** 22 
Total 908 
       (Source www.ambion.com) 
_____________________________________________________________________ 
*   Unique probes those are not human. 
** Unique probes that are not human or mouse. 
*** The positive control provided with the Ambion® mirVana™ miRNA Labelling Kit is 
complementary to multiple control probe spots on the Ambion mirVana miRNA 
Bioarray, which allow for alignment of the array for scanning. 
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1.8.3 MiRNA detection  
                              
_____________________________________________________________________                                 
Figure 1.8.3A  A represents pre-miRNA and matured miRNA after Dicer 
processing. Figure B shows schematics of TaqMan based MicroRNA assays, the 
advantages of stem-loop primer: (I) specificity for only mature miRNA target, and 
(II) formation of a RT primer/mature miRNA–chimera, extending the 5' end of the 
miRNA. The resulting longer RT amplicon presents a template amenable to 
standard real-time PCR, using TaqMan assays. 
(Source www.ambion.com) 
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. 
1.8.4 MicroRNAs as tumour suppressors and Oncomir 
 
 
Figure 1.8.4A Schematic of roles of miRNA (http://rogermallak.tripod.com).   
 
a) MiRNA biogenesis in normal tissues, as a result of normal rates of cellular growth, 
proliferation, differentiation and cell death, b) microRNAs as tumor suppressors, a defect 
in miRNA biogenesis represented in fig b as (?) at different levels, as a result 
inappropriate expression of miRNA target- oncoproteins, c) As oncogene, increased 
amounts of a miRNA, which might be produced at inappropriate times or in the wrong 
tissues, would eliminate the expression of a miRNA-target tumor-suppressor gene and 
lead to cancer progression (Slack et.al. 2006). 
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Studies reveal possible links between miRNAs and viral disease, neurodevelopment, and 
cancer. MiRNA expression in brain development (Krichevsky et al, 2003), chronic 
lymphocytic leukemia (Calin et al, 2004a), colonic adenocarcinoma (Michael et al, 2003), 
Burkitt’s lymphoma (Metzler et al, 2004), and viral infection (Pfeffer et al, 2004). Lately 
miRNAs had been shown to act as both tumour suppressors and oncogenes. More than 
50% of miRNA genes have been found localised in cancer-associated genomic regions or 
in fragile sites (Calin et al, 2004b). Expression profiling methods were developed to 
analyse 217 mammalian miRNAs from a panel of 200 human cancers. Results showed an 
overall reduction in expression of miRNAs in cancer compared to normal samples. This 
indicates that miRNAs act predominately as tumour suppressors (Yang et al, 2005). 
However, a cluster of miRNAs, miR-17 ~ 92, is overexpressed is some lymphoma and 
solid tumours. Ectopic expression of these miRNAs in a mouse model of Burkitt’s 
lymphoma led to accelerated and disseminated disease (He et al, 2005a) 
 
A study was carried out in 2004 in which Chronic Lymphocytic Leukemia (CCL) 
samples were analysed to investigate the involvement of miRNA in cancer. They 
obtained 41 tissue samples from CLL patients. The results they found suggested that 
miRNA played important roles in the pathogenesis of human CLL (Calin et al, 2004b). 
They observed that when both pre-miRNA and mature miRNA were dysregulated (such 
as miR-123, miR-132, or miR-136), the same type of variation in CLL samples were 
observed in normal samples. They found that upon deletion of the 13q14 chromosome, 
miRNAs (miR-24-2, miR-195, miR-203, miR-220, and miR-221) are reduced as well as 
other miRNAs (miR-7-1, miR-19a, miR-136, miR-154, miR-217, precursor miR-218-2) 
which were significantly increased (Calin et al, 2004b). This indicates that deletion or 
down-regulation of miRNAs is associated with human tumours. They also reinforced that 
a large portion of miRNAs are encoded at fragile sites, suggesting that miRNA had an 
important role in the pathogenesis of human cancer (Calin et al, 2004b). 
  
 
In 2005, the affect of c-Myc on the regulation of miRNA expression was studied by 
(Mendell, 2005). The c-Myc is a helix-loop-helix leucine zipper transcription factor 
which regulates cell proliferation, growth and apoptosis. They found with Chromatin 
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immunoprecipitation experiments that c-Myc activates expression of six miRNAs 
grouped together on human chromosome 13. Mendell et al, (2005) also discovered that 
the transcription factor E2F1 is down-regulated by two miRNAs (miR-17-5p and 
miR20a) located in the activated group of miRNAs. E2F1 promotes cell cycle progression 
and is also targeted by c-Myc. Therefore, c-Myc simultaneously  
Up-regulates and down-regulates E2F1 translation causing a proliferation signal 
(Mendell et al, 2005). 
 
 
The emergence of miRNAs as potential cancer interventions is likely to have a large 
effect on gene therapies that are designed to block tumor progression.  Large-scale 
expression screens, to compare miRNA levels in tumors versus normal tissues, will be 
useful in identifying novel miRNAs that are involved in cancer. Also, functional screens 
that are designed to select miRNA genes that specifically control cancer-related 
processes, such as cell proliferation and apoptosis, will also help in this search. 
 
 
 
 
1.9 MicroRNAs and Proteomics  
 
1.9.1 Proteomics Background 
 
 Proteomics includes not only the identification of proteins but also the determination of 
their locations, modifications, interactions, activities and ultimately their functions. 
Proteomics is regarded as the sister technology to genomics (Scott et al, 2000) 
complementing the knowledge derived from genomic analysis. The ultimate goals of 
proteomics go beyond a catalogue of proteins expressed by healthy and diseased cells. 
The eventual objective is to elucidate the organisation and dynamics of the metabolic, 
signalling and regulatory networks through which the life of the cell is transacted. Cancer 
proteomics seeks to understand how networks become dysfunctional, predict how their 
function can be manipulated through interventions by drugs or genetic manipulations 
(Anderson et al, 2001) and enables the identification of disease-specific proteins, drug 
targets and markers of drug efficacy and toxicity. Furthermore, cancer proteomics seeks 
to identify markers to improve diagnosis, classification of tumours and also to define 
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targets for more effective therapeutic measures (Simpson and Dorow, 2001). Given the 
late stage at which cancers often present, the identification of early detection biomarkers 
by proteomic analysis will offer better prognosis and aid in individualizing treatments for 
certain cancers.    
 
The first proteomic study of lung cancer was published in 2002 and in contrast, several 
dozen microarray studies of lung cancer have been published since 1999. Proteomics 
analysis attempts to identify the protein complement expressed by the genome (Pedersen 
et al, 2003) and is the systematic separation, identification and characterisation of proteins 
present in a biological sample (Scott et al, 2000).  Validation of changes in gene 
expression at the protein level would improve many of these studies, because changes in 
protein expression provide a more functional readout. Although evaluating protein 
expression may not be necessary to develop fingerprints for diagnostic use, it is necessary 
if markers that are identified by this method are to be used in their own right as diagnostic 
markers or as targets for therapy. Thus, despite the fact that many genes were identified as 
potential biomarkers, all of them require further validation. Even though proteomics 
provides a more functional approach than genomics, proteomics alone might provide an 
insufficient readout because post-translational modifications such as phosphorylation 
control the stability and function of many proteins. The development of sophisticated 
proteomic techniques such as phospho-proteomics will add another level of complexity to 
these systematic analyses (Blagoev and Pandey, 2001). 
 
 
1.9.2    Impact of Advanced Proteomics on MiRomics  
 
Analysis of the proteome has added layers of complexity compared to the genome. A 
simple gene can encode multiple different proteins by alternative splicing of the mRNA 
transcript, by varying translation start or stop sites, by frameshifting during which a 
different set of triplet codons in the mRNA is translated or by posttranslational 
modifications (Anderson and Seilhamer, 1997). A single protein may be multifunctional 
and conversely similar functions may be performed by different proteins (Fields, 2001).  
The result is a proteome estimated to be an order of magnitude more complex than the 
genome. The fact that miRNAs can cause degradation of their targets has been widely 
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exploited to identify such targets through microarray analysis. However, targets that are 
not susceptible to degradation would be missed. Vinther et al, (2006) showed with a 
method known as SILAC (stable-isotope labeling by amino acids in cultured cells), it is 
possible to label proteins during translation through incorporation of “heavy” amino 
acids. Proteomes from cells grown in the presence of different labels, exposed to different 
experimental manipulations, can be compared side by side with the analyzed peptides 
showing up as distinct peaks in the mass spectrometer. A new approach by Selbach et al, 
(2008) and co-workers used a particular implementation of SILAC termed pulsed SILAC 
(pSILAC). In this approach, labeling is restricted to newly synthesized proteins, 
permitting the determination of protein synthesis rates and providing high sensitivity. In 
contrast, conventional SILAC quantifies changes in protein concentrations, which 
respond to additional factors including intrinsic protein half-lives and regulated turnover. 
However, assuming that the total concentration of a protein rather than its current rate of 
synthesis determines biological outcomes, changes identified by SILAC might be equally 
relevant, such that SILAC and pSILAC should be viewed as complementary approaches 
(Großhans H. 2008). 
 
A recent study by Iliopoulos D. et al, (2008) involving microRNA profiling of patient-
derived osteoarthritic cartilage in comparison to normal cartilage, revealed a 16 
microRNA osteoarthritis gene signature. Using reverse-phase protein arrays in the same 
tissues they were able to detected 76 differentially expressed proteins between 
osteoarthritic and normal chondrocytes. Reverse phase protein microarray technology 
offer a new opportunity to measure and profile signaling pathways, providing data on 
post-translational phosphorylation events not obtainable by gene microarray analysis. 
Proteins such as SOX11, FGF23, KLF6, WWOX and GDF15 not implicated previously 
in the genesis of osteoarthritis were identified. Iliopoulos D group were able to identify  
potential "interactome" network consisting of 11 microRNAs and 58 proteins linked by 
414 potential functional associations by integrating microRNAs and proteomic data with 
microRNAs gene-target prediction algorithms. Such comparison of the molecular and 
clinical data, revealed specific microRNAs (miR-22, miR-103) and proteins (PPARA, 
BMP7, IL1B) to be highly correlated with Body Mass Index (BMI). Further experimental 
validation revealed that miR-22 regulated PPARA and BMP7 expression and its 
inhibition blocked inflammatory and catabolic changes in osteoarthritic chondrocytes 
(Iliopoulos D. et al, 2008).  
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As alternatives to SILAC there exists iTRAQ (isobaric tag for relative and absolute 
quantitation) is a non-gel based technique used to identify and quantify proteins from 
different sources in one single experiment. It uses isotope coded covalent tags. iTRAQ is 
used in proteomics to study quantitative changes in the proteome (Aggarwal K et al, 
2006). Shadforth IP et al, (2005) evaluated the advantage of iTRAQ over SILAC and 
metabolic labelling which is more robust and high throughput which can analyse four 
samples simultaneously, thereby reducing the amount of mass spectrometry time needed 
for analysis. In addition, the b- and y- ions derived from peptides labelled with the four 
iTRAQ tags are indistinguishable, resulting in higher MSMS intensity and therefore more 
confident peptide identifications in comparison to SILAC and metabolic labelling, in 
which the MSMS spectra for the differentially labelled peptides are acquired 
independently. The marriage of miRomics and proteomics might help delineating the 
spectrum of targets that are regulated by miRNAs. New knowledge about the functional 
roles of oncomiRs is revolutionizing cancer biology and will open up new opportunities 
in biomedical research (William CS Cho, 2007). 
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1.15 Aims of Thesis 
 
The research work carried out in this thesis can be divided into two main sections, 
 
a) Development of genetic tools for stable, targetable transgene 
overexpression 
 
Major complicating factors with in vitro transgene integration and exogenous gene 
expression in mammalian cells include instability and inconsistency due to 
chromosomal position effects and/ or copy number variation between different clones. 
To address this variation we set out to design and construct two different Cre-LoxP 
based mammalian expression plasmid vectors to generate targetable cell lines. We 
planned to modify these for random insertion of LoxP sites and LINE-1 site-specific 
insertion of LoxP sites in a model lung cancer cell line (DLKP) using the following 
strategies: 
 
 Random insertion of a targeting site with a plasmid vector carrying a 
reporter fusion gene Geo (GFP+Neo) flanked by LoxP sites, followed by 
selection of stable GFP positive and neomycin resistant DLKP clones. 
 
 Use of LINE-1 elements as targeting arms for homologous recombination. 
The rationale behind using LINE-1 elements was a) they constitute 17-
20% of the genome which should make them easily available targets and 
b) using human L1 element as target would help avoid targeting and 
disrupting endogenous functional genes.  
 
 To address stability issues with transgene overexpressing cell lines, we 
planned to subject the GFP positive DLKP clones to selection and multiple 
passaging with freeze thaw cycles while monitoring GFP expression, in 
order to identify stable clones. 
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b) Investigation of the role of differential expression of a group of genes  
 including microRNAs, in cancer invasion.  
 
 Based on existing microarray data from our laboratory and qRT-PCR analysis 
to stably overexpress four genes (invasion related) KCNJ8, TFPI2, S100A13 
and GLP1R in the targetable DLKP cell lines as a proof-of-concept of their 
utility.  
 
 To investigate roles of miRNAs in cancer invasion in DLKP Vs DLKPA cell 
lines, as well as to identify possible invasion and proliferation related targets 
through comprehensive proteomic profiling studies and  to investigate further 
roles of these proteins using siRNA knockdown. 
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2.0 Materials and Methods 
 
 
2.1. Water 
 
Ultra pure water was used in the preparation of all media and solutions. This water 
was purified by a reverse osmosis system (Millipore Milli-RO 10 Plus, Elgastat UHP) 
to a standard of 12-18M/cm resistance. 
 
2.2. Glassware 
 
Solutions pertaining to all cell culture and maintenance were prepared ad stored in 
sterile glass bottles. Bottles and lids and all other glassware used for any cell related 
work were prepared as follows: - all glassware lids were soaked in a 2% (v/v) solution 
of RBS-25 (AGB Scientific) for at least 1 hour. Following scrubbing and several 
rinses in tap water, the bottles were then washed by machine using Neodisher 
detergent, an organic, phosphate-based acid detergent. The bottles were then washed 
with distilled water, followed by a rinse with ultrapure water and were sterilised by 
autoclaving. 
 
2.3. Sterilisation 
 
Water, glassware and all thermostable solutions were sterilised by autoclaving at 
121oC for 20 minutes (min) under a pressure of 1bar. Thermolabile solutions were 
filtered through a 0.22m sterile filter (Millipore, millex-gv, SLGV-025BS). Low 
protein-binding filters were used for all protein containing solutions.  
 
2.4. Media Preparation 
 
Medium was routinely prepared and sterility checked by Joe Carey (lab technician). 
The basal media used during routine cell culture were prepared according to 
formulations shown in Table 2.1 10x media were added to sterile ultrapure water, 
buffered with HEPES and NaHCO3 and adjusted to a pH of 7.45-7.55 using sterile 
1.5M NaOH and 1.5M HCl. The media were then filtered through sterile 0.22m bell 
 51
filters (Gelman, 121-58) and stored in 500ml sterile bottles at 4oC. Sterility checks 
were carried out on each 500ml bottle of medium as described in section 2.6.4 The 
basal media were stored at 4oC up to their expiry dates as specified on each individual 
10x medium container. Prior to use, 100ml aliquots were supplemented with 5% 
foetal calf serum (BATCH #) and this was used as routine culture medium. This was 
stored for up to 2 weeks at 4oC, after which time, fresh culture media was prepared. 
For all DLKP cell lines ATCC (Hams F12/DMEM (1:1) supplemented with 5% FCS 
was routinely used. For the RPMI cell lines, Minimum Essential Medium (MEM) 
supplemented with 5% FCS, 1% Sodium pyruvate, 1% Non essential amino acids 
(NEAA) and 1% L-glutamine was used. 
 
Table 2.1 Preparation of basal media 
 
 
 DMEM (Dulbecco's 
Modified Eagle Medium) 
(mls) 
(Sigma, D-5648) 
Hams F12 (mls) 
(Sigma, N-6760) 
10X Medium 500 Powder 
Ultrapure H2O (UHP) 4300 4700 
1M HEPES1 100 100 
7.5% NaHCO3 45 45 
 
1 The weight equivalent of 1M N- (2-Hydroxyethyl) piperazine-N'- (2-ethanesulfonic 
acid) (HEPES) was dissolved in an 80% volume of ultra-pure water and autoclaved. 
The pH was adjusted to 7.5 with 5M NaOH. 
 
 
2.5 Cell Culture 
 
All cell work was carried out in a class II down-flow re-circulating laminar flow 
cabinet (Nuaire Biological Cabinet) and any work that involved toxic compounds was 
carried out in a cytoguard (Gelman). Strict aseptic technique was adhered to at all 
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times. The laminar flow cabinet was swabbed with 70% industrial methylated spirits 
(IMS) before and after use, as were all items used in the cabinet. Each cell line was  
assigned specific media and waste bottles. Only one cell line was worked with at a 
time in the cabinet, which was allowed to clear for 15min between different cell lines. 
The cabinet itself was cleaned each week with industrial detergents (Virkon, Antec 
International; TEGO, TH. Goldschmidt Ltd.), as were the incubators. The cell lines 
used during the course of this study, their sources and their basal media requirements 
are listed in Table 2.2 Lines were maintained in 25cm2 flasks (Costar; 3050), 75cm2 
(Costar; 3075) or 175cm2 flasks (Corning, 431079) at 37oC and fed every two to three 
days.  
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Table 2.2 Cell lines used in this study    
 
Cell Line Cell type Basal Media Source FCS (%)
DLKP Poorly differentiated squamous cell lung carcinoma ATCC** NICB* 5
DLKPA Adriamycin resistant variant of DLKP ATCC** NICB* 5
DLKP-17 Targetable Clonal subpopulation of  DLKP with LoxP site ATCC** NICB* 5
DLKP-11 Targetable Clonal subpopulation of  DLKP with LoxP site ATCC** NICB* 5
DLKP-17-GLP1R GLP1R transfected DLKP 17 clone ATCC** NICB* 5
DLKP-17-KCNJ8 KCNJ8 transfected DLKP 17 clone ATCC** NICB* 5
DLKP-17-TFPI2 TFPI2 transfected DLKP 17 clone ATCC** NICB* 5
DLKP-17-S100A13 S100A13 transfected DLKP 17 clone ATCC** NICB* 5
DLKP-11-GLP1R GLP1R transfected  DLKP 11 clone ATCC** NICB* 5
DLKP-11-KCNJ8 KCNJ8 transfected  DLKP 11 clone ATCC** NICB* 5
DLKP-11-TFPI2 TFPI2 transfected  DLKP 11 clone ATCC** NICB* 5
DLKP-11-S100A13 S100A13 transfected  DLKP 11 clone ATCC** NICB* 5
DLKPA-mir29a-1 hsa-mir-29a transfected  DLKP A clone 1 ATCC** NICB* 5
DLKPA-mir29a-3 hsa-mir-29a transfected  DLKP A clone 3 ATCC** NICB* 5
DLKPA-mir29a-4 hsa-mir-29a transfected  DLKP A clone 4 ATCC** NICB* 5
DLKPA-mir29a-11 hsa-mir-29a transfected  DLKP A clone 11 ATCC** NICB* 5
DLKPA-mir-negative control Mir-negative control transfected  DLKP A ATCC** NICB* 5
MCF-7 Human Breast adenocarcinoma DMEM**** ATCC*** 10
PANC-1 Pancreatic Ductal carcinoma DMEM**** ATCC*** 5  
 
 
*          NICB, National Institute for Cellular Biotechnology, Dublin, Ireland 
**        ATCC Basal media consists of a 1:1 mixture of DMEM and Hams F12. 
***      ATCC, American Type Culture Collection, Rockville, MD, USA 
****    DMEM, Dulbecco’s Modified Eagles Medium 
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2.6 Subculture of Adherent Lines 
 
During routine sub culturing or harvesting of adherent lines, cells were removed from 
their flasks by enzymatic detachment. Waste medium was removed from the flasks 
and the cells were rinsed with a pre-warmed (to 37oC) trypsin/EDTA (TV) solution 
(0.25% trypsin (Gibco, 5090-028), 0.01% EDTA (Sigma, EDS) solution in PBS A 
(Oxoid BR14a)). The purpose of this was to remove any naturally occurring trypsin 
inhibitor that could be present in the residual serum. Fresh TV was then placed on the 
cells (2ml/25cm2 flask, 4ml/75cm2 flask) and the flask incubated at 37oC until the 
cells were seen to have detached (5-10min). The trypsin was then deactivated by 
addition of an equal volume of complete (i.e. containing 5% FCS) growth medium. 
The entire solution was transferred to a 30ml sterile universal tube (Sterilin; 128a) and 
centrifuged at 1,000rpm for 5 min. The resulting cell pellet was resuspended in pre-
warmed fresh complete growth medium, counted (Section 2.6.1) and used to re-seed a 
flask at the required cell density or to set up an assay. 
  
2.6.1 Cell Counting 
 
Cell counting and viability determinations were carried out using a trypan blue 
(Gibco, 15250-012) dye exclusion technique. An aliquot of trypan blue was added to a 
sample from a single cell suspension in a ratio of 1:5. After 3 min incubation at room 
temperature, a sample of this mixture was applied to the chamber of a 
haemocytometer over which a glass coverslip had been placed. Cells in the 16 squares 
of the four outer corner grids of the chamber were counted microscopically; an 
average per corner grid was calculated with the dilution factor being taken into 
account, and final cell numbers were multiplied by 104 to determine the number of 
cells per ml. The volume occupied by the chamber is 0.1cm x 0.1cm x 0.1cm i.e. 
0.0001cm3. Therefore cell number x 104 is equivalent to cells per ml. Non-viable cells 
were those that stained blue while viable cells excluded the trypan blue dye and 
remained unstained.  
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2.6.2 Cell Freezing 
 
To allow long-term storage of cell stocks, cells were frozen and cryo-preserved in 
liquid nitrogen at temperatures below –180oC. Once frozen properly, such stocks 
should survive indefinitely. Cells to be frozen were harvested in the log phase of 
growth (i.e. actively growing and approximately 60-70% confluent) and counted as 
described in Section 2.6.1. Pelleted cells were resuspended in serum. An equal 
volume of a DMSO/serum (1:9, v/v) was slowly added drop wise to the cell 
suspension to give a final concentration of at least 5x106 cells/ml. This step was very 
important, as DMSO is toxic to cells. When added slowly the cells had a period of 
time to adapt to the presence of the DMSO, otherwise cell lysis can occur. The 
suspension was then aliquoted in cryovials (Greiner, 122278), which were then 
quickly placed in the vapour phase of liquid nitrogen containers (approximately –
80oC). After 2.5 to 3.5 hours, the cryovials were lowered down into the liquid 
nitrogen where they were stored until required. 
 
2.6.3 Cell Thawing 
 
Immediately prior to the removal of a cryovial from the liquid nitrogen stores for 
thawing, a sterile universal tube containing pre-warmed complete growth medium was 
prepared for the rapid transfer and dilution of thawed cells to reduce their exposure 
time to DMSO freezing solution which is toxic at room temperature. The suspension 
was centrifuged at 1,000rpm for 5 min, the DMSO-containing supernatant removed 
and the pellet resuspended in fresh growth medium. Cell count was carried out 
(Section 2.6.1) to determine the efficiency of the freezing/thawing procedures. 
Thawed cells were placed into tissue culture flasks with an appropriate volume of 
medium (5ml/25cm2 flask and 10ml/75cm2 flask) and allowed to attach overnight. 
After 24 hours, the cells were re-fed with fresh medium to remove any residual traces 
of DMSO. 
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2.6.4 Sterility Checks 
 
Sterility checks were routinely carried out on all media, supplements and trypsin used 
for cell culture. Samples of basal media were inoculated into Columbia (Oxoid, 
CM331) blood agar plates, Sabauraud (Oxoid, CM217) dextrose and Thioglcollate 
(Oxoid, CM173) broths, which detect most contaminants including bacteria, fungus 
and yeast. Complete growth media were sterility checked at least two days prior to use 
by incubating samples at 37oC, which were subsequently examined for turbidity and 
other indications of contamination. 
 
 
2.7   Specialised Techniques in Cell Culture 
 
2.7.1 Isolation of  sub-population of cell lines by limited dilution 
single cell cloning 
 
To obtain single cell clones the cell lines were plated in 96 well plates, the 
plate was divided into two sections of 6 columns each so that two sets of 
cloning can be done in a single plate 
a) The initial concentration of 1000 cells per ml was obtained as described in 
(section 2.6.1)  
b) Wells in first columns of two sets in 96 well plates were seeded with 125l 
of media with cells (125 cells per well). 
c) The adjacent wells were pipetted with 100l normal media without cells 
d) With a multichannel pipette 25l of cell suspension from the first column 
was pipetted out and seeded into adjacent wells in the second column, and 
from second column to the third, and so on in a serial manner. 
e) This technique resulted in one cell per well, with a  minimum of 12-15 
single cells per plate. 
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2.7.2 X-Gal staining  of DLKP cells grown in monolayer 
  
This method is used for the detection of β-galactosidase on formalin-fixed, monolayer 
cells, for cells in 6 well plates: 
a) Cells washed twice with 3ml cold 1X PBS and aspirated 
b) 5ml ice cold  0.5%  glutaraldehyde ( made in 1X PBS) was added on to cells 
c) Incubated 5 minutes at room temperature and then aspirated 
d) washed twice with  cold 1X PBS and aspirated 
e) X-gal staining solution (table 2.3 ) added (approx. 1.5ml ) and incubated at 370C 
f) the staining evaluated  after 24 hrs. 
 
Tabe 2.3 X-gal staining solution preparation for 30ml  
Components Requirements 
1M MgCl2 39l 
5M NaCl 90l 
0.5M HEPES, pH 7.3 2.64ml 
30mM potassium ferricyanide 3ml 
30mM potassium ferrocyanide 3ml 
2% X-gal(dissolved in DMSO) 750l 
Distilled water To 30ml 
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2.7.3 Assessing GFP stable overexpresssion using Guava EasyCyte 
            flowcytometer 
 
Guava EasyCyte system was used for cell cycle monitoring as well for GFP stable 
overexpression screening. Stable GFP overexpressing cell lines were trypsinised from 
24 well plates and resuspended by diluting 1:6 (50l cell suspension, 300l final 
volume). Initial system check was performed with manufacturer provided control to 
avoid any flaw in the flow. So according to manufacturer recommendations 1/20th 
dilution of control beads was prepared and monitored for bead flow, and ensured that 
there is no block in the system. The samples in 96 well U-bottom plates were placed 
in the plate holder, the cell flow was adjusted for ~ 200cells/l. Forward scatter gating 
as well as % fluorescence (log ) gating  were fixed at 600volts . The data acquired was 
based on these settings and always maintained for the entire experiments. 
 
2.7.4 Cell Cycle analysis using Guava EasyCyte flowcytometer 
 
The Guava® Cell Cycle Assay was used for measuring G0/G1, S, and G2/M phase 
distributions. Whole-cell staining was prepared with propidium iodide (PI). The guava 
cell cycle software was set for assessment of G0/G1, S, and G2/M phase cell cycle 
percentages. The cells were seeded in multiple wells for time point based data 
acquisition. The cells were serum starved 24 hrs before the experiment to synchronize 
the majority of cells at a similar cell cycle stage. After 24 hrs cells were fed media 
with serum and samples collected at time points 0, 2, 4, 8, 12, 16, 24, 32 hrs. The cells 
were processed with cell cycle assay kit (Catalogue No. 4500-0220, 100 tests) and 
data acquired on a Guava EasyCyte flow-cytometer. 
 
Culturing and harvesting adherent cells in 24-well tissue culture plates 
 
1. Cell concentration seeded at 2x103 cells in 2 mL of medium to each well of a 24-
well cell culture plate. 
2. Incubated the cells at 37°C to allow the cells to attach to the plate and to grow to 
60-80% confluency before proceeding. 
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• Cells were first synchronized in G0 by culturing cells for 24hrs in basal medium 
without serum. 
3. 24 hrs later cells were supplemented with serum media and from then every 0, 2, 4,  
 8, 12,16,24,32 hrs cells were harvested  
4. Harvest the cells from the 24-well plates (Section 2.6) 
 
Cell Fixation 
 
A. Cell fixation in a 96-well plate 
1. Cell samples were transferred from the 24-well plate to a 96-well round bottom 
plate if the cells are not already in a round bottom plate. 
 
2. Centrifuged cells at 450 x g for 5 minutes with the brake on low and at room 
temperature. 
 
3.  Discarded the supernatant and care taken not to touch the pellet. 
 
4.  200 µL of 1X PBS added to each well using a multi-channel pipettor. 
 
5. Cells in the well mixed by pipetting up-and-down several times. 
 
6. Centrifuged the cells in the round bottom plate at 450 x g for 5 minutes with the 
brake on low and at room temperature. 
 
7. Discarded the supernatant. 
 
8. Using a multi-channel pipettor, thoroughly resuspended the cells by repeat pipetting 
in the residual PBS, pipetting up and down several times. 
 
9. Placed the round bottom plate containing the resuspended cells on a lab shaker. 
 
10. 200 µL of ice-cold 70% ethanol added dropwise into the wells while shaking 
at low speed (speed 3). 
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11. Sealed the plate with a microplate sealer and refrigerate cells for at least one and 
up to 12 hours prior to staining. Fixed cells are stable for several weeks at 4°C and for 
two to three months at –20°C. 
 
12. Proceeded to Cell Staining Protocol in 96-well format. 
 
NOTE: It is important to have a single cell suspension prior to fixation. Otherwise the 
fixation process will result in a high percentage of doublet cells that will decrease the 
accuracy of the results. 
 
Cell Staining Protocol 
 
A. Cell staining in 96-well format 
 
1. Warm Guava Cell Cycle Reagent to room temperature; shield from excessive light 
exposure. Warm 1X PBS to room temperature. 
 
2. 200 µL of the samples transferred into the wells of a 96-well round bottom plate if 
the samples have not yet been transferred. 
 
3. Centrifuged the 96-well round bottom plate containing the samples at 450 x g for 5 
minutes with the brake on low and at room temperature. 
 
4. Removed and discard the supernatant being careful not to touch the pellet. (After 
centrifugation, the well should contain a visible pellet or a white film on the bottom of 
the plate.) 
 
5. Using a multi-channel pipettor 200 µL of 1X PBS was added to each well. Cells 
were mixed in the wells by pipetting up and down several times. The plate was 
allowed to stand at room temperature for one minute. 
 
6. Centrifuged the 96-well round bottom plate at 450 x g for 5 minutes with the brake 
on low and at room temperature. 
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7. Remove and discard the supernatant being careful not to touch the pellet. 
 
NOTE: The PBS washing step (steps 5 to 7) can be omitted if the user has first shown 
that this wash step is not necessary to minimize the %CV of the G0/G1 peak. 
However, the cells should still be centrifuged once to remove the ethanol. The Guava 
Cell Cycle Reagent should not be added to cells still in ethanol. 
 
8. 200 µL of Guava Cell Cycle Reagent was added to each well. 
 
9. Mixed by pipetting up and down several times. 
 
10. Incubated the 96-well round bottom plate at room temperature shielding away 
from light for 30 minutes. 
 
11. Acquire the samples on the Guava PCA-96 system. 
 
EXPECTED RESULTS 
 
 
 
Figure represents Cell cycle  phases                        (http://guavatechnologies.com) 
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Figure show typical results obtained with the Guava Cell Cycle Reagent. Log-phase 
cells were serum starved for 24 hours and treated with media containing serum. 
Ethanol fixed overnight and stained in 96-well plates according to the protocol 
described above. The upper plot shows the distribution of the cell cycle phases 
(G0/G1, S and G2/ M) in histogram format. The DNA Histogram Results show the 
result for the percentage of cells in G0/G1 (M1), S (M2) and G2/M (M3) under % 
Total. The bottom plot shows the Forward Scatter (FSC) versus DNA content of the 
cell sample.  
 
2.8 Transfection 
2.8.1 Optimisation of Transfection of cDNA’s 
Lipofectamine 2000 (Invitrogen, 11668019) and Green Fluorescent Protein (GFP) 
plasmid DNA was prepared with the volumes of Lipofectamine 2000 and cDNA 
being varied. The conditions investigated to ascertain the most efficient transfection 
conditions were as follows, briefly, the Lipofectamine 2000 and optiMEM (serum free 
media) were incubated at room temperature for 5min. During this time the plasmid 
and optiMEM were also incubating at room temperature. Both incubations were 
combined, mixed gently and formed complexes over 20min at room temperature. 1ml 
of this complex (DNA:Lipofectamine 2000) was added on top of adherent cells per 
well. The cells were viewed using a fluorescent microscope after 24-48hrs and the 
optimum transfection efficiency determined for each cell line by comparing the 
number of cells that fluoresced green with the number of cells in a particular field 
(Section 3.5.1). The Lipofectamine 2000 had a toxic effect on the cells, thus the 
lowest volume of transfection reagent was used while maintaining high transfection 
efficiencies. 5l Lipofectamine 2000 was used to transfect 2g plasmid cDNA in all 
transient cDNA transfections in this study. 
 
2.8.2 Transfection  of miRNAs and siRNAs 
 
The siPORT NeoFX (Ambion) transfection agent volume was optimised for the cell 
lines i.e., 0.15l for 96 well cell culture plate to transfect 50nM or 100nM of miRNAs 
and 50nM or 100nM of siRNA. Cell concentrations of 4x104 cells per ml (100l/each 
well) in 96 well cell culture plates for proliferation assay was used. In 24 well cell 
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culture plates, 2l of NeoFX to transfect 50nM or 100nM of miRNAs and 50nM or 
100nM of siRNA was used. Cell concentration of 3x105 per ml for 24 well cell culture 
plates was used for the invitro invasion assay. Scrambled siRNA and/or negative 
miRNA controls were also used in our studies (Table 2.4 and 2.5).  Kinesin specific 
siRNA was used as positive control (Ambion Inc., 16704).  
 
 96 well plate/well 24 well plate/well 
 
siPORT NeoFX 
 
0.15l 
 
2l 
siRNAs 50 – 100nM 50-100nM 
miRNAs 50 – 100nM 50-100nM 
Opti-MEM Made up to 10l Made up to 100l 
Cell seeding 
density 
4X103   cells/well 3X105 cells/well 
 
 
The miRNAs with 50nM and/or 100nM concentration was prepared in optiMEM 
(GibcoTM, 31985) media. Similarly siRNAs with 50nM and/or 100nM concentration 
was prepared in optiMEM (GibcoTM, 31985) media. The siPORT NeoFX and 
optiMEM mix was also prepared simultaneously. These mixtures were incubated at 
room temperature for 10min. After incubation NeoFX: optiMEM solution was added 
to each tube containing target miRNAs, negative miRNA controls as well as kinesin 
siRNA. For siRNA experiments similar method was followed with scrambled siRNA 
as controls along with kinesin as positive control. These solutions were mixed well 
and incubated for a further 10 minutes at room temperature. 10l/well of 96 well cell 
culture plates and 100l/well for 24 wells cell culture plates of siRNA and/or 
miRNA/NeoFX solutions were added. 100l cell suspension for each well in 96 well 
cell culture plate or 1ml of cell suspension in each well of 24 well cell culture plate  
were added on top of miRNA: NeoFX or siRNA: NeoFX complex. The plates were 
mixed gently and incubated at 37C for 24 hours. After 24hr, the transfection mixture 
was removed from the cells and the plates were fed with fresh medium. The plates 
were assayed for changes in proliferation at 72hr using the acid phosphatase assay 
(Section 2.7.8) or in vitro invasion assay (section 2.7.9). 
 64
 
Table 2.4 Synthetic miRNA Oligo nucleotides 
 
MiRNA Catalogue No. Product ID 
Pre-hsa-mir-21 AM17100 PM10206 
Anti-hsa-mir-21 AM1700 AM10206 
Pre-hsa-mir27a AM17100 PM10939 
Ani-hsa-mir27a AM1700 AM10939 
Pre-hsa-mir29a AM17100 PM10932 
Anti-hsa-mir-29a AM1700 AM10932 
Pre-mir-control AM17110    ---- 
Anti-mir-control AM17010    ---- 
  
Table 2.5 Synthetic siRNA Oligo nucleotides 
 
siRNA Ambion ID 
Scrambled 4390843 
Kinesin 4392420 
GLP1R s194615(1)   s5826(2) 
RAN s11768(1)     s11767(2) 
MIF s194615(1)   s194614(2) 
ANX2 s1384(1)       s1385(2) 
GRB2 s6119(1)       s6120(2) 
 
2.8.3   Selection of transgenic clones 
 
5-6 hrs post transfection with cDNA (section 2.8), fresh media was added. 48hrs post 
transfection the cells were fed with media containing (400g, 600g or 800g/ml 
G418 disulphate salt (Sigma A1720; cell culture tested).  Every second day the cells 
were fed with fresh selection media, and observed until the non transfected cells were 
all killed due to selection pressure. The minimum concentration at which cells were 
killed and the time required to achieve this was found to be 800g/ml for 5-6 days. 
The surviving cells were expanded and used for single cell cloning as mentioned 
(2.7.1). 
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2.9 Assessment of cell number –Acid Phosphatase Assay 
 
1. Following the incubation period of either cDNA transfection or 
siRNA/miRNA treatments (48-72hrs) in cells, media was removed from the 96 
well cell culture plates. 
2. Each well on the plate was washed with 100 ls PBS. This was removed and 
100 ls of freshly prepared phosphatase substrate (10mM p-nitrophenol 
phosphate (Sigma 104-0) in 0.1M sodium acetate (Sigma, S8625), 0.1% triton 
X-100 (BDH, 30632), pH 5.5) was added to each well. The plates were 
wrapped in tinfoil and incubated in the dark at 37C for 2 hours. 
3. The enzymatic reaction was stopped by the addition of 50 ls of 1M NaOH to 
each well. 
The plate was read in a dual beam plate reader at 405 nm with a reference 
wavelength of 620 nm. 
 
2.10 In vitro invasion assay – experimental procedure 
 
Invasion assays were performed using the method of Albini (1998) using commercial 
invasion assay kits (Beckton Dickinson, CAT # 354480). The invasion assay kits were 
allowed to come to room temperature before use, were rehydrated on the top and 
bottom of the insert with 0.5ml pre-warmed serum-free media for 2 hours at 37oC.  
                                     
 
Following this incubation, the media underneath the insert was replaced with pre-
warmed media containing 5% FCS. The cells were trypsinised, counted and 
resuspended in pre-warmed media containing 5% FCS at a density of 1x106 cells/ml. 
100l of the cell suspension was added to each insert. The cells were incubated at 
37oC for 24 hours. After this time, the inside of the insert was wiped with a wet cotton 
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swab and the underside of the insert stained with 0.25% crystal violet for 10 minutes, 
followed by washing with UHP and allowed to air dry. The inserts were then viewed 
under the microscope and photographed. The number of invasive cells was 
determined by microscopically counting 10 representative fields at 20X. 
 
 
2.11 Molecular Biology Techniques 
 
2.11.1 Genomic DNA extraction from 96 well plate cultures 
 
This simple method, based on a protocol described by Miller et al.(1998), involves 
precipitation of genomic DNA out with a saturated NaCl solution.  
Reagents required : Lysis buffer (10mM Tris[pH 7.7],10mM EDTA, 10mM NaCl, 
05%[w/v] sarcosyl), adding  1mg/ml proteinase K just before use , 5M NaCl  and 
absolute ethanol mixture ( 150l of 5M NaCl to 10ml of cold absolute ethanol), 
multichannel pipettor , paper towels, 70% ethanol. 
Procedure: 
a) Cells were cultured in 96 well plates until 80-90 % confluency, media removed and 
washed twice with 1X PBS. 
b) 50l lysis buffer was added in each well, incubated the plate in humid atmosphere 
at 600C overnight (by placing plates into closed plastic Tupperware-type container 
with wet paper towels in a conventional oven.) 
c) Next day 100l of ethanol/NaCl added into each well using multichannel pipettor. 
d) 96 well plate allowed to stand at room temperature on the bench for 30 minutes 
without mixing. (The nucleic acid precipitates as a filamentous network). 
e) The 96 well plate carefully was inverted onto paper towel to discard NaCl/ethanol 
solution,  
f) The bound nucleic acid in the wells was washed three times by dripping 150l of 
70% ethanol per well and discarded by inverting after each wash. 
g) After the final 70% ethanol rinse, 96 well plates were inverted to dry on the bench, 
and the DNA resuspended in TE buffer. 
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2.11.2 Preparation of total RNA from cells using Rneasy Mini Prep 
Kit® (QIAGEN, 74104) 
RNA extraction was achieved using the Qiagen RNeasy mini kit (Qiagen, 74104). 
This extraction is based on the guanidine thiocyanate method of extraction and yields 
high quality RNA. The procedure was performed as follows: 
1. To harvest RNA, culture media was removed from cells in culture and the 
cells were washed with PBS. 
2. Cells were then lysed directly in the culture dish by the addition an appropriate 
volume of buffer RLT containing 10l -mercaptoethanol per ml of buffer 
RLT. 350l RLT was used to lyse less than 5 x 106 cells, while 600l RLT 
was used to lyse between 5 x 106 and 1 x 107 cells. 
3. This suspension was then homogenised by passing it through a 20-guage 
needle fitted to an RNAse free syringe at least five times. 
4. One volume of 70% ethanol was then added to the homogenised sample and 
mixed well by pipetting. This sample was then applied to an Rneasy mini 
column placed in a 2ml collection tube and centrifuged for 15s at 10,000rpm. 
The flow through was discarded. 
5. 700l of buffer RW1 was applied to the Rneasy column. The tube was closed 
and centrifuged for 15s at 10,000rpm to wash the column. The flow through 
and the collection tube were discarded at this point and the Rneasy column 
transferred to a new collection tube. 
6. 500l of buffer RPE was applied to the column, the lid closed and the tube 
centrifuged for 15s at 10,000 rpm to wash the column. The flow through was 
discarded and a further 500l of buffer RPE applied to the Rneasy column. 
The tube was then closed and spun for 2 min at 10,000rpm to dry the silica-gel 
membrane. 
7. The RNA was then eluted in a new 1.5ml collection tube using 20l Rnase-
free water. The tube was closed and allowed to stand for 1min and then spun 
for 1 min at 10,000rpm. 
 
8. The RNA was then quantified and diluted as appropriate. 
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 RNA concentrations were calculated by measuring OD at 260nm and 280nm and 
using the following formula: 
OD260nm x Dilution Factor x 40 = g/l RNA 
The purity of the RNA extraction was determined by calculating the A260:A280 ratio. 
An A260:A280 ratio of 2 in indicative of pure RNA. Only those samples with ratios 
between 1.7 and 2.1 were used in this study. 
 
2.11.3    Using the Nanodrop to measure nucleic acids 
 
The NanoDrop is a cuvette free spectrophotometer. It uses just 1l to measure from  
5 ng/l to 3000 ng/l of nucleic acids in solution. Before applying the RNA sample 
the pedestal was wiped down using a lint-free tissue dampened with UHP. 1l of 
UHP was then loaded onto the lower measurement pedestal. The upper sample arm 
was then brought down so as to be in contact with the solution. “Nucleic acid” was 
selected on the Nanodrop software to read the samples. After the equipment was 
initialised the “blank” option was chosen, and after a straight line appeared on the 
screen the “measure” option was selected. All sample readings were automatically 
saved as text  files which could be viewed using Microsoft excel. The upper and lower 
pedestals were cleaned with a clean dry wipe between samples. When finished, the 
pedestal was cleaned with a wipe dampened with UHP followed by drying with a dry 
wipe. The purity of the RNA extraction was determined by calculating the A260:A280 
ratio. An A260:A280 ratio of 2 is indicative of pure RNA. Only those samples with 
ratios between 1.7 and 2.1 were used in this study. 
 
2.11.4       Relative qRT-PCR  
The number of copies of an mRNA transcript of a gene in a cell or tissue is 
determined by the rates of its expression and degradation. The real-time PCR system 
is based on the detection and quantitation of a fluorescent reporter (Lee, 1993; Livak, 
1995). There are two conventional real time PCR methods SYBR® Green and 
TaqMan probe based. The former was the first to be used in real-time PCR. It is a 
fluorescent dye that binds to double-stranded DNA and emits light when excited. 
Unfortunately, it binds to any double-stranded DNA which could result in a non-
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specific signal, especially compared with the specificity found with TaqMan probe 
based method.  This uses a fluorogenic probe which is a single stranded 
oligonucleotide of 20-26 nucleotides and is designed to bind only the DNA sequence 
between the two PCR primers. So total RNA was extracted (Section 2.8.2 or 2.8.3) 
and cDNA synthesised as per Section 2.8.5 and experiments were performed in 
triplicate, according to the manufacturer’s instructions. Reverse transcriptase (RT) 
reactions were performed using micropipettes which were specifically allocated to 
this work. To form cDNA, high-capacity cDNA reverse transcription kit (Applied 
Biosystems) was used the following reagents were thawed and mixed on ice (Table 
2.6) in a 0.5ml eppendorf (Eppendorf, 0030 121.023)  
 
Table 2.6 to prepare 2X RT Master mix (per 20 l reaction) 
Components In 20 l reaction  
10X RT buffer 2.0 
25X dNTP mix(100mM) 0.8 
10X RT Random Primers 2.0 
MultiScribeTM reverse transcriptase 1.0 
RNase inhibitor 1.0 
Nuclease free H2O 3.2 
Total per reaction 10.0 
 
 
The master mix was placed on ice and mixed gently, cDNA reverse transcription 
reaction was prepared by adding 10 l 2X RT master mix into an individual tube, 10 
l of RNA sample (200-500ng final concentration recommended) was pipetted into 
master mix containing tubes, sealed briefly, centrifuged and loaded onto thermal 
cycles( Hybaid)  
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Thermal cycles  
  
Temperature Hold Time duration in min. 
             250C    10 
  370C  120 
  850C  5 
  40C     ∞ 
 
After completion of the reaction cDNA was ready for quantitative PCR. 
Component Per Reaction 
2x Sybergreen master mix 12.5 
Forward & Reverse primer (10M)   1l each 
UHP 8.5l 
cDNA  2.0l 
Total 25l 
 
Thermal cycles  
 
Step Temperature Hold Time  Cycle 
Denature 950C 10 minutes 1 
Denature 950C 15 seconds  
Annealing & Extend 600C 30 seconds 40  
 
 
2.11.5 Non-Quantitative Polymerase chain reaction 
A standardised polymerase chain reaction (PCR) procedure was used in this study. 
The reactions were carried out in 0.5ml safe-lock eppendorf tubes (Eppendorf, 0030 
121.023). All reagents had been aliquoted and stored at –20oC and all reactions were 
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carried out in a laminar flow cabinet. Primers and annealing temperatures are detailed 
in the Table 2.9. A typical PCR tube contained the following: 
Component Per Reaction 
25mM MgCl2 1.5l 
10x PCR Buffer 2.5l 
Forward & Reverse primer (10M)   1l each 
UHP 6.5l 
DNA  2.5l 
Taq/dNTP mixture* 10l 
Total 25l 
*= 0.5l 10mM dNTP’s (10mM of each dNTP; Sigma, D 5038) 
0.25l of 5U/l Taq DNA polymerase enzyme (Sigma, D-4545), 9.25l of UHP  
Platinum Supermix based PCR reaction  
Component Per Reaction 
DNA 2.5l 
Forward primer(10M) 1l 
Reverse primer (10M)  1l 
Platinum Supermix         21.5l 
Total 25 l 
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DNA was amplified by PCR as follows: 
Step Temperature Hold Time  Cycle 
Denature 950C 5 minutes 1 
Denature 950C 30 seconds  
Anneal X0C 30 seconds        *35 
Extend 720C 30 seconds  
Final Extension 720C 10minutes 1 
Hold 40C        ∞  
*The cycle number varied with primers used but was generally 35 cycles.  
X = the annealing temperature varied with primer set used (see over) 
The reaction tubes were then stored at 4oC for analysis by gel electrophoresis.   
 
Table 2.9 PCR primers used for developing targetable plasmid vector  
 
Primer Name Sequence => 5’->3’ Direction Tm.*(0C)  
pEGFP-C1-2864.s 
pEGFP-C1-
3012.as 
GTG CTC GAC GTT GTC ACT GAA 
GCC GGA TCA AGC GTA TGC 
59.8 
58.2 
gfp1079F 
gfp1231R 
ACA AGC AGA AGA ACG GCA TCA 
CGG ACT GGG TGC TCA GGT A 
57.9 
 
61.0 
CMV(FseI).s 
 
CMV(SpeI).as 
AAA CGT GGC CGG CCT AGT TAC TTA AT 
AAC TGA CTA GTG GAT CTG ACG GT 
63.2 
 
 
60.6 
Cla_loxp_Avr.s 
 
 
Cla_loxp_Avr.as 
ATC GAT ATA ACT TCG TAT AAT GTA TGC 
TAT ACG AAG TTA TC 
CCT AGG ATA ACT TCG TAT AGC ATA CAT 
TAT ACG AAG TTA TAT 
65.4 
 
 
 
66.5 
Mlu_Ase_linker.s 
 
Mlu_Ase_linker.as 
ACG CGT GGT CAG CAT AGT TAA GTA T 
TAA TAC TTA ACT ATG CTG ACC A 
 
61.3 
 
 
52.8 
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pEGFP-C1-810F 
pEGFP-C1-1309R 
cmv-C1-532F 
CTA CGG CGT GCA GTG CTT C 
CGA GAG TGA TCC CGG CG 
 
TAG GCG TGT ACG GTG GGA G 
61.0 
60.0 
61.0 
* Anneal Temperature typically =Tm-50C 
 
 
Table 2.10 PCR primers used for screening LINE-1 specific homologous  
  recombination 
 
Primer Name Sequence => 5’->3’ direction Tm.*(0C) 
L15'arm(FseI).as ACA TTT GGC CGG CCT CGG TTTGC 66.0 
L15'orf2_3360.s 
L1Cmv_5351.as 
5'L1orf2_3358.s 
5'L1orf2_4532.as 
CCA GAT TCA TAA AGC AAG TCC TCA 
TTA TAT AGA CCT CCC ACC GTA CAC G 
ACC CAG ATT CAT AAA GCA AGT CCT C 
 
TGG CCT CAT AAA ATG AGT TAG GG 
59.3 
63.0 
61.3 
 
58.9 
L1(1)-2611.s 
L1(1)-5895.as 
GAG AGA AAG GTC GGG TTA CCC TCAA 
TCA GGA TGA TCT GGA CGA AGA GCA T 
64.6 
63.0 
L1(2)-2615.s 
L1(2)5898.as 
GAA AGG TCG GGT TAC CCT CAA A 
CGA TCA GGA TGA TCT GGA CGA A 
60.3 
60.3 
L1(3)-2612.s 
L1(3)-3439.as 
AGA GAA AGG TCG GGT TAC CCT CAA 
AGG ATG ATC TGG ACG AAG AGC AT 
62.7 
60.6 
L1(4)-2632.s 
L1(4)-3444.as 
TCA AAG GAA AGC CCA TCA GAC TAAC 
CGA TCA GGA TGA TCT GGA CGA AGA 
61.3 
62.7 
PL1-7.s 
 
PL1-7.as 
TAC GTC TGA TTG GTG TAC CTG AAA 
GTG ATG T 
CTA ATG ACC CCG TAA TTG ATT ACT 
ATT AAT AAC GG 
65.5 
 
 
64.8 
PL1-8.s 
 
PL1-8.as 
TCC TGA AGG AAG CGC TAA ACA TGG 
AAA GG 
CAT TTA CCG TAA GTT ATG TAA CGC 
GGA ACT CCA T 
66.7 
 
 
67.1 
PL1-9.s 
 
PL1-9.as 
TCA TGC CAA AAT GTA AAG ACC ATC 
GAG ACT AG 
CAG TTT ACC GTA AAT ACT CCA CCC 
65.6 
 
 
68.3 
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ATT GAC GTC AAT 
PL1-10.s 
 
PL1-10.as 
AGA AAC TGC ATC AAC TAA TGA GCA 
AAA TCA CC 
ATT CTA GTT GTG GTT TGT CCA AAC 
TCA TCA ATG T 
64.4 
 
 
64.7 
* Anneal Temperature typically =Tm-50C 
 
Table 2.11 PCR primers used for Transgene overexpression studies 
 
Primer Name Sequence => 5’->3’Direction Tm.*(0C) 
glp1r.s_rea 
 
glp1r.as_rea 
CTC CTT CCA GGG GCT GAT 
GGT G 
CTG GTG GGA CAC TTG AGG 
GGC T 
65.8 
 
 
65.8 
kcj8.s_rea 
 
kcj8.as_rea 
GTG GAA TGG AGA AAA GTG 
GTT TG 
TGA TCA AAC CCA CAA TAT 
TCT GG 
58.9 
 
 
57.1 
tfpi2.s_rea 
 
tfpi2.as_rea 
AGC TAC TTG TAT GGG CTT 
CTG C 
TTT GCA ATC CTC CCT GCT 
AAC AA 
60.3 
 
 
58.9 
s100a13.s_rea 
 
s100a13.as_rea 
ACC TCT TCA GGA AAG CCA 
TCT GA 
TTC CGG CCC TCC TGC CTT 
GCA AA 
60.6 
 
 
66.0 
actinB.s 
 
actinB.as 
TGG ACA TCC GCA AAG ACC 
TGT AC 
TCA GGA GGA GCA ATG ATC 
TTG A 
62.4 
 
 
58.4 
* Anneal Temperature typically =Tm-50C 
 
Table 2.12 PCR primers used for mir-29a cloning 
Primer 
Name 
Sequence=> 5’->3’ direction Tm.*(0C) 
mk29a.s AAA CCG GAT CCG AGC CCA ATG TAT GCT GGA 
TTT AG 
70 
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mk29a.as CCC AAC TCG AGT TAA GCT TTG TTT TCT TAG 
TTC TTG TCC ATG G 
69 
* Anneal Temperature typically =Tm-50C 
 
Table 2.13 PCR primer used for siRNA knockdown studies 
 
Primer Name  Sequence=> 5’->3’ direction Tm.*(0C) 
ran_mk-160F 
ran_mk-285R 
GTT GGT GAT GGT GGT ACT GGA A 
TCC TCT GTT GGT GTG GAA CAC T 
60.3 
 
 
60.3 
mif_mk-216F 
 
mif_mk-317R 
GAA CCG CTC CTA CAG CAA GCT 
TTG GCC GCG TTC ATG TC 
61.8 
 
55.2 
anxa2_mk-136F 
anxa2_mk-286R 
TGT TCA CGA AAT CCT GTG CAA 
CTC ATC CAC ACC TTT GGT CTT G 
55.9 
 
60.3 
grb_mk-464F 
 
grb_mk-964R 
TGG TAC AAG GCA GAG CTT AAT GG 
AGG CAG CTT GTG GGT TTA ATT C 
60.6 
 
 
58.4 
myc-MK-1312F 
myc-MK-1457R 
CCA GCA GCG ACT CTG AGG A 
GAC CAG TGG GCT GTG AGG AG 
61.0 
 
 
63.5 
 
* Anneal Temperature typically =Tm-50C 
 
Table 2.14 PCR primers used for 3’RAN UTR cloning 
 
Primer Name Sequence => 5’->3’ direction Tm.*(0C) 
ran_3'utr-753F AAA AAG CTT TGA GAA TGA AGC TGG AGC 
CCA G 
66.8 
ran_3'utr-
1656R 
CCC GGA TCC CGG CTT GCG TAT CAA CTT CAC 
A 
72.1 
* Anneal Temperature typically =Tm-50C 
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2.12     MicroRNAs  
 
2.12.1 Organic RNA extraction using MirVana miRNA isolation Kit 
 
The mirVanaTM miRNA isolation kit (catalogue # 1560, 1561) designed for 
purification of RNA suitable for studies of both siRNA and miRNA. The kit employs 
organic extraction followed by immobilization of RNA on glass-fibre filters to purify 
either total RNA, or RNA enriched for small species, from cells or tissue samples. 
The total RNA from cell samples was isolated as per the manufactures protocol a 
recommended 102-107 cells were used for RNA extraction.  
 
 
I  Cell lysis 
a) Trypsinised cells  (section 2.6) were washed cells by gently re-suspending     
 in  1ml of 1XPBS and pelleted at low speed. 
 b) PBS removed and cells resuspended in 300-600l lysis/binding solution. 
 c) Samples vortexed vigorously to ensure complete lysis of the cells and to            
     obtain a homogenous lysate. 
 
II Organic Extraction 
  a) MiRNA homogenate was added, 1/10th volume of cell lysate and vortexed  
       and left on ice for 10 minutes. 
 b)  Equal volume of Acid-phenol: Chloroform added to lysed homogenate  
       samples and vortexed for 30-60s. 
 c)  Centrifuged samples for 5 min at maximum speed (10,000xg) at room 
      temperature to separate the aqueous and organic  phases 
d) The upper aqueous  phase was pipetted out into fresh tube without       
      disturbing the lower phase and volume removed was noted  
 
III Final RNA isolation 
  
 a)  1.25 volumes of room temperature 100% ethanol was added to aqueous  
 77
      phase. 
b) Pipetted lysate/ethanol mixture onto  filter cartridge placed in collection 
tube, and centrifuged for ~15 sec to pass the mixture through the filter at  
10,000xg. 
 c)  Flow through was discarded , and to the filter cartridge 700l of miRNA  
      wash solution 1 was added and centrifuged for ~ 5-10 sec. 
d) Flow through discarded and to the filter cartridge 500l wash solution 2/3  
was added and centrifuged, these steps repeated and flow through 
discarded. 
e) The filter cartridge was transferred to a new collection tube , 100l of  
pre-heated (950C) nuclease free water added to the center of the filter, and  
the cap closed. Centrifuged for ~20-30 sec at maximum speed to recover 
the RNA. The collected eluate was quantified as mentioned Section 2.11.3 
and stored at -800C until further use. 
 
2.12.2   Relative quantity of mirs by qRT-PCR  
 
Reagent preparation  
 
Dilution of mir Vana RT primer to 1X concentration 
mirVana gene-specific RT Primers are supplied as 10X stock solutions. These were 
diluted to 1 X concentration with nuclease-free water to make a working stock. They 
were mixed thoroughly by vortexing and briefly centrifuged. 
 
Volume and amount 
RNA concentration was adjusted with nuclease-free water so that 1 µL of RNA 
solution was used per reaction (25ng/l).  
 
Preparation for reverse transcription (RT) Master Mix  
a) Vortex all the RT reagents, except the Array Script™ Enzyme which is mixed just 
before use. RT reagents were kept on ice.  
b) A RT Master Mix was prepared with the reagents that were shared across most of 
samples using Table 2.7  
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Table 2.7    Final composition of the RT reaction 
Per Reaction Component 
to 10l  Nuclease free water 
2l mirVana 5X RT buffer 
1l 1X mirVana RT primer* 
1l 25ng/l RNA 
0.4 l  ArrayScript Enzyme mix 
10l Final volume 
Diluted from the 10X stock supplied 
a) 9l of RT master mix was aliquoted into individual wells of a 96 well PCR plate 
b) 1l RNA samples were added to each aliquot of RT master mix aliquoted wells,  
c) For the no-template control reactions, nuclease-free water was added. For the 
primer control, nuclease free water was substituted instead of primers 
d) The RT reaction was performed by incubating for 30 min at 37°C, then for 10 min 
at 95°C in thermal cycler (Applied Biosystems 7500) After completion of reaction 
sample plate was placed on ice and PCR was performed immediately. 
 
For real-time PCR, add SYBR Green I to the mir Vana 5X PCR Buffer 
 
To prepare the PCR master mix the components shown in table (2.8) were assembled 
on ice. SYBR Green I (provided at 10,000 X concentration) was diluted, 1:7 (v/v) 
with dimethyl sulfoxide or nuclease-free water. Then 1.2 µL of the diluted dye was 
added to the mir Vana 5 X PCR Buffer supplied with the kit. Vortex to mix followed 
by a brief centrifuge. 
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Table 2.8 PCR Master Mix 
Per Reaction Component 
5l  mirVana5X PCR buffer 
0.5l 50X ROX  
1U(0.2l) Thermostable DNA polymerase 
0.5l mirVana PCR primers 
to 15 l  Nuclease free water 
 
f) The PCR master mix was mixed gently and 15l was added to each RT 
reaction  
g) Thermal cycling  was done as follows 
 
Step Temperature Hold Time  Cycle 
Denature 950C 3 minutes 1 
Denature 950C 15 seconds  
Annealing & Extend 600C 30 seconds 40  
 
 
2.13   Plasmid DNA isolation 
E.coli cultures were streaked on LB agar (table surface was sterilised before use), 
containing appropriate selection antibiotic (Ampicillin or Chloramphenicol) and 
incubated at 37oC overnight. From these, a single colony was inoculated into 5ml LB 
broth (table 2.5, autoclaved before use) containing appropriate selection antibiotic and 
was grown for 8 hours with shaking at 37oC and was subject to a DNA mini 
preparation using the Qiagen Plasmid DNA Extraction Mini Kit (Qiagen, 12143) 
according to the manufacturer’s instructions. The DNA concentration was determined 
by measuring the OD260nm. Plasmid was stored at –20oC until required. 
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2.13.1  Restriction Enzyme Digestion 
 
5 ls of each isolated plasmid sample was run out on a 1% agarose gel to check for 
degradation. Restriction digestion was then carried out to confirm orientation of the 
insert. All digestions were carried out using the recipe as outlined in Table 2.15 
 
Table 2.15 Standard DNA digestion mix 
 
Component Volume (ls) 
DNA sample (0.5-1g) 2 
undiluted enzyme (5units)  1 
BSA (10mg/ml) 0.2 
10X appropriate  buffer    2 
UHP  14.8 
 
All 20 ls were run out on a 1% agarose gel together with 3 ls loading dye (Section 
2.8.12). From this information, samples were selected for large-scale plasmid 
preparation. 
 
2.13.2    Plasmid DNA Ligation or sub cloning 
A known quantity (section 2.8.7) of each plasmid or PCR product was digested with 
the appropriate restriction endonuclease for 3hr at 37oC to remove the sequence of 
interest for insertion into the target expression vector. These restriction digests were 
analysed by TAE low melt 1% gel electrophoresis and the relevant fragment size 
excised from the gel using a fresh clean blade for each excision. The DNA was 
purified from the gel by the addition of PB buffer (Qiagen Gel Purification Kit) to 
each gel slice; this was melted at 55oC for 10min and applied under vacuum to a gel 
purification column. The DNA was column washed with 750l of PE buffer under 
vacuum and centrifuged at 13,000rpm for 1min to dry. The pellet was re-dissolved in 
15l EB buffer and a portion of this run out on a 1% TAE agarose gel. This ensured 
that the cDNA fragment was not contaminated and thus suitable for ligation. Each 
insert was ligated with known plasmid vector backbone (digested with matching REs) 
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at 15oC overnight in a mastermix typically containing expression vector (100ng), 
target insert cDNA (300ng), water, 10X ligation buffer and T4 ligase (2.5U) in a total 
volume of 10l.  
 
2.13.3    Transformation procedure 
 
A bacterial cell suspension (100l) of competent JM109 (Promega, L2001) or XL 
Blue-1 (Stratagene, # 200130) was mixed with ligated DNA and placed on ice for 
40min after which the mixture was heat-shocked at 42oC for 30 to 90s and then placed 
on ice for 3min. LB broth (1ml as mentioned in table 2.8 autoclaved before use) was 
added to the competent cell suspension and incubated at 37oC for 1hr. Different 
volumes of this suspension was spread on a selecting agar plates LB agar (table 2.16) 
containing appropriate antibiotic concentration of Ampicillin or chloramphenicol) and 
incubated overnight at 37oC. Single colonies that grew on these selecting plates were 
incubated into 5ml LB broth containing appropriate selection antibiotic. Single 
colonies inoculated into 5ml LB broth (table 2.16,autoclaved before use) containing 
appropriate selection antibiotic and were grown for 8hr with shaking at 37oC and were 
subject to a DNA mini preparation (Section 2.8.7) or Large Scale Preparation (Section 
2.8.13). For a large scale DNA preparation this culture was then inoculated into 
270ml LB broth containing 0.3ml Ampicillin (100mg/ml) in 1L baffled flask with 
shaking overnight at 37oC. 
 
 
Table 2.16   LB Media preparation 
 
Requried materials LB broth LB Agar 
NaCl (Merk, K1880814) 10g 10g 
Tryptone(Oxoid, L42) 10g 10g 
Yeast extract(Oxoid, L21) 5g 5g 
Bacto Agar  - 20g 
Distilled water    1000ml 1000ml 
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2.13.4 Agarose Gel Electrophoresis of Plasmid DNA or PCR 
Products 
A 1% agarose gel (Sigma, A-9539) was prepared in 1X TAE buffer ( diluting 50X 
TAE buffer)  (242g Tris base, 57.1ml Acetic acid, 100ml 0.5M EDTA, 996ml UHP) 
and melted in a microwave oven. After being allowed to cool down, 0.003% (v/v) of a 
10mg/ml ethidium bromide solution was added to the gel which was then poured into 
an electrophoresis apparatus (BioRad). Combs were placed in the gel to form wells 
and the gel allowed to settle. 5l of loading buffer (50% glycerol, 1mg/ml xylene 
cyanol, 1mg/ml bromophenol blue, 1mM EDTA) was added to 20l plasmid 
restriction digestion reaction or 25l PCR samples and 10l was run on the gel at 80-
90mV for approximately 2 hours. When the dye front was seen to have migrated the 
required distance, the gel was removed from the apparatus and examined on a UV-
transluminator and photographed. 
 
2.13.5    Plasmid DNA sequencing  
In order to fully confirm the orientation and the origin of the inserted DNA in the 
plasmids, each plasmid was sent for sequencing ( MWG DNA sequencing facility, 
Germany, typically plasmid sample with known primer sequence sent) and 
approximate 500-900bp sequence read out were received from each successful 
sequencing reaction. Once these parameters had been confirmed, transfection could be 
carried out.  
 
2.13.6  Maxi preparation of Plasmid DNA 
Plasmid DNA was purified using an endofree plasmid maxi kit (Qiagen, 12362). 
Following growth of plasmid culture in into 270ml LB (table 2.16) broth containing 
0.3ml ampicillin (100mg/ml) in 1L baffled flask with shaking overnight at 37oC, the 
culture was split into 2 x 250ml centrifuge bottles and spun at 3,500rpm for 15min at 
4oC. Pellets were weighed and either frozen at –80oC until required or processed 
further.  The bacterial pellet was resuspended in 10ml buffer P1. To this, 10 ml buffer 
P2 was added, mixed gently and incubated at room temperature for 5min. A volume 
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of 10ml chilled buffer P3 was added to the lysate and mixed immediately and gently. 
The lysate was poured into the barrel of the QIA-filter cartridge and incubated at 
room temperature for 10min. The cap from the QIA filter outlet nozzle was removed 
and the plunger was gently inserted in to the cartridge. The cell lysate was filtered into 
a 50ml tube. To the lysate, 2.5ml buffer ER was added and mixed by inverting 
repeatedly. This was incubated on ice for 30min.  Quiagen-tip 500 was equilibrated by 
applying 10ml buffer QBT and the column was allowed to empty by gravity flow. The 
filtered lysate was then applied to the Quiagen-tip and allowed to enter the resin by 
gravity flow. The Quiagen-tip was washed twice with 30ml buffer QC. The DNA was 
eluted by addition of 15ml buffer QN and the eluate was collected in a 30ml tube. The 
DNA was precipitated by adding 10.5ml isopropanol to the eluted DNA. This was 
mixed and centrifuged at ~10,000rpm for 30min at 40C. The DNA pellet was washed 
with 5ml of 70% ethanol and this was centrifuged at ~10,000rpm for 10min. The 
pellet was air-dried and dissolved in 500l buffer TE. The DNA concentration was 
determined by measuring the OD260nm. 
 
2.14 Western Blot analysis 
Proteins for western blot analysis were separated by SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE). 
       
2.14.1 Sample preparation  
Cells were scraped directly on culture dishes using lysis buffers: (8M urea (Sigma, 
U6504), 4 % (w/v) CHAPS (Sigma, C5070),  2M thiourea (Sigma 88810)  30mM, 
Tris Base (Sigma, T1378), pH to 8.5 with dilute HCl).  Lysis was carried out over 
twenty min on ice and following vortexing, the lysate was spun at 4oC for 15 min at 
maximum speed to remove any insoluble debris. The protein was quantified using the 
method of Bradford (Bio-Rad; 500-0006) and the protein samples were supplemented 
with 2X Lamelli sample buffer (contains loading dye, Sigma-Aldrich S 3401) and 
water to a final stock concentration of 2g/l. Sample and then boiled for 2 min and 
stored at –20oC until required. 
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2.14.2  Quantification of protein  
Protein levels were determined using the Bio-Rad protein assay kit (Bio-Rad; 500-
0006) with a series of bovine serum albumin (BSA) (Sigma, A9543) solutions as 
standards. A stock solution of 2 mg/ml BSA(Bio-Rad) was used to make a standard 
curve. 10 l samples were diluted into tubes in a stepwise fashion from 0 – 2 mg/ml 
BSA. The Biorad was first filtered through 3MM filter paper (Schleicher and Schuell, 
311647) and then diluted 1/5 with UHP as it was supplied as a 5-fold concentrate. The 
diluted dye reagent (490 ls) was added to each standard and sample tube and the 
mixtures vortexed. The 500 l samples were diluted out in 100 l aliquots onto a 96-
well plate (Costar, 3599). After a period of 5 min to 1h, the OD570 was measured, 
against a reagent blank. From the plot of the OD570 of BSA standards versus their 
concentrations, the concentration of protein in the test samples was determined. From 
this, a relative volume for each protein sample was determined for loading onto the 
gels. Usually 10-20 g protein per lane was loaded. 
     
2.14.3 SDS Acrylamide Gel electrophoresis 
     
Resolving and stacking gels were prepared as outlined in (Table 2.17) and poured into 
clean 10cm x 8cm gel cassettes that consisted of 2 glass plates separated by a plastic 
spacer. The resolving gel was poured first and allowed to set. The stacking gel was 
then poured and a comb placed in the stacking gel in order to create wells for sample 
loading. Once set, the gels could be used immediately or wrapped in aluminium foil 
and stored at 4oC for 24 hours. 
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Table 2.17 Preparation of electrophoresis gels 
 
Components Resolving gel 
(10%) 
Resolving gel 
(12%) 
Stacking gel 
30% Acrylamide stock*1 2.38 mls 2.8 mls 330 ls 
Ultrapure water 2.66 mls 2.24 mls 1.4 mls 
1.5M-Tris/HCl, pH 8.8 1.82 mls 1.82 mls - 
0.5M-Tris/HCl, pH 6.8 - - 250ls 
10% SDS (Sigma, L-4509) 70 ls 70 ls 20 ls 
10% Ammonium persulphate 
 (Sigma, A-1433) 
70 ls 70 ls 20 ls 
TEMED 
 (Sigma, T-8133) 
2.8 ls 2.8 ls 2ls 
 
 
1 Acrylamide stock solution consists of 29.1g acrylamide (Sigma, A8887) and 0.9g NN’-methylene bis-
acrylamide (Sigma, 7256) dissolved in 60ml UHP water and made up to 100ml final volume. The solution 
was stored in the dark at 4oC for up to 1 month. All components were purchased from Sigma, SDS (L-
4509), NH4-persulphate (A-1433) and TEMED, N,N,N,N’-tetramethylethylenediamine (T-8133). 
 
 
2.14.4 Protein transfer and Western blotting  
Following electrophoresis, the acrylamide gels were equilibrated in transfer buffer 
(25mM Tris, 192mM glycine (Sigma, G-7126) pH 8.3-8.5 without adjusting) for 20 
min. Proteins in gels were transferred onto Hybond ECL nitrocellulose membrane 
(Amersham, RPN 2020D) using a semi-dry transfer cell (Biorad). Eight sheets of 
Whatman 3mm filter paper (Whatman, 1001824) were soaked in transfer buffer and 
placed on the cathode plate of a semi-dry transfer cell. Excess air was removed from 
between the filters by moving a glass pipette over the filter paper. Nitrocellulose 
membrane, cut to the same size of the gel, was soaked in transfer buffer and placed 
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over the filter paper, ensuring that there were no air bubbles. The acrylamide gel was 
placed over the nitrocellulose and four more sheets of pre-soaked filter paper were 
placed on top of the gel. Excess air was again removed by rolling the pipette over the 
filter paper. The proteins were transferred from the gel to the nitrocellulose membrane 
at 0.34 Amps (15 Volts) for 30 min.  
From this point on, all further steps were carried out on a revolving apparatus to 
ensure even exposure of the membrane blot to all reagents. Following transfer, the 
membranes were blocked in fresh filtered 5% non-fat dried milk (Cadburys; Marvel 
skimmed milk) in PBS (20mM Tris, 0.15M NaCl)/0.1% Tween 20 (Sigma, P1379), 
pH 7.4 for 2 hours. After blocking, the membranes were rinsed with TBS/0.1% Tween 
and incubated with primary antibody overnight at 4oC. Primary antibodies used are 
listed in Table 2.18. The following day the primary antibody was removed and the 
membranes rinsed three times with PBS/0.1% Tween. The membranes were then 
incubated in 1/1000 dilution of suitable HRP-labelled secondary antibody (Anti-
Mouse (abcam); anti-Rabbit (abcam) or Goat;) in 1% marvel for 1 hour at room 
temperature (R.T.). The secondary antibody was then removed and blots were washed 
three times for 15 min in PBS/0.1% Tween. Bound antibody was detected using 
enhanced chemiluminescence (ECL) (Section 2.9.4). 
 
All incubation steps from now on, including the blocking step, were carried out on a 
revolving apparatus (Stovall, Bellydancer) to ensure even exposure of the blot to all 
reagents. The Nitrocellulose membranes (Amersham,) were blocked for 2 hours at 
room temperature with fresh filtered 5% non-fat dried milk (Cadburys, Marvel 
skimmed milk) in Phosphate-buffered saline (PBS) with 0.5% Tween (Sigma, P-1379) 
pH 7.5. After blocking, the membranes were rinsed once in 1X PBS and incubated 
with 5 to 10 mls primary antibody. The specific conditions for each antibody are 
outlined in table 2.18 below. Bound antibody was detected using enhanced 
chemiluminescence (ECL). 
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Table 2.18  List of primary antibodies used for western blot analysis 
 
        Antibody        Dilution/ 
concentration 
            Supplier Catalogue    
no. 
GFP (R)2 
GAPDH (M)1 
GLP1R(R)2 
KCNJ8 (C)3 
TFPI2(M)1 
RAN(R)2 
1/500 
1/5,000 
1/1000 
1/1000 
1/200 
1/1000 
Abcam 
Abcam 
Abcam 
Gift 
Gift 
Abcam 
ab610270 
ab 9482 
ab1583816 
--- 
---- 
    ab4781 
 
(M)1 = Mouse anti-human IgG 
(R)2 = Rabbit anti-human IgG 
(C)3 = Chicken IgG 
 
Table 2.19  List of secondary antibodies used for western blot analysis 
 
        Antibody        Dilution/ 
concentration 
            Supplier Catalogue    
no. 
Mouse 
Rabbit 
Goat 
Chicken 
1/1000 
1/1000 
1/1000 
1/1000 
Abcam 
Abcam 
Abcam 
Abcam 
 
abP0260 
abP0448 
abE0466 
ab49710 
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2.14.5 Enhanced chemiluminescence detection 
Protein bands were developed using the enhanced chemiluminescence kit (ECL) 
(Amersham, RPN2109) according to the manufacturer’s instructions. 
After blots were washed in PBS/0.1% Tween three times for 5 min, a sheet of 
parafilm was flattened over a smooth surface, e.g. a glass plate, ensuring all air 
bubbles were removed. 1.5ml of ECL detection reagent 1 and 1.5ml of reagent 2 were 
mixed and covered over the membrane. Charges on the parafilm ensured the fluid 
remained on the membrane. The reagent was removed after one min and the 
membrane wrapped in cling film. The membrane was exposed to autoradiographic 
film (Roche) in an autoradiographic cassette for various lengths of time, depending on 
the strength of signal obtained. The autoradiographic film was then developed for 5 
min in developer (Kodak, LX24), diluted 1:6.5 in water. The film was briefly 
immersed in water and transferred to a Fixer solution (Kodak, FX-40) diluted 1:5 in 
water, for 5 min. The film was transferred to water for 5 min and then air-dried. 
 
2.14.6  2-D Fluorescence Difference Gel Electrophoresis 
 
The proteomics work mentioned in the thesis was carried with the help of Dr. 
Paul Dowly and Mr. Michael Henry, NICB). Cell samples were collected (section 
2.7.7). The cell samples were lysed in 2D-DIGE lysis buffer ((8M urea (Sigma, 
U6504), 4 % (w/v) CHAPS (Sigma, C5070), 2M thiourea (Sigma 88810) 30mM, Tris 
Base (Sigma, T1378), pH to 8.5 with dilute HCl) and protein quantified (section 
2.14.1 and 2.14.2). 3 biological replicates with 4 conditional transfection were used in 
the study.  The protein samples were cleaned up using Ready PrepTM 2D clean up kit 
(Bio-Rad, catalogue # 163-2130). DIGE analysis or for the identification of proteins 
of interest by mass spectrometry was used (see section 2.20) 
 
 
2.14.7   Preparation of dye stock solution (1 nmol/µl) 
 
The three CyDye DIGE Fluor Minimal dyes (Cy3, Cy5 and Cy2 (Amersham, 25-
8010-65) were thawed from –20 oC to room temperature for 5 minutes. To each 
microfuge tube dimethylformamide (DMF) (Aldrich, 22,705-6) was added to a 
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concentration of 1 nmol/ µl. Each microfuge tube was vortexed vigorously for 30 
seconds to dissolve the dye. The tubes were then centrifuged for 30 seconds at 
14,000rpm in a microcentrifuge. The reconstituted dyes were stored at –20 oC for up 
to two months. 
 
2.14.7.1   Preparation of 10 µl working dye solution (200 pmol/µl) 
 
On thawing, the dye stock solutions were centrifuged in a micro centrifuge for 30 
seconds. To make 10 µl of the three working dye solutions, 8 µl of DMF was added to 
three fresh eppendorf labelled Cy2, Cy3 and Cy5. A 0.2 nmol/µl volume of each of 
the reconstituted dye stock solutions was added to their respective tubes. The dyes 
were stored at -20 oC in tinfoil in the dark for 3 months. 
2.14.7.2  Protein sample labelling  
4  samples equivalent to 50 µg was placed into twelve eppendorf tubes in biological 
triplicates and were used for labelling. They are Anti microRNA inhibitor negative 
control , Anti hsa-mir-29a inhibitor(treated with each 1l Cy3) and Pre microRNAs 
negative control, Pre hsa-mir-29a(treated with Cy5)   3 treated protein (6 for Cy3 and 
the other 6 for Cy5). Each tube was mixed by vortexing, centrifuged and then left on 
ice for 30 minutes in the dark. To stop the reaction, 1µl of 10 mM lysine was added; 
the tubes were vortexed, centrifuged briefly and left on ice for 10 minutes in the dark. 
The labelled samples were stored at –80 oC. The Cy2 pool for each gel (50 µg) to this 
tube 1µl of working dye solution was added.  
 
 
2.14.7.3 Preparing the labelled samples for the first dimension 
 
The protein samples labelled with Cy2 (pooled internal standard), Cy3 and Cy5 were 
thawed on ice (in the dark), combined by placing into a single eppendorf tube and 
mixed. An equal volume of 2X sample buffer (2.5 ml rehydration buffer stock 
solution (8M urea, 4 % CHAPS), pharmalyte broad range pH 3-11 (2%) (Amersham, 
17-6000-86), DTT (2%) (Sigma, D9163) was added to the labelled protein samples. 
The mixture was left on ice for at least 10 minutes then applied to Immobiline 
DryStrips for isoelectric focussing. 
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2.14.7.4 Strip rehydration using Immobiline DryStrip  
                    reswelling tray  
 
Isoelectric focussing of all samples was carried out using immobiline pH gradient 
(IPG) strips. The protective lid was removed from the Immobiline Dry Strip 
Reswelling tray. The tray was levelled using the spirit level. A 350µl volume of 
rehydration buffer solution (with 2 % pharmalyte broad range pH 3-11 and 2 % DTT) 
was slowly pipetted into the centre of each slot, all air bubbles generated were 
removed. The cover film from the IPG strip (pH range 3-11, Amersham, 17-1233-01) 
was removed and positioned with the gel side down and lowered. To ensure the entire 
strip was evenly coated the strip was gently lifted and lowered onto the entire surface 
of the solution avoiding trapping air bubbles. Each strip was overlaid with about 3 ml 
of  IPG Cover Fluid (Amersham, 17-1335-01) starting on both ends of the strip, 
moving to the centre. The protective lid was then replaced and the strips were left at 
room temperature to rehydrate overnight (or at least 12 hours). 
 
2.14.7.5   Isoelectric focussing using the IPGphor manifold 
 
Following the rehydration procedure, the Manifold (Amersham) was placed onto the 
IPGphor unit by inserting the “T” shape into the hollow provided. A 9 ml volume of 
Cover Fluid was placed into each of the twelve lanes in the tray in order to cover the 
surface. Two wicks (Amersham, 80-6499-14) per strip were placed on tinfoil and 150 
µl of UHP was pipetted onto each one to rehydrate them. The rehydrated strips were 
placed in the correct orientation (+ to anode) and aligned just below the indented 
mark, to allow for the wicks to overlap the strip. The rehydrated wicks were then 
placed over both the cathodic and anodic ends of all the strips. The wicks were 
checked to ensure they were positioned over the gel portion of the strip and avoiding 
the indent in the lane so as to guarantee a good contact with the electrodes. The 
sample cups (Amersham, 80-6498-95) were then positioned approximately 1 cm from 
the cathodic end of the strip and an insertion tool was used to securely “click” the 
cups into place. The electrodes were then fitted with their “Cams” open and in direct 
contact with the wicks. 
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The amount of protein loaded per strip was 75ug for screening, 150ug for DIGE or 
300ug for spot picking. The protein samples were prepared by centrifuging to remove 
any insoluble material and the appropriate volume was loaded with a pipette tip 
placed just beneath the surface of the cover fluid. The cover of the IPGphor unit was 
closed and the desired programme selected. The temperature was set for 20oC with 
50A/strip. The IEF parameters are as follows: step 1: 300 volts for 3 hours (step-
and-hold), step 2: 600 volts for 3 hours (gradient), step 3 1000 volts for 3 hours 
(gradient), step 4: 8000 volts for 3 hours (gradient). The IEF was left at 8000 volts 
(step-and –hold) until ready for SDS-PAGE step. On completion of the IEF run, the 
strips were drained of the cover fluid and stored in glass tubes at –80oC or used 
directly in the second dimension.  
 
2.15    Second Dimension – SDS polyacrylamide gel electrophoresis 
 
2.15.1   Casting gels in the ETTAN Dalt-12 gel caster 
The 12.5 % acrylamide gel solution was prepared in a glass beaker (acrylamide/bis 40 
%, 1.5 M Tris pH 8.8, 10 % SDS). Prior to pouring, 10 % ammonium persulfate and 
neat TEMED were added.  Two types of plates were used, low fluorescent for DIGE 
experiments and hinged for preparative and screening silver stained gels. All plates 
(both normal hinged and low fluorescent) and casting equipment were inspected to 
ensure they were clean. The gel caster frame was placed on a level bench leaning on 
its “legs” so that the back of the caster was open and facing the operator. The plates 
were assembled so that the front and back plates were evenly aligned and all seals and 
hinges in place. A thin spacer was placed in the gel caster unit followed by an 
assembled plate followed by a thin spacer then another plate. The plates were 
positioned in the caster unit so that the lower, front plate was the furthest away from 
the operator and the spacers packed with their curved edges to the top. This layering 
was repeated until all 6 plates and spacers were in place. All plates and spacers were 
checked to ensure they were packed tightly together so as to minimise any gaps and 
air pockets. If all 6 gels were not required, up to 4 dummy plates could be substituted 
instead of the glass plates. When the desired amount of plates had been added, the 
thicker spacers were placed next to bring the level marginally over the edge of the 
back of the caster. The backing plate was then added to the caster frame and screwed 
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into place with the 6 screws provided. The silicone tubing was added to the outlet of 
the glass beaker and the glass tube was inserted to the other end of the silicone tubing. 
The glass tube was inserted into the inlet of the reservoir and the glass beaker 
containing the gel solution was then clamped to a retort stand. The gel solution was 
held in place using arterial clamps on the top tube and the tube running down from the 
reservoir to the caster chamber. The top tube was unclamped and the gel solution was 
allowed to fill the tubing and the reservoir drain. Air bubbles that had been generated 
were dislodged by flicking the tube. When all air bubbles had been removed the 
bottom clamp was released allowing the gel solution into the gel caster. When the gel 
solution reached the indicator line across the top of the caster, the bottom and top 
tubes were reclamped. The displacement solution (0.375M Tris-Cl 1.5M pH 8.8, 30% 
glycerol, UHP and bromophenol blue) was added to the reservoir and the glass tubing 
was slowly removed from the reservoir inlet. The clamp was removed from the 
bottom tube allowing the displacement solution into the tube and forcing the 
remaining gel solution into the gel caster. The gels were overlaid with 1 ml saturated 
butanol or sprayed with 0.1 % SDS solution. The gels were left to set for at least three 
hours at room temperature. Following this, the caster was gently unlocked and the 
gels removed and rinsed with distilled water. If the gels were not used immediately 
they were stored for up to four days in 1X running buffer at 4 oC. If gels were to be 
used for “spot picking” the plates were silanised to stick the acrylamide mixture to the 
plates. A volume of 2ml of (8ml ethanol, 200l glacial acetic acid, 10l bind-silane 
and 1.8ml UHP) was pipetted over the glass plate and wiped over with a lint free 
cloth. This was left to air dry for 15 minutes, after which 2ml ethanol and 2 ml UHP 
were each pipetted over the plate and wiped off respectively. The plate was left to air 
dry for approximately 1 hour 30 minutes.  
 
2.15.2   Preparing the ETTAN DALT 12 electrophoresis unit 
 
The electrophoresis chamber was prepared by adding 6.48 litres of UHP and 720 ml 
of 10X SDS running buffer. The pump was then turned on to cool the system to 10 
oC.  
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2.15.3   Equilibration of focussed Immobiline DryStrips 
 
The SDS equilibration buffer (30% glycerol, 6M urea, 50mM 1.5M Tris-Cl pH 8.8, 
2% SDS, bromophenol blue and UHP) which had been prepared, aliquotted into 30 ml 
volumes and frozen at –20oC was allowed to thaw to room temperature. Two SDS 
equilibration buffer solutions with DTT (65 mM) or iodoacetamide (240 mM)  
(Sigma, I1149) were then prepared. Using a forceps, the IPG strips* were removed 
from the IPGphor unit, the cover fluid was drained off by holding the strips at an 
angle and they were placed into individual glass tubes with the support film toward 
the wall. Equilibration buffer (10 mls containing DTT) was added to each tube and 
incubated for 15 minutes with gentle agitation using an orbital shaker. During this 
equilibration step, the gel cassettes were rinsed with UHP and then the tops rinsed 
with 1X running buffer. After the first equilibration, DTT containing equilibration 
solution was removed and 5 mls of the iodoacetamide containing equilibration buffer 
added. The strips were incubated for 10 minutes with gentle agitation. During this 
equilibration step, the agarose overlay solution (0.5% agarose in running buffer) was 
prepared and 50 ml of 1X running buffer was placed in a glass tube. 
 *If the strips had been frozen at this stage they were left at room temperature to thaw 
before the DTT-containing equilibration solution was added. 
 
2.15.4   Loading the focussed Immobiline DryStrips 
 
Using a forceps and holding the anode end, the IPG strips were rinsed in 1X SDS 
electrophoresis running buffer and placed between the two glass plates of the gel. The 
strip was pushed down gently using a thin plastic spacer until it came in contact with 
the surface of the gel. Any air bubbles trapped between the gel surface and the strip 
were gently removed. Approximately 1 ml of the 0.5 % agarose overlay solution was 
applied over the IPG strip to seal it in place. 
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2.15.5 Inserting the gels into the Ettan DALT 12 electrophoresis 
buffer tank 
 
When the running buffer reached the desired temperature (10oC) the loaded gel 
cassettes were wetted with UHP and inserted into the tank through the slots provided 
in the same orientation. When all 12 slots were filled, 2X running buffer was added to 
the upper chamber until the mark on the side of the chamber was reached. The cover 
of the unit was replaced and the required running conditions selected. The unit was 
run for 18–24 hours at 1.5 Watts per gel at 10°C or until the bromophenol blue dye 
front reached the bottom of the gel. When the run was completed, the gel cassettes 
were removed from the tank one at a time using the DALT cassette removal tool and 
rinsed with UHP to remove the running buffer.  
 
2.16 Method for scanning DIGE labelled samples 
 
The Typhoon Variable Mode Imager (GE Healthcare) was turned on and left to warm 
up for 30 minutes prior to scanning. The scanning control software was opened and 
the fluorescence mode was selected. The appropriate emission filters and lasers were 
then selected for the separate dyes (Cy2 520 BP40 Blue (488), Cy3 580 BP30 Green 
(532) and Cy5 670 BP 30 Red (633)). The first gel was placed in the scanner and pre-
scanned at a 1000 pixel resolution in order to obtain the correct photo multiplier tube 
(PMT) value was always maintained between 60,000-80,000 for every scan event (to 
prevent saturation of the signal from high abundant spots). Once the correct PMT 
value was found, the gel was scanned at 100 pixel resolution, resulting in the 
generation of three images, one each for Cy2, Cy3 and Cy5. Once the scanning was 
completed, the gel images were imported into the ImageQuant software. All gels were 
cropped identically to facilitate spot matching in the Decyder 6.5 BVA module. 
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2.17 Analysis of gel images 
 
2.17.1 Differential in-gel analysis (DIA) 
 
The DIA module processes a triplet of images from a single gel. The internal standard 
is loaded as the primary image followed by the secondary and tertiary image, derived 
from, for example, a control and treated sample. Spot detection and calculation of 
spots properties were performed for each image from the same gel. The Batch process 
programme determined the margins of the spots, quantified the spot intensities and 
calculated the relative spot intensity as the ratio between the total intensity of the gel 
and the intensity of each individual spot. The protein spots were then normalised 
using the in-gel linked internal standard. The data from the first gel was XML 
formatted and exported into the Biological Variation Analysis (BVA) software for 
further analysis. This procedure was repeated for each gel in the experiment.  
 
2.17.2 Biological variation analysis (BVA) 
 
Once all gels from the experiment were loaded into the BVA module, the experiment 
design was set up and the images were assigned into three groups (standard, control 
and treated). The spots on the gels were then matched across all gels in the 
experiment. This module detects the consistency of the differences between samples 
across all the gels. The software standardises the relative spot intensity of the Cy5 
image to that of the Cy3 image in the same gel. The standardised spot intensity was 
then averaged across the triplicate gels. The BVA module detected the consistency of 
the differences between samples across all the gels and applied statistics to associate a 
level of confidence for each of the differences. The protein spots with statistically 
significant protein expression changes were designated “proteins of interest” and 
placed in a pick list.  Preparative gels for spot picking with 300 ug of protein/gel were 
focussed and run out on SDS-PAGE gels. The gels were then stained with colloidal 
coomassie (section 2.18). Spots that showed differential protein expression were 
picked with the ETTAN Spot Picker (section 2.19).  
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2.18  Brilliant blue G Colloidal coomassie staining of preparative gels 
for spot picking  
 
After electrophoresis, the smaller lower plates with the gels attached were placed in 
the gel boxes containing fixing solution (7% glacial acetic acid in 40% (v/v) methanol 
(Aldrich, 200-659-6)) for at least one hour. During this step a 1X working solution of 
Brilliant Blue G colloidal coomassie (Sigma, B2025) was prepared by adding 800ml 
UHP to the stock bottle. When the fixing step had nearly elapsed a solution containing 
4 parts of 1X working colloidal coomassie solution and 1 part methanol was made, 
mixed by vortexing for 30 seconds and then placed on top of the gels. The gels were 
left to stain for 2 hours. To destain, a solution containing 10% acetic acid in 25% 
methanol was poured over the shaking gels for 60 seconds. The gels were then rinsed 
with 25% methanol for 30 seconds and then destained with 25% methanol for 24 
hours. The glass surface was dried and two reference markers (Amersham) attached to 
the underside of the glass plate before scanning. The resulting image was imported 
into the ImageMaster software (Amersham) and the spots were detected, normalised 
and the reference markers selected. While keeping the shift key depressed, all spots of 
interest were manually selected. The resulting image was saved and exported into the 
Ettan Spot Picker software.  
 
2.18.1 Spot picking 
 
The stained gel was placed in the tray of the Ettan Spot Picker (Amersham, 18-1145-
28) with reference markers (Amersham, 18-1143-34) aligned appropriately and 
covered with UHP. The imported pick list was opened, the syringe primed and the 
system was set up for picking the spots from the pick list. The spots were robotically 
picked and placed in 96-well plates, which were stored at 4oC until spot digestion. 
 
2.19 Spot digestion and identification with MALDI-TOF 
 
The 96-well plate was placed in the Ettan Digester (Amersham, 18-1142-68) to digest 
the protein as follows: Step 1 – the gel plugs were washed three times for 20 minutes 
each with 50µl 50mM ammonium bicarbonate (Sigma, A6141) in 50% methanol. 
Step 2 – the gel plugs were washed twice for 15 minutes with 50µl 70% acetonitrile 
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(Sigma, 34967). The gel plugs were left to dry for at least 60 minutes. After drying, 
the individual gel pieces were rehydrated in 10µl digestion buffer (12.5ng trypsin 
(Promega, V5111) per µl of 10% acetonitrile, 40mM ammonium bicarbonate). 
Exhaustive digestion was carried out overnight at 37oC. After digestion, the samples 
were transferred as follows: Step 1 – A volume of 40µl of 0.1% trifluoroacetic acid 
(Sigma, 302031) in 50% acetonitrile was added to the wells, mixed and left for 20 
minutes. A volume of 60µl of this solution was transferred to a fresh 96-well plate. 
Step 2 - A volume of 30µl of 0.1% trifluoroacetic acid in 50% acetonitrile was added 
to the wells, mixed and left for 20 minutes. A volume of 50µl of this solution was 
transferred to the fresh 96-well plate. The liquid in the plate was vacuum-dried in a 
maxi dry plus. After drying, the 96-well plate was placed in the Ettan Spotter 
(Amersham, 18-1142-67) for spotting onto the target plates. A volume of 3µl of 0.5% 
trifluoroacetic acid in 50% acetonitrile was added to the desiccated peptides and 
mixed 5 times. A volume of 0.3µl of this mixture was spotted onto the target plate 
after which a volume of 0.3µl matrix solution [7.5mg/ml a-cyano-4-hydroxycinnamic 
acid (LaserBio labs, 28166-41-8) in 0.1% trifluoroacetic acid in 50% acetonitrile].  
 
Peptide-mass fingerprinting was performed using Ettan MALDI-ToF Pro. The 
instrument setting was reflector mode with 175 ns delay extraction time, 60-65% grid 
voltage and 20kV accelerating voltage. Laser shots at 250 per spectrum were used to 
acquire the spectra with mass range from 600-3000Da with 8-shot mode. A total of 
three spectra were generated for each sample analysed. MALDI-generated mass 
spectra were internally calibrated using trypsin peaks or commercially available 
peptide standards (Pep4 Laser BioLabs). The peptide masses were searched against 
the National Centre for Biotechnology Information (NCBI) Homo-sapien database 
using ProFoundTM. One missed cleavage per peptide was allowed and an initial mass 
tolerance of 100ppm was used in all searches. Fixed carbamidomethylation of 
cysteines and partial oxidation for methionine was assumed. 
 
MALDI-time of flight (ToF) MS was carried out using Ettan pro MALDI-ToF Mass 
Spectrophotometer (GE Healthcare). Peak lists were generated and calibrated against 
internal trypsin autolysis peaks (m/z 842.501 and 2211.104) and or commercially 
available peptide standards (Pep 4 LaserBio Lab). PMF identifies a protein by 
measuring the molecular mass of all major trypsin products and matching these 
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molecular masses using the NCBI database with ProFound. Proteins were identified 
using ProFound with a mass tolerance of +/- 0.2 m/z, a maximum of 1 missed 
cleavage, fixed carbamidomethylation of cysteines and partial oxidation of 
methionines.  
 
Mass spectra were recorded operating in the positive reflector mode at the following 
parameters: accelerating voltage 20 kV; and pulsed extraction: on (focus mass 2500). 
Internal and external calibration was performed using trypsin autolysis peaks at 
842.509 m/z, 2211.104 m/z and PepMix 4 respectively. Calibration using Pep4 was 
performed as follows: Once two spectra were generated for the PepMix 4 mix 
(position 1 on the slide), the acquisition of spectra was stopped. The first spectrum of 
sample one was selected and the calibrant peaks readjusted for accuracy. The five 
individual peaks cover the 500-3500 Da mass range and include bradykinin fragment 
1-5 (573.315), angiotensin II human (1046.5424), neurotensin (1672.9176) and 
insulin B chain oxidised (3494.6514). Once calibration was completed it was saved as 
the new “system calibration”. The MALDI was then restarted. The mass spectra 
generated for each of the proteins were analyzed using MALDI evaluation software 
(Amersham Biosciences). Protein identification was achieved with the PMF Pro-
Found search engine for peptide mass fingerprints with expectation value < 0.01 (this 
refers to the probability that the identification is 99% accurate). 
 
 
2.20 Spot digestion and identification with nanoLC-MS/MS 
 
Tryptically digested samples were resuspended in 20µL of a LC-MS grade water 
containing 0.1%TFA and analysed by one-dimensional LC-MS using the EttanTM 
MDLC system (GE Healthcare) in highthroughput configuration directly connected to 
a FinniganTM LTQTM(Thermo Electron). Samples were concentrated and desalted on 
RPC trap columns (ZorbaxTM 300SB C18, 0.3mm x 5mm, Agilent Technologies) and 
the peptides were separated on a nano-RPC column (ZorbaxTM 300SB C18, 0.075mm 
x 100mm, Agilent Technologies) using a linear acetonitrile gradient from 0-60% 
Acetonitrile (Riedel-de Haën LC-MS grade) over 60 minutes directly into the LTQ 
via a 10µm nanoESI emitter (Presearch FS360-20-10-CE-20). Thermo linear ion trap 
 99
mass spectrometer was used for MS/MS. A scan time of ~0.15 s (one microscans with 
a maximum ion injection time of 10ms) over an m/z range of 300-2000 was used 
followed by MS/MS analysis of the 3 most abundant peaks from each scan which 
were then excluded for the next 60 seconds followed by MS/MS of the next next three 
abundant peaks which in turn were excluded for 60 seconds and so on. A “collision 
energy” setting of 35% was applied for ion fragmentation and dynamic exclusion was 
used to discriminate against previously analysed ions (data dependent analysis).  
All buffers used for nanoLC separations contained 0.1% Formic Acid (Fluka) as the 
ion pairing reagent. Full scan mass spectra were recorded in profile mode and tandem 
mass spectra in centroid mode. The peptides were identified using the information in 
the tandem mass spectra by searching against SWISS PROT database using 
SEQUESTTM using an Xcorr value of 1.5 for singly charged peptides, 2.0 for doubly 
charged peptide and 2.5 for triply charged peptides. 
 
2.20 Overview of Bioinformatic Analysis 
2.20.1   Pathway Assist ® 
 
Pathway Assist is a product aimed at the visualisation and analysis of biological 
pathways, gene regulation networks and protein interaction maps. It comes with a 
comprehensive database that gives a snapshot of all information available in PubMed, 
with the focus on pathways and cell signalling networks. This product was useful in 
assisting in the interpretation of proteomics results. It allowed visualisation of results 
in the context of pathways, gene regulation networks and protein interaction maps. 
This was done using curated and automatically created pathways. Graph drawing, 
layout optimisation, data filtering, pathway expansion and classification and 
prioritization of proteins were all possible. Pathway Assist worked by identifying 
relationships among genes, small molecules, cell objects and processes and built 
pathways based on these relationships. 
 
2.20.2 Pubmatrix  
 
Molecular experiments using multiplex strategies such as cDNA microarrays or 
proteomic approaches generate large datasets requiring biological interpretation. Text 
based data mining tools have recently been developed to query large biological 
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datasets of this type of data, (Kevin G Becker 2003). PubMatrix is a web-based tool 
that allows simple text based mining of the NCBI literature search service PubMed 
using any two lists of keywords terms, resulting in a frequency matrix of term co-
occurrence. In this way, lists of terms, such as gene names, or functional assignments 
can be assigned, genetic, biological, or clinical relevance in a rapid flexible systematic 
fashion (http://pubmatrix.grc.nia.nih.gov/). 
 
2.20.3 PANTHER (Protein Analysis Through Evolutionary Relationships) 
 
The PANTHER classification system is a unique resource that classifies genes by 
their functions, using published scientific experimental evidence and evolutionary 
relationships to predict function even in the absence of direct experimental evidence. 
Proteins are classified by expert biologists into families and subfamilies of shared 
function, which are then categorized by molecular function and biological process 
ontology terms. For an increasing number of proteins, detailed biochemical 
interactions in canonical pathways are captured and can be viewed interactively 
(http://www.pantherdb.org/). 
 
2.21 Statistical Methods 
The Statistics applied to analyze the significance of our research findings were by 
unpaired t-Test for proliferation and invasion assay and 1 way ANOVA for 
proteomics. The unpaired t test compares the means of two groups, assuming that data 
are sampled from Gaussian populations. The one-way analysis of variance 
(abbreviated one-way ANOVA) is a technique used to compare means of two or more 
samples (using the F distribution). This technique can be used only for numerical data. 
The ANOVA tests the null hypothesis that samples in two or more groups are drawn 
from the same population. To do this, two estimates are made of the population 
variance. The error bar in the graphs represents standard deviation (SD) or standard 
error mean (SEM) as mentioned in the figure legends. 
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Results: 3.0 ; SECTION A 
3.1 Design and Construction of targetable plasmid vectors for random 
integration 
In order to evaluate the mode of action and function of a gene product it is often useful to 
alter the expression levels of individual genes. The challenges one faces during gene 
overexpression studies include genetic instability, loss of observed phenotype in real 
time, and as a result unreliable data may be observed. So the aim of this study was to 
develop genetically stable and transcriptionally active targetable cell lines. Refer to 
Figure 3.1.5 and 3.1.7 for an overview of the way the Cre-LoxP system works.  
A random targeting plasmid was designed and constructed, then used for developing 
targetable stable cell lines. The random targeting plasmid vector was basically a modified 
pBluescript vector, which was cut with NotI-KpnI restriction enzyme (Section 2.13.1). A 
LoxP (target sequence of Cre recombinase) linker was designed and the sequence was 
synthesized by MWG Biotech, Germany. The LoxP linker sequence had the following 
restriction enzyme sites 5’ NotI, XhoI, FseI, SpeI, LoxP, AseI, MluI, LoxP, HindIII, 
Cla, KpnI 3’. The two LoxP sequences were designed in such a way that they were 
oriented in the same direction, to facilitate knock out of intervening sequence.  The 
synthesized sense and antisense LoxP linker sequences were annealed, cut with NotI- 
KpnI restriction enzymes and ligated (section 2.13.1) into pBluescript with NotI-KpnI cut 
ends.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1.1a Schematic representation of plasmid used to generate targetable  
            DLKP cell lines. 
 
pBKS-Geo 
5879bp 
Cla1 
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Primers were designed to PCR amplify the Neo gene. These primers also contained BglII-
HpaI restriction enzyme sites (Fig. 3.1.2a), to facilitate insertion in frame with GFP gene 
from the pEGFP-C1 plasmid (Fig. 3.1.3). The entire fusion construct including promoter 
[CMV-Geo (GFP+Neo)] was cut out using AseI and MluI restriction and cloned into 
pBluescript vector with AseI-MluI cut ends, from now on called as pBKSgeo (Fig. 
3.1.1a). Another CMV promoter was amplified using the pEGFP-C1 vector as a template 
and with AseI and SpeI sites in the primer sequences. The pBKSgeo plasmid and the 
amplified CMV promoter fragment were digested with AseI-SpeI and the CMV was 
ligated upstream of the Geo sequence and 5’ LoxP construct. 
 
 
b) 
 
 
        
  a)   
                M              N                   G                    M      
  
4.7kb 
 
~794bp
  
         
         
  
  
2mM MgSO 4          4mM MgSO 4
 
     M
   
   54.1   55.7    58     54.1     55.7   58   
  
a) 
Figure 3.1.2 a) PCR conditions optimization for amplifying Neo gene from pEGFP-C1 plasmid 
with different temperature conditions and with different MgSO4. b) Restriction enzyme 
digestion. M: DNA molecular weight marker, N: Neo PCR product cut with BglII and G: pEGFP-C1 
cut with BglII and HpaI restriction enzyme. 
Amplified Neo gene  
Annealing  Temp. 0C  
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To obtain stable single cell stable clones the plasmid was transfected into the DLKP cell 
line. A ratio of 1:3 of DNA to Lipofectamine 2000 was used for 6 well cell culture plates 
as it was observed to be minimally toxic with maximum transfection efficiencies.  
 
 
 
 
 
 
 
 
Release of ~794bp
 
4.7kb 
 
Control release of ~ 300bp 
 
 
 
 
 
 
  
  
A          B           C                    D          E             F
  
 
  
   
 
 
 
 
 
   
Release of 1.5kb fragment with BglII and 
ClaI digestion 
Linearized plasmids with BglII and 
ClaI digestion 
Figure 3.1.3 Neo fused with GFP in pEGFP-C1 confirmed through restriction 
digestion.  The neo gene was released by BglII and HpaI digestion. 
Figure 3.1.4 Restriction Enzyme digestion analysis of pBKS-geo clone. Lane A: 
MluI cut pBKSgeo construct, B: 1kb plus DNA ladder, C: uncut, pBKSgeo plasmid cut 
with BglII and ClaI in lane D, E, F. An expected release of 1.5kb fragment from clone in 
lane F . 
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Figure 3.1.5 schematic representation of targetable cell line development. 
 
 
 
 
In conclusion the fusion protein GFP+Neo is functional as evident from figure 3.1.6, 
although the GFP was less brighter compared to wild type plasmid and neomycin 
phosphotransferase was conferring resistance to G418 selection. 
 
 
 
 
 
 
 
 
 
 
 
Cre 
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                  a)        b) 
At 10x magnification 
 
       
     
 
At 20x magnification 
 
                
 
At 40x magnification 
 
               
 
 
 
 
Figure 3.1.6 Photographic representation of the transfection optimization.  a) Geo 
(GFP+Neo) in pEGFP vector (b) represents the wild type pEGFP-C1 vector transfected in 
DLKP cells using lipofectamine as transfection reagent, and observed through FITC and 
Normal light filter at different magnification. 
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Figure 3.1.7 Schematic representation of retargeting the targetable locus with 
pShuttle plasmid. 
 
GFP positive/ G418 resistant DLKP clones were transiently transfected with a cre 
recombinase expressing plasmid. Cells with LoxP sites in their genome express with Cre, 
the protein catalyzes a reciprocal recombination event between the LoxP sites. As a 
result, the DNA in between the LoxP sites is excised and subsequently degraded (refer 
fig. 3.1.7). In this case the geo fusion gene was excised (fig.3.4.3) resulting in a cell 
containing a randomly generated targetable locus with a CMV promoter upstream of 
LoxP sequence. 
 
The developed targetable cell lines were GFP negative/G418 sensitive. These constituted 
our master targetable cell lines, and could now be re-targeted by using a shuttle plasmid. 
This consisted of a single LoxP site with a promoter less selection marker gene (Neo), 
and gene of interest for overexpression. This shuttle plasmid was co-transfected in GFP 
negative/G418 sensitive cell lines along with cre expressing plasmid. Once again due to 
Cre-LoxP targeting mechanism the cells incorporate the construct, in our case 
promoterless Neo and gene of interest (schematics represented in fig 3.1.7). The promoter 
at the targetable site facilitates transcription of the inserted Neo gene, resulting in G418 
resistant cells. G418 selection pressure was applied to generate stable DLKP cell lines 
that overexpress the transgene of interest for use in subsequent gene-specific functional 
studies. 
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3.2     Stability and transgene expression level assessment of DLKP  
 geo clones using flowcytometer analysis 
 
Before removing the geo sequence by Cre expression to generate the ‘master’ targetable 
cell lines we wished to assess a panel of clones for stability of expression The reason for 
this was that potential problems that are often incurred during transgene overexpression 
include variability in gene expression levels and sudden loss in transgene expression and 
constitute a significant hurdle in gene functional studies. To investigate the stability of 
transgene overexpression we decided to perform a time course assessment by using thirty 
three “stable” DLKP clones expressing geo. These were generated as described in section 
3.1. The clones were grown over a 20 week period with regular passaging and each was 
measured for GFP positivity at each passage. Two freeze thaw cycles were also included 
as this process is often a trigger for loss of transgene overexpression in unstable clones. 
At the outset the 33 clones had varying levels of GFP expression (figure 3.2.2, 3.2.3, 
3.2.4, 3.2.5, 3.2.6). An example of the read-out by flow cytometry is shown in fig. 3.2.1. 
To gate the populations correctly GFP negative cells were analyzed first and the voltage 
of the PMT detector adjusted to place these cells below 15 on the green fluorescence 
scale. The population was also gated based on forward scatter to exclude small particles 
in the culture (fig. 3.2.1a). As a positive control, DLKP cells transfected with the vector 
pEGFP-C1 were analysed with the established gating and settings. These cells 
represented a stable mixed population with varying degrees of green fluorescence. This 
was reflected in the broad spread of fluorescence observed (fig.3.2.1b).  In contrast, a 
clonal population of DLKP cells transfected with the Geo fusion construct displayed a 
much more uniform signal across the population. What is notable is the small percentage 
of GFP negative (green dots) cells in what would be expected to be a homogenous 
population (fig.3.2.1c). This flow cytometry analysis was applied to all clones which were 
cultured in presence of G418 selection pressure, using the same settings over several 
months to observe any variations in this expression pattern with time in culture. 
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DLKP Geo clone DLKP GFPC1 mixed population 
 
Optimising Gating 
                            DLKP  
a 
c 
b 
Figure 3.2.1 Gating standardisation on flowcytometer. a) GFP negative cells 
(group of green cells) b) mixed population of GFP +ve cells (red cells) c) One of the 
stable DLKPgeo clones(group of red cells). Forward scatter optimised at (FSC-HLog 
10e2.4)   and Green fluorescence at (GRN-HLog 10e1.5)   
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To gate the populations correctly GFP negative cells were analyzed first and the voltage 
of the PMT detector adjusted to place these cells below 15 on the green fluorescence 
scale. The population was also gated based on forward scatter to exclude small particles 
in the culture (fig. 3.2.1a). As a positive control, DLKP cells transfected with the vector 
pEGFP-C1 were analysed with the established gating and settings. These cells 
represented a stable mixed population with varying degrees of green fluorescence. This 
was reflected in the broad spread of fluorescence observed (fig.3.2.1b).  In contrast, a 
clonal population of DLKP cells transfected with the Geo fusion construct displayed a 
much more uniform signal across the population. What is notable is the small percentage 
of GFP negative (green dots) cells in what would be expected to be a homogeneous 
population (fig.3.2.1c). This flow cytometry analysis was applied to all clones which were 
cultured in presence of G418 selection pressure, using the same settings over several 
months to observe any variations in this expression pattern with time in culture. 
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Figure 3.2.2 Percentage GFP fluorescence of DLKP Geo clones over 16 passages.  
DLKP parent and DLKPgeo negative cell line 11(1) used as negative controls. The 
eleven clones included here represent those with a high percentage of the population 
being GFP positive. The two stars represent freeze thaw cycles included during the 
experiment. 
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The above graph illustrates a subgroup of DLKP clones displaying consistent GFP 
expression levels over a period of four and half months. Within this subgroup there is a 
broad range in terms of percentage GFP positivity. The stars represent the time at which 
all clones were subjected to a freeze thaw cycle (24hrs at -800C). It is notable that clones 
58 and 59 in particular had considerably reduced percentage of GFP positive cells 
subsequent to the first freeze thaw. Both clones appeared to have recovered within a 
couple of passages.  
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The above graph illustrates a subgroup of DLKP clones displaying increased GFP 
expression levels over a period of four and half months. The stars represent the time at 
which all clones were subjected to a freeze thaw cycle. It is notable that all clones have a 
considerably increased percentage of GFP positivity after the first freeze thaw, and after 
the second freeze thaw clone 57, in particular, had no reduction in GFP expressing 
population compared to the rest. 
Figure 3.2.3 Percentage GFP fluorescence of a subset of DLKP Geo clones over 16 
passages. DLKP parent and DLKPgeo negative cell line 11(1) used as negative controls. 
The five clones included here represent those with increased percentage GFP expressing 
population. The two stars represent freeze thaw cycles included during the experiment. 
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The above graph illustrates a subgroup of DLKP clones displaying decreased GFP 
expression levels over a period of four and half months. The four clones initially had very 
high GFP expressing populations, and as the passages continued this fell to as low as 
20%.  But one clone in particular (28) was interesting in that it was showing reduced  
GFP expression until just after the second freeze thaw when this trend was reversed to 
show an increased GFP expressing population. The stars represent the time at which all 
clones were subjected to a freeze thaw cycle (24hrs at -800C).  
 
 
 
Figure 3.2.4 Percentage GFP fluorescence of DLKP Geo clones during 16 passages. 
DLKP parent and DLKPgeo negative cell line 11(1) were used as negative controls. The 
four clones included here represent those with decreased percentage GFP expressing 
population. The two stars represent freeze thaw cycles introduced during the experiment. 
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The above graph illustrates a subgroup of DLKP clones displaying medium GFP 
expression levels over a period of four and half months. The four clones displayed a 
relatively broad GFP positivity (30-60%) and as the passages progressed the detection 
level was reduced as low as 10% (clone 9 and 27). The stars represent the time at which 
all clones were subjected to a freeze thaw cycle (24hrs at -800C). Subsequent to freeze 
thaw cycles it was observed that the clones regained the initial GFP positive levels. 
 
 
 
Figure 3.2.5 Percentage GFP fluorescence of DLKP Geo clones representing 16 
passages. DLKP parent and DLKPgeo negative cell line 11(1) were used as negative 
controls. The four clones included here represent those with medium level of GFP 
expressing population. The two stars represent freeze thaw cycles included during the 
experiment. 
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The above graph illustrates a subgroup of DLKP clones displaying low and somewhat 
erratic GFP expression levels over the duration of the experiment. The four clones from 
the beginning were observed to have low GFP positivity and as the experiment continued 
the expression levels became inconsistent. The stars represent the time at which all clones 
were subjected to a freeze thaw cycle (24hrs at -800C).  The break in the clone 53 line 
accounts for the fact that no data was acquired during that passage.  
 
This study provided us with a substantial amount of information about the stability issues 
one has to face during gene overexpression studies. From the stability assessment of a 
panel of DLKP geo overexpressing clones we learned that, although the clones are from 
an isogenic population they had very different stability profiles. This may be due to 
genomic integration at different sites demonstrating clearly the problems with generating 
transgenic clones. Out of 33 clones only clones 19,17,13,21 and 50 were stable and all the 
remaining clones were observed to have stochastisity in their stability and expression 
levels.  
Figure 3.2.6 Percentage GFP fluorescence of DLKP Geo clones over 16 passages. 
DLKP parent and DLKPgeo negative cell line 11(1) were used as negative controls. The 
four clones included here represent those with low levels of GFP expressing cells. The two 
stars represent freeze thaw cycles included during the experiment. 
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3.3 Cell cycle assay for Stable GFP expressing DLKP cell lines 
 
One of the most striking observations made during the stability assessment (section 3.2) 
of the DLKP geo clones was that cells derived from a single cell clone appeared to have 
both GFP positive and negative cells within the population. One would expect to see 
variations between clones but not within them. To further investigate this observed 
phenomenon an experiment was designed to measure variations in fluorescence which we 
thought was related to cell cycle (section 2.7.4).To address this a propidium iodide (DNA 
binding dye) based cell cycle assay was performed.  The comparison between DLKP vs. 
DLKP geo clones over 32 hrs showed no dramatic difference either in GFP expressing 
population (fig. 3.3.1), monitored by flow cytometry although we observed variation in 
cell percentage at different cell cycle checkpoints (G0/G1, S and G2/M) (fig. 3.3.2). 
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Figure 3.3.1 Percentage of  GFP positive cells of DLKP Geo clones over time. DLKP 
parent was used as negative control. The five DLKP geo clones 19,17,59,11 and 14 
included here were representative of a broad range of GFP expressing populations. 
 
Figure 3.3.1 illustrates a subgroup of DLKP clones displaying broad range of GFP 
positivity. The rationale behind selecting such varied DLKP geo clones was to represent 
every kind of expression that we observed during our stability assessment. The GFP 
expression level of five clones was consistent across (2-32hrs) time, suggesting that there 
was no difference in GFP expression during cell division. The doubling time of DLKP is 
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approximately 22hrs (data not shown). Most notable was the sudden increase in GFP 
positivity observed 2hrs after addition of serum media. This was possible due to reduced 
translation under serum starved conditions used to synchronize the cultures followed by a 
burst of translation upon addition of serum. 
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Figure 3.3.2 illustrates the comparison of parent DLKP with one of the GFP expressing 
DLKP clones (high expresser), the different shades of colour in each bar  
Figure 3.3.2 represents cell population content captured at different cell cycle stages. The 
doubling time for DLKP is approximately 22hrs (data not shown). Cell cycle trend was 
observed, though there was no drastic change in cell number at different cell cycle stages. 
Figure 3.3.2 Cell cycle assay performed with DLKP and a stable DLKPgeo clone at 
0, 2, 4, 8, 12, 16, 24, 32 hrs intervals. Y axis represents the percentage of cells at each 
phase of the cell cycle (G0/G1, S and G2/M) at each time point. 
DLKP                            DLKP-geo 19
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So the stochastic GFP positivity observed was unlikely to be due to cell cycle dependent 
variation in expression. It would appear that the geo clone generally had a higher 
percentage of cells in the G0/G1 phase and less in the G2/M phase than the parental 
control. However, the pattern observed over time was similar for both cell lines and, more 
importantly, didn’t correlate with any fluctuations in GFP positivity. 
 
3.4 Generation of geo knockout cell lines. 
 
The method chosen to develop targetable, master DLKP cell lines was based on the Cre-
LoxP system. After the stability assessment (Section 3.2), we selected a range of DLKP 
geo clones with high to low expression levels. The clones chosen in this experiment were 
DLKP geo 17, 19 and 11.  These cell lines were transiently transfected (section 2.8) with 
a Cre expressing plasmid vector. 48hrs after transient transfection the cells were 
trypsinised (section 2.6) and were single cell cloned in 96 well plates (section 2.7.1). 
Upon reaching confluency the cells were trypsinised and seeded in duplicate 96 well 
plates. One set of clones was incubated with G418 media selection (800g/ml).  The 
clones that lost the Geo gene were killed. These were the clones of interest to us (fig 
3.4.1). These clones were GFP negative/G418 sensitive and constituted the master 
targetable DLKP clones.  
 
To confirm that these clones were genuine “geo knock outs”, we screened them both at 
the transcriptional and translational level. Western blot analysis (section 2.14) of the 
parent DLKP-geo clones and their geo knock out progeny was performed (refer fig. 
3.4.2). An expected band of 55kDa (Geo) was observed in the DLKP-geo parents and no 
band in their knock out counterparts, confirming absence of expression. Similarly 
genomic DNA was isolated from DLKP-geo (section 2.11.1) and their geo knockout 
derivative cell lines and PCR was performed (section 2.11.5) to confirm removal from the 
genome (refer fig 3.4.3). The expected 600bp amplicon product was observed in DLKP 
geo clones but no product in the knock out clones. Two DLKP geo knockout master 
targetable clones were chosen for future functional studies. They were DLKP 17(high 
expresser) and DLKP 11 (low expresser).  
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Figure 3.4.1 illustrates the screening process to identify the knockout of geo gene from 
DLKP geo clones. The knockout was confirmed both by applying G418 selection and 
visualising through fluorescent microscope. From the figure it’s evident that the clones 
which were sensitive to G418 selection are also GFP negative. Figure 3.4.2 confirms the 
functionality of the molecular tool that was explored based on the Cre-LoxP system. The 
three DLKP geo clones 17, 19 and 11 were subjected to transient Cre overexpression, 
resulting in Cre-LoxP mediated knockout of the Geo gene.  In the western blot DLKP 
parent was used as a negative control. DLKP transfected with pEGFP-C1 was used as 
positive control. A 55kda band was detected in Geo expressing DLKP cell lines 
(GFP+Neo fusion product), and a 27 kDa (GFP) band in the wild type control was 
observed. Conversely no 55 kda band was observed in Cre treated DLKP geo clones, 
confirming the knockout. 
 
 
 
        A)       B) 
 
 
 
 
 
 
                                                              C) 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4.1 Cured clone (geo knockout), which is GFP negative and G418 sensitive. 
A+B; phase contrast, C; FITC filter, A+C; no G418 in media, B; with G418 in media. 
Cured DLKP Geo knockout clone 
GFP negative 
With G418 Without G418  
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Figure 3.4.2 Western blot analysis of DLKP-geo clones and their knockout sub 
clones.  Lane 1: DLKP parent negative control, lane 2: DLKP-GFP-C1 expressing cell 
line, 27 kDa GFP band detected, lane 3,5and7: DLKP-geo 11,17 and 19 expressing cell 
lines, 55 kDa band detected, lane 4,6and8: DLKP-geo 11,17 and19 ‘knockout’ sub 
clones, no geo band detected. GAPDH loading control identified 38 kDa. 
 
 
 
 
 
 
 
  
         
 
 
 
 
 
 
 
 
Figure 3.4.3 illustrates Geo knockout in DLKP-geo cre treated genomic DNA samples.  
Genomic DNA was extracted from GFP negative and G418 sensitive clones along with 
their GFP positive and G418 resistant parental cell lines. GFP-specific primers were used 
in a PCR- based screen for geo knockout in DLKP geo clones, transiently transfected 
with Cre. Several different gDNA controls were used involving wild type DLKP, Mouse 
embryonic stem cells, GFP positive DLKP and no template control. 
Figure 3.4.3 PCR analysis of genomic DNA from DLKP geo and their cre treated sub 
clones. Lane M :  DNA Marker , 11 : DLKP 11geo clone, 11(1) : DLKP 11(1) cre treated, 
11(2) : DLKP 11(2) cre treated, 14 :  DLKP 14 geo clone, 14(1) : DLKP 14(1) cre treated, 
14(2) : DLKP 14(2) cre treated, W: wild type DLKP,  Es: mouse embryonic stem cell 
DNA,  Ntc : no template. 
 
 
  
 
      M   11 11(1)11(2) 1414(1) 14(2) W Es ntc        M     GFP                  
GFP 27kDa 
Geo  55 kda 
GAPDH  38 kda 
    1           2           3          4          5          6         7          8 
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3.5 Design and construction of re-targeting vector, pTarshuttle 
 
To develop targetable cell lines we utilized the Cre-LoxP based system, and accordingly 
the two LoxP sequence were oriented in the same direction. Subsequently geo knock out 
DLKP clones are left with a single LoxP sequence with a CMV promoter upstream of it 
in the genome.  To make use of this targetable locus we designed and constructed a 
shuttle vector to be used for knock in of any gene of interest. This pShuttle was 
constructed in the Invitrogen pTarget vector background (mammalian expression vector). 
As the pTarget vector was a TA open ended cloning vector we used Klenow polymerase 
and ligase enzyme to re-circularise the vector. A screen of 14 plasmid extracted from XL-
Blue 1 competent E. coli colonies (section 2.13) revealed that pTarget vector was 
successfully circularized (fig. 3.5.2). The pTarget vector was further modified by 
removing the CMV promoter region upstream of Neo and cloning in its place a LoxP 
sequence. The LoxP sequence was synthesized (MWG Biotech, Germany) with ClaI-
AvrII restriction enzyme sites at the ends. The synthesized sense and antisense sequences 
were annealed and digested with ClaI-AvrII as was the pTarget vector. The double 
stranded LoxP sequence was ligated with the pTarget plasmid vector. Restriction enzyme 
screening of miniprep (refer section 2.13.1) of E.coli colonies confirmed six out of twelve 
plasmids contained the insert (fig 3.5.2).   
 
 
 
 
 
 
 
 
Figure 3.5.1 Schematic representation of pShuttle LoxP vector used for transgene 
targeting studies. 
 
 
 
pShuttle 
5371bp 
 120
                
  
 
 
 
 
 
 
3.6   Proof of concept of targeting tool with pShuttle LacZ in DLKP 
targetable cell line. 
 
The final step in validating the use of the DLKP targetable cell lines as a research tool 
was to demonstrate that a transgene could be specifically introduced at the LoxP site in 
the cells. As proof of concept we cloned the LacZ gene into pShuttle vector (which has 
promoterless Neo and LoxP site). The pShuttle LacZ plasmid was co-transfected along 
with pCre into targetable DLKP clones.  The pSVGal containing LacZ under control of 
SV40 promoter was included as a positive control. X-gal staining (section 2.7.2) was 
done with transiently transfected cells to estimate efficiency and ensure successful 
expression of the galactosidase enzyme from the pShuttle-LacZ.  G418 selection was also 
applied to select for stable clones that had incorporated the plasmid. 
 
Figure 3.6.1 illustrates the process that is undergone during re-targeting the LoxP site in 
targetable cell lines. The re-targeting vector has a single LoxP site, downstream of it a 
promoter-less Neo gene. Upstream of LoxP, we have cloned in LacZ reporter gene 
followed by its own CMV promoter. The re-targeting plasmid was co-transfected with 
pCre. LoxP reciprocal recombination is triggered which facilitates LacZ insertion 
Figure 3.5.2 pTarget vector, circularized by treatment with klenow polymerase 
followed by ligation. Lane M: 1kb plus DNA ladder, lane uncut: circularized plasmid, 
lane 1 to 14 linearized plasmid preps by digestion with ClaI. 
  M uncut     1     2      3    4      5      6    7      8     9   10   11   12    13    14  
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between the two regenerated LoxP sites along with the promoter less Neo upstream. The 
CMV promoter already present in the targetable locus facilitates Neo expression to confer 
resistance in cell lines for G418 stable selection. The stable cell lines are assayed for -
galactosidase activity to confirm LacZ translation.  The cells with non-targeted, randomly 
integrated plasmid should be sensitive to G418 selection due to inactive Neo and hence 
killed. 
 
              
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                   
 
Figure 3.6.1 Schematic representation of re-targeting the loxP site in targetable cell 
lines.  A) Targeted integration, promoterless neo being driven by CMV at integration site. 
B) Random integration, neo still being inactive due to random insertion and hence cells 
killed during selection.  
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3.7   Design and construction of targeting LacZ reporter plasmid vector 
 
The LacZ gene was cut from pSVGal reporter plasmid vector with XhoI-KpnI; similarly 
the pShuttle vector was digested with XhoI-KpnI.  The LacZ gene was ligated with 
pShuttle and screening the mini-preped plasmid samples confirmed two out of three 
positives (fig 3.7.3). The pShuttle-LacZ targeting vector was transiently co-transfected 
with the Cre expressing plasmid in the targetable DLKP clones and the cells were stably 
selected for G418 resistance. The surviving cells were stained for -gal activity (section 
2.7.2). From the results it was confirmed that although the transfection worked not all 
cells which survived selection were X-gal positive (fig. 3.7.4).   
This suggested that the pShuttle targeting vector may be leaky, i.e. LacZ negative /G418 
resistant cells with or without Cre expression. This may be due to two possible reasons. 
Though Neo is promoterless in the pShuttle vector and should only become active upon 
Cre-mediated insertion at the genomic LoxP site, it may be that independent of Cre, the 
plasmid 1) randomly integrates in the genome near an endogenous promoter/enhancer 
element (As shown in fig 3.7.1) or 2) randomly integrates in the genome in an orientation 
that facilitates activation of transcription from the CMV on the plasmid. The most likely 
reason is (1) and the lack of X-gal staining is due to inactivation of the LacZ gene before 
or during insertion in the genome by endogenous exo & endonucleases. 
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Figure 3.7.1 Schematic representation of possible random integration at Enhancer 
sites in the Genome. A) Targeted integration, promoterless neo being driven by CMV at 
the integration site. B) Random integration, neo still being inactive due to random 
insertion and hence cells killed during selection. C) Random integration in the vicinity of 
endogenous enhancer/promoter which drives neo and hence resistance to G418 selection. 
Nucelase activity may be responsible for inactivation of LacZ sequence prior to 
integration to give X-gal negative cells (green). 
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Figure 3.7.2 Schematic representation of shuttle vector carrying LacZ reporter gene 
which was used as proof of concept for our developed targetable system. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7.3 LacZ gene cloning confirmation in pShuttle vector. XhoI and EcoRV 
enzymes were used to check for the desired fragment release, lane M: 1kb plus DNA 
ladder, uncut plasmid, 6 and 16 confirmed released of the desired fragment length and 14 
was a negative clone. 
 
      M      uncut        6             14              16 
pShuttle-LacZ 
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 -Galctosidase staining with pShuttle LacZ & pShuttle-INS 
transfected DLKP targetable cell line 
 
From this result it was clear that the genetic tool required improvement. We thought the 
phenomenon was most likely due to endogenous enhancer/promoters and not due to the 
CMV in the plasmid. So to avoid any positional effect we used an insulator sequence to 
counteract the effect of local promoters upon random insertion.  Insulators possess two 
properties: an anti-enhancer activity that blocks enhancer-promoter communication, and 
an anti-silencer activity that prevents the spread of repressive chromatin (Emily J Kuhn et 
al 2003). Figure 3.8.2 provides proof of the insulator element being cloned in pShuttle-
INS-LacZ plasmid. A restriction digestion enzyme confirmed (fig. 3.8.2) that six out of 
A B 
Figure 3.7.4 Transfection of targetable DLKP cell line with pSVGal & pShuttle-
LacZ with pCre. Blue colour indicates positive cells. C&D cells transfected with 
pShuttle LacZ & without pCre. E&F cells transfected with pShuttle LacZ & pCre.  
A,C&E cells stained for gal activity before selection. B,D&F cells stained for gal activity 
after selection in G418 for 4-5 days. 
Transient  pSVgal  expression
After selection with G418
Transient  pshuttlelacZ  expression G418 Stable pshuttlelacZ expression
Co-transfected 
with Cre
expressing 
vector
without Cre After selection with G418
C D 
E 
F 
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twelve minipreped samples were positive for desirable fragment release when digested 
with   HpaI-AvrII  enzymes.  
 
Figure 3.8.1 illustrates a schematic representation of the re-targeting vector similar to that 
mentioned in section 3.7.1, but with one modification, i.e., incorporation of an insulator 
element upstream of LoxP. The rationale was to try to prevent inappropriate transcription 
of the Neo gene, which was resulting in survival of cells with non-specific integration 
events. Accordingly re-targeting plasmid was co-transfected with Cre in the targetable 
cell lines. The Cre-LoxP reciprocal recombination should facilitate LacZ insertion in 
between LoxP sites along with the promoter-less Neo. The CMV promoter already 
present at the targetable locus should allow transcription of Neo to confer G418 resistance 
on cell lines correctly targeted. The stable cell lines were assayed for -galactosidase 
activity to confirm LacZ expression.   
 
Figure 3.8.3 demonstrates X-gal staining of cells transfected with pSVGal and pShuttle-
LacZ–INS plasmid vector. From the observed results it is evident that there was a 
dramatic reduction in cell survival post selection (figure 3.8.3f (i)).  These DLKP cells 
were co-transfected with pShuttle LacZ-Ins plasmid and pCre. This result suggested that 
the insulator worked, however a small population still remained negative for -gal 
activity (figure 3.8.3f (ii)). However, the number of cells surviving selection was greatly 
reduced compared to previously, in the absence of an insulator sequence.  
 
In conclusion though we were able to overcome the inappropriate transcription of the Neo 
gene, it was not 100% “clean”. There were always surviving cells which were -gal 
negative/G418 resistant. This necessitated an extra step where transgene expression 
needed to be verified. 
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Figure 3.8.1 Schematic representation of re-targeting the loxP site in targetable cell 
lines with pShuttle containing an insulator. A) Targeted integration, promoterless neo 
being driven by CMV at integration site. B) Random integration, promoter/enhancer 
effect being blocked by insulator sequence 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
     M      1          2        3      4          5        6         7        8         9        10    11   12 
Figure 3.8.2 Restriction enzyme digestion analysis of plasmids to confirm insulator sequence 
cloning in pShuttle vector. Restriction enzyme digestion with HpaI and AvrII released desired 
fragment confirming successful cloning, lane M: 1kb plus DNA ladder, lane 1, 2,4,6,8 and 9 
indication of desired fragment release.  
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A)           B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8.3 A& B transfection of DLKP targetable cell line with pSVGal & 
pCre. Blue colour indicates positive cells. C&D cells transfected with pShuttle LacZ 
& without pCre. E&F (i) cells transfected with pShuttle LacZ & pCre. A, C&E cells 
stained for gal activity before selection. B, D&F (i&ii) cells stained for gal activity 
after selection in G418 for 4-5 days. F (ii) illustrates an example of LacZ –ve colony 
of cells. 
After selection with G418
Transient  pshuttleinslacZ  expression G418 Stable pshuttleInslacZ expression
Co-transfected 
with Cre
expressing 
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Transient  pSVgal  expression
without Cre After selection with G418
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SECTION: B 
 
3.9   Design and construction of LINE-1 sequence specific targeting   
plasmid vector 
 
In the previous section, the first step in generating the master targetable cell lines 
involved insertion of the plasmid containing the LoxP flanked “Floxed” geo into the 
genome in a random manner. Clones were then screened for expression and other 
properties but the site of insertion was unknown.  
In this next experiment we wished to avoid this random first step and attempt to insert the 
“floxed” geo into a chosen location or locations in the genome. We planned to use an 
approach relying on Homologous Recombination (HR) to achieve this. This method was 
developed in the late 1980’s as a means of ‘knocking out’ genes in ES cells to study gene 
function in vivo. The technique relies on HR mechanism that occurs during meiosis 
where sister chromosomes swap alleles to introduce genetic diversity. By flanking a 
selection marker with sequence that matches a genomic locus, the marker is targeted to 
that locus, albeit at low efficiency. This phenomenon occurs at very low efficiency in 
somatic cells so in this case we chose target loci that occur at very high frequency in the 
genome- Long Interspersed Nuclear Element 1 (LINE1 or L1 elements). 
There are approximately 80-100 transcriptionally active copies of this element in the 
human genome. The rationale behind using L1 elements was a) they constitute 17-20% of 
the genome which should make them abundantly available targets and b) using L1 
element as target should help avoid targeting endogenous genes. This approach would 
hopefully overcome the problem of low frequencies of homologous recombination in 
somatic cells and a possible development of a gene targeting system. The plasmid that 
was designed contained the following elements: a reporter fusion gene [Geo (GFP+Neo)] 
with two LoxP sequences flanked by split 5’ and 3’ portions of the ORF-2 sequence of 
human L1 element. A thymidine kinase outside the 5’ end arm of the L1 element was 
included for negative selection i.e. to reduce or eliminate non-targeted recombination.  
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The background vector used was a modified pBluescript (Fig 3.1.1). The 1.7kb 5’ arm 
was PCR amplified from pSP52 plasmid vector with NotI-XhoI restriction enzyme 
sequence overhangs. Later the PCR amplicon and pBluescript were digested with NotI-
XhoI, ligated to each other and restriction enzyme digestion analysis of the resulting 
plasmid (pBKS 5’L1) preps confirmed two positives out of six screened (fig 3.9.3).  
Similarly a 2.4kb 3’ arm of the L1 ORF2 was subcloned from pSP52 plasmid vector with 
HindIII-ClaI restriction enzymes and ligated with pBKS 5’L1 vector. Restriction 
digestion screening revealed one positive out of three (Fig. 3.9.3.1) and this plasmid was 
designated pBKS 5’-3’L1. Upstream of the 5’arm we cloned the Herpes Simplex 
Thymidine Kinase gene at the NotI site (fig. 3.9.3.2). The thymidine kinase produced by 
cells that have incorporated it phosphorylates ganciclovir making it toxic and killing 
incorrectly targeted cells. This L1 element-targeting vector containing reporter gene, was 
linearized with HindIII and transfected into DLKP cells. Conditions for maximum 
transfection efficiency were optimized (fig 3.9.4).  
Figure 3.9.1 illustrates the procedure involved in generating LINE-1 specific stable 
targetable cells by homologous recombination. The targeting vector was comprised of a 
reporter/selection fusion gene Geo (GFP + Neo) as represented by the green bar in the 
diagram, flanked by LoxP stie on either side to facilitate Cre mediated removal. A CMV 
promoter upstream of LoxP was also included. The LoxP sites were flanked by ORF 2 
segments of the LINE-1 element. Upstream of the 5’ end a negative selection marker 
gene thymidine kinase was cloned.  The DLKP cells transfected with this plasmid were 
grown in G418 and Ganciclovir containing media to select for homologous integration 
events. Upon identifying correctly targeted clones the geo sequence could be removed by 
transient Cre expression as described previously, leaving behind a single LoxP site and a 
CMV promoter within the ORF2 of an endogenous LINE-1 element. 
 
From the transfection data it was confirmed that the plasmid was transcriptionally active. 
Figure 3.9.4 demonstrates the transfection optimization conditions for pBKS-L1 targeting 
plasmid in DLKP cells. Different DNA: Lipofectamine 2000 ratios were used to achieve 
maximum transfection with minimum damage to the cells. From the results it was evident 
that 2g:5l of DNA to Lipofectamine ratio was optimal (Fig 2b). Although figure 2c 
appears to have brighter cells, more cells were killed.  
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Figure 3.9.1 Schematic representation of L1 element specific targeting mechanism 
and subsequent knockout of geo to create a single re- targetable LoxP site. A) HR 
event: cells are G418 resistance, GFP positive and Ganciclovir resistance. B) Non-HR: 
cells G418 resistance, GFP positive but Ganciclovir sensitive. 
The two blue boxes represent split ORF2 region of L1NE 1 element. The pink boxed 
arrows represent LoxP sites. The red box represent Thymidine kinase gene. The purplish 
box represents CMV promoter. 
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Figure 3.9.2 Schematic representation of pBKS-L1 targeting plasmid.  LINE-1 
element ORF2 region was split into two with 5’ 1.7kb (NotI and XhoI) and 3’ 2.4 kb 
(HindIII and ClaI) fragments cloned on either side of two LoxP sites. The geo 
selection/reporter cassette was inserted between the LoxP sites and a HSV-thymidine 
kinase expression cassette was placed upstream of the 5’arm. 
 
 
 
 
 
 
LoxP LoxP
pBKS-L1 
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Figure 3.9.3 DNA agarose gel confirmation of 5’arm cloning. NotI and XhoI 
restriction enzyme digestion to check cloning of 5’ arm of ORF2 of LINE-1 element in 
pBKSgeo vector, lane 2 & 4 release of expected size of ~1.7kb, lane 1: uncut plasmid, 
lane 3, 5, 6, 7: cut with NotI and XhoI   
 
 
                                
 
 
Figure 3.9.3.1 DNA agarose gel confirmation of LINE1 3’arm cloning. HindIII and 
ClaI   restriction enzyme digestion to check cloning of 3’ arm of ORF2 of LINE-1 
element in pBKSgeo vector, lane 4: release of expected size of ~2.4kb, lane 1: uncut 
plasmid, lane 2, 3: cut with HindIII and ClaI 
 
   M          1         2          3          4         5         6          7 
       M                  1           2        3       4 
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Figure 3.9.3.2 DNA agarose gel confirmation of Thymidine kinase (Tk) cloning.  
NotI and SacI restriction enzyme digestion to check cloned Tk gene in pBksgeoL1 
plasmid lane 1: NotI cut, 2: SacI cut release of ~2.1kb fragment, M: DNA ladder, 3: 
Linearized plasmid cut with ClaI. 
 
 
 
 
 
 
 
 
 
 
 
 
       M                     1            2        3                  M 
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               2d 
 
 
 
 
Figure 3.9.4 Transfection optimization with LINE-1 targeting plasmid.  2a, 2b, 2c, 
2d represent the different DNA to Lipofectamine 2000 concentrations. While the DNA 
concentration was kept constant at 2g the Lipofectamine 2000 concentration was varied 
from 2, 5, 7 and 10 l. The cell concentration was kept constant at  3x105 cells/ml and 
picture view is at 10X optical magnification. 
 
View through FITC filter                           Phase contrast View 
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3.10 Transfection of DLKP with LINE-1 specific targeting plasmid and 
isolation of single cell clones 
 
The transfected cells were stably selected with G418/Ganciclovir containing media and 
surviving cells were subjected to limiting dilution, single cell cloning in 96 well cell 
culture plates. We were able to isolate 600 single cell clones which were expanded for 
genomic DNA isolation (section 2.8.6). PCR screening was performed using primers 
which were validated with positive controls (fig 3.10.1). Several pairs of primers were 
designed and used in the screen. Sense primer designed outside the 5’ arm but still in the 
L1 element (in-between ORF1 and ORF2) and an antisense primer in the geo region. If a 
HR event occurs, these would amplify ~2kb product (Fig. 3.10.2). Since we did not have 
a perfect positive control we used sP52 plasmid which has ORF1 and ORF2 regions of L1 
element and pBKS 5’-3’ L1 targeting plasmid as control to make sure the primers were 
binding properly with expected amplicon. Unfortunately despite screening 600 clones we 
were not able to find a single positive clone with a successful L1 homologous 
recombination event. This suggested that the homologous recombination frequency in 
these cells was at the minimum less than one in six hundred compared to random 
integration. 
A) 
 
B) 
 
C) 
Figure 3.10.1 schematic representation of primer designed regions for HR 
Screening. A) Represents several sets of primers designed at 5’arm of ORF2 in L1 
element as well as from the Geo sequence. B) Primers designed in pSP52 plasmid 
containing ORF1 and ORF2 full length L1 element. C) The primers designed amplify in 
the event of HR . 
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Figure 3.10.2 Represents large scale gDNA PCR screening for homologous 
recombination. Lane M: 1kb plus DNA ladder, Clones: screened, lane 1: sp52 plasmid 
control, 2: DLKP-genomic DNA, 3: pBKS-5’-3’L1 plasmid. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         M                                               clones                                   1    2   3    M 
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SECTION: C 
 
3.11   Sub cloning of selected gene targets for stable overexpression 
studies. 
 
In order to evaluate the mode of action and function of a gene product it is often useful to 
alter the expression of the gene. This is accomplished through powerful gene 
manipulation methods including overexpression or knockdown/knockout. Major obstacles 
with transgene integration and stable transgene expression in mammalian cells are 
instability either due to chromosomal position effects and/or copy number and variation 
in expression between different clones. Studies done by Fukushige and Sauer, (1992) 
addressed the problem of gene transfer into mammalian cells and site specific integration 
of transgenes at pre-selected sites in the genome with the Cre-LoxP based targeting 
system.  
 
We also applied this system to overcome the above challenges in gene manipulation 
studies; we developed stable targetable DLKP clones. We checked the robustness of Cre-
LoxP targeting by transfecting a pShuttle LacZ reporter vector (section 3.8).  From the 
initial LacZ reporter based results, we realised the targetable system was not 100% 
efficient.  We improved this efficiency to an acceptable level by including an insulator 
element.  
 
The reason we put the effort into creating these targetable cell lines was to study gene 
function in a more predictable system. The genes that we were interested in investigating 
were identified in microarray studies in this lab [Pierce A. PhD thesis NICB, (2006)] 
comparing parent DLKP with drug resistant cell lines with variable invasive phenotypes. 
From this study, we selected 4 target genes whose differential expression was validated 
by qRT-PCR analysis. This validation confirmed that these 4 genes were differentially 
upregulated compared to mildly invasive parent DLKP cell line. These were GLP1-R, 
KCNJ8, TFPI2 and S100A13.  
 
The cDNA coding for these targets were subcloned into pShuttle vector, for transfection 
in two targetable DLKP master cell lines: DLKP-17(high expresser) and DLKP-11(low 
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expresser). The rationale behind selecting these clones was to study the dosage effect of 
transgene overexpression.  Investigation of these target genes at two different expression 
levels in the same cell line background was performed. Their functional impact on 
cellular invasion and proliferation was investigated.  
 
3.11.1 Design and construction of GLP1-R gene in targeting plasmid 
vector 
 
Glucagon like Peptide 1 Receptor (GLP1-R) cDNA was purchased from OpenBiosystems 
as a cloned sequence in pCR4-TOPO plasmid vector (cat. no. MHS4426-99238938). Both 
pCR4-TOPO and pShuttle-Ins vector were digested with EcoRI enzyme (section 2.13.1) 
and ligated with pShuttle-Ins plasmid (refer fig.3.11.1a  and section 2.13.2), restriction 
digestion screening of mini-prepped (section 2.13) plasmid DNA confirmed two out of 
eighteen samples were positive (fig. 3.11.1b). One of the positive clones was selected and 
maxi preparation (section 2.13.6) of plasmid DNA was performed. The pShuttle-Ins-
GLP1-R plasmid was co-transfected with pCre into DLKP-11 and 17 (section 2.8) and 
selected with G418. The cells surviving selection pressure were subjected to single cell 
cloning in 96 well plates (section 2.7.1). 
 
                   
INS 
pShuttle-Ins-GLP1-R 
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Figure 3.11.1a Schematic representation of pShuttle-Ins targeting vector carrying 
GLP1-R gene, EcoRI restriction enzyme was used to clone the cDNA construct. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11.1b DNA agarose gel confirmation of GLP1-R cloning. Panel of clones 
(18) screened for insertion of GLP1-R gene in pShuttle vector. EcoR1 restriction enzyme 
digestion reveals two clones (4 and 11) had the expected fragment size (~ 1.5kb release), 
lane 4 and 11 represents GLP1-R clones with the desired release of fragment 
 
3.12 Design and construction of KCNJ8 gene in targeting plasmid vector 
 
KCNJ8 cDNA was purchased from OpenBiosystems as a cloned sequence in pCMV-
Sport6 plasmid vector (cat. no. MMM1013-63162). Both pCMV-Sport6 and pShuttle-Ins 
vector were digested with BamHI-XhoI enzyme (section 2.13.1) and an insert from 
pSport ligated with pShuttle-Ins vector (refer fig.3.12.1 and section 2.13.2). Restriction 
digestion screening of mini-prepped (section 2.13) plasmid DNA confirmed that two out 
of four samples were positive (fig. 3.12.2). One of the positive clones was selected and 
maxi preparation (section 2.13.6) was performed. The pShuttle-Ins-KCNJ8 plasmid was 
co-transfected with pCre into DLKP-11 and 17 (section 2.8) and selected with G418. The 
cells surviving selection pressure were subjected to single cell cloning in 96 well plates 
(section 2.7.1). 
 
 M Uncut   0    1    2    3     4       5     6    7    8   9     10 11   12    13     14    15   16   17 18 
 
1.6kb 
 
1.0kb 
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Figure 3.12.1 The pShuttle-Ins targeting vector containing KCNJ8 (Potassium ion 
channel) gene.  BamHI and XhoI restriction enzymes were used to sub-clone the cDNA 
into the construct. 
 
 
 
 
 
 
 
 
 
 
Figure 3.12.2 DNA agarose gel confirmation of KCNJ8 cloning in pShuttle-Ins 
vector. Restriction enzyme digestion BamH1:Xho1 released the expected ~1.6kb 
fragment from clones 1, 3 and 4 confirming KCNJ8 gene insertion. 
 
 
      M          uncut         1                  3              4                6 
 
1.6kb 
1.0kb 
INS 
pShuttle-Ins-KCNJ8 
 142
3.13 Design and construction of TFPI2 gene in targeting plasmid vector 
 
Tissue Factor Pathway Inhibitor 2 (TFPI2) cDNA was purchased from Openbiosystems 
as a cloned sequence in pCMV-Sport6 plasmid vector (cat. no. MMM1013-64874). Both 
pCMV-Sport6 and pShuttle-Ins vector were digested with BglII-XbaI   enzyme (section 
2.13.1) and ligated to in pShuttle-Ins vector (refer fig.3.13.1 and section 2.13.2). 
Restriction digestion screening of mini-prepped (section 2.13) plasmid DNA confirmed 
that six out of ten samples were positive (fig. 3.13.2). One of the positive clones was 
selected and maxi preparation (section 2.13.6) of plasmid DNA was performed. The 
pShuttle-Ins-TFPI2 plasmid was co-transfected with pCre into DLKP-11 and 17 (section 
2.8) and selected with G418. The cells surviving selection pressure were subjected single 
cell cloning in 96 well plates (section 2.7.1). 
                           
Figure 3.13.1 the pShuttle-Ins targeting vector carrying TFPI2 (Tissue factor 
pathway inhibitor 2) gene.  XbaI and BglII restriction enzyme were used to sub-clone 
the cDNA construct. 
 
 
 
 
INS 
pShuttle-Ins-TFPI2 
          6871bp 
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Figure 3.13.2 DNA agarose gel confirmation of TFPI2 gene cloning in pShuttle 
vector. BglII: XbaI restriction enzyme digestion released expected fragment of ~ 1.5kb 
from clones 2, 3,6,7,9 &1 
 
 
3.14 Design and construction of S100A13 gene in targeting plasmid 
vector 
 
S100 calcium binding protein A13 (S100A13) cDNA was purchased from 
Openbiosystems as cloned sequence in pOTB7 plasmid vector (cat. no. MHS1011-
59294). Both pOTB7 and pShuttle-Ins vector were digested with BamHI-XhoI   enzyme 
(section 2.13.1) and ligated in pShuttle-Ins plasmid vector (refer fig.3.14.1 and section 
2.13.2). Restriction digestion screening of minipreped (section 2.13) plasmid DNA 
confirmed that  one clone was positive (fig. 3.14.2). The positive clone was selected and 
maxi preparation (section 2.13.6) of plasmid DNA was performed. The pShuttle-Ins-
S100A13 plasmid was co-transfected with pCre into DLKP-11 and 17 (section 2.8) and 
selected with G418. The cells surviving selection pressure were subjected to single cell 
cloning in 96 well plates (section 2.7.1). 
 
 
 
1.6kb 
 
1.0kb 
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Figure 3.14.1 the pShuttle-Ins targeting vector carrying S100A13 (calcium ion 
binding protein) gene. BamHI and XhoI restriction enzyme were used to sub-clone the 
cDNA construct. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14.2 DNA agarose gel picture of S100A13 gene cloning in pShuttle vector. 
BamH1:Xho1 restriction digestion revealed that clone (4) contained the S100A13 insert 
with the expected ~ 0.6kb release. 
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3.15   Assessment of Invasion phenotype of DLKP 17 and 11 master 
targetable clones 
 
To investigate the role of the chosen genes on invasion and proliferation we initially 
assessed the baseline invasive phenotype of the master targetable clones. Invasion assays 
were performed (section 2.7.1) on DLKP 17 (high expresser) and DLKP 11(low 
expresser). The experiment was performed in biological triplicates to ensure the 
consistency of the observation. DLKP 17 was found to be non invasive and DLKP 11 was 
highly invasive (fig. 3.15.1). Also we had demonstrated previously from the stability and 
expression level assessment (section 3.2) that DLKP-17 had a high level of transcription 
from its integration site and DLKP-11 was a low expressing clone. 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.16   To determine the targeting event through PCR screening  
 
Two DLKP targetable clones 17 and 11 were selected from our stability studies (section 
3.2), which were different in their transgene expression levels. They were Cre ‘cured’ to 
remove geo leaving a LoxP site as an endogenous, targetable locus. Stable co-
transfections were carried out (section 2.8.1), with constructed transgene shuttle vectors. 
From stable clones genomic DNA was isolated (section 2.11.1) for PCR screening. 
 
DLKP 11  DLKP 17 
Figure 3.15.1 Invasive phenotype of targetable master clones DLKP 17 and DLKP 11.   
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Figure 3.16.1A shows a schematic representation of primers designed to screen the re-
targeted locus. The sense and antisense primers are represented as red arrows.  These 
primers only result in an amplicon if re-targeting is successful.  Figure 3.16.1B shows 
PCR screening of transgene re-targeting event.  The agarose gel illustrates an example 
where re-targeting screen has been performed. A faint but expected band of ~170bp was 
observed in DLKP 17a clone. But we were not able to visualise in DLKP 11a could be 
due to much lower copy than DLKP 17a.  
 
 
  
 
 
Figure 3.16.1A  Schematic representation of targeted locus and primers location. 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16.1B PCR analysis confirming GLP1-R targeting event in DLKP. Template 
used was DNA from DLKP 11 and 17 re-targeted cell lines and their targetable clones as 
controls. Lane M: 1kb plus DNA ladder, 11: DLKP 11, 11a: DLKP retargeted, 17: DLKP 
17 and 17a: DLKP 17 retargeted.  Amplicon had expected size of ~ 170bp amplified in 
DLKP 17a but not in parent cell line.  
                  M          11               11a             17            17a 
 
CMV LoxP         Neo                GOI                       LoxP Targeted 
locus, G418r 
 
1.6kb 
 
1.0kb 
 
 
 
0.2kb 
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3.17  Investigation of  the effect of stable  GLP1-R  overexpression  in 
DLKP 17 and DLKP 11 cell lines 
 
 
The protein encoded by this gene is a member of the glucagon receptor family of G 
protein-coupled receptors.  GLP1-R cDNA was cloned into the pShuttle-Ins vector and 
co-transfected with pCre in DLKP 17 and DLKP 11 targetable cell lines. The transfected 
cells were selected for G418 resistance and limiting dilution, single cell cloning was 
performed.   
 
The single cell clones were bulked up and RNA was extracted (section 2.11.2). Initial 
overexpression of GLP1-R at transcript level was monitored by qRT-PCR analysis 
(section 2.11.4). The qRT-PCR analysis revealed (fig. 3.17 A&B) that DLKP 17 and 11 
clones had distinctively different GLP1-R expression as observed in the original stability 
screen. For all the qRT PCR studies b-actin was used as an endogenous control, which 
was used to normalize the expression levels across the samples. The protein lysates were 
also extracted from these cell lines and western blot analysis was performed (section 
2.14) revealing that the two clones expressed GLP1-R (Fig. 3.17C). For all western blot 
analysis anti-GAPDH antibody as was used to ensure equal quantity of sample loading. 
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Fig
ure 3.17A&B qRT-PCR confirmation of stable GLP1-R transgene  overexpression 
in DLKP 17 and DLKP 11. (A) Illustrates relative qRT PCR analysis of stable GLP1-R 
overexpression in DLKP 17 clone compared to empty vector control. The values were 
normalised to endogenous -actin levels.  A relative fold difference of 2300 (SEM ± 
692%) was observed. Similarly, figure (B) illustrates the stable GLP1-R overexpression 
in DLKP 11 cell line, with a relative fold difference of 400 (SEM ± 88.3%). 
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                          A)                                                                   B) 
                              
                              
 
 
 
Figure 3.17C Western blot analysis of GLP1-R expression in DLKP 11 GLP1-R and 
DLKP 17-GLP1-R compared to control. A&B illustrates a 52kDa band specific to 
GLP1-R, both in DLKP 17 and DLKP 11 overexpressing cell lines. Conversely no band 
was detected in empty vector control transfected cells. Anti GAPDH antibody was used to 
ensure similar protein loading on the gel.  
  
 
3.17.1 To evaluate the effect of stable GLP1-R overexpression on 
proliferation in DLKP 17 and 11 cell lines. 
 
To determine if there was any impact on proliferation due to constitutive GLP1-R 
overexpression, we performed a proliferation assay (section 2.9). The effect on cell 
growth was investigated by seeding 100l of 3x104 cells per ml of GLP1-R 
overexpressing DLKP 17 and 11 cell lines and their empty vector controls for relative 
measurements. 48 hrs after seeding, growth in each well on the plate was measured using 
the acid phosphatase assay as described in Section 2.9  
As can be seen in Fig. 3.17.1 A&B stable overexpression of GLP1-R in DLKP 17 and 
DLKP 11 decreased cell proliferation relatively. Significant decrease of around 40% in 
cell number was observed compared to control vector in DLKP 17 cells. Similarly 
relative to empty vector transfected DLKP 11, GLP1-R overexpressing DLKP 11 clones 
showed a significant 20% reduction in cell number.  
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Figure 3.17.1 A & B Stable GLP1-R overexpression Proliferation assay relative to 
empty vector transfected cells in DLKP 17 and DLKP 11 cell lines. A) DLKP 17: a 
significant decrease in proliferation relative to control with [p-value (<0.05)]. B) DLKP 
11: also significant decrease relatively with p-value (<0.05) and N=3. 
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3.17.2 To evaluate the effect of stable GLP1-R overexpression on the 
invasive phenotype of DLKP 17 and DLKP 11 cell lines. 
 
From our previous experiment  to establish  the baseline invasive phenotype of DLKP 17 
and DLKP 11 cell lines it was observed  that DLKP 17 was non invasive and DLKP 11 
was highly invasive. To evaluate the effect of GLP1-R overexpression on DLKP 17 and 
DLKP 11 invasion we performed an in vitro invasion assay. The invasion assays were 
performed over 48 hours using a commercial invasion assay kit containing inserts pre-
coated with Matrigel (ECM) without a serum gradient. This was to avoid induced 
invasion due to extra serum levels in the media. The cells were seeded at 105 cells per 
insert. They were incubated at 37oC for 48 hours after which the undersides of the inserts 
were stained; ten fields of view were counted per insert at 20X magnification and 
averaged. At least two inserts were used for the analysis of each condition.  
 
The effect of GLP1-R stable overexpression on DLKP 17 was dramatic (~ 700%) i.e. a 
significant induction from non a invasive to an invasive phenotype was observed in 
DLKP17 GLP1-R overexpressing cells (Fig.3.17.2A). Conversely in DLKP 11 which was 
already invasive, there was no apparent impact on invasion visually but the cell counts 
suggested that there was a small but significant (20%) decrease in invasion compared to 
empty vector control. 
A) 
 
 
 
 
 
 
 
            
 
 
 
 
 
Figure 3.17.2A Photographic representation of invasion assay in stable GLP1-R 
overexpressing DLKP 17 cell line. Invading cells stained purple. 
 DLKP 17 Vector control                                    DLKP 17 GLP1-R                         
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Figure 3.17.2B   Invasion assay in stable GLP1-R overexpressing DLKP 17 cell line. 
Significant increase in invasion was observed relative to DLKP 17 vector control  with  * 
[p-value (<0.05)] and N=3. 
 
 
 
C) 
 
 
 
 
 
 
 
 
 
Figure 3.17.2C Photographic representation of invasion assay results in stable 
GLP1-R overexpressing DLKP 11 cell line 
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Figure 3.17.2D   Invasion assay results in stable GLP1-R overexpressing DLKP 11 
cell line. A decrease in invasion was observed relative to DLKP-11 vector control. 
However it was not significant. N=3. 
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3.18 Investigation of the role of GLP1-R overexpression in non-invasive 
MCF-7 cell line. 
 
The pro invasive effect of GLP1-R overexpression in non invasive DLKP-17 was 
dramatic but, was it cell line specific? To address this we transiently overexpressed 
GLP1-R in MCF-7 (breast cancer cell line), which has been previously reported as a non 
invasive cell line. Overexpression was confirmed by western blot analysis.  
 
3.18.1 Western blot analysis of GLP1-R transient overexpression in 
MCF-7 cell line. 
 
Transient overexpression of GLP1-R in transfected MCF-7 cell line was evaluated at the 
protein level. Briefly the cells were transfected with pShuttle-Ins-GLP1-R plasmid and 48 
hrs post transfection protein was extracted from cells and used for GLP1-R specific 
western blot analysis (section 2.14) using a GLP1-R specific antibody (table 2.10). Blots 
were incubated using a 1/1000 dilution of antibody which generates a 52kDa band 
specific to GLP1-R. Anti GAPDH antibody was used as loading control and generated a 
38 kDa GAPDH specific band. Figure 3.18.1A illustrates immunoblot confirmation of 
transient GLP1-R overexpression in MCF-7 compared to empty vector control. The 
quantity of GLP1-R in the transfected MCF-7 cells was considerably higher considering 
the difference in endogenous loading control. 
 
 
                
 
                
 
 
 Figure 3.18.1A Western blot analysis of transient GLP1-R overexpression in MCF-7 
cell line.  
 
 
 
 
 
 
       Control vector                                              GLP1-R  
52kDa GLP1-R 
 
 
 
38kDa GAPDH  
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3.18.2   Investigate GLP1-R transient overexpression on invasion in non-
invasive MCF-7 cell line 
 
Stable GLP1-R overexpression in DLKP 17 (non invasive) targetable cell lines resulted in 
induction of the invasive phenotype. To evaluate the effect of GLP1-R as a modulator of 
cellular invasion we performed transient overexpression of GLP1-R in a known non 
invasive breast cancer cell line MCF-7. The pShuttleGLP1-R or empty pShuttle was 
transfected in MCF-7 cell lines and invasion assay analysis was performed 48hrs later.  
 
The invasion assays were performed over 48hrs using commercial invasion assay kit 
containing inserts pre-coated with Matrigel (ECM) without a serum gradient. The effect 
of transient GLP1-R overexpression on MCF-7 was dramatic (7 fold induction) with a 
significant induction of a non invasive to an invasive phenotype. There were occasional 
invading cells in control inserts which facilitated the fold-change calculation (not seen in 
Fig. 3.18.2A1) 
 
                         a1                                                                        a2 
A) 
 
                                            
 
                               Control Vector                              GLP1-R overexpression 
 
 
Figure 3.18.2A Invasion assay in MCF-7 cells due to transient GLP1-R expression. 
a1) Control vector transient overexpression, a2) GLP1-R transient overexpression. 
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Figure 3.18.2B Transient GLP1-R overexpression invasion assay counts relative to 
empty vector transfected cells in MCF-7 cell line.  Relative invasion assay counts 
comparing vector control transfected MCF-7 to MCF-7 GLP1-R transient overexpressing 
cell lines with** [p-value (≤0.01)] and N=3. 
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3.19   Investigation of the effect of GLP1-R siRNA knockdown in GLP1-
R stable overexpressing cell lines. 
 
Western blot analysis of DLKP 17 cells that were stably transfected with GLP1-R or the 
empty vector revealed that there was no detectable endogenous expression of this protein. 
Exogenous expression was strong. This pattern correlated with an observed induction of 
the invasive phenotype in the GLP1-R expressing cells (Fig.3.17.2B). This trend was 
reflected in MCF-7 cells also. To further establish the causal role of GLP1R in this 
induction of invasiveness we attempted to reverse the phenotype using RNAi. GLP1-R 
specific knockdown using siRNA was performed in DLKP 17 and 11 GLP1-R 
overexpressing clones (section 2.8.2) and cell proliferation and invasion was assayed as 
described previously. The knockdown of GLP1-R at the translational level was confirmed 
by western blot analysis. 
 
3.19.1 Western blot confirmation of GLP1-R knockdown post siRNA 
treatment in DLKP GLP1-R overexpressing cell lines 
 
Two independent siRNAs specific to GLP1-R were transfected into DLKP GLP1-R 
stable overexpressing cell lines and validated by western blot analysis (section 2.14). 2l 
of NeoFX transfection reagent per well of a 24-well plate was used to transfect 100nM of 
target siRNA into the cells (section 2.8.2). 72hrs later the cells were trypsinised and 
protein was extracted.  
To exclude non-specific effects on target protein expression we used scrambled siRNA 
sequence and NeoFX transfection agent as controls. To ensure transfection efficiency we 
used Kinesin-specific siRNA. Kinesin facilitates cellular mitosis, therefore silencing 
kinesin facilitates cell arrest. In the absence of kinesin dividing cells adopt a rounded 
morphology in advance of microtubule formation, and this is where the cells arrest. 
Hence the round morphology of cells transfected with kinesin siRNA. In proliferation 
assays, non-transfected control cells divide normally while the kinesin siRNA transfected 
cells do not. The difference in control cell number compared to kinesin siRNA-
transfected cells is not a measure of transfection efficiency or related to any cell death. It 
is a measure of how many times the control cells divided beyond the stage at which 
Kinesin levels became limiting in the transfected cells and they stopped dividing. Figure 
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3.19.1A illustrates the effect of two siRNA sequences used for specific GLP1-R 
knockdown. It is evident from the blot that GLP1-R (2) siRNA has a greater impact on 
knockdown than GLP1-R (1) relative to scrambled siRNA (Scr) treatment.  
 
 
 
  
 
 
Figure 3.19.1A Western blot analysis of GLP1-R knockdown in siRNA-treated 
GLP1-R overexpressing DLKP cell line. Ntmt: No treatment, Scr: Scramble, GLP1-
R(1): siRNA(1) and GLP1-R(2): siRNA (2). 
 
3.19.2 To evaluate the effect of GLP1-R siRNA on proliferation in stable 
GLP1-R overexpressing DLKP 17 and DLKP 11 cell line  
 
Stable overexpression of GLP1-R in DLKP 17 and 11 cells had a negative impact on cell 
proliferation. Both cell lines had decreased proliferation relative to their empty vector 
transfected counterparts. One would expect that if GLP1-R expression was knocked 
down, it should result in a rescue of the phenotype. Two GLP1-R specific siRNAs were 
used in the proliferation assay (section 2.9). 0.15l of NeoFX transfection reagent per 
well of a 96-well plate was used to transfect 100nM of target siRNA into the cells 
(section 2.8.2). Figure 3.19.2A&B illustrates the impact of the siRNA treatment on DLKP 
17 proliferation.  GLP1-R siRNA treated cells showed a small rescue in the proliferation 
and especially siRNA (1) had significantly increased proliferation in both DLKP 17 and 
DLKP 11 cell lines. From western blot analysis it was evident that siRNA (2) was more 
effective than siRNA (1), though the rescue was more evident in DLKP 11 than DLKP 17 
cell line. GLP1-R (1) siRNA showed a significant (4%) small increase in DLKP 17 and a 
significant (7%) small increase in DLKP 11.  
 
 
 
 
         Ntmt                  Scr                GLP1-R (1)        GLP1-R (2) 
52kDaGLP1-R 
 
 
 
38kDa GAPDH 
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Figure 3.19.2A Effect of GLP1-R siRNA knockdown on proliferation in DLKP 17 
GLP1-R overexpressing clone. Ntmt: no treatment, Scr: scramble control, Kinesin: 
control, GLP1-R-1: siRNA(1), GLP1-R-2: siRNA(2). A) DLKP 17: GLP1-R-1 siRNA 
treatment induced proliferation slightly higher than GLP1-R-2 treatment. *p-value 
(<0.05) and, error bar represents SEM. Kinesin was used as positive transfection control 
and N=3 
         
Figure 3.19.2B  Effect of GLP1-R siRNA knockdown on proliferation in DLKP 11 
GLP1-R overexpressing clone. Ntmt: no treatment, Scr: scramble control, Kinesin: 
control, GLP1-R-1: siRNA (1), GLP1-R-2: siRNA (2). B) DLKP 11: treatment with 
GLP1-R-1 and error bar represents SEM. Kinesin was used as positive transfection 
control. N=3. 
. 
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3.19.3 To evaluate the effect of GLP1-R siRNA on the invasion 
phenotype in stable GLP1-R overexpressing DLKP 17 and DLKP 11 cell 
lines  
 
We already established that stable GLP1-R overexpression in DLKP 17 (non invasive) 
targetable cell line resulted in an induced invasion phenotype. Furthermore to evaluate the 
effect of GLP1-R on invasion we performed knockdown of GLP1-R expression in both 
DLKP 17 and DLKP11 GLP1-R overexpressing cell lines. If the induced invasion is 
directly due to GLP1-R then knocking down its expression should result in a reversal of 
the invasive phenotype. GLP1-R siRNA treated DLKP 17 and DLKP 11 cell lines 
showed rescue in invasion phenotype relative to no treatment and scrambled controls. 
Though both GLP1-R siRNA 1 and 2 had significant impact on invasion phenotype, 
GLP1-R siRNA (2) impact was more intense (62% in DLKP-17 and 73% in DLKP-11). 
From our western blot confirmation it was evident that GLP1-R siRNA (2) resulted in 
greater knockdown at the protein level than siRNA (1).  
 
 
                                   
 
                              
 
 
3.19.3A Effect of siRNA transfection on invasion in stable GLP1-R overexpressing 
DLKP 17 cell line. Ntmt: no treatment, Scr: scramble control, Kinesin: control, siRNA-1: 
GLP1-R-1, siRNA-2: GLP1-R-2. 
          Ntmt                                            Scr 
          siRNA-1                           siRNA-2 
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 Figure 3.19.3B  Graphical representation of invasion assay in DLKP 17 cells. Ntmt: 
no treatment, Scr: scramble control, Kinesin: control, siRNA(1): GLP1-R-1, siRNA(2): 
GLP1-R-2. Significant decrease was observed with p value **(<0.005), SEM ± 0.38% 
with GLP1-R (2) siRNA treatment and p-value **(<0.05), SEM ± 11.87% with GLP1-R 
(1) on invasion compared to scramble treatment and N=3. 
 
 
                                           
 
                                           
 
 
3.19.3C Effect of siRNA transfection on invasion in stable GLP1-R overexpressing  
DLKP 11 cell line  Ntmt: no treatment, Scr: scramble control, Kinesin: control, 
siRNA(1): GLP1-R-1, siRNA(2): GLP1-R-2. 
          siRNA-1                                               siRNA-2 
          Ntmt                                            Scr 
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 Figure 3.19.3D Graphical representation of invasion assay in DLKP 11 cells. Ntmt: 
no treatment, Scr: scramble control, Kinesin: control, siRNA (1): GLP1-R-1, siRNA(2): 
GLP1-R-2. Significant decrease was observed with p value ** (<0.005) with GLP1-R (2) 
siRNA treatment and with GLP1-R (2) siRNA a decrease was observed on invasion 
compared to scramble treatment. N=3. 
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3.20    Investigation of the effect of stable KCNJ8 overexpression in 
DLKP 17 and   DLKP 11 cell lines 
 
 
Inagaki et al., (1995) identified a KATP channel, uKATP-1 (KCNJ8/Kir6.1), which 
represented a new subfamily of the inwardly rectifying K+ channel family. This gene was 
identified in the microarray-based screening in our lab (A. Pierce, PhD 2006 thesis) as 
correlating with invasiveness in DLKP variant cell lines. To investigate any potential 
role in this phenotype, KCNJ8 cDNA was cloned in pShuttle-Ins targeting vector and co-
transfected with pCre into DLKP 17 and DLKP 11 targetable cell lines. The transfected 
cells were selected for G418 resistance and limiting dilution and single cell cloning was 
performed to obtain individual cell line clones. Clones overexpressing KCNJ8 in both 
cell lines were selected as well as control clones transfected with empty vector.  The 
effect of KCNJ8 on non invasive DLKP 17 and invasive DLKP 11 was investigated, 
including confirmatory analyses by qRT-PCR and western blot. The functional impact 
was monitored by proliferation and invasion assays.  
 
Initial overexpression of KCNJ8 at transcript level was monitored by qRT-PCR (section 
2.11.4). Figure 3.20A illustrates relative expression of KCNJ8 in a stable DLKP 17 clone 
compared to the empty vector control. DLKP 17 had a high level of transcription from the 
targetable locus region. However, we observed only a 2.6 fold increase (SD ± 0.31%) in 
KCNJ8 expression. It could be that the endogenous KNCJ8 concentration was already at 
its maximum tolerable level. Similarly figure 3.20B illustrates the degree of KCNJ8 
overexpression in the DLKP 11 cell line, confirmed through qRT-PCR analysis. It was 
already established that DLKP 11 had a low level of transcription from its targetable 
locus. This was reflected in the levels of KCNJ8 expressed in the re-targeted DLKP11, 
where a 1.2 fold (SD ± 0.06%) increase was observed in mRNA. Though the magnitude 
of transgene up-regulation was lower than expected in both cell lines, the relative levels 
compared to each other were consistent with the known activity of their targetable loci.  
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A)     DLKP-17 
 
 
B)    DLKP-11 
 
Figure 3.20A&B qRT-PCR confirmation of stable KCNJ8 transgene overexpression 
in DLKP 17 and DLKP 11 cell lines. A) DLKP 17: KCNJ8 2.25 fold relatively 
overexpressed  and B) DLKP 11: KCNJ8 1.2 fold overexpression compared to vector 
control and N=3. 
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3.20.1 Western blot analysis confirmation of KCNJ8 stable 
overexpression in DLKP 17 and DLKP 11 cell lines. 
 
Cells were transfected with a pShuttleKNCJ8 targetable vector and empty vector as a 
control to ensure that the transfection process did not affect target protein expression. The 
polyclonal anti-kir6.1 (KCNJ8) CAF-1 antibody used in these experiments was a gift 
from Prof. William A. Coetzee (NYU School of Medicine). Western blot analysis was 
performed as described previously, which identified a 44kDa band specific to KCNJ8. 
GAPDH was used as a loading control.   
 
Immunoblot analysis revealed that there was no difference in KCNJ8 overexpression in 
both DLKP 17 and DLKP 11 cell lines relative to their empty vector control samples.  
 
 
 
 
                       
                       
 
 
Figure 3.20.1A Western blot analysis of KCNJ8 overexpression in DLKP 17 and 
DLKP 11 cell lines. Polyclonal anti KCNJ8 antibody was used at 1/1000 dilution and 
generates a 44kDa band specific to KCNJ8 
 
 
 
 
 
 
 
    Control             DLKP 17 KCNJ8       Control                DLKP 11 KCNJ8     
 44kDa KCNJ8 
 
 
38kDa GAPDH 
 A)               DLKP 17                           B)           DLKP 11    
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3.20.2 To evaluate the effect of stable KCNJ8 on proliferation in DLKP 
17 and DLKP 11 cell lines 
 
To determine if there was any impact on proliferation due to KCNJ8 stable 
overexpression, we performed a proliferation assay (section 2.9). The effect on 
proliferation was investigated by seeding in 96 well cell culture plates, 100l of 3x104 
cells per ml of KCNJ8 overexpressing DLKP 17 and 11 cell lines and their empty vector 
controls. 48hrs after seeding the plate was assayed using the acid phosphatase assay as 
described in section 2.9  
 
Stable overexpression of KCNJ8 in DLKP 17 had reduced proliferation relative to empty 
vector transfected cells. Conversely an increase in cell proliferation was observed in 
KCNJ8 overexpressing DLKP 11 cell line. Figure 3.20.2 A&B illustrates the impact of 
stable KCNJ8 transgene overexpression on DLKP proliferation. A 15% decrease 
proliferation was observed compared to control vector in DLKP 17. With DLKP 11 
samples, relative to empty vector transfected DLKP 11, KCNJ8 overexpressing DLKP 11 
clone displayed a 45% increase in cell proliferation compared to empty vector control.  
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B)      DLKP-11 
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Figure 3.20.2 A&B Effect of stable KCNJ8 overexpression on proliferation assay in 
DLKP 17 and DLKP 11 cell lines. A) DLKP 17: significant effect on proliferation with  
p-value ** (<0.005). B) DLKP 11: no significant increase in proliferation compared to 
vector control and N=3. 
 
 3.20.3 Investigation of effect of stable KCNJ8 overexpression on 
invasion in DLKP 17 and DLKP 11 cell lines. 
 
From our previous experiment  to establish  the baseline invasive phenotype of DLKP 17 
and DLKP 11 cell lines it was observed  that DLKP 17 was non invasive and DLKP 11 
was highly invasive. To evaluate the effect of KCNJ8 overexpression on DLKP 17 and 
DLKP 11 invasion we performed an in vitro invasion assay. The invasion assays were 
performed over 48 hours using commercial invasion assay kit containing inserts pre-
coated with Matrigel (ECM) without a serum gradient. The cells were seeded at 105 cells 
per insert. They were incubated at 37oC for 48 hours after which the undersides of the 
inserts were stained; ten fields of view were counted per insert at 20X magnification and 
averaged. At least two inserts were used for the analysis of each condition.  
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The effect of KCNJ8 stable overexpression on DLKP 17 was dramatic (50 fold), i.e. a 
significant induction of non invasive to invasive phenotype was observed both visually as 
well as by cell counts in DLKP17 KCNJ8 overexpressing cells. Similarly in DLKP 11, 
which was already invasive, there was a further 18% increase in invasion.  
 
 
                                             
 
 
 
 
Figure 3.20.3A Crystal violet stained representation of KCNJ8 overexpressing 
DLKP 17 cell line invasion assay.  
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Figure 3.20.3B Graphical representation of invasion assay in DLKP 17 cells  
Significant increase in invasion, was observed relative to DLKP 17 vector control with * 
[p-value (<0.02)] and N=3. 
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 169
 
 
                                           
 
 
 
Figure 3.20.3C Crystal violet stained representation of KCNJ8 overexpressing 
DLKP 11 cell invasion assay. 
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Figure 3.20.3D    Graphical representation of invasion assay in DLKP 11 cells. 
An increase in invasion was observed relative to DLKP 11 vector control and N=3. 
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3.21      Investigation of the effect of stable TFPI2 overexpression in 
DLKP 17 and DLKP 11 cell lines 
 
TFPI2 is a 32kDa serine protease inhibitor that is associated with the ECM. This gene 
was identified in the microarray-based screening in our lab (Pierce A. PhD thesis 2006) 
as correlating with invasiveness in DLKP variant cell lines. TFPI2 cDNA was cloned in 
pShuttle-Ins targeting vector and co-transfected with pCre into DLKP 17 and DLKP 11 
targetable cell lines. The transfected cells were selected for G418 resistance and limited 
dilution single cell cloning was performed to obtain cell line clone. Clones 
overexpressing TFPI2 in both DLKP 17 and 11 cells were selected as well as pShuttle 
control cells. The effect of TFPI2 on non invasive DLKP 17 and invasive DLKP 11 was 
investigated, including confirmatory analyses by qRT-PCR and western blot. Initial 
overexpression of TFPI2 at the transcript level was monitored by qRT-PCR (section 
2.11.4). An 80 fold increase (Fig. 3.21A) in TFPI2 expression in DLKP 17 and a 1.3 fold 
increase (Fig. 3.21B) in DLKP11 cells was observed compared to empty vector control.  
Protein was extracted from these cell lines and western blot was performed (section 
2.14). The antibody used did not detect TFPI2 protein either in parental or TFPI2 
overexpressing cells. 
 
A)      DLKP-17 
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B)      DLKP-11 
 
Figure 3.21A&B qRT-PCR confirmation of stable transgene TFPI2, overexpression 
in DLKP 17 DLKP and 11 cell lines. A) DLKP 17: TFPI2 overexpression compared to 
control B) DLKP 11: TFPI2 expression relative to control and N=3. 
 
3.21.1 To evaluate the effect of stable TFPI2 expression on proliferation 
in DLKP 17 and 11 cell lines. 
 
To determine if there was any impact on proliferation due to TFPI2 stable overexpression, 
we performed a proliferation assay (section 2.9). The effect on proliferation was 
investigated by seeding in 96 well cell culture plates. A seed density of TFPI2 
overexpressing DLKP 17 and 11 cells at 3x103 cells per well of a 96 well cell culture 
plate was used. 48 hrs after seeding each well the plate was assayed using the acid 
phosphatase assay as described in section 2.9.  A significant decrease (24%) in cell 
proliferation was observed compared to control vector in DLKP 17 as represented in fig 
3.21.1(A). Similarly relative to empty vector transfected DLKP 11 the TFPI2 stable 
overexpressing DLKP 11 clones had a significant 31% increase in rate of proliferation as 
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represented in fig 3.21.1(B) with compared to vector control. Suggesting role of TFPI2 in 
proliferation is cell line specific. 
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Figure 3.21.1 A&B Effect of stable TFPI2 expression on proliferation in DLKP 17 
and DLKP 11 cell lines.  A) DLKP 17:  decrease in cell proliferation was observed  B) 
DLKP 11:  increase in proliferation observed and N=3. 
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3.21.2   Investigation of effect of stable TFPI2 expression on invasion in 
DLKP 17 and DLKP 11 cell lines. 
 
To evaluate the effect of TFPI2 overexpression on DLKP 17 and DLKP 11 invasion we 
performed an in vitro invasion assay. The invasion assays were performed over 48 hours 
using a commercial invasion assay kit containing inserts pre-coated with Matrigel (ECM) 
without a serum gradient. The cells were seeded at 105 cells per insert. They were 
incubated at 37oC for 48 hours after which the undersides of the inserts were stained; ten 
fields of view were counted per insert at 20X magnification and averaged. At least two 
inserts were used for the analysis of each condition.  
 
The effect of TFPI2 stable overexpression on DLKP 17 was dramatic (25 fold), i.e. a 
significant induction from a non invasive to an invasive phenotype was observed both 
visually as well as by cell counts in DLKP17 TFPI2 overexpressing cells. Conversely in 
DLKP 11, invasiveness was observed to be decreased by ~12%. 
 
 
                       
 
 
 
 
3.21.2A Crystal violet stained representation of TFPI2 overexpressing DLKP 17 cell 
invasion assay. 
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3.21.2B Graphical representation of invasion assay results.  
Significant increase in   invasion observed with stable TFPI2 expression compared to 
vector control with **p-value (≤0.004) N=3. 
 
 
                                        
 
 
 
3.21.2C Crystal violet stained representation of TFPI2 overexpressing DLKP 11 cell 
invasion assay. 
  
      
       DLKP 11                                                     DLKP 11 TFPI2 
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3.21.2D  Graphical representation of invasion assay results. A decrease in invasion 
was observed due to TFPI2 overexpression, N=3. 
 
In conclusion the opposing invasive and proliferative effects of TFPI2 in DLKP17 and 11 
clones suggested the gene dosage and/or existing phenotype may dictate the impact of 
TFPI2 overexpression. 
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3.22       Investigation of the effect of stable S100A13 overexpression in    
    DLKP 17 and DLKP 11 cell lines 
 
S100 proteins are small EF hand Ca2+ binding proteins of variable length and sequence. 
There are a number of functions associated with S100 proteins, many associated with 
tumour development. In 1996, Wicki et al. identified a new S100 member termed 
S100A13 by screening expressed sequence tag (EST) databases. It was found to have a 
novel role in invasion by Pierce, et.al, (2008).  Initial overexpression of S100A13 at the 
transcript level was monitored by qRT PCR (section 2.11.4).  After several attempts we 
were not able to generate a stable S100A13 overexpressing DLKP cell line.  
 
A)       DLKP-17 
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B)     DLKP-11    
 
Figure 3.22A&B qRT-PCR analysis of S100A13 expression in DLKP 17 and 
DLKP11 cell lines. Figure illustrates  that there was no S100A13 overexpression in 
DLKP 17 clone compared to empty vector control. Similarly figure 3.22.1B illustrates no 
stable S100A13 overexpression in DLKP 11 cell line. 
 
 
 
In conclusion, even after several attempts it was not possible to overexpress S100A13 in 
either DLKP 17 or 11 cell lines. This was not expected, as the targetable overexpression 
system worked with three other transgenes GLP1-R, KCNJ8 and TFPI2. Also, transient 
overexpression worked before as shown by Pierce et.al (2008).  A possible reason could 
be that DLKP cells may not tolerate stable S100A13 overexpression. 
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SECTION: D   
3.23.0  MicroRNAs  
 
3.23.1 Overview of approach and key results 
 
MicroRNAs (miRNAs) are a class of small endogenous non coding RNA molecules 
whose normal function involves the regulation of gene expression post-transcriptionally. 
It is estimated that 3% of the genome encodes miRNAs and approximately 30% of human 
protein coding genes are predicted to be regulated by miRNAs. Several studies suggest 
that uncontrolled expression of miRNAs or clusters of miRNAs may lead to abnormal 
cellular functions including proliferation, differentiation and apoptosis resulting in human 
diseases. Recently much attention has been focused on the role of miRNAs in cancer. 
 
The focus of this study was to investigate the potential role of miRNAs in lung cancer 
invasion. In collaboration with Ambion, we performed miRNA bioarray profiling of 
DLKP (parent, non invasive) Vs DLKP-A (Adriamycin drug resistant, highly invasive) 
human lung cancer cell lines. As a result, there were several differentially expressed 
miRNAs identified.  Among them we selected five miRNAs for PCR validation. The five 
miRNAs were mir-21, mir-27a, mir-29a, mir-30a5p and mir-30c. From PCR validation 
(section 2.12.2) we selected three miRNAs for further functional validation: mir-21, mir-
27a and mir-29a.  
 
Table 3.23A   Endogenous miRNA levels in DLKP-A relative to DLKP 
  
MiRNAs Bioarray results 
Relative expression 
qRT-PCR  results 
Relative expression 
Hsa-mir-21           Up           Up 
Hsa-mir-27a          Up           No change 
Hsa-mir-29a          Up           Down 
Hsa-mir-30c          Up           Down 
Hsa-mir-30a5p          Up           No change 
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As these miRNAs were differentially regulated in DLKPA compared to DLKP (Table 
3.23A), we suspected they may play a role in cancer invasion mechanism. The role of 
mir-21 in lung cancer was already known from several studies. Hence, we used it as our 
experimental control. Mature sense (pre-miRNAs: Pre-mir sequence is a double stranded 
21-mer identical to the mature form of the miRNA, so transfecting these is like 
overexpression) and antisense sequences (anti-miRNAs: Anti-mir is a single stranded 
nucleotide sequence complementary to target miRNA which inhibits miRNA activity) 
were transiently transfected in DLKP and DLKP-A cell lines (Section 2.8.2).To make 
sure the transfection worked we used kinesin as a transfection control and 72hrs post 
transfection the cells were harvested for miRNA isolation (section 2.12).  qRT-PCR was 
then performed (fig. 3.25A).   
 
To assess if these miRNAs had any effect on cell proliferation, we subjected both anti and 
pre miRNA treated cells to proliferation assay (section 2.9). The results confirmed that 
transient overexpression of these miRNAs did not have a significant impact on DLKP or 
DLKPA cell proliferation (fig.3.25B& 
C). We also checked for effects on drug sensitivity due to overexpression or knockdown 
of these miRNAs to investigate the role of miRNAs in chemotherapeutic drug resistance 
(CDRs). No significant impact was observed (fig. 3.25.1A&B). 
 
Our main aim was to investigate if any of these chosen target miRNAs had any impact on 
the invasion phenotype. Hence, anti-mir and pre-mir treated DLKP and DLKPA cells 
were subjected to invasion assay (section 2.10). The mir-21 and 27a miRNAs were found 
to be pro- invasive and mir-29a was found to be anti-invasive (fig. 3.26A, 3.26B, 3.26C). 
The experiment was repeated in biological triplicate to confirm the observation. From the 
literature it was already known that mir-21 and mir-27a are involved in cancer 
invasion/metastasis related pathways, which was in agreement with our observations too. 
But there was no previous evidence of mir-29a as an anti-invasiomer; therefore we 
further proceeded to delineate the role and effect of mir-29a in cancer cell invasion. 
 
To establish that the anti invasive effect of mir-29a expression was not only lung cancer 
cell line specific we included another cell line in our study PANC-1, which is a pancreatic 
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cancer cell line with a highly invasive phenotype. We transiently transfected pre-mir-29a 
or control sequence into PANC-1 cells.  qRT-PCR analysis of extracted RNA samples 
confirmed mir-29a to be overexpressed by 2.3 fold  (refer fig. 3.27A).  A significant 
decrease of about 55% in PANC-1 invasion phenotype was observed relative to control 
transfected cells (Figure 3.27B). 
 
Further we asked the question, what would be the phenotypic impact of stable mir-29a 
overexpressed in DLKPA cell line?  To address this we PCR amplified endogenous pre 
mir-29a from DLKP genomic DNA and subcloned in p4.1CMV-Neo plasmid vector 
(Ambion) (fig. 3.28A).  A negative sequence was also cloned in p4.1CMV-Neo vector 
which was used as control during stable overexpression studies. The p4.1CMV-Neo-mir-
29a plasmid vector was transfected into DLKPA and stable clones were generated. The 
clones were checked for mir-29a expression by qRT-PCR (fig. 3.28D). The DLKPA 
clones displaying mir-29a overexpression were subjected to invasion and proliferation 
assay (section 3.29 and 3.30), and it was observed that the clones had significantly 
reduced invasion and cellular proliferation. Genes that are predicted to be regulated by 
miRNAs are usually based on in silico analysis. When this study was undertaken only one 
publication reported proteomic data on miRNA expression (Zhu et al., 2007. To identify 
possible gene targets being regulated by mir-29a we performed a comprehensive 
proteomic profiling of anti and pre-mir-29a treated DLKPA cells  using 2D-DIGE 
(section 2.14.6)  followed by MALDI-TOF and/or LC-MS for identification of 
differentially regulated protein spots  (Table 3.43.i).   
 
From the proteomic analysis we selected four gene targets for functional validation 
studies by siRNA knockdown. These were downregulated due to pre-mir-29a treatment 
(which reduces invasion) in the DLKPA cell line. The rationale behind this selection was 
that if they mediated the mir-29a effect then knockdown of these genes should reduce 
cancer cell invasion. The target genes RAN, GRB2, MIF and ANX2 were all previously 
identified in studies on mechanisms of cancer invasion/metastasis. SiRNA knockdown of 
these targets was confirmed by qRT-PCR analysis (fig. 3.34.1A, 3.35A, 3.36A, 3.37A). 
The siRNA treated cells were subjected to invasion assay (section 2.10). Only RAN 
knockdown had any significant impact on the invasive phenotype of DLKPA (fig. 
3.38.2A&B). Investigation of the effect of siRNA treatment on proliferation (section 2.9) 
confirmed that RAN knockdown reduced proliferation (fig. 3.38.1A) as well. No other 
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target had any significant impact on proliferation in DLKPA (fig. 3.34.2A, 3.35.1A, 
3.36.1A).  RAN knockdown was confirmed by western blot analysis (fig. 3.38A). 
 
The siRNA target knockdown studies suggested that RAN could be a direct target of mir-
29a regulation. To investigate this further we performed a 3’RAN UTR reporter assay. 
The rationale behind this experiment was that we know that miRNAs target the 3’UTR 
region of target genes to regulate translation. So by cloning the 3’RAN UTR sequence at 
the 3’ end of GFP, and co-expressing mir-29a, knockdown of GFP expression would 
provide evidence of interaction between the mir-29a and RAN-UTR. RAN 3’UTR was 
PCR amplified and cloned downstream of GFP in a reporter vector (fig.  3.39A, B, C), the 
pEGFP RAN 3’UTR plasmid was transfected in DLKPA cell line and a mixed stable cell 
line was developed. Pre-mir-29a was then transiently overexpressed in DLKPA-GFP-
RAN 3’UTR and monitored for GFP knockdown by qRT-PCR analysis (fig. 3.39.D) as 
well as by flow-cytometry (fig. 3.39E). There was a reduction in both GFP mRNA level 
as well as at the protein level. Although the protein reduction was statistically significant 
it was small (5-6%), suggesting RAN could be a secondary rather than a primary target of 
mir-29a though further work would be required to establish this. 
 
3.24 qRT-PCR Validation of selected differentially regulated miRNAs. 
 
In collaboration with Ambion, we performed miRNA microarray studies comparing 
DLKP with DLKPA. The RNA samples were sent to Ambion for hybridization, scanning 
and data normalization. This data was sent to us and from the list we chose 5 
differentially expressed miRNAs. They were mir-21, mir-27a, mir-29a, mir-30a5p and 
mir-30c.  To confirm these findings we performed Sybr green based qRT-PCR analysis. 
Total RNA was isolated from both cell lines in biological triplicate (n=3) using mirVana 
RNA isolation kit. 1l (25ng) of total RNA sample was used for each RT reaction. 5s 
RNA was used as the endogenous control. The PCR was performed and analyzed with 
Applied Biosystems 7500 SDS software programme. 
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From the qRT-PCR analysis it was confirmed that 3 target miRNAs were differentially 
regulated. The mir-30a5p and mir-27a were not found to be differentially regulated. The 
mir-21 was ~2 fold upregulated in DLKPA relatively; mir-29a was ~0.3 fold and hsa-mir-
30c was ~0.5 fold downregulated in DLKPA compared to DLKP. Figure 3.25A illustrates 
qRT- PCR validation of the five chosen miRNAs.  
 
 
Figure 3.24A qRT-PCR validation of miRNA genes, in DLKP Vs DLKPA.   
 The graph represents the miRNA expression trend which was observed over several 
biological and technical repeats.  It is evident that mir-21 is upregulated and mir-29a and 
mir-30c are downregulated. But mir-27a and mir-30a-5p were unchanged. Error bar 
represents at least n=3 
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3.25   Effect of transient overexpression and knockdown of chosen 
miRNAs on cell proliferation. 
 
Based on qRT-PCR results three miRNA targets were chosen, hsa-mir-21, hsa-mir-27a 
and hsa-mir-29a, to determine if there was any impact on proliferation due to their 
transient overexpression and/or knockdown. NeoFX was used to transfect 50nM of target 
pre-mir and anti-mir sequences into the cells (section 2.8.2). Pre-mir sequence is a double 
stranded 21-mer identical to the mature form of the miRNA ( so transfecting these is like 
overexpression) and anti-mir is a single stranded nucleotide sequence complementary to 
target miRNA which behaves as siRNA or antisense to miRNA. To control for non 
specific effects of the transfection process on phenotype, we also used negative pre and 
anti miRNA sequence, which are random 21-mer sequences. NeoFX transfection agent 
alone was also included as control. Finally to ensure transfection efficiency we used 
Kinesin specific siRNA.  
 
The effect on proliferation was investigated by seeding 100l of 3x104 cells per ml in a 96 
well plate. The cells were seeded on top of the already pipetted NeoFX: miRNA complex. 
This facilitates efficient ‘reverse’ transfection. 72 hrs post incubation each well on the 
plate was assayed using the acid phosphatase method. Before proceeding further we 
wanted to confirm the actual level of transfected miRNA sequence. We performed 
miRNA qRT-PCR analysis on pre and anti mir transfected cells. 72hrs later total RNA 
was isolated and qRT-PCR analysis was done. 
 
From the qRT-PCR analysis it was confirmed that pre-mirRNAs were upregulated (23 
fold) in the transfected cells relatively. An example of mir-29a overexpression is 
represented in figure 3.25A. However, we were not able to detect knockdown. This was 
probably due to the fact that anti-mir, unlike siRNAs, does not catalyse degradation of the 
target miRNA, but merely binds to target miRNA. During extraction of miRNAs or PCR 
reaction, they get dissociated hence, no knockdown is observed in the miRNA level.   
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3.25A   qRT-PCR analysis of pre and anti-mir-29a transfected DLKPA cell line. 
A significant increase in mir-29a levels was observed, error bar represents (SEM ± 1.51), 
with ** (<0.005) p-Value,  
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From figure 3.25B&C a small but significant (12% in DLKP and 7% in DLKPA) increase 
due to pre-mir-21 treatment was observed in proliferation and there was no impact on 
proliferation by mir-27a or 29a treatments, though kinesin control confirmed the efficient 
transfection. 
 
 
B) DLKP 
Figure 3.25B Effect on proliferation due to Anti and Pre miRNA treatment in DLKP 
cell line. Ntmt; no treatment, neofx; NeoFX transfection agent control, Kinesin; positive 
control, anti-mir-control; control for miRNA sequence, anti-mir-21, 27a and 29a, pre-mir-
21, 27a and 29a. The effect of anti and pre-miRNA treatments were normalized with anti-
miRNA controls and pre-miRNA control treated samples. Figure represents anti and pre 
miRNA treatments in DLKP with * p-value (<0.05) seen only with pre-mir-21 treatment 
relative to control treatment.  The error bar represent SD and n=3. 
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C)      DLKPA 
Figure 3.25C Effect on proliferation due to Anti and Pre miRNA treatment in 
DLKPA cell line. Ntmt; no treatment, NeoFX; NeoFX transfection agent control, 
Kinesin; positive control, anti-mir-control; control for miRNA sequence, anti-mir-21, 27a 
and 29a, pre-mir-21,27a and 29a. Figure represents anti and pre miRNA treatments in 
DLKPA with * p-value (<0.05) seen only with pre-mir-21 treatment relative to control 
treatment.  The error bar represent SD and n=3. 
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3.25.1   To evaluate the effect of Adriamycin sensitivity in miRNA 
treated DLKP and DLKPA cell lines.  
 
One of the model cell lines used in this study DLKPA, was an Adriamycin resistant cell 
line, developed in the NICB (Heenan et al., 1997). Adriamycin, an active medicine 
against many cancers, is one of the older chemotherapy drugs, having been in use for 
decades. Like most chemotherapeutics, there is always the chance of tumours developing 
drug resistance. To study this phenomenon the lung cancer cell line DLKP (mildly 
invasive) was pulse treated with Adriamycin, resulting in the selection and isolation of a 
drug-resistant, highly invasive variant cell line, referred to as DLKPA. 
 
For this reason the targets chosen from our miRNA profiling of DLKP Vs DLKPA, may 
be associated with either the resistance to drug and/or the invasive phenotype. We 
decided to perform drug sensitivity assay (by monitoring proliferation phenotype) post 
miRNA treatment and drug treatment. 50nM of pre-mir and anti-mirs were transfected 
into the cells (section 2.8.2).  72hrs later the media from the 96 wells was replaced with 
drug containing media (122g/ml of Adriamycin, previously established to represent 
IC50 for DLKPA cell line) and incubated for a further 24hrs.  Each well on the plate was 
measured by acid phosphatase assay. Though our effort was to determine the impact drug 
sensitivity in DLKPA, we also used DLKP in the same experiment to with IC50 similar to 
DLKPA to check whether it had any impact due to miRNAs inhibition and 
overexpression. From the results it was evident that DLKP cells were 7-8% more 
sensitive to drug after anti-mir treatments of 21, 27a and 29a (Fig. 3.25.1A). Conversely a 
12-18% increase in resistance was observed due to miRNA overexpression. No effect in 
the DLKPA cell line was observed (Fig 3.25.1B). 
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A)DLKP 
Figure 3.25.1A Anti and Pre miRNA treatment and 24 hrs Adriamycin drug treated 
proliferation assay in DLKP cell lines. Ntmt; no treatment, NeoFX; NeoFX transfection 
agent control, Kinesin; positive control, anti-mir-control; control for miRNA sequence, 
anti-mir-21,27a and29a, pre-mir-21,27a and 29a. Adriamycin pulsing (IC50=122g/ml). 
Error bar represents ± SEM. The effect of anti and pre-miRNA treatments were 
normalized with anti-miRNA controls and pre-miRNA control treated samples. 
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B) DLKPA 
Figure 3.25.1B Anti and Pre miRNA treatment and 24 hrs Adriamycin drug treated 
proliferation assay in DLKPA cell lines. Ntmt; no treatment, NeoFX; NeoFX 
transfection agent control, Kinesin; positive control, anti-mir-control; control for miRNA 
sequence, anti-mir-21,27a and29a, pre-mir-21,27a and29a. Adriamycin pulsing 
(IC50=122g/ml).Error bar represents ± SEM. The effect of anti and pre-miRNA 
treatments were normalized with anti-miRNA controls and pre-miRNA control treated 
samples. 
 
3.26   Investigation of the effect on invasion due to miRNA treatment in 
DLKP and DLKPA cell lines.    
 
The aim of this study was to investigate the potential role of miRNAs in controlling or 
influencing the invasive phenotype in lung cancer cells. We performed a miRNA 
microarray study to identify differentially regulated miRNAs. The DLKP parent cell line 
in these subsequent validation experiments was found to be more invasive. This frozen 
culture came from a separate stock to that which was profiled originally. And the nature 
of DLKP being a poorly differentiated cell line could have caused this difference.  From 
microarray studies we chose three miRNAs which we suspected to have a role in cancer 
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cell invasion. We performed an in vitro invasion assay with DLKP and DLKPA cell lines 
to evaluate the impact if any on the invasive phenotype in these cell lines. 50nM of target 
pre-mir and anti-mirs were transfected into the cells (section 2.8.2). To control for non-
specific effects of the transfection process we used negative pre and anti miRNA 
sequences, which are random 21-mer sequences. To ensure transfection efficiency we 
used Kinesin specific siRNA (figure.3.26A, 3.26B and 3.26C).  
 
The effect on invasion was investigated by seeding 24 well cell culture plates with 1ml of 
2x105 cells per ml cell suspension of DLKP and DLKPA cell lines. The cells were seeded 
on top of the NeoFX: miRNA solution mixtures which facilitate efficient reverse 
transfection. 72hrs later invasion assay analysis was performed using commercial 
invasion assay kits containing inserts pre-coated with matrigel without a serum gradient. 
The cells were seeded in a 100l volume at 106 cells per ml. The cells were incubated at 
37oC for 48 hours after which, at least two inserts were used for the analysis of each 
condition.  
 
The anti-mir-21 treated DLKP and DLKPA cell lines were observed to have impact on 
invasion with 51% and 37% reduction respectively. Similarly anti-mir-27a treated DLKP 
with 36%) and DLKPA (40%) cell lines showed significant impact on invasion. 
Conversely increased invasion due to anti-mir-29a in DLKP (38%) was observed and no 
effect on DLKPA invasion phenotype was observed as shown in (figure.3.26D, and 
3.26F).  
 
The pre-mir21 treated DLKP (41%) and DLKPA (38%) cells were observed to have 
increased invasion. A similar impact due to pre-mir-27a treated DLKP (38%) and 
DLKPA (26%) was observed, as shown in (figure.3.26E).  Conversely decreased invasion 
due to pre-mir-29a treatment (21% in DLKP and 29% in DLKPA) was observed as 
shown in (figure.3.26.G). These results indicated that mir-21 and 27a were proinvasive 
and mir-29a was an anti invasive miRNA species. 
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Figure 3.26A Impact of transient transfection of pre and anti-mir-21 on the in vitro 
invasiveness of DLKP and DLKPA cells.  
Ntmt: No treatment; NeoFX: cell treated with transfection agent only; Anti-mir and Pre-
mir control: transfection with non-specific pre and anti-mir molecules; Pre- and anti-
mir21: cells treated with mir-21 specific anti-and pre-mir sequences. Matrigel inserts 
were stained and counted for invasive cells 48hrs after seeding. Cells were transfected 
72hrs before seeding. Magnification =20X. 
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DLKP                                       DLKPA 
Pre-mir control                        Anti-mir control                       Pre-mir control                        Anti-mir control                       
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Figure 3.26B Impact of transient transfection of pre and anti-mir-27a on the in vitro 
invasiveness of DLKP and DLKPA cells.  
Ntmt: No treatment; NeoFX: cell treated with transfection agent only; Anti-mir and Pre-
mir control: transfection with non-specific pre and anti-mir molecules; Pre- and anti-
mir27a: cells treated with mir-27a specific anti-and pre-mir sequences. Matrigel inserts 
were stained and counted for invasive cells 48hrs after seeding. Cells were transfected 
72hrs before seeding. Magnification =20X. 
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Figure 3.26C    Impact of transient transfection of pre and anti-mir-29a on the in 
vitro invasiveness of DLKP and DLKPA cells.  
Ntmt: No treatment; NeoFX: cell treated with transfection agent only; Anti-mir and Pre-
mir control: transfection with non-specific pre and anti-mir molecules; Pre- and anti-
mir29a: cells treated with mir-29a specific anti-and pre-mir sequences. Matrigel inserts 
were stained and counted for invasive cells 48hrs after seeding. Cells were transfected 
72hrs before seeding. Magnification =20X. 
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Figure 3.26D Graphical representation of invasion assay post anti-mir-21, mir-27a 
and mir-29a treatment in DLKP cell line. Ntmt: No treatment; NeoFX: cell treated with 
transfection agent only; Anti-mir control: transfection with non-specific anti-mir 
molecules; Anti-mir21, 27a and mir29a: cells treated with mir-21,27a and 29a specific 
anti-mir sequences. Figure represents anti miRNA treatments in DLKP.  The error bar 
represent ±SEM and n=3. 
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Figure 3.26E Graphical representation of invasion assay post pre-mir-21, mir-27a 
and mir-29a treatment in DLKP cell line. Ntmt: No treatment; NeoFX: cell treated with 
transfection agent only; Anti-mir control: transfection with non-specific anti-mir 
molecules; Pre-mir21, 27a and mir29a: cells treated with mir-21,27a and 29a specific pre-
mir sequences. Figure represents anti and pre miRNA treatments in DLKP with * p-value 
(<0.05) seen only with pre-mir-29a treatment relative to control treatment.  The error bar 
represent ±SEM  and  n=3 
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Figure 3.26F Graphical representation of invasion assay post anti-mir-21, mir-27a 
and mir-29a treatment in DLKPA cell line. Ntmt: No treatment; NeoFX: cell treated 
with transfection agent only; Anti-mir control: transfection with non-specific anti-mir 
molecules; Anti-mir21, 27a and mir29a: cells treated with mir-21,27a and 29a specific 
anti-mir sequences. Figure represents anti and pre miRNA treatments in DLKPA  The 
error bar represent ±SEM and n=3. 
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Figure 3.26G Graphical representation of invasion assay post pre-mir-21, mir-27a 
and mir-29a treatment in DLKPA cell line. Ntmt: No treatment; NeoFX: cell treated 
with transfection agent only; Anti-mir control: transfection with non-specific anti-mir 
molecules; Pre-mir21, 27a and mir29a: cells treated with mir-21,27a and 29a specific pre-
mir sequences. Figure represents anti and pre miRNA treatments in DLKPA.  The error 
bar represent SD and n=3. 
 
 
 
 
 
 
 198
3.27 Investigation of the effect of mir-29a transient overexpression on 
PANC-1 cell line (pancreatic carcinoma) invasion phenotype 
 
 To establish that the anti invasive effect of mir-29a expression was not only lung cancer 
cell line specific we included another cell line in our study, PANC-1 which is a pancreatic 
cancer cell line with a highly invasive phenotype. We transiently transfected pre-mir-29a 
and control sequence into PANC-1 cells in 24-well cell culture plates. TaqMan based 
qRT-PCR was performed to confirm mir-29a overexpression. The qRT-PCR analysis of 
RNA samples confirmed mir-29a overexpression of 2.3 fold relatively (Fig. 3.27A).  
 
Briefly, 50nM of target pre-mir-29a was transfected into cells (section 2.8.2). 72hrs later 
invasion assay analysis was performed with 48 hours incubation. The cells were seeded in 
100l volume at 106 cells per ml and cells were incubated at 37oC for 48 hours after 
which the underside of the inserts were stained with crystal violet and counted per insert 
at 20X magnification. At least two inserts were used for the analysis of each condition.  
 
The invasion assay results further confirmed the impact of mir-29a as an anti invasive 
miRNA. A significant decrease of about 55% in PANC-1 invasion phenotype was 
observed relative to control transfected cells. Figure 3.27 A&B illustrates post mir-29a 
transient overexpression with PANC-1 in vitro invasion assay. This illustrated that the 
impact of mir-29a on invasion was not necessarily tissue specific but may play a more 
general role in the control of cellular invasiveness.  
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 Figure 3.27A   qRT-PCR confirmation of transient mir-29a overexpression. 
Pre-mir-control: pre-mir control sequence transfected as control; Pre-mir-29a: pre-mir- 
29a mature sequence transfected; error bar represents SEM ± 0.26. 
 
a)                                                   b)                                               c) 
        
 
 
Figure 3.27B Effect of mir-29a transient overexpression on invasion in PANC-1 cell 
line. a) Ntmt: no treatment control; b) Pre-mir control; transient overexpression of Pre-
mir- control, c) Pre-mir-29a: pre-mir-29a treated, magnifications 20X.  
 
 
   PANC-1 Ntmt                  Pre-mir control              Pre-mir-29a 
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Figure 3.27C Impact of transient mir-29a overexpression.  
Ntmt: no treatment; Pre-mir-control: pre-mir control sequence treated; Pre-mir-29a: pre-
mir-29a mature sequence treated. Invasion assay counts represents SEM ±  with * (≤0.05) 
p-Value and n=3. 
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3.28  Effect of stable overexpression of mir-29a on invasion and 
proliferation of DLKPA cell line 
 
Transient overexpression of hsa-mir-29a was observed to have an anti-invasive effect on 
DLKPA cells with a 40% decrease in invasion observed. But, no significant impact on 
proliferation was observed. To further investigate this we designed primers to amplify 
pre-mir-29a (228nt in length) from DLKP genomic DNA and clone the amplicon in a 
mammalian expression vector for stable overexpression in DLKPA to generate cells that 
stably overexpressed the mir-29a transcript. The pSilencer™ 4.1-CMV plasmid vector 
was purchased from Ambion. This is a mammalian expression vector designed for long-
term gene silencing experiments in a broad range of cell lines. The vector carries an RNA 
polymerase II-type CMV promoter (human cytomegalovirus immediate-early promoter) 
and an optimized SV40 polyadenylation signal to drive high-level expression of hairpin 
siRNA/miRNA. Endogenously miRNAs are expressed as longer hairpin molecules. 
These primary transcripts (pri-miRNAs) are then cleaved in the nucleus by the Drosha 
protein to release 60-70nt pre-miRNA hairpins.  We designed primers to amplify the 
endogenous pri-mir-29a in such a way that the amplified region contained at least 70-
90nt flanking the 64nt pri-mir-29a; this would facilitate processing by Drosha to a 
functional pre-mir-29a sequence (Fig.3.28A). Pre-mir-29a is exported to the cytoplasm 
by an Exportin 5-dependent mechanism where it is processed by Dicer to generate mature 
21-24 nt miRNAs (Lee et al., 2003). The cloning of mir-29a was successful (Fig. 3.28B) 
and was sent for sequence confirmation (MWG sequencing facility in Germany). A 
negative control vector was also used to generate stable DLKPA cell lines. The 
sequencing results confirmed the mir-29a sequence, when blasted against human 
genomic DNA database. A perfect match of 228nt hit was observed (refer Fig.3.28C).  
 
The mir-29a plasmid was transfected in DLKPA cells and stable cell lines were 
generated. To confirm mir-29a specific overexpression, total RNA was isolated and 
quantified. TaqMan based qRT-PCR was performed to confirm stable mir-29a 
overexpression. The qRT-PCR analysis of RNA samples identified at least three DLKPA 
cell lines with confirmed mir-29a overexpression, ranging from 2-4 fold relatively 
(Fig.3.28D).  
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                                                     M           Vector          pre-mir-29a 
 
Figure 3.28A  Restriction enzyme digestion of pSilencer™ 4.1-CMV-Neo vector.  
M: 1kb plus DNA ladder; Vector: digested vector backbone; pre-mir-29a:  ~250 bp pri-
mir-29a amplicon  digested with BamHI and HindIII. 
 
 
 
 
 
 
 
 
 
 
 
                                            M           1             2            3           4              C 
 
Figure 3.28B Restriction enzyme digestion analysis to check cloning of pre-mir-29a. 
Lanes M: 1kb plus DNA ladder; 1, 2, 3, 4: BamHI and HindIII digestion release expected 
product ~ 250 bp confirming insert cloning; C: negative control. 
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Figure 3.28C ClustalW alignment of cloned hsa-mir-29a sequence. Confirmation of 
mir-29a sequence compared to genomic sequence. The region showed in pink represents 
the exact match of pri-mir-29a sequence (64nt) and blue regions represent flanking 
sequences on either side of pri-mir-29a. 
 
Figure 3.28D qRT-PCR confirmation of stable mir-29a overexpression in DLKPA 
cell line.  Three DLKPA clones (3,4 and 11) had confirmed  hsa-mir-29a stable 
overexpression with a 2-3.5 fold up regulation compared to control, and clone 1 
demonstrated  mir-29a downregulation  where  * (< 0.05) p-value. The values were 
normalized to mir-negative control treatment and (n=3). 
mir-29a clone 
mir-29a clone 
mir-29a clone 
mir-29a clone 
mir-29a clone 
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3.29   Investigation of effect of mir-29a stable overexpression on 
DLKPA Proliferation 
 
72hrs after transient mir-29a overexpression in DLKPA cells there was no significant 
impact on proliferation. But, we did see decreased invasive phenotype in these cells.  
Once we established the stable mir-29a overexpressing DLKPA clones we decided to 
investigate if there was any effect on proliferation. This was investigated by seeding the 
stable clones in 100l volume at 3x104 cells per ml in a 96 well plate. 48 hrs after seeding 
each well on the plate was assayed using the acid phosphatase assay as described in 
(Section 2.9). An impact on proliferation was observed due to mir-29a stable 
overexpression. DLKPA clone 3 was observed to have reduced proliferation by [36%], 
Clone 4 reduced by [25%] and Clone 11 by [44%].  
  
 
Figure 3.29A Effect of stable mir-29a overexpression on DLKPA proliferation.  
Mir-negative control: miRNA sequence as negative control for mature sequence; mir-
29a(3); mir-29a(4) and mir-29a(11): stable overexpressing mir-29a DLKPA clone 3,4 and 
11, (N=3). 
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3.30   Investigation of effect of mir-29a stable overexpression on DLKPA 
 invasive phenotype 
 
Transient pre-mir-29a overexpression reduced invasiveness of DLKPA by 40%, 
suggesting that mir-29a may be actively involved in cancer cell invasion. But was this 
just due to the transient effect of a synthetic mir-29a sequence? To address this we 
developed stable overexpressing DLKPA cell lines. This was achieved through 
transfecting mir-29a plasmid (mir-29a, PCR amplified from endogenous genomic DNA 
and cloned in pSilencer mammalian expression vector) in DLKPA and applied selection 
pressure to generate mir-29a stable expression cell lines. Stable overexpression was 
confirmed through qRT-PCR analysis. These stable clones were used for evaluation of 
the effect on the invasion phenotype in DLKPA. The cells were seeded on MatrigelTM 
inserts in 100l volume at 106 cells per ml and incubated at 37oC for 48 hours after which 
the underside of the inserts were stained and counted at 20X magnification. At least two 
inserts were used for the analysis of each condition.  
There was a significant reduction in invasion of mir-29a stable overexpressing DLKPA 
cell lines compared to negative control expressing DLKPA. Three DLKPA cell lines mir-
29a (3), 58%, mir-29a (4) 44% and mir-29a (11) 47%. The degree of reduction in 
invasion correlated closely with the level of overexpression detected by qPCR. 
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                                                  a) Mir-negative-control 
        b) 
Mir-29a (3)                      c) Mir-29a (4)                       d) Mir-29a (11) 
Figure 3.30A In vitro invasion of stable mir-29a overexpression in DLKPA through 
matrigel. a) Mir-negative control; negative sequence expressing cells, b) Mir-29a(3); 
clone (3) expression mir-29a, c) Mir-29a(4); clone(4) expressing mir-29a and d) Mir-29a 
(11); clone (11) expressing mir-29a. Magnifications at 20X. 
 
 
Figure 3.30B Impact of stable mir-29a overexpression.  
Mir-negative control; negative sequence expressing cells, Mir-29a (3); clone (3) 
expression mir-29a, Mir-29a (4); clone (4) expressing mir-29a and Mir-29a (11); clone 
(11) expressing mir-29a, with ** (≤ 0.005) and * (≤0.05) p-value where (n=3). 
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3.31 To evaluate the expression of c-Myc in a panel of cell lines, differing 
in their invasive phenotype  
 
C-Myc a well studied oncogene has been reported to be involved in regulating the 
expression of mir-29a. Myc is known to directly upregulate a pro-tumorigenic group of 
miRNAs known as the miR-17–92 cluster (Tsung-Cheng et.al, 2008). From our qRT-
PCR analysis of the relative mir-29a levels in DLKP versus DLKPA, it was evident that 
mir-29a was downregulated in DLKPA. DLKPA is a highly invasive cell line. We 
theorised based on previous studies and our functional results that mir-29a expression in 
our model cell lines might reflect c-Myc expression which is upstream of mir-29a and 
regulates mir-29a transcription. We decided to evaluate the endogenous c-Myc levels in 
our panel of cancer lines, DLKP (mildly invasive), DLKPA and PANC-1 (both highly 
invasive). A c-Myc specific primer pair was designed to analyse endogenous c-Myc 
transcript levels by qRT PCR. RNA was isolated from cell lines and used to generate 
cDNA for quantitative PCR.  
 
The qRTPCR data represents (fig.3.31A) technical replicates and relative c-Myc levels. 
The initial qRT-PCR data suggested there was no significant increase in c-Myc in the 
more invasive cell lines compared to mildly invasive cell line DLKP, though this was a 
first observation with technical replicates. Further confirmation would be required to 
evaluate the impact of c-Myc regulation via mir-29a.   
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 Figure 3.31A Graphical representation of relative endogenous c-Myc levels. 
DLKP: mildly invasive lung cancer line; DLKPA: highly invasive drug resistant cell line; 
PANC-1: highly invasive pancreatic carcinoma cell line. The error bar represents 
technical replicates (n=4), minimum and maximum values as derived from the software 
analysis. 
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3.32   2-Dimensional difference in gel electrophoresis analysis of 
DLKPA cells transfected with pre-mir-29a 
 
The transient overexpression of pre-mir-29a in DLKP and DLKPA was found to reduce 
invasion by between 20-30% and conversely anti-mir treatment increased invasion by 
36% in DLKP.  During the time of this study there were no reports in the literature on 
mir-29a being anti invasive in cancer cells. We decided to perform proteomic profiling to 
discover potential targets of mir29a.  Pre and anti mir-29a transfection were performed as 
before. 72hrs later cells were trypsinised (multiple samples for each treatment to ensure 
enough protein extract for the proteomic study), and protein was extracted. 50g of 
protein from each sample was used in this study. 2D-DIGE proteomic analysis was 
performed as described (sections 2.14.6). 
 
3.32 .1 Experimental outline for 2-D DIGE analysis of the samples 
 
Proteins that were differentially regulated due to pre and anti-mir-29a overexpression in 
DLKPA were analysed by 2-D DIGE. Triplicate biological repeats with duplicate 
technical repeats were reverse labelled with Cy3 and Cy5. All samples used in the 
experiment were pooled and labelled with the internal dye Cy2. Each sample was 
compared internally to the same standard, to account for any gel-to-gel variation. 
 
3.32.2 DeCyder analysis 
 
Differential protein expression between Pre-mir-29a versus Pre-mir-control and Anti-mir-
29a versus anti-mir-control was detected using 2D-DIGE. DeCyder image analysis 
merged the Cy2, Cy3 and Cy5 images for each gel and detected spot boundaries for the 
calculation of normalised protein abundance. All paired images were then matched to 
generate comparative cross-gel statistical analysis. DeCyderTM software revealed 
confirmed protein spots as represented in the Table 3.32.2i 
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Table 3.32.2i 
Comparisons Up Down Total Spots Identified Proteins 
Pre-mir-29a 11 110 121 60 
Anti-mir-29a 21 64 85 29 
 
 
Spot identification was based on BVA (Biological variation analysis) of the spots 
showing greater ±1.2 fold change in expression with 1 WAY ANOVA score of ≤ 0.05. A 
representative 2D-DIGE protein map is shown in Fig. 3.32.2A including the master spot 
numbers. 
 
A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.32.2A 2D DIGE scan of protein gel from pre-mir-29a transfected DLKPA. 
The protein spots (green spots with software generated ID numbers) were picked for 
identification using MALDI-TOF and LC-MS. 
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3.32.3 Protein identification and Generation of Differentially regulated 
protein lists 
 
For protein identification, all proteins were digested and identified at least twice from 
separate gels with MALDI-TOF MS. An expectation value of <0.02 was used for all 
reported identifications, which indicates 0.2% of the identifications would occur by 
chance. It is broadly accepted that miRNAs regulate gene expression at the post 
transcriptional level, resulting in down regulation of target proteins. Previous studies have 
shown that miRNAs target at the posttranscriptional level by binding to the 3’UTR region 
of an mRNA and as a result protein translation is downregulated. In theory if we 
overexpress a miRNA we would expect genuine target genes to be downregulated at the 
protein level. Conversely to block a particular miRNA with anti miRNA, then its target 
proteins should be upregulated. In our experiment we observed proteins upregulated and 
downregulated in both pre-mir and anti-mir treated DLKPA cells. 
 
Accordingly we generated two lists of proteins as represented in Table 3.32.3i (down 
regulated proteins due to Pre-mir-29a), and Table 3.32.3ii (up regulated proteins due to 
Anti-mir-29a). In addition we also observed sets of proteins that were up-regulated due to 
pre-mir-29a treatment and downregulated due to anti-mir-29a treatment. These probably 
represent proteins downstream of mir-29a target proteins, i.e. secondary targets of mir-
29a action. 
 
The differential expressed protein spots were identified by either MALDI-TOF and/or 
LC-MS and were analyzed with different bioinformatics software programs including 
PATHWAY STUDIO, PANTHER, and PUBMATRIX to predict biological functions 
affected and the importance of the protein targets. RNAhybrid, a widely used programme 
to identify predicted miRNA gene targets was also employed.  This programme applies 
seed match criteria, i.e. Watson-Crick seed matches that are conserved in the UTR 
regions of whole-genome alignments to assign target prediction. 
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Master Spot Gene symbol Gene Name GI Accession Ref.seq.mRNA 
Accession
 Mass[Da] Av Ratio 1-ANOVA(p-value) Matched 
peptide
1428 ALDOA ALDOLASE A, FRUCTOSE-BISPHOSPHATE gi|113606| NM_184041 39395.3 -1.23 0.061 6
1437 NDUFA10 SUPEROXIDE DISMUTASE 1, SOLUBLE (AMYOTROPHIC LATERAL SCLEROSIS 1 (ADULT)) gi|13097333| NM_004544 41070 -1.25 0.0013 6
1443 HIBCH 3-HYDROXYISOBUTYRYL-COENZYME A HYDROLASE gi|146324905| NM_014362 43454.4 -1.42 0.005 4
1499 GALE UDP-GALACTOSE-4-EPIMERASE gi|68056598| NM_001008216 38257.3 -1.21 0.037 2
1520 ANXA1 ANNEXIN A1 gi|113944| NM_000700 38690 -1.24 0.006 2
1548 ANXA2 ANNEXIN A2 gi|56967119| NM_001002858 36640 -1.21 0.0059 17
1691 SFRS1 SPLICING FACTOR, ARGININE/SERINE-RICH 1 (SPLICING FACTOR 2, ALTERNATE SPLICING FACTOR)gi|45708738| NM_006924 22560 -1.29 0.042 7
1706 ESD ESTERASE D/FORMYLGLUTATHIONE HYDROLASE gi|12654663| NM_001984 32020 -1.25 0.0013 7
1711 GNB2L1 GUANINE NUCLEOTIDE BINDING PROTEIN (G PROTEIN), BETA POLYPEPTIDE 2-LIKE 1 gi|54037164| NM_006098 35054.6 -1.32 0.048 2
1721 ATP6V1E1 ATPASE, H+ TRANSPORTING, LYSOSOMAL 31KDA, V1 SUBUNIT E1 gi|549207| NM_001696 26128.8 -1.34 0.013 2
1748 HIBADH 3-HYDROXYISOBUTYRATE DEHYDROGENASE gi|12643395| NM_152740 35305.8 -1.2 0.0074 2
1782 CACYBP CALCYCLIN BINDING PROTEIN gi|46576651| NM_014412 26193.7 -1.2 0.036 5
1816 PAFAH1B2 PLATELET-ACTIVATING FACTOR ACETYLHYDROLASE IB SUBUNIT BETA gi|55977293|  NM_002572 25553.1 -1.21 0.0043 3
1819 PGAM1 PHOSPHOGLYCERATE MUTASE 1 (BRAIN) gi|67464305| NM_002629 29970 -1.22 0.0021 8
1827 FKBP3 PEPTIDYL-PROLYL CIS-TRANS ISOMERASE gi|232096|  NM_002013 25161.3 -1.24 0.03 3
1839 CLPP ATP DEPENDENT CLP PROTEOLYTIC SUBUNIT gi|3023512|  NM_006012 30160.6 -1.42 0.03 2
1848 ERP29 ENDOPLASMIC RETICULUM PROTEIN 29 gi|6015110| NM_006817 28975.2 -1.29 0.0027 3
1872 HSPB1 HEAT SHOCK 27KDA PROTEIN 1 gi|19855073| NM_001540 22768.5 -1.24 0.03 2
1892 PRDX6 PEROXIREDOXIN 6 gi|1718024| NM_004905 25019.2 -1.22 0.041
1902 Psma6 PROTEASOME (PROSOME, MACROPAIN) SUBUNIT, ALPHA TYPE, 6 gi|46397655| NM_002791 27381.8 -1.28 0.017 2
1908 HPRT HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE 1 (LESCH-NYHAN SYNDROME) gi|459815| NM_000194 24730 -1.27 0.0046 7
1922 1RRP  RAN, MEMBER RAS ONCOGENE FAMILY gi|5107684| NM_006325 23300 -1.35 0.00024 5
1924 GRB2 GROWTH FACTOR RECEPTOR-BOUND PROTEIN 2 gi|28876| NM_002086 18620 -1.25 0.0059 8
1925 PSMA2 PROTEASOME (PROSOME, MACROPAIN) SUBUNIT, ALPHA TYPE, 2 gi|39644890| NM_002787 24970 -1.23 0.0096 5
1935 SLMO2 CHROMOSOME 20 OPEN READING FRAME 45 gi|26392626| NM_016045 21481 -1.28 0.019 7
1936 LYPLA2 LYSOPHOSPHOLIPASE II gi|41017276| NM_007260 24720.7 -1.25 0.0003 2
1938 GSTK1 GLUTATHIONE S-TRANSFERASE SUBUNIT 13 HOMOLOG gi|12643338| NM_015917 25480.3 -1.39 0.0015 1
1959 VBP1 VON HIPPEL-LINDAU BINDING PROTEIN 1 gi|1465751| NM_003372 19520 -1.27 0.015 5  
5 
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(Cont’d) 
Master Spot Gene symbol Gene Name GI Accession Ref.seq.mRNA 
Accession
 Mass[Da] Av Ratio 1-ANOVA(p-value) Matched 
peptide/s1961 PRDX3 PEROXIREDOXIN 3 gi|32483377| NM_006793 26110 -1.32 0.0031 1
1966 PRDX1* PEROXIREDOXIN 1 gi|55959887| NM_002574 19130 -1.304 0.0249 6
1976 PSMB4 PROTEASOME (PROSOME, MACROPAIN) SUBUNIT, BETA TYPE, 4 gi|116242733| NM_002796 29185.5 -1.41 0.0024 3
1998 PSMB2 PROTEASOME (PROSOME, MACROPAIN) SUBUNIT, BETA TYPE, 2 gi|1709762| NM_002794 22821.7 -1.21 0.029 1
2004 PARK7 PARKINSON DISEASE (AUTOSOMAL RECESSIVE, EARLY ONSET) 7 gi|42543006| NM_007262 20060 -1.26 0.00072 10
2006 Sfrs3 SPLICING FACTOR, ARGININE/SERINE-RICH 3 gi|51338673| NM_003017 19317.9 -1.26 0.011 3
2008 CMPK1 CYTIDYLATE KINASE gi|12644008| NM_016308 22208.3 -1.29 0.00039 15
2018 TPx-B PEROXIREDOXIN 2 gi|9955016| NM_005809 21680 -1.36 0.0011 9
2029 ARL3 ADP-RIBOSYLATION FACTOR-LIKE PROTEIN 3 gi|543851  NM_004311 20442.8 -1.31 0.046 1
2031 APRT ADENINE PHOSPHORIBOSYLTRANSFERASE gi|114074| NM_000485 19595.4 -1.35 0.015 2
2047 PEBP1 PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN 1 gi|1352726| NM_002567 21043.7 -1.53 0.0004 13
2075 PPIB PEPTIDYLPROLYL ISOMERASE B (CYCLOPHILIN B) gi|1310882| NM_000942 19700 -1.41 0.027 8
2083 NME1 NON-METASTATIC CELLS 1, PROTEIN (NM23A) EXPRESSED IN gi|127981| NM_198175 17137.7 -1.28 8.40E-05 16
2085 RPL11 RIBOSOMAL PROTEIN L11 gi|51701767| NM_000975 20239.7 -1.45 0.0005 3
2103 CFL1* COFILIN 1 (NON-MUSCLE) gi|116848| NM_005507 18490.7 -1.53 0.0019 6
2104 BTF3L4 BASIC TRANSCRIPTION FACTOR 3-LIKE 4 gi|75042131| NM_152265 17260 -1.43 0.0019 2
2136 SOD1 SUPEROXIDE DISMUTASE 1, SOLUBLE (AMYOTROPHIC LATERAL SCLEROSIS 1 (ADULT)) gi|134611| NM_000454 15925.9 -1.39 0.043 3
2149 PPIA* PEPTIDYLPROLYL ISOMERASE A (CYCLOPHILIN A) gi|75766275| NM_021130 180300 -1.355 0.010125 9
2169 IGH2bM35a IMMUNOGLOBIN HEAVY CHAIN gi|7161037| AJ253041 10600 -1.35 0.004 4
2182 ISG15 INTERFERON, ALPHA-INDUCIBLE PROTEIN (CLONE IFI-15K) gi|386837| NM_005101 17910 -1.63 0.0026 4
2186 FABP5 FATTY ACID BINDING PROTEIN 5 (PSORIASIS-ASSOCIATED) gi|232081| NM_001444 15154.6 -1.42 0.005 8
2188 GMFB GLIA MATURATION FACTOR, BETA gi|46577593| NM_004124 16702.5 -1.43 0.0021 3
2199 RPS12 RIBOSOMAL PROTEIN S12 gi|133742| NM_001016 14516.5 -1.43 0.012 2
2205 SH3BGRL SH3 DOMAIN BINDING GLUTAMIC ACID-RICH PROTEIN LIKE gi|75042673| NM_003022 12766.4 -1.22 0.012
2207 HIST4H4* Histone H4 gi|75061938| NM_175054  11360.4 -1.55 0.0011 2
2210 HINT1 HISTIDINE TRIAD NUCLEOTIDE-BINDING PROTEIN 1 gi|1708543|  NM_005340 13793.1 -1.33 0.0048
2213 LGALS1 GALECTIN-1 gi|42542978|  NM_002305 14910 -1.45 0.0005 6
2232 MIF MACROPHAGE MIGRATION INHIBITORY FACTOR (GLYCOSYLATION-INHIBITING FACTOR) gi|1170955| NM_002415 12468.2 -1.63 0.035 3  
 
Table 3.32.3i    List of differentially downregulated proteins due to pre-mir29a treatment compared to negative control.  Cut off value of   
≤ -1.2 fold and 95% confidence in 1 way ANOVA was applied for screening differentially regulated proteins, the list bears mRNA reference 
sequence and gi sequence recognition IDs for each identified protein spot. * represents proteins identified more than once i.e. in more than one 
spot position. 
Peptides 
4 
4 
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Gene symbol Gene Name Protein ID Ref.Seq.ID  Mass [Da] Av Ratio 1-ANOVA 
(p-value)
Matched 
peptide
DDT D-dopachrome decarboxylase gi|2828192| NM_001355 12703.7 1.35 0.039 1
ACTC1 Alpha-actin-1 gi|55976646| NM_005159 42023.9 1.22 0.036 3
SHOT1 Shootin-1 gi|156637366| NM_018330 71595.7 1.21 0.034 3
ALDH1A1 Aldehyde dehydrogenase 1 gi|2183299| NM_000689 55.44 1.28 0.047 8
CCT3 T-complex protein 1 subunit gamma gi|66774185| NM_005998 60495.4 1.24 0.024 4
LOC652797 Pyruvate kinase isozymes M1/M2 gi|20178296| XM_001719890 57900.2 1.27 0.024 8
ATP5A1 ATP synthase subunit alpha, mitochondrial precursor gi|158514235| NM_001001937 59713.7 1.22 0.013 6
SERBP1 Plasminogen activator inhibitor 1 RNA-binding protein gi|52783206| NM_001018067 44938.5 1.24 0.0036 3
TRXR1 Thioredoxin reductase 1 gi|50403780| NM_003330 55.49 1.25 0.02 5
EEF1A1 Eukaryotic translation elongation factor 1 alpha 1 gi|31092| NM_001402 50.45 1.23 0.022 7
PTBP1 Polypyrimidine tract-binding protein 1 gi|131528| NM_002819 57185.8 1.29 0.0074 3
ENO1 Alpha-enolase gi|31873302| NM_001428 47.42 1.24 0.055 12
PGK1* Phosphoglycerate kinase 1 gi|48145549| NM_000291 44.98 1.24 0.034 5
RuvB-like 2 48 kDa TATA box-binding protein-interacting protein gi|28201890| NM_006666 51124.6 1.22 0.049 1  
 
Table 3.32.3ii   List of differentially upregulated proteins in DLKPA due to anti-mir29a expression compared to negative control.  Cut 
off value of   ≥ +1.2 fold and 95% confidence in 1 way ANOVA was applied for identification. The list bears mRNA reference sequence and gi 
sequence recognition IDs for each identified protein spots. * represents proteins being identified more than once i.e. in more than one spot 
position.
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3.33   Bioinformatics analysis of differentially regulated protein ID’s 
 
3.33.1 PANTHER (Protein Analysis through Evolutionary 
Relationships) 
 
In the genomic era, one of the fundamental goals is to characterize the function of 
proteins on a large scale. Computational algorithms and databases for comparing 
protein sequences have reached a relatively mature stage of development. PANTHER 
is a freely available, comprehensive software system for relating protein sequence 
evolution to the evolution of specific protein functions and biological roles. The 
PANTHER classification system is a unique resource that classifies genes by their 
function (Thomas et al., 2003) using published scientific experimental evidence and 
evolutionary relationships to predict function even in the absence of direct 
experimental evidence (http://www.pantherdb.org/) . PANTHER is designed to be 
structured such that absolute depths in different parts of the ontology correspond to 
roughly equivalent levels of functional specificity. Protein family trees are 
constructed computationally from sequence data and roles in biological processes and 
pathways, based on experiments performed. The proteomic profiling of mir-29a 
treated DLKPA cell line identified several possible gene targets. To identify the 
global distribution of these genes in terms of their biological process, molecular 
function and biological pathways, we used the PANTHER programme. The genes 
were found to be involved in a wide range of molecular functions (fig. 3.33.1A), 
biological process (fig. 3.33.1B) and biological pathways (fig. 3.33.1C). Briefly, 
under molecular functions, categories such as nucleic acid binding (14%) and 
oxidoreductase (11%) were observed to have relatively significant representation of 
target proteins. Similarly, in biological process, two main categories were found to 
have relatively large numbers of protein targets represented i.e. Protein Metabolism 
and Modification (18%) and Immunity and Defence (16%). Conversely under 
biological pathways (fig. 3.33.1C) a wide spread among the pathways was observed 
with no particular pathway overly represented possibly due to the limited size of the 
dataset. 
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11%
5%
5%
5%
14%
1% 4%
1 Isomerase (MF00166)
2 Miscellaneous function (MF00197)
3 Transferase (MF00131)
4 Transfer/carrier protein (MF00087)
5 Ion channel (MF00024)
6 Transporter (MF00082)
7 Synthase and synthetase (MF00118)
8 Phosphatase (MF00113)
9 Transcription factor (MF00036)
10 Hydrolase (MF00141)
11 Ligase (MF00170)
12 Molecular function unclassified (MF00208)
13 Receptor (MF00001)
14 Select regulatory molecule (MF00093)
15 Membrane traffic protein (MF00267)
16 Cytoskeletal protein (MF00091)
17 Select calcium binding protein (MF00188)
18 Lyase (MF00157)
19 Oxidoreductase (MF00123)
20 Protease (MF00153)
21 Signaling molecule (MF00016)
22 Chaperone (MF00077)
23 Nucleic acid binding (MF00042)
24 Cell adhesion molecule (MF00040)
25 Kinase (MF00107)
 
Figure 3.33.1A PANTHER based classification of all identified protein targets based on Molecular function. 
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1%
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5%11%
18%
2%
5%
1%
4%
2%1%
8%
1%
1 Neuronal activities (BP00166)
2 Signal transduction (BP00102)
3 Developmental processes (BP00193)
4 Other metabolism (BP00289)
5 Cell proliferation and differentiation (BP00224)
6 Coenzyme and prosthetic group metabolism
(BP00081)
7 Cell structure and motility (BP00285)
8 Immunity and defense (BP00148)
9 Apoptosis (BP00179)
10 Transport (BP00141)
11 Carbohydrate metabolism (BP00001)
12 Nucleoside, nucleotide and nucleic acid
metabolism (BP00031)
13 Protein metabolism and modification (BP00060)
14 Cell cycle (BP00203)
15 Intracellular protein traffic (BP00125)
16 Cell adhesion (BP00124)
17 Lipid, fatty acid and steroid metabolism
(BP00019)
18 Electron transport (BP00076)
19 Amino acid metabolism (BP00013)
20 Biological process unclassified (BP00216)
21 Protein targeting and localization (BP00137)
 
Figure 3.33.1B PANTHER  classification based on Biological Process.  
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2%
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2%
5%
5%
2%
2% 3%
1 Beta3 adrenergic receptor signaling pathway (P04379)
2 Beta2 adrenergic receptor signaling pathway (P04378)
3 Beta1 adrenergic receptor signaling pathway (P04377)
4 De novo pyrimidine deoxyribonucleotide biosynthesis (P02739)
5 5HT4 type receptor mediated signaling pathway (P04376)
6 De novo purine biosynthesis (P02738)
7 Angiogenesis (P00005)
8 Interleukin signaling pathway (P00036)
9 Integrin signalling pathway (P00034)
10 5-Hydroxytryptamine degredation (P04372)
11 Phenylethylamine degradation (P02766)
12 Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade (P00032)
13 Inflammation mediated by chemokine and cytokine signaling pathway (P00031)
14 Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway (P00026)
15 Glycolysis (P00024)
16 Allantoin degradation (P02725)
17 Xanthine and guanine salvage pathway (P02788)
18 Ras Pathway (P04393)
19 Adenine and hypoxanthine salvage pathway (P02723)
20 FGF signaling pathway (P00021)
21 T cell activation (P00053)
22 TGF-beta signaling pathway (P00052)
23 Endothelin signaling pathway (P00019)
24 EGF receptor signaling pathway (P00018)
25 p38 MAPK pathway (P05918)
26 Parkinson disease (P00049)
27 Cytoskeletal regulation by Rho GTPase (P00016)
28 PI3 kinase pathway (P00048)
29 PDGF signaling pathway (P00047)
30 Histamine H2 receptor mediated signaling pathway (P04386)
31 Enkephalin release (P05913)
32 Fructose galactose metabolism (P02744)
33 Dopamine receptor mediated signaling pathway (P05912)
34 Salvage pyrimidine ribonucleotides (P02775)
35 B cell activation (P00010)
36 Cortocotropin releasing factor receptor signaling pathway (P04380)
37 De novo pyrmidine ribonucleotides biosythesis (P02740)  
Figure 3.33.1C PANTHER  classification based on Biological Pathway. 
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3.33.2 Pathway Studio Analysis of identified proteins 
 
Pathway Studio permits the identification of biological interactions among genes and 
proteins of interest from the published literature, and provides links to the supporting 
sentences in the matching journal article citations (for articles available online in Pub 
Med). The software can also connect two genes/proteins with the shortest possible 
path; import a list of genes/proteins, which can then be arranged into a pathway. We 
used the programme to interrogate the list of proteins identified in our study.  
Apoptosis, motility, proliferation, differentiation and mutagenesis, were the most 
frequent cellular processes impacted by the proteins on our list. 
Figure 3.33.2A Pathway Studio analysis of protein targets. The rectangular boxes 
represent key biological process and ovals represent genes. The red lines connected 
between and among the genes and processes are known to have negative impact and 
similarly green lines depict known positive regulation. The grey lines denote 
unknown impact.
3.33.3 Insilco based 3’UTR seed match of mir-29a and its targets 
 
Vertebrate mRNAs are targeted for post-transcriptional repression by miRNAs 
through mechanisms involving pairing of 3′ UTR seed matches to bases at the 5′ end 
of miRNAs (Nielsen, 2007). Potential miRNA targets may be predicted by finding 
perfect Watson-Crick seed matches (fig. 3.33.3A) that are conserved in the UTR 
regions of whole-genome alignments. Moreover, the requirement of a 7-nt match to 
the seed region of the miRNA (nucleotides 2–8) could be relaxed to require a 6-nt 
match to a reduced seed comprising nucleotides 2–7 of the miRNA while still 
retaining specificity (Lewis et al., 2005). To elucidate the microRNA regulatory 
network, it is important to have prior knowledge of potential targets. Among existing 
target prediction methods RNA-hybrid predicts multiple potential binding sites of 
miRNAs in large target RNAs (Rehmsmeier et al., 2004). The analysis of seed match 
regions between mir-29a and 3’UTR sequences of the gene targets was done with 
RNAhybrid. We uploaded our target sequences and mir-29a reference sequence and 
ran the programme. 
 
 
Adopted from http://hollywood.mit.edu/targetrank/seedMatchTypes.html 
____________________________________________________________________ 
Figure 3.33.3A Seed match criteria. Segments have Watson-Crick (WC) 
complementarity ("matching") to positions 2-7 ("seed") of a miRNA. 
 
 
 
miRNA 
W-C match 
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From the target prediction programme we were able to identify 14 protein targets 
from both down regulated as well up regulated list of identified proteins, which had 
satisfactory W-C match and/or 2-7 mer match between 3’UTR mRNA and 5’seed 
region of mir-29a sequence.  
 
 
 
TARGET : PRDX6 
length: 989 
MIRNA  : hsa-miR-29a 
length: 22 
 
mfe: -20.2 kcal/mol 
 
position  6 
target 5'   U G  GA    C        U 3' 
             U GA    AG UGGUGCUG     
             G CU    UC ACCACGAU     
miRNA  3' AUU G  AAAG  U          5'       
 
 
 
 
TARGET : CMPK1 
length: 2119 
MIRNA  : hsa-miR-29a 
length: 22 
 
mfe: -23.8 kcal/mol 
 
position  1738 
target 5' A       G     CUA      U 3' 
           GACUGAU   AGA   GGUGCU     
           UUGGCUA   UCU   CCACGA     
miRNA  3' A       AAG   A        U 5' 
 
 
 
TARGET : PEBP1 
length: 2119 
MIRNA  : hsa-miR-29a 
length: 22 
 
mfe: -23.8 kcal/mol 
 
position  1738 
target 5' A       G     CUA      U 3' 
           GACUGAU   AGA   GGUGCU     
           UUGGCUA   UCU   CCACGA     
 222
miRNA  3' A       AAG   A        U 5' 
 
 
TARGET : ANX2 
length: 488 
MIRNA  : hsa-miR-29a 
length: 22 
 
mfe: -25.1 kcal/mol 
 
position  10 
target 5' C    U  GCGUC    AA       C 3' 
           GGCC GA     CAGA  UGGUGCU     
           UUGG CU     GUCU  ACCACGA     
miRNA  3' A       AAA               U 5' 
 
 
 
 
TARGET : CNN2 
length: 1185 
MIRNA  : hsa-miR-29a 
length: 22 
 
mfe: -18.1 kcal/mol 
 
position  796 
target 5'   C    GUAGCUA   CUGCA      C 3' 
             CUGA       GGA     GGUGCU     
             GGCU       UCU     CCACGA     
miRNA  3' AUU    AAAG      A          U 5' 
 
 
 
TARGET : SFRS1 
length: 4512 
MIRNA  : hsa-miR-29a 
length: 22 
 
mfe: -20.9 kcal/mol 
 
position  2948 
target 5' A    UUAAC     CCUUG       A 3' 
           GACU     AUUUC     GGUGCUA     
           UUGG     UAAAG     CCACGAU     
miRNA  3' A    C         UCUA          5' 
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TARGET : PSMA2 
length: 713 
MIRNA  : hsa-miR-29a 
length: 22 
 
mfe: -19.5 kcal/mol 
 
position  463 
target 5'  U           UGAAAUCCUAG      C 3' 
            AUUGA  UCAG           GGUGCU     
            UGGCU  AGUC           CCACGA     
miRNA  3' AU     AA    UA               U 5' 
 
 
 
 
TARGET : ARL3 
length: 3184 
MIRNA  : hsa-miR-29a 
length: 22 
 
mfe: -22.13 kcal/mol 
 
position  2402 
target 5' G      AGGG    CAAGGCCUGGGG      C 3' 
           GGCCGG    CAGG            GGUGCU     
           UUGGCU    GUCU            CCACGA     
miRNA  3' A      AAA     A                 U 5' 
 
 
 
TARGET : PPIB 
length: 225 
MIRNA  : hsa-miR-29a 
length: 22 
 
mfe: -19.1 kcal/mol 
 
position  65 
target 5' G     CACUGGCCCC       G 3' 
           AGCUG          GGUGCUG     
           UUGGC          CCACGAU     
miRNA  3' A     UAAAGUCUA          5' 
 
 
 
 
 
 
 
 224
 
TARGET : PPIA 
length: 1695 
MIRNA  : hsa-miR-29a 
length: 22 
 
mfe: -21.9 kcal/mol 
 
position  1152 
target 5' A    A   ACU           C 3' 
           AGCC GGU      UGGUGCUA     
           UUGG CUA      ACCACGAU     
miRNA  3' A        AAGUCU          5' 
 
 
 
 
TARGET : GMFB 
length: 3597 
MIRNA  : hsa-miR-29a 
length: 22 
 
mfe: -19.3 kcal/mol 
 
position  3542 
target 5' G   AGUC    GUUA  C        U 3' 
           GAC    UUUU    AG AUGGUGCU     
           UUG    AAAG    UC UACCACGA     
miRNA  3' A   GCU                    U 5' 
 
 
 
 
TARGET : ACTC1 
length: 1956 
MIRNA  : hsa-miR-29a 
length: 22 
 
mfe: -21.3 kcal/mol 
 
position  760 
target 5' A   A   GG     CUGGUA       A 3' 
           GAC UGG   CAGG      GGUGCUG     
           UUG GCU   GUCU      CCACGAU     
miRNA  3' A       AAA    A              5' 
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TARGET : KIAA1598 
length: 1767 
MIRNA  : hsa-miR-29a 
length: 22 
 
mfe: -20.6 kcal/mol 
 
position  547 
target 5'  U     AAG  U         U 3' 
            GCUGA   UU GA GGUGCU     
            UGGCU   AG CU CCACGA     
miRNA  3' AU     AA   U  A      U 5' 
 
 
 
TARGET : SERBP1 
length: 5397 
MIRNA  : hsa-miR-29a 
length: 22 
 
mfe: -24.2 kcal/mol 
 
position  1679 
target 5'  U     GCAUG   U CAC        A 3' 
            GCUGA     UUC G   UGGUGCUA     
            UGGCU     AAG C   ACCACGAU     
miRNA  3' AU     A       U U            5' 
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SECTION: E 
 
3.34 Functional validation of selected gene targets from proteomics 
study using siRNA 
 
From the proteomic profiling of possible mir-29a targets we generated two lists of 
differentially regulated proteins. These were further put through bioinformatic 
analysis to delineate their relevance in biological pathways. Pubmatrix based 
literature mining with relevance to cancer cell invasion, proliferation, metastasis and 
drug resistance was performed. From these studies we selected four gene targets with 
established roles in cancer cell invasion/metastasis for functional validation. The 
targets chosen were all downregulated due to pre-mir-29a overexpression. Having 
identified that mir-29a had an anti-invasive effect and having identified several 
differentially regulated genes upon mir-29a overexpression we wanted to establish 
whether modifying some of these proteins individually would mediate the same effect 
on phenotype. Therefore, specific gene targets were knocked down to investigate the 
effect on cancer cell invasion and/or proliferation. The target genes RAN, GRB2, MIF 
and ANX2 were chosen from literature searches due to an established role in cancer 
invasion/metastasis. Two separate siRNA sequences for each target were used in our 
experiments.  
 
To summarize this section, knockdown of these targets was confirmed by qRT-PCR 
analysis (fig. 3.34.1A, 3.35A, 3.36A, 3.37A). 72hrs post siRNA treatment; cells were 
subjected to invasion assay. Of the 4 genes chosen, only RAN had any significant 
impact on the invasion phenotype of DLKPA. RAN knockdown was observed to 
reduce invasion significantly in DLKPA (Section 3.37). 72hrs post siRNA treatment; 
a proliferation assay confirmed that RAN knockdown significantly reduced cellular 
proliferation as well. Knockdown of the other three targets did not show any 
significant impact on either phenotype in DLKPA (Section 3.34, 3.35, 3.36). 
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3.34.1 MIF Specific siRNA knockdown at mRNA levels in DLKPA 
cell line 
 
Proteomics study indicated that MIF expression was downregulated due to pre-mir-
29a transient overexpression in DLKPA, which also reduced the DLKPA invasive 
phenotype. Thus it was decided to specifically knockdown MIF expression using two 
independent siRNA sequences in the invasive DLKPA cell lines to determine any 
functional effect on invasion or proliferation. 2l of NeoFX transfection reagent per 
well of a 24-well plate was used to transfect 50nM of target siRNA into the cells. 
MIF-specific knockdown was confirmed by qRT-PCR and the effect of MIF 
knockdown on proliferation and invasion investigated.  
 
MIF knockdown was examined using RT-PCR (Figures 3.34.1A). The RT negative 
control consisted of PCR master mix with RNA that was not reverse transcribed. A no 
template control (NTC), and no primer control was also used. The control was 
observed to have no amplification. MIF specific PCR primers were used to accurately 
measure relative MIF mRNA expression. The data was normalised using -actin as an 
endogenous control. The results confirmed that MIF knockdown was achieved at the 
mRNA level. 
 
As shown in figure 3.34.1A qRT PCR analysis demonstrate MIF specific knockdown 
at mRNA level. The graph is a composite of three biological repeats and relative to 
scrambled siRNA treated sample. The siRNA-MIF 2 was observed to have higher 
knockdown efficiency (60%) than siRNA-MIF 1 (40%) compared to the scramble 
control. 
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Figure 3.34.1A Relative qRT-PCR analysis of MIF siRNA knockdown. 
Ntmt: No treatment; Scr: Scramble sequence negative control; MIF-1: MIF specific 
siRNA 1; MIF-2: MIF specific siRNA2 , compared to scramble control and n=3. 
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3.34.2 Evaluation of MIF knockdown on DLKPA proliferation 
 
The effect of transfecting MIF siRNA on proliferation of DLKPA was investigated. 
Cells were seeded at 2 x 103 cells/well of a 96-well plate (Figure 3.34.2A), which was 
the same density used to seed all the siRNA transfections in six-well plates. Relative 
cell number was determined using the acid phosphatase assay at 72hrs post 
transfection. Transfection with any of the siRNA sequences did not have a significant 
affect on proliferation compared to non-treated and scrambled siRNA transfected 
cells. Kinesin was used as transfection positive control and a significant decrease 
(62%) in cellular proliferation was observed (Fig. 3.34.2A). 
 
 
 
Figure 3.34.2A Effect on proliferation of DLKPA cells transfected with MIF 
specific siRNAs. Ntmt: No treatment; Scr: Scramble sequence negative control; 
Kinesin: kinesin specific siRNA used as positive control; MIF-1: MIF specific siRNA 
1; MIF-2: MIF specific siRNA2. Kinesin observed to have significant impact,  and **     
p-value (<0.01) and n=3. 
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3.34.3 Evaluation of MIF siRNA effect on DLKPA invasion 
 
 
The effect of decreasing MIF expression on DLKPA invasion was investigated. 
Invasion assay analysis was performed 72 hours after transfection, to allow the cells 
to recover from the transfection procedure. At least two inserts were used for the 
analysis of each condition. The counts per number of inserts used were then also 
averaged and this figure was used to generate graphs of relative invasive capacity. 
 
From the figure 3.34.3A&B it’s evident that MIF knockdown had no impact on 
invasion phenotype of the DLKPA cell line.  
 
 
 
                        a)   Ntmt                                           b) Scr 
 
                                  
                       c) MIF-1                                             d) MIF-2 
 
                                   
 
Figure 3.34.3A Crystal violet staining representation of in vitro invasion assay of 
MIF siRNA treated DLKPA cell line. Ntmt: No treatment; Scr: Scramble sequence 
negative control; Kinesin: kinesin specific siRNA used as positive control; MIF-1: 
MIF specific siRNA 1; MIF-2: MIF specific siRNA2; Magnification 20X. 
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Figure 3.34.3B Graphical representation of in vitro invasion assay counts, post 
72 hrs MIF siRNA treatments in DLKPA cell line. Ntmt: No treatment; Scr: 
Scramble sequence negative control; Kinesin: kinesin specific siRNA used as positive 
control; MIF-1: MIF specific siRNA 1; MIF-2: MIF specific siRNA2. 
 
 
3.35 ANX2 specific siRNA knockdown at mRNA levels in DLKPA 
cell line 
 
Annexin A2 (ANX2) is a Ca2+ dependent phospholipid-binding protein. Proteomics 
study indicated that ANX2 expression was downregulated due to pre-mir-29a 
transient overexpression in DLKPA, which could account for the reduced DLKPA 
invasion phenotype. Hence, it was decided to knockdown ANX2 expression using 
two independent siRNA sequences in the invasive DLKPA cell lines to determine any 
functional effect on invasion or proliferation. 2l of NeoFX transfection reagent per 
well of a 24-well plate was used to transfect 50nM of target siRNA into the cells. 
ANX2-specific knockdown was confirmed by qRT-PCR. 
 
ANX2 knockdown was examined using RT-PCR (Figures 3.35A). The RT negative 
control consisted of PCR master mix with RNA that was not reverse transcribed. A no 
template control (NTC), and no primer control was also used. The control was 
observed to have no amplification. ANX2 specific PCR primers were used to 
accurately measure relative MIF mRNA expression. The data was normalised using 
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-actin as an endogenous control. The results confirmed that ANX2 knockdown was 
achieved at the mRNA level. The graph is a composite of three biological repeats and 
relative to scrambled siRNA treated sample. The siRNA-ANX2-2 observed to have 
higher knockdown efficiency of 83% fold, SE ± 0.02) than siRNA-ANX2-1 which 
also was observed to have 70% knockdown SE ± 0.13) compared to scramble control. 
 
 
 
 Figure 3.35A Relative qRT-PCR analysis of ANX2 siRNA knockdown. 
Ntmt: No treatment; Scr: Scramble sequence negative control; ANX2-1: ANX2 
specific siRNA 1; ANX2-2: ANX2 specific siRNA2. The error represents SEM ± 
0.02 for ANX2-2, and SEM ± 0.13 for ANX2-1 relatively. 
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3.35.1 Evaluation of ANX2 siRNA effect on DLKPA proliferation 
 
 
The effect of transfecting ANX2 siRNA on proliferation of DLKPA was investigated. 
Cells were seeded at 2 x 103 cells/well of a 96-well plate (Figure 3.35.1A), which was 
the same density used to seed all the siRNA transfections in six-well plates. Relative 
cell number was determined using the acid phosphatase assay at 72hrs post 
transfection. No significant effect was observed due to ANX2 knockdown compared 
to scramble control; kinesin was used as transfection positive control and a significant 
decrease in cellular proliferation was observed (62%) 
 
 
 
 
 Figure 3.35.1A Effect on proliferation of DLKPA cells transfected with ANX2 
specific siRNAs. Ntmt: No treatment; Scr: Scramble sequence negative control; 
Kinesin: kinesin specific siRNA used as positive control; ANX2-1: ANX2 specific 
siRNA 1; ANX2-2: ANX2 specific siRNA2. Kinesin observed to have significant ** 
p-value (<0.01) and n=3. 
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3.35.2 Evaluation of ANX2 siRNA effect on DLKPA invasion 
 
 
The effect of decreasing ANX2 expression on DLKPA invasion was investigated. 
Invasion assay analysis was performed 72 hours post transfection, to allow the cells to 
recover from the transfection procedure, using commercial invasion assay kits 
containing inserts pre-coated with matrigel. At least two inserts were used for the 
analysis of each condition. The counts per number of inserts used were then also 
averaged and this figure was used to generate graphs of relative invasive capacity. 
 
From the graph (Fig. 3.35.2B) it is evident that ANX2 knockdown has no impact on 
the invasive phenotype of DLKPA cell line. No significant effect was observed on the 
invasive phenotype due to siRNA knockdown compared to scrambled treatment. 
 
                        a)  Ntmt                                            b) Scr 
 
                                  
 
                         c) ANX2-1                                      d) ANX2-2 
                                   
 
 
Figure 3.35.2A Crystal violet staining representation of in vitro invasion assay of 
ANX2 siRNA treated in DLKPA cell line. Ntmt: No treatment; Scr: Scramble 
sequence negative control; ANX2-1: ANX2 specific siRNA 1; ANX2-2: ANX2 
specific siRNA2; Magnification 20X. 
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Figure 3.35.2B  ANX2 siRNA in vitro invasion assay in DLKPA cell line. Ntmt: 
No treatment; Scr: Scramble sequence negative control; ANX2-1: ANX2 specific 
siRNA 1; ANX2-2: ANX2 specific siRNA2; 
 
 
3.36 GRB2 specific siRNA knockdown at mRNA levels in DLKPA 
cell line 
 
Proteomics study indicated that GRB2 expression was downregulated due to pre-mir-
29a transient overexpression in DLKPA, which could account for the reduced 
DLKPA invasion phenotype. Hence, it was decided to knockdown GRB2 expression 
using two independent siRNA sequences in the invasive DLKPA cell lines to 
determine any functional effect on invasion or proliferation. 2l of NeoFX 
transfection reagent per well of a 24-well plate was used to transfect 50nM of target 
siRNA into the cells. GRB2-specific knockdown was confirmed by qRT-PCR.  GRB2 
knockdown was examined using RT-PCR (Figures 3.36A). The RT negative control 
consisted of PCR master mix with RNA that was not reverse transcribed. A no 
template control (NTC), and no primer control was also used. The control was 
observed to have no amplification. GRB2 specific PCR primers were used to 
accurately measure relative GRB2 mRNA expression. The data was normalised using 
-actin as an endogenous control. 
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The graph (Fig. 3.36A) is a composite of biological repeats and relative to scrambled 
siRNA treated sample, which was set to 1 for the analysis. The siRNA-GRB2-1 was 
observed to have a higher knockdown efficiency (65%) than siRNA-GRB2-2 (14%), 
compared to the scramble control. 
 
 
 
 
 
Figure 3.36A Relative qRT-PCR analysis of GRB2 siRNA knockdown. Ntmt: No 
treatment; Scr: Scramble sequence negative control; GRB2-1: GRB2 specific siRNA 
1; GRB2-2: GRB2 specific siRNA2 relatively and n=3. 
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3.36.1 Evaluation of GRB2 siRNA effect on DLKPA proliferation 
 
 
The effect of transfecting GRB2 siRNA on proliferation of DLKPA was investigated. 
Cells were seeded at 2 x 103 cells/well of a 96-well plate (Figure 3.36.1A), which was 
the same density used to seed all the siRNA transfections in six-well plates. Relative 
cell number was determined using the acid phosphatase assay at 72hrs after 
transfection. Transfection with either of the siRNA sequences did not have a 
significant effect on proliferation compared to non-treated and scrambled siRNA 
transfected cells. Kinesin was used as transfection positive control and a significant 
decrease in cellular proliferation was observed (62%) compared to scramble 
treatment. 
 
 
 
Figure 3.36.1A Effect on proliferation of DLKPA cells transfected with GRB2 
specific siRNAs. Ntmt: No treatment; Scr: Scramble sequence negative control; 
Kinesin: kinesin specific siRNA used as positive control; GRB2-1: GRB2 specific 
siRNA 1; GRB2-2: GRB2 specific siRNA2. Kinesin observed to have significant 
impact with ** p-value (<0.01) and n=3. 
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3.36.2 Evaluation of GRB2 siRNA effect on DLKPA invasion 
 
 
The effect of decreasing GRB2 expression on DLKPA invasion was investigated. 
Invasion assay analysis was performed 72 hours post transfection, to allow the cells to 
recover from the transfection procedure, using commercial invasion assay kits 
containing inserts pre-coated with matrigel. At least two inserts were used for the 
analysis of each condition. The counts per number of inserts used were then also 
averaged and this figure was used to generate graphs of relative invasive capacity. 
From the graph (Fig. 3.36.2B) it is evident that GRB2 knockdown has no impact on 
the invasive phenotype of the DLKPA cell line compared to scrambled treatment. 
 
 
                      a)                                                       b) 
 
                                  
 
                       c)                                                         d) 
                                    
 
 
Figure 3.36.2A Crystal violet staining representation of in vitro invasion assay of 
GRB2 siRNA treated DLKPA cell line. Ntmt: No treatment; Scr: Scramble 
sequence negative control; GRB2-1: GRB2 specific siRNA 1; GRB2-2: GRB2 
specific siRNA2; Magnification 20X. 
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Figure 3.36.2B  GRB2 siRNA in vitro invasion assay in DLKPA cell line. Ntmt: 
No treatment; Scr: Scramble sequence negative control; GRB2-1: GRB2 specific 
siRNA 1; GRB2-2: GRB2 specific siRNA2. 
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3.37 RAN specific siRNA knockdown at mRNA levels in DLKPA cell 
 line 
 
RAN (RAS-related nuclear protein) was identified by MALDI-TOF as 1RRP-C chain 
of the RAN-GPPNHP-RANBD1 complex and found to be decreased by 1.35 fold in 
mir-29a treated DLKPA cells. Vetter et al., 1999 showed the complex has four chains 
A, B, C, D. Chain A and C are composed of RAN and chain B and C composed of 
‘Nuclear Pore Complex Protein’ NUP358 (RBP2).  In order to investigate if RAN 
specifically played a role in the concomitant reduction in invasion we decided to 
specifically knockdown RAN expression using two independent siRNA sequences in 
the invasive DLKPA cell line. The siRNA transfection was performed as described 
previously. RAN-specific knockdown was confirmed by qRT-PCR and the effect of  
RAN knockdown on proliferation and invasion investigated.  
 
RAN knockdown was examined using RT-PCR (Figures 3.37A). The RT negative 
control consisted of PCR master mix with RNA that was not reverse transcribed. A no 
template control (NTC), and no primer control was also used. RAN specific PCR 
primers were used to accurately measure relative RAN mRNA expression. The data 
was normalised using -actin as an endogenous control. As shown in figure 3.38A 
RAN specific decrease in mRNA, was observed for samples at 72hrs. The siRNA-
RAN-2 was observed to have higher knockdown efficiency (48%) than siRNA-RAN-
1 (35%) compared to scramble control. 
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Figure 3.37A qRT-PCR analysis of siRNA mediated RAN knockdown in DLKPA 
cell line. Ntmt: No treatment; Scr: Scramble sequence negative control; RAN-1: RAN 
specific siRNA 1; RAN-2: RAN specific siRNA2. The siRNA-RAN-2 was observed 
to have higher knockdown efficiency compared to scramble control. 
 
 
 
3.38 Western blot analysis of RAN siRNA knockdown  
  
Two independent siRNAs specific to RAN were transfected in DLKPA cell line and 
the protein level was analysed by western blot (section 2.14). 72hrs after treatments 
the cells were trypsinised; protein was extracted, and used for western blot analysis. 
From figure 3.38.1A it is evident that both siRNAs mediated RAN knockdown and 
more precisely RAN-2 was observed to have a higher knockdown efficiency than 
RAN1 compared to scramble control, which agrees with the transcriptional 
quantification (fig.3.38A).  
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Figure 3.38A western blot analysis of RAN siRNA knockdown in DLKPA.  
Ntmt: No treatment; Scr: Scramble sequence negative control; RAN-1: RAN specific 
siRNA 1; RAN-2: RAN specific siRNA2. The polyclonal anti RAN antibody 
generates approximately 25kDa band specific to RAN. Anti GAPDH antibody was 
used as loading control and generated a 38 kDa GAPDH specific band. 
 
 
 
3.38.1 Evaluation of RAN siRNA knockdown effect on DLKPA cell 
proliferation 
 
The effect of transfecting RAN siRNA sequences on proliferation was investigated. 
Figure 3.38.1A represents the results of the proliferation assay. A significant effect 
was observed due to RAN knockdown compared to scramble control i.e. 49% 
decrease with RAN-2 and 44% decrease with RAN-1 siRNA. Again this correlated 
with the level of protein knockdown. Kinesin was used as a transfection positive 
control and a significant decrease in cellular proliferation was observed (62%). 
  Ntmt                Scr           RAN-2   Ntmt                Scr              RAN-1 
25kDa RAN 
 
 
38kDa GAPDH 
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Figure 3.38.1A Effect on proliferation of DLKPA cells transfected with RAN 
specific siRNAs. Ntmt: No treatment; Scr: Scramble sequence negative control; 
Kinesin: kinesin specific siRNA used as positive control; RAN-1: RAN specific 
siRNA 1; RAN-2: RAN specific siRNA2. Kinesin was used as transfection positive 
control and a significant decrease in cellular proliferation was observed, for kinesin 
with ** p-value (<0.01). RAN-2 and RAN-1 with * p-value (<0.05) and N=3. 
 
 
 
 
3.38.2 Evaluation of RAN siRNA effect on DLKPA invasion 
 
 
The effect of decreasing RAN expression on DLKPA invasion was investigated. 
Invasion assay analysis was performed 72 hours post transfection, to allow the cells to 
recover from the transfection procedure. At least two inserts were used for the 
analysis of each condition. The counts per number of inserts used were then also 
averaged and this figure was used to generate graphs of relative invasive capacity. 
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The effect of RAN siRNA on DLKPA invasion phenotype was observed to be 
dramatic, i.e. a significant 42% reduction due to RAN-1 siRNA treatment and 80% 
reduction due to RAN-2 siRNA treatment were observed in DLKPA cells compared 
to scramble treatment (Fig. 3.38.2B). 
 
 
                        a) Ntmt                                              b) Scr 
 
                                  
 
c) RAN-1                                     d) RAN-2 
 
                                  
 
Figure 3.38.2A Crystal violet staining of in vitro invasion assay of RAN siRNA 
treated DLKPA cell line. Ntmt: No treatment; Scr: Scramble sequence negative 
control; Kinesin: kinesin specific siRNA used as positive control; RAN-1: RAN 
specific siRNA 1; RAN-2: RAN specific siRNA2; Magnification 20X. 
 
 
 
 
 
 
 245
 
 
Figure 3.38.2B 72hrs post RAN siRNA in vitro invasion assay in DLKPA cell 
line. Ntmt: No treatment; Scr: Scramble sequence negative control; Kinesin: kinesin 
specific siRNA used as positive control; RAN-1: RAN specific siRNA 1; RAN-2: 
RAN specific siRNA2 with p-value *(<0.05) and N=3. 
 
 
 
3.39 Investigation of whether RAN may be a direct target of  
 mir-29a  
 
 
From the siRNA knockdown studies it was evident that the effect of RAN on invasion 
was similar to mir-29a overexpression in the DLKPA cell line.  To further evaluate 
whether RAN may be a direct target of mir-29a we amplified the 3’UTR region of 
RAN and cloned it downstream of GFP in a reporter plasmid. The rationale behind 
this relied on the fact that miRNAs target 3’UTR region of mRNAs. Accordingly, cell 
lines expressing 3’UTR sequence of RAN cloned downstream of a reporter gene, 
upon treatment with pre-mir-29a, would be expected to display reduced reporter 
protein expression if RAN was a direct target. Hence, RNA was isolated from 
DLKPA cell line and using random primers; we reverse transcribed cDNA. The 
cDNA thus amplified was further used to PCR amplify RAN using specific primers 
with restriction enzymes overhangs at the both 5’ and 3’ ends. The BamHI/HindIII 
digested 3’UTR of RAN was cloned downstream of GFP coding sequence in pEGFP-
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C1. The GFP-RANUTR plasmid was transfected and a mixed stable DLKPA cell 
population was generated. Furthermore this stable cell line was transiently transfected 
with pre-mir-29a and pre-mir-control (100nM), and 72hrs later cells were harvested 
for RNA and protein analysis. We used a flowcytometer to measure GFP expression 
levels in live cells. The initial flowcytometer experiments were done at 48, 72 and 
96hrs. This analysis revealed that at 72hrs there was a shift in the GFP expressing cell 
population. Numerous biological replicates were conducted at 72hrs. Similarly the 
RNA extracted from these samples was subjected to qRT-PCR to evaluate the 
knockdown in GFP mRNA levels. 
 
The RAN 3’UTR cloning was successful as represented in figures (3.39A, 3.39B, 
3.39C), the qRT-PCR analysis of GFP expression due to pre-mir-29a treatment 
revealed that there was knockdown at the mRNA level in mir-29a transfected cells 
(figure 3.39D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3.39A PCR amplification of Ran 3’UTR using RNA as template for 
cDNA preparation from DLKP cell line. The cDNA generated with 1) Random 
primer, 2) sequence specific primer, M- 1Kb plus DNA ladder. 
 
 
 
        M                                                           1                           2 
1kb 
 
0.5kb 
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Figure 3.39B DNA agarose gel confirmation, of BamHI and HindIII digestion. 
PEGFP-C1 (lane 1) and pcr amplified 3’RAN UTR (lane 2), lane M: 1kbplus DNA 
ladder. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.39C RAN 3’UTR cloning restriction enzyme digestion reaction to check 
for GFP-C1-RAN-3’UTR clone.  M- 1kb plus DNA ladder, C- Uncut control, 1-6 
plasmid prepped samples, all the samples released expected ~950bp size product. 
 
           M                                            1                                                                 2 
   M                C                  1                  2                 3               4             5              6  
1kb 
 
0.5kb 
1kb 
 
0.5kb 
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In the figure 3.39E the rationale behind plotting segments of total population was to 
determine whether a decrease in GFP expression was observed due to data collected 
at a single point or is it a genuine decrease within the population as a whole. So if that 
is true then we should expect a shift towards more low expressing cells and less high 
expressing cells in mir-29a transfected cells. From the graph it is evident that the 
decrease in GFP expression was across the population in pre-mir-29a treated cells 
which is represented in red line, relative to blue line (control) in figure 3.39E. 
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Figure 3.39D qRT-PCR analysis 72 hrs after pre-mir-29a treatment. 
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Figure 3.39E Flowcytometer analysis of GFP expression. Post mir-29a transfected 
DLKPA cell line expressing stable GFP-RAN 3’UTR. X-axis represents individual 
segments of a mixed GFP expressing DLKPA population where some cells are low 
expressers (segment 2-3), some are medium (3-4) and so on. Some have expression 
levels below the detectable ‘threshold (1). The Y-axis represents the amount of cells 
in that segment as % of whole population. And the shift was significant with p –value 
(<0.05), error bar represents (n=10). 
 
 
3.40 GLP1-R a possible mir-29a target 
 
During our in silico analysis of predicted mir-29a targets, we discovered Glucagon 
like Peptide 1 Receptor (GFLP1R) was predicted as a possible target of mir-29a using 
miRBase miRNA target prediction programme from the Sanger Institute 
(http://microrna.sanger.ac.uk/sequences/). From our stable transgene overexpression 
studies it was confirmed that GLP1-R was a potential mediator of invasion in our 
model cell lines. This was also further confirmed with siRNA based knockdown 
studies (refer section 3.17, 3.18 and 3.19). From our mir-29a experiments it was 
evident that mir-29a is anti invasive, so we decided to check the levels of GLP1-R in 
mir-29a stable overexpressing cell line to investigate whether there might be a 
common regulation pathway involving both molecules. 
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Initially we checked the endogenous mRNA levels of GLP1-R by qRT-PCR analysis 
in mir-29a DLKPA stable clones, mir-29a (3) and mir-29a (4) relative to mir-negative 
sequence expressing clone. GLP1-R mRNA levels were decreased (70%) in mir-29a 
DLKPA clone (3) and a significant (81%) decrease in mir-29a clone (4). From the 
first set of results (Fig. 3.40D) it was observed that pre-mir-29a treatment had 
decreased GLP1-R levels compared to pre-mir-negative treatment.  No difference was 
observed with anti-mir-29a treatment. Further work would be required to confirm the 
observation. 
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Figure 3.40C qRT-PCR analysis endogenous GLP1-R in mir-29a stable 
overexpressing DLKPA cell line. Mir-29a (3): DLKPA mir-29a expressing clone 3; 
mir-29a(4): DLKPA mir-29a expressing clone 4; mir-negative control: DLKPA 
expressing negative sequence as control and for mir-29a(4) clone with a significant p-
value (≤0.05) and N=3. 
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Figure 3.40D Representative western blot analysis of GLP1-R in pre and anti 
mir-29a transiently transfected DLKPA cell line. Anti-control: anti-mir sequence 
control; Anti-mir-29a; anti-mir29a sequence treated sample; Pre-control: pre-mir 
sequence treated; Pre-mir-29a: pre-mir-29a sequence treated sample. Pre-mir-29a 
treated samples appeared to have reduced GLP1-R expression. GLP1-R antibody 
developed 52kDa bands and GAPDH was used as loading control with 38 kDa bands. 
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4.0 DISCUSSION 
 
4.1 Overview 
 
Lung cancer is the most lethal and prevalent of malignancies in the world with deaths 
exceeding those from breast, colon and prostate cancer combined (Akehurst et al, 
2002; Danesi et al, 2003). The use of chemotherapy in the treatment of non-small cell 
lung cancer (NSCLC) patients has greatly increased over the last twenty years, with 
agents being used in combination more effectively than alone. The most commonly 
used drugs for the treatment of NSCLC are the taxanes and platinum drugs with 
platinum-based doublets remaining the preferred option (Socinski, 2004). However, 
the development of resistance to these drugs is frequent and a major obstacle in lung 
cancer treatment.  
(Akehurst et al, 2002) 
 
The purpose of this research thesis was to study molecular mechanisms of 
invasion/metastasis in lung cancer cell lines. In particular, we investigated the 
impact of expression of four specific genes on invasion in lung cancer cell lines; 
and the role of specific microRNAs in regulation of the invasion phenotype in lung 
cancer cell lines. In order to have optimal cell lines with which to approach the 
questions, we also attempted to generate stable targetable cell lines.   
 
Invasion is a prerequisite step in cancer metastasis. Invading tumour cells appear to 
have lost the control mechanism that prevents normal cells from invading neighbouring 
tissue at inappropriate times and places (Friedl and Wolf, 2003b). Metastasis is the 
spread of cancer from a primary tumour to distant sites in the body. A distinguishing 
feature of malignant cells is their capacity to invade surrounding normal tissues and 
metastasise through the blood and lymphatic systems to distant organs. This process of 
metastasis is the most devastating aspect of cancer. The loss of tight regulatory 
mechanisms is mainly due to gene mutations resulting in genetic instability (Friedl and 
Wolf, 2003a). The difference must lie in the proteins that start, stop or maintain the 
invasion programme at times and places that are inappropriate for non-malignant cells. 
A major goal is to understand what signals and signal transduction pathways are 
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perpetually activated or deregulated in malignant invasion (Kohn et al, 1997). 
Microarrays have been utilised to identify gene signatures that would differentiate 
between various primary and metastatic adenocarcinoma (Deutsch, 2003). This group 
reported a metastasis-associated gene signature that contained eight up regulated and 
nine down-regulated genes.  
 
The lung cancer cell lines models used in our study were DLKP (non invasive) and 
DLKPA (invasive) carcinoma cell lines. DLKP was isolated from a tumor 
histologically diagnosed as a poorly differentiated lung carcinoma (Law et al, 1992) in 
the National Institute for Cellular Biotechnology (NICB). The DLKPA variant is 
resistant to Adriamycin, a chemotherapeutic drug, and was also generated in the NICB 
(Heenan, 1997). The research work carried out in this thesis can be divided into two 
main sections. 
 
 Development of genetic tools for stable, targetable transgene 
overexpression. 
 
The impact of dysregulated expression of a particular gene is often studied by 
generating cell lines that overexpress the gene after random insertion in the genome. 
The problem with random transgene integration is variation in stable gene expression 
in the resulting clones and is usually due to chromosomal position effects and/or copy 
number variation between different clones. This often results in genetic instability, loss 
of observed phenotype in real time and as a result, cell lines with unpredictable 
behaviour.  To address this variation, we attempted to design and construct two 
different Cre-LoxP based mammalian expression systems to generate targetable lung 
cancer cell lines. A GFP based reporter system was used initially to generate stable cell 
lines and used to monitor the expression and stability characteristics of the cell lines. 
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  Investigation into the role of differential expression of a group of genes 
including miRNAs, in cancer invasion.  
 
As mentioned above, in order to investigate the mode of action and function of a gene 
product it is often useful to alter the expression of the gene either by overexpression or 
specific knockdown. Microarray profiling studies done in this lab (Pierce A. PhD thesis 
2005) on a panel of lung cancer cell lines with various invasive phenotypes identified a 
list of differentially expressed genes. It was also demonstrated that transiently altering 
the expression of several of these genes could modulate the invasive capacity of these 
cell lines (Pierce et al, 2008). Based on this microarray data and subsequent qRT-PCR 
analysis we selected 4 genes (KCNJ8, TFPI2, S100A13, GLP1-R) for evaluation of the 
effect on proliferation and invasion of stable over expression in targetable DLKP cell 
lines.  
 
MiRNAs (miRNAs) are noncoding, small regulatory RNAs. Recent studies have 
revealed their involvement in cell development and various cellular processes. We 
investigated miRNAs potentially involved in cancer invasion in DLKP Vs DLKPA cell 
lines.  In particular we followed up our studies with one miRNA (mir-29a) which was 
observed to have an anti-invasive impact in our model cell lines. To identify possible 
gene targets being dysregulated due to reduced or increased expression of mir-29a we 
performed proteomics analysis and functional investigation of selected targets.  
 
 
 
Section I:   
 
4.2 Development of targetable lung cancer cell lines for stable 
transgene    overexpression 
 
The possibility of stably integrating genes into the genome of mammalian cells has an 
important impact on many biomedical research areas as well as for the development of 
pharmaceutical products. While transient transfection is advantageous for fast analysis 
of genes, it is frequently desirable to observe the effect of stable long-term, 
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reproducible, as well as defined, gene expression. Major applications of stable 
transfection are the analysis of gene function and regulation (Grimm et al, 2004) large 
scale protein production (Wurm, 2004), drug discovery and gene therapy (Glover et al, 
2005).  
 
The major drawback of generating transgenic cell lines by random integration of 
plasmid DNA is the unpredictability in expression between clones. Other problems 
associated with non-targeted, random insertion of exogenous transgenes include: 
 
 Loss of expression due to instability or silencing at the epigenetic level, at 
particular chromosomal loci. 
 Prolonged screening process for sub clones suitable for experimentation.  
 Risk of possible disruption of important endogenous sequences or genes 
 
 
4.3 How the targeting system works 
 
A review by Sherratt et al (1995) showed that the DNA rearrangements catalyzed by 
site-specific recombinases from the tyrosine recombinase family are used in a variety 
of important gene recombination events. In addition to the integration and excision of 
viral genomes into and out of host chromosomes, site-specific recombinases recognize 
specific DNA sequences and catalyze DNA rearrangements only between those 
sequences (Sherratt et al, 1995). Based on sequence similarity, over 100 tyrosine 
recombinases were identified (Nunes-Duby et al, 1998). The most well-studied 
examples include the integrase protein from bacteriophage  (Sarkar et al, 2002), the 
bacterial XerC and XerD recombinases (Aussel et al, 2002), the Cre recombinase from 
bacteriophage P1 (Hoess et al, 1984), and the Flp recombinase from the 
Saccharomyces cerevisiae 2 micron circle plasmid (Sadowski, 1995). Craig (1988) and 
others showed that these proteins catalyse site-specific recombination between DNA 
substrates in a stepwise manner, exchanging one pair of DNA strands to form a 
Holiday junction (HJ) intermediate and then resolving the HJ intermediate to produce 
an exchange of the second pair of strands (refer to figure 1.13) (Craig, 1988). 
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The Cre gene which encodes a site specific DNA recombinase can catalyse 
recombination between specific sites in a DNA sequence (Ray et al, 2000). These sites 
are known as LoxP (locus of X-over P1) sequences, which are 34 base pairs long and 
bear binding region for the Cre to recombine the DNA surrounding them (fig. 4.3A). 
Two Cre subunits bind to each loxP site and the sites associate to form a complex.  As 
a result, the DNA in between the LoxP sites is excised and subsequently degraded.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3A Mechanism of Cre recombination. Cre specifically recognizes and 
binds to the recombinase binding elements (RBEs), which are arranged as inverted 
repeats surrounding a central 8-bp crossover region (in bold) 
 
 
4.3.1 Why Cre/LoxP excision of DNA is so useful 
 
The LoxP sequence originally comes from the P1 bacteriophage, which is a bacterial 
virus that contains DNA that is not found in animals or plants. Since LoxP sequences 
are 34 base pairs long there is virtually no chance that one would randomly find them 
in a genome. Therefore, LoxP sequences can be artificially inserted into animals or 
plants and used for the precise excision of DNA. In our study system, since we have 
flanked the geo gene with LoxP sites, after inserting in the genome of the host would 
act as targets for Cre. Cre recombinase represents one of the simple tyrosine 
recombinase. Studies reported by Lin et al, (1985), confirmed that Cre will recombine 
essentially any DNA substrates which contain the LoxP sites, with no requirements for 
5’ ATAACTTCGTATAGCATACATTATACGAAGTTAT 3’
3’ TATTGAAGCATATCGTATGTAATATGCTTCAATA 5’
Cre Cre
RBE RBE
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accessory proteins. The mode of action is dependent on the orientation of the LoxP 
sites (fig. 4.3B). Any sequence in-between forward directed LoxP sites (>->) will be 
removed by Cre enzyme, and sequence in between LoxP sites facing each other (>-<) 
would be inverted and re ligated. In our study we are using the forward orientation as 
we are interested in targeting strategies. 
 
4.4 Stability  assessment of stable DLKPgeo clones 
 
Before generating the clones for stability assessment there was a need to optimize the 
transfection conditions for the cell lines. This was found to be 1:3 ratio of DNA to 
Lipofectamine 2000 with minimal cell toxicity and maximum transfection efficiency.   
 
More importantly we wanted to ensure that the GFP-Neo fusion that was constructed in 
the pBKS-geo plasmid retained its dual functionality. Fusion proteins such as this have 
been used by other groups to minimise the use of extra promoters or IRES sequences in 
plasmids in order to reduce plasmid size. These have included LacZ-neo fusions 
(Baker, 1997) and similar GFP-neo fusions (Hansen, 2002). The construct assembled 
in this work was shown to retain both its fluorescent GFP properties (Fig. 3.1.6) though 
to a slightly lesser extent than wild type GFP, and an active neomycin 
phosphotransferase capable of conferring G418 resistance on transfected cells (Fig. 
3.1.6).  
 
To generate a panel of targetable DLKP clones, cells were transfected with pBKS-geo. 
The plasmid carried a recombination cassette and contained the following elements a) 
A reporter fusion gene Geo [GFP fused with Neo (neomycin resistance gene)] both 
driven by a strong CMV promoter (Constien et al, 2001), b) LoxP sequences placed on 
either side of the Geo cassette which would eventually be knocked out by transient 
expression of Cre recombinase (Stec and Sigmund, 1998) to generate LoxP based 
targetable cell line. GFP positive and G418 resistant cells were selected by single cell 
cloning. Each well containing a single cell was identified and expanded before stocks 
of each were frozen. These stable DLKPgeo clones were thawed back in 24 well cell 
culture plates. Of the 50 clones thawed back only 33 clones survived the initial freeze 
thaw. This was not surprising as we know either due to freezing processes involved or 
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the ability of clones to recover back, one would always experience this. These 33 
clones were passaged regularly with constant monitoring visually under fluorescent 
microscope. In addition GFP expression was recorded by flowcytometer 
measurements.  
 
During this process, which lasted for four and a half months, we observed clones with 
various Geo expression levels. It is evident from our results that clones with a range of 
expression levels (monitored through flow cytometer) were observed (Section 3.2). In 
addition, though they were all single cell clonal populations, there were what appeared 
to be non-fluorescing, G418 resistant cells as well as cells with different levels of GFP 
expression. An in vitro study in mammalian cellular systems shows that the 
spontaneous emergence of phenotypic heterogeneity is a rule rather than an exception 
(Stockholm et al, 2007). Transcriptional heterogeneity has been observed in cultures of 
various lines of genetically identical cells even in controlled environments (Rubin, 
1993). These different expression phenotypes can be strikingly different; for example, 
non malignant cells can spontaneously produce neoplastic sub-clones at a frequency 
dependent on the culture conditions (Rubin, 2001). Conversely, cells in isogenic (from 
same parental clone) populations of malignant cell lines in culture can spontaneously 
revert to stable non-malignant phenotypes (Lavrovsky et al, 1992 and Sun et al, 1996). 
Snapka et al, (1997) reported that cells with higher levels of transgene amplification 
displayed a low rate of G1/S transition suggesting that amplified sequences may 
activate a cell cycle checkpoint. It has also been shown that extinction of expression is 
caused not just by transgene elimination but by transcriptional silencing and that this in 
turn, is influenced by the nature of the transgene itself (Migliaccio et al, 2000). Besides 
copy number, another factor influencing the stability of transgenic cell lines is the 
genomic location of the integration event(s).  Neildez-Nguyen et al, (2008) observed in 
their studies that  a) factors acting on the promoter account mainly for the generation of 
variability and, consequently, the phenotypic diversification of the cell population, b) 
epigenetic mechanisms act to increase the robustness of the cellular state by stabilizing 
the gene transcription levels or by reinforcing the silenced state. We suspected the 
appearance of GFP negative population in our model studies could be a cell cycle 
effect.  
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4.5 Cell cycle analysis 
 
In order to investigate the differences in cell cycle phase which we thought contributed 
to differences in DLKP-geo clonal expression we used propidium iodide (DNA 
binding dye) based cell cycle analysis. The comparison between DLKP parent and 
several DLKP-geo clones revealed that at each time point there was a higher 
percentage of cells in G0/G1 phase in the DLKP-geo clone and less in G2/M compared 
to the parent. In both cell lines there was a decrease in the percentage of cells in G0/G1 
with increasing time after serum activation as expected. However, more importantly 
there was no fluctuation in the level of fluorescence measured in the DLKP-geo clone 
after the initial burst of translation associated with the addition of serum. This 
observation eliminated the possibility of transgene expression levels varying due to cell 
cycle stage. The most likely explanation and one for which more evidence was seen 
subsequently in the studies with several transgenes, is that the fluorescence data 
captured during the guava analysis was somewhat misleading. During flowcytometer 
analysis, the cut off setting that the user applies to define the positive and negative 
population is based on non-transfected control. In the case of clones with low 
transgene expression i.e. low fluorescence, there is a greater chance of a cell falling 
below this line. This results in it being ‘recorded’ as GFP negative. The cell that passes 
through laser and amount of signal detected will depend on shape of cell, GFP 
localisation and the way the cell is facing. 
 
Therefore even though the output data is represented in percentage GFP positive cells 
in the population, it most probably reflects the level of GFP expression in the clone in 
general. That is in a clonal population of strongly positive cells the majority will fall 
above the cut off. In a clone that has low GFP expression there is a greater likelihood 
of a cell falling below the cut off. Therefore a higher percentage appears negative. In 
reality this just indicates a clonal population with a low level of transgene expression. 
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4.6 Proof of concept of targeting tool 
 
To prove the targeting tool worked we constructed a shuttle vector that consisted of a 
promoterless neo, downstream of a single LoxP site, and a CMV promoter to drive 
transgene expression. Neo confers resistance to G418 drug therefore; if the 
promoterless Neo transfected cells had not undergone recombination at LoxP locus in 
the DLKP genome then the cells should lack resistance to G418 and die. Conversely, if 
targeted recombination occurs then the CMV already present at the targetable locus 
would drive neo expression and in turn, the cells would survive G418 that confirms 
targeted integration. A LacZ reporter gene was cloned into the shuttle vector pShuttle 
(Fig.3.7.3, 3.7.4) and co-transfected with Cre. The cells were subjected to G418 
selection for 5-6 days (DLKP parent cell line base level threshold for G418 selection) 
the surviving cells were fixed and stained with X-gal; pSVGal plasmid was used as a 
positive control (section 2.7.2). Cells expressing -gal were stained blue (Fig 3.7.4). In 
the cultures transfected with pShuttle without Cre there was large number of surviving 
cells, many of which were not LacZ positive.  
 
Possible reasons for this could be A) Random insertion of the pShuttle plasmid near an 
endogenous enhancer/promoter element resulting in activation of neo. This would 
result in G418 resistant cells. These random insertion events often include degradation 
of part of the exogenous sequence by intracellular nucleases potentially resulting in 
inactivation of the LacZ gene in some cases.  
 
B) Re-arrangements of the exogenous sequence prior to random integration in the 
genome resulting in activation of neo, by the plasmid-encoded CMV sequence.  
C) Chromatin silencing events that only affect the LacZ sequence. Keeping in mind 
that the selection process enriches for clones that express neo therefore cells that had 
silenced neo transcription (but not those that had silenced LacZ) would die. 
 
It has been reported that the silencing effect can be avoided by the inclusion of 
chromatin insulators proximal to the transgene (Felsenfeld et al, 1996). Insulators are 
DNA sequences that can function as directional blocking elements either by interfering 
with promoter/enhancer interactions when positioned in the intervening sequence or by 
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reducing position effects imparted on transgenes when flanking the integrated 
transcription units (Rivella, 2000).  
 
An insulator sequence (kind gift from Prof. Gary Felsenfeld) was cloned between the 
CMV and promoterless neo to try to minimise the observed phenomenon. As a result, 
there was a dramatic difference i.e. there were much fewer surviving cells after G418 
selection and most stained positive for X-gal. However the system was still not 100% 
effective i.e. we did find a small population of cells which were X-gal negative and 
G418 positive (section 3.11).  Despite the slight “leakiness” observed in the targeting 
system we have demonstrated the development of a panel of DLKP clones with various 
transgene expression levels from a re-targetable genetic locus. Though the re-targeting 
procedure resulted in some background, non-targeted clones it was sufficiently robust 
to provide a useful tool for subsequent gene studies. 
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Section II:   
 
4.7 LINE-1 (Long Interspersed Nuclear Element 1) Specific Targeting   
 
Homologous recombination (HR) refers to any process in which two similar DNA 
sequences interact and exchange genetic information. Cells have the inherent ability of 
performing HR. The most obvious natural occurrence of HR is in meiotic 
recombination (Smith, 2001). 
 
Adopted from  http://nobelprize.org/nobel_prizes/medicine/laureates/2007/adv.html 
 
________________________________________________________________________ 
 
 Figure 4.7A represents specific targeted as well as random targeted gene 
recombination mechanisms. Figure illustrates an example of mechanism of specific 
and random integration of target gene recombination in genomic DNA environment. In 
both gene targeting (A) and random integration (B), the upper line shows the targeting 
vector, the middle one the chromosomal gene, and the lower one the modified gene. 
The type of vector used for stable integration defines the integration mechanism, the 
regulation of transgene expression and the selection conditions for stably expressing 
cells. After integration the level and time of expression of the gene of interest depends 
on the promoter cloned upstream on the expression vector and on the particular 
integration site.  
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Studies involving gene targeting of artificially introduced defective genes by Lin et al. 
reported a ratio of random integration to gene targeting of 100000:1. This indicated a 
high frequency of random integration events (Lin et al, 1985). An overview study 
concluded that absolute frequencies of gene targeting in mammalian cells remain low, 
and the ratio of targeted to random integration is still heavily weighted in favour of the 
latter (Smith, 2001). Until the frequencies are improved, the potential use of gene 
targeting in non-selective systems will be limited. Such improvement is likely to 
depend upon a more detailed understanding of gene targeting. The random integration 
effect could be eliminated by generating a targeting locus in the system prior to 
transgene introduction.  
 
Our first approach relied on initially introducing the LoxP site into the genome in a 
random manner followed by assessment of a panel of resulting clones for their level of 
transgene expression. The second approach we took was to introduce the re-targetable 
LoxP site into the genome in a more controlled, directed manner. This relied on the 
phenomenon of homologous recombination (HR).  In mitotic eukaryotic cells, the 
primary use of homologous recombination is to repair DNA double-strand breaks 
(DSBs). In meiotic eukaryotic cells, homologous recombination is the way cells 
exchange genetic material between homologous chromosomes to create genetic 
diversity and is the way that cells synapse homologous chromosomes to allow proper 
chromosomal segregation (Porteus, 2007). This phenomenon has been taken advantage 
of to study gene function in mice and other model organisms by generating gene 
deletion mutants. Typically a selective marker is flanked by sequences homologous to 
the target locus and is introduced into embryonic stem cells. In cells where 
homologous recombination occurs, these flanking arms replace the endogenous allelic 
sequence and place the selection marker at the locus simultaneously disrupting the 
exon/intron structure, and ‘breaking up’ the gene. We chose this method to place the 
LoxP site in the DLKP genome in a directed manner. However, HR occurs at very low 
frequency even in germ cells and its frequency is extremely low in somatic cells. Gene 
targeting frequencies of 10−2 (one homologous integration event per hundred random 
integration events) or higher typically occur in ES cells depending on numerous 
criteria (Jasin et al, 1996). 
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An attempt was made to generate stable, targetable cell lines, using human Long 
Interspersed Nuclear Elements or LINE-1or L1 element as the targetable locus. L1 
elements are ubiquitous human transposons which replicate through an RNA 
intermediate mechanism. L1’s are the most common family of non-LTR 
retrotransposons in the human genome. There are approximately 80-100 
retrotransposition competent active copies of this element in the human genome. The 
full length mammalian L1 is ~6000 bp long and is composed of the 5’ UTR region 
bearing an internal promoter, two open reading frames ORF1 and ORF2 separated by 
intergenic region and 3’UTR containing a poly(A) tail. The ORF1 is non-sequence-
specific RNA binding protein and the ORF2 harbours three domains involved in L1 
retrotransposition activity: endonuclease, reverse transcriptase and a 3’ terminal Zn 
finger-like domain (Dombroski, 1991). Studies done by Feng et al, (1996) have shown 
that the transposition of engineered L1s in cultured human cells occurs at reasonable 
frequency. The human genome is estimated to be comprised of ~17-20% of L1 
elements (Lander et al, 2001), the majority of which are inactive. We knew that the 
frequency of homologous recombination is very low in somatic cells compared to stem 
cells (Yamane-Ohnuki et al, 2004). To increase the possibility of encountering a HR 
event we deliberately selected an abundant target sequence in the genome. Using 
human L1 element as target would also help avoid targeting endogenous genes, and 
possibly shed light on homologous recombination efficiency in somatic cells which 
hasn’t yet been completely explored.   
 
The complete human L1 sequence was a kind gift from Dr. Olga Piskareva (NICB). 
The plasmid that we designed and constructed contained the following elements, a 
reporter fusion gene [Geo (GFP+Neo)] and LoxP sequences flanked by split 5’ and 3’ 
ORF-2 sequence of human L1 element. An external CMV promoter was cloned in-
between 5’ arm and LoxP sequence.  Herpes Simplex Virus thymidine kinase 
expression cassette was cloned upstream of the 5’ L1 flanking sequence to negatively 
select for random integration events (Fig. 3.9.3.2).  
 
600 stably transfected single cell clones were screened by PCR to try to identify 
homologous targeting events. Several pairs of primers were designed and used in our 
screen with the sense primer designed outside the 5’ arm but still within the L1 element 
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(in-between ORF1 and ORF2) and antisense primer in the Geo region. In the event of 
HR these would amplify ~2kb product (fig. 3.10.2). Since, we did not have a perfect 
positive control we used sP52 plasmid which had ORF1 and ORF2 regions of L1 
element and pBKS 5’-3’ L1 targeting plasmid to make sure the primers were capable 
of binding to their sequence. Unfortunately we were not able to find even a single 
positive clone which displayd a LINE-1 homologous recombination event, suggesting 
that the homologous recombination frequency was at least less than one in six hundred, 
compared to random integration. 
 
Considering the factors that improved gene targeting in mouse, various attempts have 
been undertaken in the following years to improve the ratio of homologous to 
illegitimate recombination. However, in plants neither extending the length of 
homology in the transferred DNA to up to 22 kb (Thykjaer et al, 1997) nor including 
negative selectable markers outside of the homology of the targeting vector to be able 
to select against random integration (Risseeuw et al, 1997, and Gallego et al, 1999) did 
not  result in a significantly higher frequency of gene targeting. Yamane-ohnuki et al 
(2004) reported screening over 70,000 clones to identify just one clone with the desired 
homologous recombination event, i.e. establishment of fut8 knockout in Chinese 
hamster ovary cells.  
 
This work demonstrates that even when targeting an extremely abundant genetic 
element in the genome, homologous recombination rates remain very low. 
Transfection efficiency plays an important role in recombination events. Maximum 
efficiency is directly proportional to increased frequency of homologous 
recombination. Vectors based on adeno-associated virus (AAV) can efficiently modify 
homologous chromosomal target sequences (Russell and Hirata, 1998). In vivo analysis 
of retroviral gene transfer to chondrocytes within collagen scaffolds for the treatment 
of osteochondral defects showed that far higher transfection rates (up to 100%) can be 
achieved with AAV viral transfection methods (Ueblacker et al, 2007). A replication-
defective adenovirus can be used for high transfection efficiency as already been 
extensively used in recent past (Fujita et al, 1995). Therefore future work was 
considered to improve transfection efficiency by viral based methods. 
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Section III:   
4.8 Stable Transgene Overexpression studies 
 
The main focus of this thesis was to investigate genes that may have a potential role in 
cancer cell invasion/proliferation and potentially result in downstream metastasis of 
cancer.  Previously in the lab a comparative gene expression profiling between highly 
invasive (DLKP-1, DLKP-2 and TXT-2) and less invasive (TXT-1 and VCR) lung 
cancer variant lines was performed. This work identified many differentially regulated 
genes some of which may potentially serve as molecular ‘signatures’ for invasiveness 
in lung cancer cell lines. These types of signatures may help provide earlier diagnosis 
and influence and individualise the therapies prescribed to cancer patients thereby 
improving prognosis. The results in the thesis identified transcripts associated with a 
more aggressive invasive phenotype and demonstrate that transiently altering the 
expression of some of these mRNAs can modulate the invasive capacity of these lung 
cancer cells (Pierce et al, 2008).  
 
The gene targets GLP1R, KCNJ8, TFPI2 and S100A13 were differentially upregulated 
in DLKP-1, DLKP-2 and TXT-2 invasive cell lines. Except GLP1R the other 3 gene 
targets, of which functional relevance had been transiently validated in the lab 
previously and were predicted to be of potential therapeutic importance.  
 
 KCNJ8 knockdown reduced invasion and proliferation in invasive cell lines but 
transient cDNA overexpression in non-invasive cell lines did not have any 
impact on invasion. It was therefore an interesting target to validate in our 
stable overexpression system, because as we know from the previous study that 
transient overexpression did not have any significant impact on in vitro 
invasion.  
 TFPI2 knockdown increased invasion and proliferation in non invasive cell 
lines but transient overexpression did not have any impact on the invasive 
phenotype in invasive cell lines. Therefore stable overexpression to further 
investigate its role in cancer invasion was necessary.  
 Similarly it was found that S100A13 was differentially expressed in the panel 
of cell lines studied, correlating with qPCR data. Decreasing S100A13 
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expression had no effect on proliferation but did decrease invasion. However 
transiently increasing S100A13 expression had no effect on invasion in the 
less/non-invasive cell lines, despite a measurable increase in protein expression 
following transient transfection (Pierce et al, 2008). S100A13 was therefore 
chosen to determine whether stable overexpression in our targetable system 
would impact on this phenotype in the cell line models.  
 
Furthermore to investigate the stable overexpression of these chosen gene targets in 
our model cell lines and to monitor the impact of gene dosage effect on cell invasion in 
our stable overexpression studies we also included GLP1-R (Glucagon like peptide 1 
receptor) which was found to be differentially up-regulated in invasive compared to 
mildly invasive cell lines.  
These genes were subcloned into pShuttle vector (Section 3.11) co-transfected with 
Cre individually into two selected master targetable DLKP cell lines. DLKP targetable 
clones 17 and 11 were selected from our stability studies (section 3.2), which were 
different in their transgene expression levels as illustrated in figure 4.8A. The rationale 
behind selecting these two targetable clones was to investigate the dosage effect of 
transgene expression.  They were Cre treated to remove geo leaving a LoxP site as an 
endogenous, targetable locus. Subsequent co-transfections were carried out (section 
2.8.1), with constructed transgene shuttle vectors and Cre.  
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Figure 4.8A GFP expressing DLKP clones 17 (high expresser) and 11 (low 
expresser) compared to DLKP parent and DLKP geo knock out clone. 
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4.8.1 Targeted stable GLP1-R transgene overexpression in DLKP 17 
and 11 cell lines 
 
Glucagon like peptide 1 receptor (GLP1-R) is a 463 amino-acid member of the G 
protein coupled receptor (GPCR) superfamily which is highly expressed in islet -
cells. It has been recently reported that it is differentially expressed in several tumor 
types, but its role in cancer cell invasion has not been reported (Korner et al, 2007).  
A study involving screening of GLP1-R expression by northern blot analysis revealed 
the constitutive expression of GLP1-R in stomach, islets and lungs (Thorens, 1992).  
 
A 50% decrease in proliferation was observed in DLKP 17 GLP1-R and an  ~18-20% 
decrease in DLKP 11 GLP1-R overexpressing cells relative to empty vector transfected 
stable cells. In vitro invasion assay of DLKP 17 and 11 GLP1-R overexpressing cells 
revealed that non-invasive DLKP 17 became invasive due to GLP1-R overexpression 
but there was no significant effect on the invasive DLKP 11 cell line was observed 
(Section 3.17.2). In order to investigate whether the GLP1-R effect was cell line 
specific or not we transiently overexpressed GLP1-R in non invasive MCF-7 breast 
carcinoma cell line. GLP1-R overexpression induced invasion in vitro in this cell line 
suggesting a more general role for GLP1-R in invasion. 
 
To investigate whether we could reverse the effect of GLP1-R overexpression on 
invasion and proliferation we performed GLP1-R siRNA functional knockdown in 
GLP1-R stably overexpressing cell lines. We observed a significant rescue in the 
proliferation (~15%) in both DLKP 17 and 11 GLP1-R overexpressing clones. 
Similarly a significant reversal (40-60%) in the invasion phenotype was observed in 
both DLKP 17 and 11 GLP1-R overexpressing clones. This provided further evidence 
that the observed induction in invasion in GLP1-R transfected cells was specifically 
due to elevated expression of this protein. 
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4.8.2 Assigning role for GLP1-R in cancer cell invasion 
 
This work suggests a previously unreported role for GLP1-R in invasion and 
proliferation. Drucker et al, (1987) reported that stimulation of GLP1-R and GLP2R in 
islet cells via GLP1 or GLP2 induces proliferation, differentiation and inhibits 
apoptosis. Multiple G-protein coupled receptors act through the cAMP/PKA signal 
transduction pathway. These receptors are coupled to G-proteins which either stimulate 
(Gs) or inhibit (Gi) (Kamp, 2000). Normally activation of GLP1-R leads to activation 
of Adenylate cyclase (AC) which catalyses the conversion of ATP to cAMP which 
then activates Protein kinase A (PKA) (Thorens, 1992). Our experimental observations 
definitely suggest an important role of GLP1-R in cancer cell invasion which may be 
independent of proliferation. This was evident from our results that the stable 
overexpression of GLP1-R in non invasive DLKP 17 cell line induced invasion but 
decreased proliferation. DLKP 11 which is already an invasive cell line did not appear 
to any impact on invasion due to GLP1-R overexpression but reduced proliferation.   
Korner et al, (2007) surveyed the expression pattern of GLP1-R in a wide spectrum of 
human tumours (n=149) and nonneoplastic human tissues (n=209) using receptor 
autoradiography. Their study concluded that GLP1-R is expressed at relatively high 
levels in tumor tissues. Therefore. 
, it could be used as novel molecular target for identification and targeted therapy. The 
mechanism by which GLP1-R specifically induces the invasive phenotype remains 
unclear at present and further investigation is required to delineate its role.  
 
4.9 Targeted stable KCNJ8  transgene overexpression in DLKP 17 
and 11 cell lines 
 
This work was done with previous knowledge of a role for KCNJ8 in cancer cell 
invasion previously observed in our laboratory (Pierce, A PhD (2006 NICB). KCNJ8 
was identified as a gene potentially involved in invasion in microarray studies 
involving DLKP and its drug variants with altered invasion phenotype. KCNJ8 
expression was increased in the more invasive cell lines compared to less invasive cell 
lines. A study of KCNJ8 mRNA expression by qRT-PCR confirmed increased 
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expression in the invasive cell lines DLKP-1, DLKP-2 and TXT-2 compared with the 
less invasive cell lines TXT-1 and VCR (Pierce A, PhD thesis 2005).  
The observations were limited to transient overexpression and siRNA knockdown 
studies. Therefore we wanted to evaluate the role of KCNJ8 using our targetable stable 
overexpression model. Following cDNA transfections stable overexpression was 
confirmed in both DLKP 17 and DLKP 11 cell lines by qRT-PCR but western blot 
analysis did not indicate any difference at the protein level relative to empty vector 
transfected cell lines. Because KCNJ8 levels in the DLKP 17 and 11 cells was already 
at high levels any small increase may not have been detected by western blot analysis.  
We examined DLKP 17 and DLKP 11 KCNJ8 in an in vitro invasion assay and found 
that non invasive DLKP 17 had become invasive and invasive DLKP 11 was 15% 
more invasive. However an inverse effect on proliferation was observed in the two cell 
lines. 
 
 
4.9.1 Assigning a function for KCNJ8 
 
KCNJ8 mRNA levels were 2.5 fold in upregulated in DLKP 17 compared to vector 
control and 1.2 fold in upregulated DLKP 11 compared to vector control.  Our results 
indicate that KCNJ8 contributes to the induction of invasion in both DLKP 17 and 11.  
However, a 20% decrease in proliferation in DLKP 17 and a 45% increase in 
proliferation in DLKP11 suggested that the increased invasion in DLKP 17 is 
independent of proliferation but were not same with already invasive DLKP 11. It may 
be that the phenotype observed was cell line specific.  
 
Potassium channel (KCh) is composed of two main sub-families of channels 1) KCh 
voltage dependent (Kv) 2) Inward-rectifier KCh (Kir) family. Kv1.3 the most 
documented of the Kv1 family and it is overexpressed in breast, colon and prostate 
cancer. Kv1.1 and Kv1.5 show impaired expression in breast and glioma malignant cell 
lines, respectively. KCNJ8 belongs to the Kir family. Besides the role of potassium 
channel (KCh) during cell growth, it is also found to be de-regulated in highly 
proliferating cancer cells. Furthermore, the expression of KCh is impaired in several 
types of tumours. Studies suggest that a certain grade of malignancy correlates with the 
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expression of KCh. Although several types of KCh have been associated with a highly 
proliferative state only a few types have clearly oncogenic effects such as Kv10.1 and 
K2p9.1 that generate oncogenic phenotypes when introduced in healthy animals. 
Altered expression of members from all groups of KCh has been found in different 
types of tumours and cancer cells (Pei et al, 2003 and  Pardo et al, 1999).  
 
The qPCR results from (Pierce A. PhD 2005) indicated that KCNJ8 was differentially 
expressed in the panel of cell lines studied, in agreement with array data. Decreasing 
KCNJ8 expression had no effect on proliferation, but did increase invasion. Increasing 
KCNJ8 expression had no effect on invasion in the non-invasive cell lines. However, 
western blots for KCNJ8 overexpression were not conclusive. Our western blots were 
not suggestive of any differential expression at protein levels. Conclusion is that the 
impact on invasion and proliferation may not be as a direct impact of KCNJ8 
overexpression, but could be due to off-target effects. Studies by Felipe et al, (2006) 
show increase of Kir proteins in breast and lung cancers.  Further they have also 
noticed that the expression of KCa1.1, Ca2+-activated K+ (BK) and KCa3.1 
Intermediate K conductance (IK) is also abundant in neuroblastoma and prostate 
cancer and correlated malignancy in breast and lung cancer cell lines due to altered 
expression of K2p9.1 (Felipe et al, 2006).   
 
There is also increasing interest in the potential implications of K+ channels as 
pharmacological targets for cancer therapy and for use as biomarkers to aid diagnosis 
(Wang, 2004). Binggeli and Weinstein (1986) proposed that altered signalling of 
plasma membrane electric potential of cancer cells could contribute to tumour growth. 
Bianchi et al, (1998) showed that plasma membrane electric potential in tumour cells is 
often modulated by the activity of K+ channels. Though our experiments are 
inconclusive in terms of a function for KCNJ8 in the regulation of proliferation, there 
is a strong indication for a role in cancer cell invasion, independent of proliferation. 
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4.10   Targeted stable TFPI2 transgene overexpression in DLKP 17 
and 11 cell lines 
 
The observations in our laboratory previously concerning the effect of TFPI2 on the 
invasive phenotype with transient overexpression and siRNA induced knockdown. 
Hence, we decided to use this gene in our stable overexpression model cell line system. 
We had two cell lines with inverse invasive phenotype, i.e. DLKP 17 (non-invasive) 
and DLKP 11(invasive). Investigation of the effect of prolonged expression of TFPI2 
in these cells with different transgene expression as well as invasive characteristics was 
considered of interest. 
 
TFPI2 is an ECM-associated serine protease inhibitor with a role in ECM degradation 
during tumour cell invasion and metastasis, wound healing and angiogenesis (Konduri 
et al, 2001). An early study by Sawaya et al, (1998) reported that recombinant TFPI2 
inhibits plasmin that is bound to HT-1080 cells, preventing matrix degradation and 
invasion.  Increasing TFPI2 expression, thereby inhibiting plasmin may be of 
therapeutic benefit in cancer therapy. Decreased TFPI2 mRNA expression was 
observed in our lab in the invasive cell lines, particularly in TXT-2, compared with the 
poorly invasive cell lines TXT-1 and VCR (Pierce A, PhD thesis 2005). 
 
From qRT-PCR analysis in both DLKP 17 and 11 clones it was evident that the two 
clones had distinctively different TFPI2 stable overexpression in accordance with their 
parental expression levels. Unfortunately the antibody used was not able to detect 
TFPI2 protein in western blot analysis. In vitro invasion assay of TFPI2 overexpressing 
DLKP 17 and 11 cells revealed that non invasive DLKP 17 became invasive and 
invasive DLKP 11 was less, but it was not a significant decrease (refer fig. 
3.21.2A&B). A proliferation assay showed decreased cell growth in DLKP 17 and 
increased in DLKP 11 (fig. 3.21.1A&B).  TFPI2 expression exogenously by transient 
cDNA transfection had no effect on proliferation, but did decrease invasion 
dramatically (Pierce A, PhD 2005).  
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4.10.1 Assigning a function for TFPI2 
 
The anti-invasive and increased proliferation phenotype of TFPI2 overexpression in 
invasive DLKP 11 was in agreement with previous studies. Konduri et al, (2001), 
stably transfected a vector expressing TFPI2 in the melanoma cell line C-32 and 
observed a decrease in invasion in TFPI2 over expressing clones. Sense and antisense 
vectors to TFPI2 were also used to examine the role of TFPI2 in human glioma 
invasiveness. Sense clones were much less invasive compared to antisense clones in 
vitro and formed smaller tumours in vivo. A study revealed that TFPI2 expression 
inhibited the invasive, but not the migratory capability of ovarian tumour cells in vitro 
(Zhong et al, 2003). Tanaka, (2003) reported that REF-1 (Retinal pigment epithelial 
cell factor) which is similar to TFPI2, showed growth promoting activity when 
overexpressed in Chinese hamster ovary (CHO) cells. The same effect was not 
observed in human fibroblasts.  
 
From our work we found TFP12 stable overexpression increased invasion and 
decreased proliferation in DLKP 17 TFPI2 stable overexpressing cell line. Possible 
reasons why TFPI2 overexpression in non invasive DLKP 17 induced invasion could 
be a) DLKP is a poorly differentiated cell line (McBride et al, 1998). It can be 
subcloned into three different types i) Mesenchymal (M) ii) Squamous (S) and iii) 
Intermediate (I). DLKP 17 cell line appeared to resemble the squamous epithelial type. 
In addition, when it was analysed for its basal invasion ability it was found to be non-
invasive. Conversely, the DLKP 11 cell line was invasive and appeared 
morphologically to resemble the mesenchymal type. B) Our model cell lines were 
DLKP 17(high expresser) and DLKP 11 (low expresser) in which TFPI2 was stably 
overexpressed. The gene dosages cold have impacted on invasion in DLKP 17; a non-
invasive cell line has become invasive due to TFPI2 stable overexpression. Compared 
to DLKP 11 the overexpression of TFP12 in DLKP 17 was high. It appears to be that 
after a certain threshold of TFP12 levels in non-invasive DLKP 17 has induced 
invasion. As reported from other studies (Zhong et al, 2003). Tanaka, (2003), the 
TFPI2 effect may be cell type specific and could be dosage related as well. 
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4.11 Stable S100A13  transgene overexpression in DLKP 17 and 11 
cell lines 
 
In 1996 a new S100 member termed S100A13 was identified by screening expressed 
sequence tag (EST) databases (Wicki et al, 1996). Smirnov et al, (2005) identified 
S100A13 as a novel predictor of metastasis following its detection in circulating 
tumour cells in blood. Pierce et al, (2008) show that decreasing S100A13 expression in 
invasive cell lines can reduce their invasive capacity by as much as 84%. This is the 
first study to provide causal evidence for a role of S100A13 in invasion. Conversely, 
overexpression of exogenous S100A13 in less invasive cell lines (DLKP-1, DLKP-2 
and TXT-2) was not sufficient to stimulate invasion. This may have been due to the 
transient nature of the experiment. 
 
Therefore we decided to investigate S100A13 in our stable overexpression model 
system. After several attempts we were not able to isolate a stable S100A13 
overexpressing DLKP cell line. The qRT-PCR screening of several clones confirmed 
no overexpression in both DLKP 17 and 11 clones.  In our study we found that three 
out of four genes could be overexpressed but not S100A13. This was despite the 
presence of a strong viral promoter (CMV) and the generation of G418 resistant 
clones. A possible reason could be that DLKP cells may not tolerate stable S100A13 
overexpression. 
 
4.12 Summary  
 
The qRT-PCR and western blot analysis revealed overexpression of GLP1-R as well as 
differences in the level of expression between two targetable DLKP (17 and 11) 
clones.  A novel in vitro role of GLP1-R in cancer cell invasion was identified and we 
propose that GLP1-R may be sufficient to induce invasion. GLP1-R was anti-
proliferative in our cell lines and the proinvasive effect was independent of 
proliferation. 
 
qRT-PCR confirmed KCNJ8 overexpression but no distinct overexpression at the  
protein level was detectable. The pro invasive effect of KCNJ8 on non invasive cell 
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line was interesting. The proliferation assay results were inconclusive and suggested 
that it could be cell line specific. 
  
Though there was differential up regulation of TFPI2 at the transcript level, there were 
issues with the antibody for western blot analysis. TFPI2 overexpression in non-
invasive cell line background would not be expected to induce invasion and/or 
proliferation, but it did in our cell line model. On the other hand, overexpression in the 
invasive cell line reduced invasion and proliferation in agreement with other reports 
and confirming the observations in the transient experiments. 
 
After several attempts we were unable to stably overexpress S100A13. It is not 
uncommon for cells to remain recalcitrant to overexpression of certain proteins due to 
detrimental physiological effects, and it may be that S100A13 is one such molecule. 
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Section IV:   
 
4.13  MiRNAs in Invasion 
 
MicroRNAs (miRNAs) are a class of small endogenous non coding RNA molecules 
whose normal function involves the regulation of gene expression post-
transcriptionally. It is estimated that 3% of the genome encodes for miRNAs and 
roughly around 30% human protein coding genes are regulated by miRNAs 
(Barbarotto et al, 2008).  Several studies have shown that uncontrolled variation in the 
expression levels of miRNAs or cluster of miRNAs may lead to abnormal cellular 
functions such as proliferation, differentiation and apoptosis. This can result in altered 
physiological homeostasis leading to disease and in particular there is evidence of a 
role in cancer. Although much effort is focussed on functional identification of the role 
of miRNAs and their related target genes in human physiology very few studies have 
concentrated on identifying translational targets of a particular miRNA. Target 
prediction has been performed using computational algorithms, comparing 
complementary 3’UTR sequence of target mRNAs to mature miRNA sequence. 
Several miRNA-target prediction software packages  are currently available based on 
criteria such as a) Orthologous phylogenetic conservation of complementary 3’UTR 
target sequences, b) binding energy of duplex between miRNA-target, c) sequence 
complementarity between  miRNA-target of 6-8bp of continuous pairing in the 5’ half 
of the miRNA.  
 
A single miRNA has the potential to bind to multiple mRNAs making it a key 
regulator of expression of several mRNAs simultaneously, unlike siRNAs which are 
target specific.  Hsu et al, (2008) suggested that miRNAs regulate protein-protein 
interacting networks. However, it still remains a challenging task for proper 
identification of physiologically relevant miRNA-target interactions. The main focus 
of this project was to investigate miRNAs involved in cancer invasion/proliferation in 
an in vitro model system as well as to identify potential gene targets through proteomic 
profiling and comparing it with available insilico target predicting programmes. 
 
 277
 
4.13.1    MiRNAs Bioarray  
 
In collaboration with Ambion, we performed miRNA bioarray studies comprising 
DLKP (parent, mildly invasive) Vs DLKPA (Adriamycin resistant, highly invasive) 
human lung cancer cell lines. Among several differentially regulated miRNAs we 
selected five miRNAs for PCR validation. The five miRNAs were mir-21, mir-27a, 
mir-29a, mir-30a5p and mir-30c. Based on miRNA qRT-PCR validation we selected 
three miRNAs for functional validation (fig. 3.25A). The selected miRNAs were mir-
21, mir-27a and mir-29a. Functional validation, including effect on proliferation, drug 
toxicity, and invasion phenotype of DLKP and DLKPA was monitored. We 
investigated the effect due to overexpression and inhibition of miRNA activity in both 
cell lines. As these miRNAs were differentially regulated in DLKPA compared to 
DLKP, we suspected a role in cancer cell invasion. 
 
4.13.2 Impact of transient overexpression of mir-21, mir-27a and mir-
29a on invasion and proliferation phenotype in  DLKP and 
DLKPA cell lines 
 
Commercially available synthetic miRNA (anti and pre miRNAs) were transfected in 
DLKP and DLKPA cells and subjected to invasion and proliferation assay. Transient 
overexpression of mir-21 resulted in a small but significant increase in cellular 
proliferation. Mir-27a and mir-29a did not have any significant impact on DLKP and 
DLKPA proliferation (fig. 3.25.1 A&B).  Mir-21 has previously been shown to act as 
an oncogene by down-regulating a tumor suppressor (Zhu et al, 2007). They found 
mir-21 is overexpressed in tumor tissues compared to their normal counterparts. 
Similarly Liu et al, (2008) showed mir-27a is an oncogene, whereby suppression of 
mir-27a inhibits gastric cancer cell growth. Therefore, we used mir-21 and mir-27a as 
biological controls in our experiments.  
 
Both mir-21 and mir-27a miRNAs were pro invasive (refer to Section 3.26). Mertens-
Talcott et al, (2007) studies in breast carcinoma cell lines, showed that mir-27a 
downregulates the expression of Myt-1. MYT1 inhibits cell cycle through enhanced 
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phosphorylation and inactivation of Cdc2 and transcription repressor ZBTB10. This 
further leads to overexpression of Sp1, Sp3, and Sp4 transcription factors which 
happens to promote tumor growth and angiogenesis. In addition, prohibitin has been 
identified as a direct target of mir-27a from a 3’UTR reporter assay and target specific 
knockdown of prohibitin ( a DNA synthesis inhibitor) which decreased cancer cell 
growth (Scott et al. 2006). Our results also showed a decrease in cancer cell invasion 
but do not have any impact on proliferation, suggesting a transient effect of mir-27a 
may not have any impact on growth in our cell line models. Conversely mir-29a was 
anti invasive (refer fig. 3.26.A, B, C and D). A very interesting study by  Fabbri M, 
(2007) revealed that enforced expression of mir-29a (as well as other family members 
mir-29b and mir-29c) in lung cancer cell lines rescued normal patterns of DNA 
methylation and induced re-expression of methylation-silenced tumor suppressor genes 
FHIT and WWOX. Although there were very few studies relating mir-29a with cancer 
from our initial results and the existing literature it is evident that the mir-29 family is a 
very important miRNA in cancer therapeutics. 
  
 
4.13.3 Effect of Transient overexpression of mir-21, mir-27a and mir-
29a on drug sensitivity  in DLKP and DLKPA cell lines 
 
One of the model cell lines used in this study DLKPA was an Adriamycin resistant cell 
line, developed in the NICB (Heenan et al, 1997). Adriamycin, an active medicine 
against many cancers, is one of the older chemotherapy drugs, having been in use for 
decades. The fact that we had identified miRNAs that were differentially expressed 
between DLKP and DLKPA meant that these could be related to either (or both) the 
invasive phenotype or the drug resistance phenotype. In light of this we wished to 
discover if any of the chosen targets impacted on the sensitivity of DLKPA to 
Adriamycin when dysregulated. Our proliferation assay results showed no significant 
impact on cell survival due to transient overexpression of target miRNAs in our model 
cell line (fig. 3.26.3A&B). A study involving a panel of paclitaxel-(A2780TAX, 
A2780TC1 and A2780TC3) and cisplatin-resistant (A2780CIS) cells was assessed by 
microarray analysis (Sorrentino et al, 2008). They found a target in miR-130a, whose 
down regulation was linked to the translational activation of the M-CSF gene, a known 
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resistance factor for ovarian cancer.  Other studies with doxorubicin-resistant MCF-7 
cells (MCF-7/DOX) show considerable dysregulation of the miRNAome profile 
(Kovalchuk et al, 2008). Transfection of the MCF-7/DOX-resistant cells with mir-451 
resulted in increased sensitivity of cells to DOX, indicating that correction of altered 
expression of miRNA may have significant implications for therapeutic strategies 
aimed at cancer drug resistance. So far there are no known reports involving mir-21, 
mir-27a and mir-29a with respect to drug sensitivity studies in cancer.  Our 
experiments based on impact on proliferation showed no significant effect of miRNA 
expression on drug sensitivity. Based on this it would appear that the differential 
expression of these particular miRNAs in DLKPA is not related to or at least not the 
cause of the drug resistant phenotype.  
 
4.14 Stable overexpression of mir-29a in DLKPA cell line 
 
When we first observed mir-29a as differentially expressed in our system, there was no 
previous evidence of mir-29a having an anti-invasive role. Therefore we proceeded to 
investigate the role and effect of mir-29a in cancer cell invasion. We cloned mir-29a in 
p4.1CMV-Neo plasmid vector (fig. 3.28A&B).  A negative sequence was also cloned 
in p4.1CMV-Neo vector which was used as a control during stable overexpression 
studies. The qRT-PCR analysis confirmed clones were overexpressing mir-29a (fig. 
3.28D). The clones were subjected to invasion and proliferation assay (fig. 3.29A, 
3.30A&B). A significant decrease in cellular proliferation was observed due to mir-29a 
stable overexpression.  A very interesting study by  Fabbri M, (2007) revealed that 
enforced expression of mir-29a (as well as other family members mir-29b and mir-29c) 
in lung cancer cell lines rescued normal patterns of DNA methylation and induced re-
expression of methylation-silenced tumor suppressor genes FHIT and WWOX. Mott et 
al, (2007) showed that mir-29 family members are involved in Mcl-1(anti-apoptotic 
Bcl2 family member) protein regulation and apoptosis. This might explain the 
observed impact on proliferation in DLKPA. Furthermore we demonstrate this effect is 
not cell type specific. Transiently transfected mir-29a in pancreatic cancer cell line 
PANC-1(highly invasive) considerably reduced invasion.  
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C-Myc, a well studied oncogene, has been reported to be involved in regulating the 
expression of mir-29a. From our qRT-PCR analysis of the relative mir-29a levels in 
DLKP versus DLKPA, it was evident that mir-29a was downregulated in DLKPA. We 
theorised based on previous studies and our functional results, that mir-29a-promoter 
activity in our model cell lines might reflect c-Myc expression which is upstream of 
mir-29a and represses mir-29a transcription. We decided to evaluate the endogenous c-
Myc levels in our panel of cancer lines, DLKP (mildly invasive), DLKPA and PANC-1 
(both highly invasive).  The initial qRT-PCR data suggested there was no significant 
increase in c-Myc in the more invasive cell lines compared to mildly invasive cell line 
DLKP, though this was a first observation with technical replicates.  Tsung-Cheng et.al 
(2008) reported that Myc directly up- regulates a pro-tumorigenic group of miRNAs 
known as the miR-17–92 cluster. This suggested that the reduced endogenous 
concentration of mir-29a in invasive cells may be in part due to increased c-Myc 
expression resulting in repression of mir-29a transcription. Further analysis including 
the impact of c-Myc dysregulation on mir-29a expression in our cell lines would be 
required to show this effect. 
 
Recent literature revealed that not only mir-29a but its other two family members mir-
29b and mir-29c are also involved in regulation of tumor progression. Overexpression 
of mir-29b reduced Mcl-1 protein expression in KMCH cholangiocarcinoma cell lines. 
This effect was direct, as mir-29b negatively regulated the expression of a reporter 
construct (Mcl-1 3' untranslated region UTR-based). Enforced mir-29b expression 
reduced Mcl-1 cellular protein levels and sensitized the cancer cells to tumor necrosis 
factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity (Mott, 2007). A study in 
nasopharyngeal carcinomas (NPCs) showed miRNA mir-29c was expressed at one-
fifth the levels in tumours as in normal epithelium (Sengupta et al, 2008). In NPC 
tumours, the lower mir-29c levels correlated with higher levels of multiple proteins 
whose 3′ UTRs can bind mir-29c at target sequences conserved across many 
vertebrates. Most of the mir-29c targeted genes identified encode extracellular matrix 
proteins, including multiple collagens and laminin γ1 that are associated with tumor 
cell invasiveness and metastatic potential, prominent characteristics of NPC. So from 
the existing literature it is evident that mir-29 family might prove to be important 
targets in cancer therapeutics. 
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4.15 Proteomic profiling of  anti and pre-mir-29a treated DLKPA cell 
line 
 
The transient overexpression of pre and anti mir-29a in our cell line model was found 
to modulate invasion by reducing it by 40% with pre-mir treatment and conversely 
increases invasion by 36% with anti-mir treatment. At the time this work was 
performed most of the genes that were predicted to be regulated by miRNAs were 
based on insilico analysis. Only one study involving mir-21 where the miRNAs targets 
were identified based on 2D-DIGE based proteomic analysis has been reported (Zhu et 
al, 2007). More recent emerging reports on mir-29 family members being involved in 
cancer and our initial experimental observation relating to effect on cancer cell 
invasion in vitro prompted us to proceed further with 2D-DIGE proteomic profiling of 
cells with dysregulated expression of mir-29a to identify and functionally evaluate 
possible gene targets. 
 
4.16 Identification of Differentially Expressed Proteins 
 
To identify possible gene targets being regulated by mir-29a in DLKPA cells we 
performed  proteomic profiling of anti and pre-mir-29a treated DLKPA cell line by 
2D-DIGE. The differentially regulated spot identification was based on BVA 
(Biological variation analysis). Spots representing ±1.2-fold change in expression and 
with a 1-WAY ANOVA score of ≤ 0.05 were considered for further identification. 
The differentially regulated protein list was normalized for control treatments. 
Identification of differentially regulated protein spots was performed (Table 3.33.i & 
ii) by MALDI-TOF or LC-MS. Recent studies involving stable isotope labelling of 
amino acids (SILAC) in cell culture based work to investigate the effect of specific 
miRNAs dysregulation on the cell proteome have provided greater insight (Vinther, 
2006). A study involving mir-1 expression in HeLa cells revealed that 12 out of 504 
investigated proteins were repressed by mir-1 transfection. This repressed set of genes 
significantly overlaps with mir-1 regulated genes that have been identified with DNA 
array technology and are predicted by computational methods (Vinther, 2006). Their 
findings demonstrate that SILAC can be used for miRNA target identification and 
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highly expressed miRNA can regulate the levels of many different proteins. In our 
study we show 121 spots being downregulated due to pre-mir-29a treatment and 85 
spots upregulated by inhibiting mir-29a. Out of 121 spots 60 were identified and out 
of 85, 29 spots were identified. The unidentified spots tended to be low abundant 
protein spots which are always a challenge to identify. Bioinformatic analysis 
(PANTHER, Pathway studio and Pubmatrix) was applied to the list of differentially 
regulated proteins. Pathway Studio assigned possible functional roles of these proteins 
with the majority of the proteins biased towards apoptosis, differentiation, 
proliferation, and mutagenesis. PANTHER classified the differentially regulated 
proteins into ontological categories. Genes involved in a wide range of molecular 
functions (fig. 3.33.1A), biological processes (fig. 3.33.1B) and biological pathways 
(fig. 3.33.1C), were identified. Several genes which were interesting in relation to 
cancer cell invasion and metastasis and were downregulated due to pre-mir-29a 
overexpression were PRDX6, ANX2, CMPK1, PEBP1, CNN2, SFRS1, PSMA2, 
ARL3, PPIB, PPIA and GMFB. ACTC1, SHOT1 and SERBP1 were upregulated 
due to anti-mir-29a treatment in the DLKPA cell line. Vertebrate mRNAs are targeted 
for post-transcriptional repression by miRNAs through mechanisms involving pairing 
of 3′ UTR seed matches to bases at the 5′ end of miRNAs (refer to Fig. 3.33.3A) 
(Nielsen, 2007). The above target mRNAs were also identified as possible mir-29a 
targets, based on in silico RNAhybrid prediction program that predicts seed match 
regions between a 5’miRNA and 3’UTR sequences of gene targets (Rehmsmeier, 
2004).   
 
 
4.17   Overview of Protein targets involved in different cellular    
 processes 
 
The proteomic profiling of possible targets of mir-29a left us with a valuable target 
gene list which was subjected to bioinformatics analysis to gain further insight into 
their potential role in cancer cell invasion. We used Pathway Studio 5.0, a 
bioinformatic programme aimed at the visualisation and analysis of biological 
pathways, gene regulation networks and protein interaction maps. It has an inbuilt 
database which connects to the available PubMed information. Pathway Studio works 
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by identifying relationships among genes, small molecules, cell objects and processes 
and builds pathways based on these relationships. The other important aspect of this 
software programme is that it allows a focussed search on pathways and cell signalling 
networks. We uploaded the list of differentially regulated protein targets and from the 
out put it was evident that majority of proteins were implicated in cellular process like 
proliferation, differentiation, motility, apoptosis, and mutagenesis. The first three 
would be in keeping with our observed effect on invasion and cell growth. However, it 
is important to note that the knowledge that more commonly studied process are more 
likely to score ‘hits’ in this type of database. At the same time, it is a useful way to 
subgroup the targets in order to consider their importance in the context of this study. 
LGALS1 (Horie, 1999) and PPIA (Jin, 2004) were known to positively regulate 
apoptosis. HSPB1 (Dias, 2002), PRDX6 (Chen, 2003), MIF (Amin, 2003), CFL1 
(Seike, 2003), PRDX3 (Young, 2004), and PRDX2 (Lin, 2003) were reported to be 
negative regulators of apoptosis. PPIB (Rycyzyn, 2000), HSPB1 (Cornford, 2000) 
were positive regulators of cell proliferation while GMFB (Lim, 1990), and ANXA1 
(Rhee, 2000) were negative regulators. Similarly PPIB (Vanpouille, 2004), GRB2 
(Atabey, 2001) and ANXA1 (Ernst, 2004) had known positive impact on motility and 
ANXA2 (Barwe, 2005) was a negative regulator of this process.  
 
 
4.17.1 Apoptosis  
 
LGALS1 and PPIA were known to positively regulate apoptosis. HSPB1, PRDX6, 
MIF, CFL1, PRDX3, and PRDX2 are negative regulators of apoptosis. All these 
targets were found to be downregulated due to mir-29a overexpression. There are 
different apoptotic pathways in high and low metastatic ability lung cancer cells. 
Apoptosis involves a series of biochemical events that lead to a variety of 
morphological changes, including blebbing, changes to the cell membrane such as loss 
of symmetry and attachment, chromatin condensation, cell shrinkage (Kerr et al, 1972; 
Wyllie et al, 1980). Several studies categorically substantiated that the cells that escape 
programmed cell death result in malignancy. HSPB1 (HSP27) is reported to negatively 
regulate apoptosis and also reported to have positive impact on proliferation. 
Peptidoprolyl isomerase A or PPIA or Cyclophillin A, the protein encoded by this gene 
 284
is a member of the peptidyl-prolyl cis-trans isomerase (PPIase) family (Yurchenko et 
al, 2002). Studies by Li et al, (2006) with pancreatic cancer cells showed that PPIA 
was significantly overexpressed as a result of increased proliferation and growth. 
Bostwick et al, (2000) proposed that HSP27 expression is associated with poor 
prognosis in gastric, liver, and prostate carcinoma. LGALS1 is a positive regulator of 
apoptosis and has been reported to have a negative role in cell proliferation. Galectins 
constitute a gene family of β-galactoside-specific lectins that show high homology in 
their carbohydrate-binding site. Barondes et al, (1994) showed lectins are involved in 
many biological events and Galectin-1 is a laminin binding protein that recognizes 
poly N-acetyllactosamine chains on the basement membrane. Basement membrane 
proteins have a major influence on cell adhesion, migration, proliferation and also in 
tumor invasion and metastasis (Barsky et al, 1983). Van den Brule et al, (1995) 
examined in vitro galectin 1 mediated adhesion assay in melanoma, and results suggest 
that galectin-1 might participate in melanoma cell adhesion to laminin and therefore 
constitutes a possible modulator of invasion and metastasis. Low galectin-1 expression 
in tumours is associated with unusually long survival periods in patients. Conversely, 
high levels of galectin-1 expression have been observed for highly invasive tumours in 
the case of human surgical samples and of animal models (Camby et al, 2005).  Camby 
et al, (2005) categorically showed that  in U87 human glioblastoma cells that stable 
inhibition of galectin-1 expression alters the expression of a number of genes like 
cullin-2, p53, ADAM-15, and MAP-2 that either directly or indirectly influence 
adhesion, motility and invasion of human glioblastoma cells. A recent study involving 
both stable knockdown and transient-targeted knockdown by siRNA treatment induced 
an intracellular accumulation of integrin-beta1 suggesting galectin-1 uses an integrin 
mediated pathway in glioma malignancy (Fortin et al, 2008). 
 
Shichi and Demar, (1990) proposed PRDX6 as a bifunctional 25 kDa protein with both 
GSH (Glutathione) peroxidase and phospholipase A2 activities. Also PRDX6 is 
expressed in many organs, with a particularly high level of expression in the lungs. 
Chen et al, (2002) and Newcomb et al, (2004) showed oxidants play an important role 
in the modulation of cell proliferation, apoptosis, and synthesis of growth factors 
associated with tumor growth and invasion. Kinnula et al, (2004) suggested the 
unbalanced activation of antioxidant enzymes can induce carcinogenesis and malignant 
transformation by intracellular redox imbalance or exaggeration of oxidative stress.  
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Manevich and Fisher, (2005) showed that stable PRDX6 expression in cells protected 
against oxidative stress, whereas antisense treatment resulted in oxidant stress and 
apoptosis. Chang et al, (2007) did proteomic profiling between the MDA-MB-435HM 
cells and their parental counterparts MDA-MB-435 cells, and found that   PRDX6 was 
highly overexpressed. Conversely, siRNA knockdown of specific PRDX6 expression 
decreased the invasive potential of breast cancer cells, partially through regulation of 
uPAR, Ets-1, MMP-9, RhoC and TIMP-2 expression. Odreman et al, (2005) compared 
the protein pattern of low-grade fibrillary astrocytomas to that of glioblastoma 
multiforme by 2D electrophoresis and mass spectrometry analysis. Their result showed 
peroxiredoxin 1 and 6, the transcription factor BTF3, and alpha-B-crystallin were more 
highly expressed in glioblastoma multiforme whereas protein disulfide isomerase A3, 
the catalytic subunit of the cAMP-dependent protein kinase, and the glial fibrillary 
acidic protein were increased in low-grade astrocytomas. From the recent research it is 
confirmed that PRDX6 is a relatively new target for cancer gene therapy. Furthermore 
it being regulated by mir-29a to reduce invasion from our results makes it a very 
interesting target to look further at its role in cancer treatment in detail. 
 
4.17.2 Motility 
 
Directed migration of cells to inappropriate locations can result in life threatening 
consequences such as the congenital defects prominent in the brain. It contributes to 
pathologies including vascular disease, chronic inflammatory diseases, and tumor 
formation and metastasis (Horwitz and Webb, 2003). Understanding cell migration is 
also becoming important to emerging areas of biotechnology which focus on cellular 
transplantation and the manufacture of artificial tissues. Down regulated protein targets 
PPIB, GRB2, PRDX5 and ANXA1 are known to have positive impacts on motility and 
this is in keeping with our observation that increased mir-29a decreases invasion. 
ANXA2 and  SFRS1 have been shown to be negative regulators of this process. A 
study was performed to investigate the role of AnxA1 in the invasion of a model 
epithelial cell line, SKCO-15, derived from colorectal adenocarcinoma (Babbin, 2006). 
Small interfering RNA-mediated knockdown of AnxA1 expression resulted in a 
significant reduction in invasion through Matrigel-coated filters. Localization studies 
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revealed a translocation of AnxA1 to the cell surface upon the induction of cell 
migration, and functional inhibition of cell surface AnxA1 using antiserum (LCO1) 
significantly reduced cell invasion. SFRS1 (splicing factor, arginine/serine-rich 1) was 
found to be decreased in Herceptin treated ErbB2-overexpressing cell lines and was 
also shown to affect cellular motility (Mukherji et al, 2006; Ghigna et al, 2005) Our 
analysis also reveals a predicted miR-29a binding site in the 3’UTR of SFRS1. 
 
4.17.3 Cell proliferation  
 
PPIB, HSPB1, GRB2, LGALS1, GMFB, and ANXA1 were identified as being 
downregulated due to mir-29a overexpression suggesting they might be direct targets 
of mir-29a action. PPIB, HSPB1 and GRB2 are known to positively regulate cell 
proliferation whereas LGALS1, GMFB, and ANXA1 are negative regulators. Heat 
shock proteins (HSPs) are overexpressed in a wide range of human cancers and have 
been implicated in tumour cell proliferation, differentiation, invasion, metastasis, death 
and recognition by the immune system. Calderwood et al, (2006) proposed two main 
strategies, based on heat shock proteins in tumour progression and response to therapy. 
Firstly, pharmacological modification of HSP expression or molecular chaperone 
activity and secondly, their use in anticancer vaccines exploiting their ability to act as 
immunological adjuvants. Ciocca and Calderwood, (2005) show they are useful 
biomarkers for carcinogenesis in some tissues and signal the degree of differentiation 
and the aggressiveness of some cancers including hyperplastic endometrium, uterine 
cervix, colon and hepatocellular carcinoma. Circulating levels of HSP and anti-HSP 
antibodies in cancer patients could be useful in tumour diagnosis.  
 
Lee et al, (2008) examined NIH3T3 cells overexpressing HSP27, which were observed 
to have a retarded cell migration and invasion phenotype in wound-healing assays. 
Later they identified that FAK phosphorylation was affected and also reduced matrix 
metalloproteinase-2 (MMP-2) expression and hence that the FAK/STAT3/MMP-2 
signalling pathway was being altered.  In contrast from our proteomics study, HSP27 
was found to be downregulated due to mir-29a treatment, which in turn reduced the 
invasive phenotype in our model cell lines.  
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Annexins belong to a family of the calcium-dependent phospholipid binding proteins. 
They are also substrates of receptor tyrosine kinases. Overexpression of Annexin II, 
which has been reported in various carcinomas, is thought to be associated with cell 
proliferation, differentiation and cell-cell adhesion in the pathogenesis of carcinoma 
(Emoto, 2001). In this study involving Annexin II and c-erbB-2 by using, 
immunohistochemistry in 153 primary gastric carcinomas revealed that Annexin II was 
expressed in 8 human gastric carcinoma cell lines (Emoto, 2001). It was more strongly 
expressed in the cell membrane than in the cytoplasm of tumor cells in primary gastric 
carcinoma tissues. Annexin II and c-erbB-2 overexpression were significantly 
correlated p = 0.0002) and patients with Annexin II had poorer prognoses (p = 0.0066).  
In our study mir-29a overexpression downregulates Annexin II and in turn reduced 
invasion in our cell line models. From literature it is clear that overexpression of 
AnnexinII indeed relating to tumor growth. Therefore AnnexinII could form a key 
regulator molecule in cancer therapeutics. 
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Section V:   
 
4.18  Protein targets chosen for siRNA functional validation 
 
From our proteomic profiling and bioinformatic analysis we selected four cancer cell 
invasion/metastasis related gene targets for specific siRNA knockdown studies. These 
target genes were differentially downregulated due to pre-mir-29a treatment in 
DLKPA cells. The rationale behind selection of specific gene targets was that 
knockdown of these genes had previously been associated with cancer cell invasion 
and/or proliferation. The target genes RAN, GRB2, MIF and ANX2 were chosen based 
on a literature search which revealed them to be involved in mechanisms of cancer cell 
invasion/metastasis.  
 
Only RAN had any significant impact on the invasive phenotype of DLKPA. RAN 
knockdown was observed to result in significantly reduced invasion in DLKPA (fig. 
3.38.2A&B). RAN knockdown at the protein level was confirmed with western blot 
analysis (fig. 3.38A). RAN knockdown also significantly reduced DLKPA 
proliferations refer fig. 3.37.1A). Knockdown of the other targets did not show any 
significant impact on invasion or proliferation in DLKPA. This was not surprising due 
to nature of miRNA regulation which involves group of genes being deregulated to 
effectively modulate any process i.e. a highly tuned regulation. 
 
RAN (RAS-related nuclear protein) was identified as 1RRP-C chain of the RAN-
GPPNHP-RANBD1 complex with -1.35 fold difference between pre-mir-control and 
pre-mir-29a treated DLKPA cell line.  Vetter et al, (1999) showed the complex has 
four chains A, B, C, D. Chain A and C are composed of RAN and chain B and C are 
composed of NUCLEAR PORE COMPLEX PROTEIN NUP358 (RBP2). RAN is a 
small GTP binding protein involved in the control of DNA synthesis and cell cycle 
progression, and also is essential for the translocation of RNA and proteins through the 
nuclear pore complex (Sazer and Dasso, 2000). Esquela-Kerscher and Slack, (2006) 
revealed that RAN is also involved in exporting pre-miRNA in a complex with 
Exportin 5 from the nucleus to the cytoplasm. Kurisetty et al (2008) have recently 
demonstrated that RAN overexpression in a non-invasive rat mammary epithelial cell 
 289
line results in increased anchorage-independent growth, cell attachment, invasion 
through Matrigel™ in vitro and metastasis in rats. With all these intriguing literature 
relating RAN and its relevance in maintaining molecular balance as well as role in 
cancer invasion which was in agreement with our results led us to further investigate 
its link to mir-29a. 
 
 
4.18.1    RAN 3’ UTR reporter assay to evaluate target specificity of 
     mir-29a 
 
To further evaluate whether RAN may be a direct target of mir-29a we amplified  the 
3’UTR region of RAN and cloned downstream of GFP in a reporter plasmid. The 
rationale behind this was that miRNAs target 3’UTR region of mRNAs. Accordingly, 
cell lines expressing 3’UTR sequence of RAN cloned downstream of a reporter gene 
upon treatment with pre-mir-29a, would be expected to display reduced reporter 
protein expression if RAN was a direct target. We developed a mixed stable RAN 
3’UTR GFP expressing DLKPA cell line by transfecting with the reporter plasmid (fig. 
3.39A, B, C). Pre-mir-29a and negative-pre-mir-control were transiently transfected 
into the cells and they were monitored for GFP expression. At 72hrs there was a 
significant drop in GFP levels. The observation that the average fluorescence signal in 
cells stably expressing a GFP reporter gene fused to the RAN 3’UTR was reduced by 
only 5-6% suggests that the impact on endogenous RAN protein expression (35% 
down-regulated in proteomics analysis) might be secondary to the effect of miR-29a. 
However, the presence of a predicted miR-29a target site in the RAN 3’UTR using 
current algorithms (5nt match at 5’ end of mir-29a) doesn’t discount the possibility of 
some interaction between miR-29a and the mRNA transcript. Another consideration 
relates to a recent report demonstrating the combined action of miR-29 and miR-181 
on Tcl1 to modulate its expression in CLL (Pekarsky et al, 2006). Like Tcl1, RAN is a 
strongly predicted target for miR-181 binding. It may be that increased expression of 
both miRNAs is required for significant reduction in protein expression. On the other 
hand, RAN is a critical protein and the concentration range at which it is tolerated in 
cells is probably narrow. It has been demonstrated recently that non-canonical seed 
matches result in less extreme modulation of expression (Baek et al, 2008). Studies 
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reporting differential expression of several thousand genes in cells overexpressing 
particular miRNAs demonstrate that the degree of down-regulation of a target protein 
may be quite low (Baek et al, 2008; Selbach et al, 2008). This is consistent with the 
theory that miRNAs act more as modulators of protein expression – smoothing out 
more dramatic influences such as transcriptional activation or repression. 
 
 
4.19   Effect of  MIF siRNA knockdown on invasion and     
   proliferation phenotype in  DLKPA 
 
Several studies relating to Macrophage Migration Inhibitory factor (MIF) in cancer 
invasion/metastasis/proliferation led us to look at its functional impact in our invasive 
cell line models. Since, MIF was downregulated in mir-29a (-1.63 fold) overexpressing 
cells, we hypothesized that siRNA induced knockdown of MIF might decrease the 
invasion phenotype in DLKPA cells. Downregulation of MIF was confirmed from 
qRT-PCR analysis (fig. 3.34.1A). Bloom and Bennett (1970) identified a product 
produced by T lymphocytes inhibited the random migration of cultured macrophages 
as Macrophage migration inhibitory factor (MIF). Li et al, (2004) studies reveal that 
MIF induced invasion through activation of MMP-9 and IL-8 in nasopharyngeal 
carcinoma cells (NPC). A recent study by Rendon BE et al (2007) reported that siRNA 
knockdown of MIF results in a >90% loss of both the migratory and invasive potential 
of human lung adenocarcinoma cells. They also found that reduction of Rac1 member 
of Rho GTPase family in MIF deficient cells. The functional impact of MIF 
knockdown was observed to have no significant impact on either invasion (fig. 
3.34.3A&B) or proliferation (fig. 3.34.2A) phenotype in DLKPA cell line. Shimizu et 
al, (1999) for the first time reported that human melanocytes and melanoma cells 
express MIF and found that anti-MIF antibody injected into mouse drastically reduced 
tumor induced angiogenesis. Ren et al, (2003) observed that increased MIF serum 
levels correlated with increased IL-8 levels in hepatocellular carcinoma (HCC) patients 
compared to normal.  A very well studied molecule in cancer progression did not seem 
to have any effect on our model cell line.   
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4.20   Effect of ANX2 siRNA knockdown on invasion and          
   proliferation  in  DLKPA 
 
Annexin A2 (ANX2) a Ca2+ -dependent phospholipid-binding protein, was found to 
be -1.21 downregulated in pre-mir-29a treated cells. Recent studies linking Annexin 
A2 to tumor invasion/metastasis (refer. Page 302) led us to select this gene target for 
siRNA specific knockdown studies in our cell line models. Knockdown was confirmed 
thorough qRT-PCR analysis. There was no significant impact on either the invasive or 
the proliferation phenotype of the DLKPA cell line. Emoto et al, (2001) compared 
annexin 2 levels in 8 gastric carcinoma cell lines to c-erb-2 overexpression. They 
found that annexin A2 overexpression is confined to the cell membrane rather than the 
cytoplasm of tumor tissues and upregulation of annexin A2 in patients had poor 
prognoses.  Huang et al, (2008) show ANX2 is involved in p53-mediated apoptosis in 
lung cancer cell line. Overexpression of p53 decreased annexin 2 levels in highly 
metastatic Anip973 lung cancer cells. ANX2 specific siRNA knockdown inhibited 
proliferation, suggesting ANX2 is involved in p53 mediated apoptosis and cell growth.  
 
Recent studies by Hastie et al, (2008) found that treatment of human prostrate cancer 
cell line 1542CP3TX with interferon gamma decreased ANX2 and its binding partner 
p11 by 4 fold. A decrease in invasion of the cells was observed due to IFNgamma 
and/or anti annexin 2 antibody treatment but not in LNCap2, which is an annexin 2 
negative prostrate cancer cell line.  From our results it is clear that, though increasing 
mir-29a expression results in decreased invasion of DLKPA cells and decreased 
expression of ANX2, reducing ANX2 alone was insufficient to replicate the 
phenotype. Indeed annexin A2 has a predicted seed 6nt seed match in its 3’UTR for 
mir-29a. This doesn’t rule out ANX2 as having a role in mediating the mir-29a 
dependent effect in conjunction with many other proteins also. On the other hand the 
differential expression of ANX2 in these cells may have no causal role in the 
phenotype but merely be a result of it. 
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4.21   Effect of GRB2 siRNA knockdown on invasion and   
   proliferation phenotype in DLKPA 
 
From our proteomics studies GRB2 was -1.25 fold downregulated in mir-29a 
overexpressing DLKPA cells. The qRT-PCR analysis of endogenous GRB2 RNA 
levels was found to be very low in the DLKPA cell line. Further siRNA specific 
knockdown was confirmed from qRT-PCR analysis (fig. 3.36A). Lowenstein et al, 
(1992) showed that Growth factor receptor-binding protein 2 (GRB2) is an adapter 
protein critical in bridging signal transduction between the activated protein receptor 
tyrosine kinase (RPTK) and the RAS-mediated MAP kinase cascade. Dharmawardana 
et al, (2006) described a role for GRB2 in the oncogenesis of human malignancies, cell 
motility and angiogenesis processes contributing to tumor growth, invasiveness and 
metastasis. Studies by Jelovac et al, (2004) showed that an increase in tumour size due 
to letrazole treated in mouse bearing MCF-7 breast tumour. Further investigation  led 
the to conclusion that overexpression of GRB2 activated Ras or MAP kinase signalling 
and possible cross talk with estrogen receptor (ER) in breast cancer cell lines treated 
with letrazole.  In our invasive cell line model we did not observe any impact of GRB2 
siRNA knockdown on invasion or proliferation. As our observation were based on 
transient knockdown of GRB2, and the fact that GRB2  key important growth related 
gene it may require a stable or prolonged knockdown to see any impact.  Further work 
needs to be done to establish a le of mir-29a regulation of GRB2. 
 
4.22   Summary 
 
In summary this section discusses the role of miRNAs in cancer cell in vitro invasion 
and proliferation.  Anti-mir29a increased and pre-mir29a decreased invasion in both 
DLKP and DLKPA (more evident in DLKPA). Conversely miRNA 21 and 27a 
treatment were observed to have the opposite effect on invasion. DLKPA cells were 
transfected with anti or pre-mir-29a and used for proteomic profiling. The 2D DIGE 
study identified more than 100 differentially regulated proteins. Two Lists were 
created, list 1 contained proteins downregulated due to pre-mir-29a treatment and list2 
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with proteins up regulated due to anti-miRNA treatment. Four gene targets were 
chosen for further siRNA specific functional validation.  
 
The qRT-PCR analysis confirmed knockdown of all the targets. In vitro invasion and 
proliferation assays were performed.  MIF, ANX2 and GRB2 did not have any effect 
on the invasive or proliferation phenotype. RAN knockdown resulted in dramatically 
decreased invasion and proliferation in DLKPA cell line. Flow-cytometer analysis 
revealed a 5-6% reduction in GFP-RAN-UTR reporter expression when transfected 
with mir-29a, implying that RAN might be a weak or downstream target of mir-29a. 
 
We confirmed the effect of mir-29a on cancer cell invasion was not tissue specific by 
transfecting pre-mir-29a in PANC-1 and developed stable mir-29a overexpressing 
DLKPA cell lines. These cell lines had a dramatic reduction in invasion which 
correlated with the level of mir-29a expression. In conclusion we provide convincing 
evidence that mir-29a is an anti-invasive microRNA.  
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5.0 Conclusion and Future Work  
 
5.1 Targetable DLKP cell Line 
 
We describe the successful development of stable Cre-LoxP based targetable DLKP 
cell lines. Furthermore we demonstrated by using an insulator element that we could 
improve the specificity of the genetic construct used. We concluded that this system 
was suitable for the generation of clones for the study of overexpression of several 
genes which correlated with lung cancer cell invasion in vitro. 
 
5.1.2 Stability assessment 
 
 
In stable transgene overexpression in vitro, clonal variability in gene expression levels 
or sudden loss in transgene expression is a major hurdle in gene functional studies. To 
investigate the stability of transgene overexpression we performed a time course 
assessment by using thirty three stable DLKP clones expressing the fusion protein 
geo. These clones were subjected to regular passaging and freeze thaw for over four 
and a half months, with monitoring of the GFP expression by fluorescent microscopy 
and as well using flow-cytometer based evaluation of expression. From the stability 
assessment of a panel of DLKP geo overexpression clones we learned that, although 
the clones are from an isogenic population they had very different stability profiles, 
which may be due to different genomic integration sites demonstrating clearly the 
problems with random integration. In addition we were able to choose clones with 
different levels of transgene expression based on the results of this experiment. 
 
5.1.3 Stable Transgene overexpression studies 
 
DLKP 17 (high expression) and DLKP 11(low expression) were chosen. DLKP 17 
was non invasive and DLKP 11 was highly invasive. Four transgenes (GLP1-R, TFPI2, 
KCNJ8, and S100A13) were selected, cloned in a shuttle vector and co-transfected with 
Cre. qRT-PCR and western blot analysis of GLP1-R overexpressing cells revealed 
difference in level of expression in the targetable DLKP (17 and 11) clones in keeping 
with the levels expected in these clones. A possible role for GLP1-R in promoting 
cancer cell invasion was established. The proliferation assay suggested that GLP1-R 
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was anti-proliferative in our cell lines and that the proinvasive effect was independent 
of cell proliferation. 
 
qRT-PCR analysis confirmed KCNJ8 overexpression but western blot analysis 
revealed no obvious increase compared to control. The pro invasive effect of KCNJ8 
on the non invasive cell line was interesting. The proliferation assay results were 
inconclusive.  TFPI2 overexpression in the non invasive cell line increased invasion 
and proliferation. Overexpression in the invasive cell line reduced invasion and 
proliferation. cDNA transfection did not result in S100A13 overexpression. 
 
 
5.2 LINE-1 element site specific targeting 
 
An attempt was made to generate stable, targetable cell lines, using human Long 
Interspersed Nuclear Elements or LINE-1or L1 element as the targetable locus 
transposition of engineered L1s in cultured human cells occurs at reasonable 
frequency. The human genome is estimated to be comprised of ~17-20% of L1 
elements. The Frequency of homologous recombination (HR) is very low (Yamane-
Ohnuki et al., 2004) in cells other than stem cells. To increase the possibility of 
encountering a HR event we deliberately selected an abundant sequence target in the 
genome.  Using human L1 element as target should help avoid targeting endogenous 
genes. This work demonstrates that even when targeting an extremely abundant 
genetic element in the genome, homologous recombination rates remain very low. 
600 stably transfected single cell clones were screened by PCR without identifying a 
LINE-1 specific homologous targeting event.   
 
5.3 MicroRNA and Proteomic studies  
 
 
MirRNA expression profiling of invasive and anti invasive lung cancer cell lines 
identified several differentially regulated gene. Five of which were chosen for 
validation. Of these mir-21 and 27a were found to be down regulated in invasive cells 
and when their expression was modified exogenously both were found to be pro-
invasive. Mir-29a upregulation caused a reduction in cell invasion as well as 
proliferation when stably overexpressed. Comprehensive proteomic profiling by 2D 
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DIGE of mir-29a treated DLKPA cells revealed more than 100 differentially 
regulated protein spots; (± 1.2 fold and 95% confidence in p-value as cut off criteria). 
 
Four gene targets which were differentially downregulated due to mir-29a 
overexpression were chosen for further functional validation using siRNA mediated 
knockdown. qRT-PCR analysis confirmed the knockdown of all the targets. 
Knockdown of MIF, ANX2 and GRB2 did not have any effect on invasion or 
proliferation phenotype. However, RAN knockdown decreased invasion in DLKPA 
cells. We have shown that mir-29a may be involved in tuning RAN expression as well 
as hundreds of other genes. 
 
Transfection of pre-mir-29a into PANC-1 (invasive pancreatic cancer cell line) also 
resulted in decreased invasion. This result suggested that anti-invasive effect of mir-
29a was more general. We also performed stable overexpression of pre-mir-29a by 
cloning the endogenous mir-29a into a mammalian overexpression vector and 
developed a stable mir-29a overexpressing DLKPA cell line. These cells exhibited a 
dramatic reduction in invasion and proliferation. In conclusion, the data provides 
convincing evidence that mir-29a is an anti-invasive miRNA. 
 
5.4 Future Work  
 
5.4.1 Developing Stable Cell lines and Transgene Overexpression 
 
Future work would involve selecting clones with similar invasiveness but with 
different transgene expression levels to further investigate dosage effect of transgenes 
on invasion and proliferation phenotype. In addition it would be interesting to select 
clones with similar transgene expression levels but different invasion phenotypes to 
investigate the impact of transgenes on invasion phenotype. 
 
5.4.1.1 GLP1-R 
 
Glucagon like Peptide 1 Receptor (GLP1-R) stable overexpression revealed a novel in 
vitro role in cancer cell invasion. This observation was not only confirmed in DLKP 
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but also in non-invasive breast carcinoma cell line MCF-7 which displayed induction 
of invasion following GLP1-R overexpression. The siRNA induced knockdown of 
GLP1-R rescued the non-invasive phenotype in DLKP 17 and 11 invasive cell lines.   
 
It would be interesting to gain further insight into possible pathway involved in this 
regulation. One could utilize GLP1-R specific blocking agents. Exendin 9-39 is a 
GLP1-R antagonist (a mutant of Exendin-4, agonist of GLP1-R and analog of GLP1) 
ligand which functions as blocking agent for GLP1-R.  Future work could involve 
blocking GLP1-R in DLKP 17 and 11 overexpressing cell lines and investigate impact 
on the invasion phenotype.  
 
GLP1-R belongs to G-Protein coupled receptor family. G protein-coupled receptors 
are involved in many diseases, and are also the target of around half of all modern 
medicinal drugs (Pierce, 2002). It is also known that phosphorylation of GPCRs by 
several other kinases, such as protein kinases A and C (PKA and PKC) (Benovic et 
al., 1985; Roth et al., 1991) can result in receptor desensitization. Pro-angiogenic 
GPCRs activate a network of small GTPases, Akt and mitogen-activated protein 
kinase (MAPK) signalling that promotes the migration, survival and growth of 
endothelial cells (Dorsam, 2007). Future work involves in investigation of the 
downstream targets (signal transduction) of GLP1-R in relevance to cancer cell 
invasion. 
 
5.4.2 To improve frequency of Homologous Recombination with 
LINE-1 element targeting  
 
Our screen for LINE-1 specific HR events from 600 single cell DLKP clones 
indicated that the frequency was at least less than 1 in 600. The application of 
recombinant adeno associated virus (rAAV) transduction to improve frequency of 
homologous recombination is already underway. Therefore future work would 
involve using these vectors to try to improve the efficiency of HR at LINE1 loci in 
these cells. 
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5.4.3 MicroRNAs  
 
So far there is no literature concentrating on the effects of mir-21, mir-27a and mir-
29a in chemo therapeutic drug resistant models. Although from our transient 
overexpression or blocking experiments we did not observe any significant impact on 
drug sensitivity, it would interesting to investigate the impact of stable expression or 
blocking of these miRNAs on chemo therapeutic drug sensitivity. NICB harbours 
several different CDR related cancer cell lines, therefore a good opportunity to 
investigate the effect on invasion, proliferation due to altered drug sensitivity with 
miRNAs treatment. 
 
Comprehensive proteomic profiling of possible mir-29a targets led us to several 
interesting candidate gene targets. Fourteen genes were predicted by RNAhybrid to be 
possessing mir-29a binding seed region in their 3’UTR. In this thesis only a few 
targets were functionally validated.  
 
C-Myc, a well studied oncogene, has been reported to be involved in regulating the 
expression of mir-29a. The qRT-PCR data suggested a increased levels of c-Myc 
trend in invasive cell lines compared to mildly invasive cell line DLKP.  Reports 
suggest that Myc directly up- regulates a pro-tumorigenic group of miRNAs known as 
the miR-17–92 cluster. This was also confirmed in our study that the reduced 
endogenous concentration of mir-29a in invasive cells may be in part due to increased 
c-Myc expression resulting in repression of mir-29a transcription. Further analysis 
including the impact of c-Myc dysregulation on mir-29a expression in these cell lines 
would be required to prove this, as well as confirming the observed increase in c-Myc 
mRNA at the protein level. Future work could also involve delineating the c-Myc/mir-
29a associated gene regulation pathway in cancer cell invasion. 
 
We also found that mir-29a has a predicted binding site for GLP1-R. mRNA qRT-
PCR analysis of stable mir-29a overexpressing DLKPA clones showed decreased 
GLP1-R at mRNA level, although western blot results were inconclusive. It is already 
established through several studies that miRNA targets the 3’UTR region of mRNA to 
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dysregulate protein synthesis. So accordingly if we can mutate the predicted seed 
region (miRNA:3’UTR mRNA binding site) in 3’UTR of GLP1-R and further check 
for rescue on the impact of mir-29a expression, then that would be convincing enough 
to establish mir-29a-GLP1-R target specificity.  Future work might involve GLP1-R 
3’UTR mutation studies. In addition it would also be interesting to do similar 3’UTR 
mutation studies to validate the fourteen RNAhybrid predicted mir-29a target proteins 
by either using luciferase or GFP based reporter assays. 
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